<SEC-DOCUMENT>0001654954-24-006411.txt : 20240515
<SEC-HEADER>0001654954-24-006411.hdr.sgml : 20240515
<ACCEPTANCE-DATETIME>20240515161731
ACCESSION NUMBER:		0001654954-24-006411
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		57
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240515
DATE AS OF CHANGE:		20240515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		24951081

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cvm_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:cvm="http://cvm.com/20240331"><head><title>cvm_10q.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html"/></head><body style="text-align:justify;font:10pt times new roman"><div style="display:none;text-align:justify;font:10pt times new roman;" id="XBRLDIV"><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2023-10-01to2024-03-31" id="ixv-7010">0000725363</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2023-10-01to2024-03-31" format="ixt:booleanfalse" id="ixv-7011">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2023-10-01to2024-03-31" id="ixv-7012">--12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2023-10-01to2024-03-31" id="ixv-7013">Q2</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2023-10-01to2024-03-31" id="ixv-7014">2024</ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-03-31" unitRef="USDPShares" decimals="INF" id="ixv-7015">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-03-31" unitRef="Shares" decimals="0" id="ixv-7016">200000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0" id="ixv-7017">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-03-31" unitRef="Shares" decimals="0" id="ixv-7018">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0" id="ixv-7019">0</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-03-31" unitRef="USDPShares" decimals="INF" id="ixv-7020">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0" id="ixv-7021">600000000</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-03-31" unitRef="Shares" decimals="0" id="ixv-7022">54083718</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0" id="ixv-7023">47422304</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2023-10-01to2024-03-31" unitRef="Shares" decimals="0" id="ixv-7024">0</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2024-01-01to2024-03-31" unitRef="Shares" decimals="0" id="ixv-7025">0</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2023-01-01to2023-03-31" unitRef="Shares" decimals="0" id="ixv-7026">0</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="From2022-10-01to2023-03-31" unitRef="Shares" decimals="0" id="ixv-7027">0</ix:nonFraction><ix:nonFraction name="cvm:NetOfDiscount" contextRef="From2022-10-01to2023-03-31" unitRef="USD" decimals="0" id="ixv-7028">11900000.0</ix:nonFraction><ix:nonFraction name="cvm:NetOfDiscount" contextRef="From2022-10-01to2023-03-31_cvm_ErgomedMember" unitRef="USD" decimals="0" id="ixv-7029">11900000.0</ix:nonFraction><ix:nonNumeric name="cvm:OperatingLeaseWeightedAverageRemainingLeaseTermOne" contextRef="From2024-01-01to2024-03-31" id="ixv-7030">P4Y7M2D</ix:nonNumeric><ix:nonFraction name="cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" contextRef="From2023-01-01to2023-03-31" unitRef="Shares" decimals="0" id="ixv-7031">45581381</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cvm-20240331.xsd"/></ix:references><ix:resources><xbrli:context id="From2023-10-01to2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-05-08_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-03-31_cvm_UnvestedRestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-03-31_cvm_UnvestedRestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-03-31_cvm_OptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-03-31_cvm_OptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-01-11_cvm_LandlordMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-03-31_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-03-31_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-10-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-03-31_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-02-01to2024-02-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-11-01to2023-11-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-11-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-02-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-03-31_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-03-31_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-10-28_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-03-31_cvm_SeriesSSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesSSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_srt_MinimumMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_ConsultantsOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-03-31_srt_MaximumMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-03-31_srt_MinimumMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-03-31_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-03-31_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-03-31_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-03-31_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-03-31_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-03-31_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-03-31_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-03-31_cvm_NonEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_cvm_NonEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-03-31_cvm_NonEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-03-31_cvm_NonEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-03-31_us-gaap_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-03-31_us-gaap_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-03-31_us-gaap_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_cvm_IncentiveStockBonusPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_us-gaap_StockCompensationPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_cvm_StockBonusPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-05-09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:DocumentType" id="ixv-7767">10-Q</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(Mark One)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="ixv-7768">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160; QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the quarterly period ended <ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" id="ixv-7769">March 31, 2024</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">OR</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="ixv-7770">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160; TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the transition period from _______________ to ______________.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Commission File Number <ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:EntityFileNumber" id="ixv-7771">001-11889</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:EntityRegistrantName" id="ixv-7772">CEL-SCI CORPORATION</ix:nonNumeric></span></strong></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="ixv-7773">Colorado</ix:nonNumeric></p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:EntityTaxIdentificationNumber" id="ixv-7774">84-0916344</ix:nonNumeric></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;State or other jurisdiction incorporation</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;(IRS) Employer Identification Number</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;<ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:EntityAddressAddressLine1" id="ixv-7775">8229 Boone Boulevard</ix:nonNumeric>, <ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:EntityAddressAddressLine2" id="ixv-7776">Suite 802</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span style="text-decoration:underline"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:EntityAddressCityOrTown" id="ixv-7777">Vienna</ix:nonNumeric>, <ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="ixv-7778">Virginia</ix:nonNumeric> <ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:EntityAddressPostalZipCode" id="ixv-7779">22182</ix:nonNumeric></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;Address of principal executive offices</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span style="text-decoration:underline">(<ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:CityAreaCode" id="ixv-7780">703</ix:nonNumeric>) <ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:LocalPhoneNumber" id="ixv-7781">506-9460</ix:nonNumeric></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;Registrant's telephone number, including area code</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Title of Each Class</p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Trading Symbol(s)</p></td><td style="width:5%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Name of Each Exchange on Which Registered</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:Security12bTitle" id="ixv-7782">Common Stock</ix:nonNumeric></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:TradingSymbol" id="ixv-7783">CVM</ix:nonNumeric>&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="ixv-7784">NYSE</ix:nonNumeric> American</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) had been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:EntityCurrentReportingStatus" id="ixv-7785">Yes</ix:nonNumeric> &#9746; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:EntityInteractiveDataCurrent" id="ixv-7786">Yes</ix:nonNumeric> &#9746; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Large&#160;accelerated&#160;filer</p></td><td style="width:20%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td><td style="width:30%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accelerated&#160;filer</p></td><td style="width:20%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="ixv-7787">Non-accelerated filer</ix:nonNumeric></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9746; </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="ixv-7788">&#9746;</ix:nonNumeric></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Emerging growth company</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="ixv-7789">&#9744;</ix:nonNumeric></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act). Yes <ix:nonNumeric contextRef="From2023-10-01to2024-03-31" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="ixv-7790">&#9744;</ix:nonNumeric> No &#9746;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:32%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Class of Stock</p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:32%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">No. Shares Outstanding</p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:32%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction contextRef="AsOf2024-05-09" name="dei:EntityCommonStockSharesOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares" id="ixv-7791">54,159,937</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">May 9, 2024</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"/></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="toc">TABLE OF CONTENTS </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>PART I FINANCIAL INFORMATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:7%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Item 1.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Page</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#bs">Condensed Balance Sheets at March 31, 2024 (unaudited) and September 30, 2023</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#op">Condensed Statements of Operations for the six months ended March 31, 2024 and 2023 (unaudited)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#op3">Condensed Statements of Operations for the three months ended March 31, 2024 and 2023 (unaudited)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#eq">Condensed Statements of Stockholders&#8217; Equity for the six months ended March 31, 2024 and 2023 (unaudited)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">6</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#cf">Condensed Statements of Cash Flows for the six months ended March 31, 2024 and 2023 (unaudited)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#fs">Notes to Condensed Financial Statements<strong>&#160;</strong>(unaudited)</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i2">Item 2.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i2">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">19</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i3">Item 3.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i3">Quantitative and Qualitative Disclosures about Market Risks</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">30</p></td></tr><tr style="height:15px;background-color:#ffffff"><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i4">Item 4.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i4">Controls and Procedures</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">30</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><a href="#p2">PART II</a></strong></p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#ii2">Item 2.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#ii2">Unregistered Sales of Equity Securities and Use of Proceeds</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">31</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#ii5">Item 5.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#ii5">Other Information</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">31</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#ii6">Item 6.</a></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#ii6">Exhibits</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">31</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#sig">Signatures</a></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">32</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="bs">CEL-SCI CORPORATION</span></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CONDENSED BALANCE SHEETS</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>MARCH 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SEPTEMBER 30, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">ASSETS</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(UNAUDITED)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1" contextRef="AsOf2024-03-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,309,321</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2" contextRef="AsOf2023-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,145,735</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3" contextRef="AsOf2024-03-31" name="us-gaap:PrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696,648</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_4" contextRef="AsOf2023-09-30" name="us-gaap:PrepaidExpenseCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">520,368</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_5" contextRef="AsOf2024-03-31" name="cvm:SuppliesUsedForRDAndManufacturingCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,489,284</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_6" contextRef="AsOf2023-09-30" name="cvm:SuppliesUsedForRDAndManufacturingCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,248,072</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_7" contextRef="AsOf2024-03-31" name="us-gaap:DepositsAssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,129</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_8" contextRef="AsOf2023-09-30" name="us-gaap:DepositsAssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,245</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_9" contextRef="AsOf2024-03-31" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,511,382</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_10" contextRef="AsOf2023-09-30" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,918,420</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_11" contextRef="AsOf2024-03-31" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,251,453</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_12" contextRef="AsOf2023-09-30" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,131,987</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating lease right of use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_13" contextRef="AsOf2024-03-31" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,598,879</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_14" contextRef="AsOf2023-09-30" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,698,243</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_15" contextRef="AsOf2024-03-31" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,113,284</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_16" contextRef="AsOf2023-09-30" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,188,126</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patent costs, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_17" contextRef="AsOf2024-03-31" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,482</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_18" contextRef="AsOf2023-09-30" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,704</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_159" contextRef="AsOf2024-03-31" name="us-gaap:DepositsAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,319,101</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_158" contextRef="AsOf2023-09-30" name="us-gaap:DepositsAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,319,101</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_160" contextRef="AsOf2024-03-31" name="cvm:SuppliesUsedForRDAndManufacturingNonCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,524</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_161" contextRef="AsOf2023-09-30" name="cvm:SuppliesUsedForRDAndManufacturingNonCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,669</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_23" contextRef="AsOf2024-03-31" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,048,105</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_24" contextRef="AsOf2023-09-30" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,528,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">LIABILITIES AND STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_27" contextRef="AsOf2024-03-31" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,015,969</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_28" contextRef="AsOf2023-09-30" name="us-gaap:AccountsPayableCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,009,786</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_29" contextRef="AsOf2024-03-31" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,219,399</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_30" contextRef="AsOf2023-09-30" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,049,581</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Due to employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_31" contextRef="AsOf2024-03-31" name="cvm:DueToEmployeeCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">751,607</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_32" contextRef="AsOf2023-09-30" name="cvm:DueToEmployeeCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">557,244</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Finance lease obligation, current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_33" contextRef="AsOf2024-03-31" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,888,767</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_34" contextRef="AsOf2023-09-30" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,771,804</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Operating lease obligation, current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_35" contextRef="AsOf2024-03-31" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,275</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_36" contextRef="AsOf2023-09-30" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,431</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Total current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_37" contextRef="AsOf2024-03-31" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,087,017</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_38" contextRef="AsOf2023-09-30" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,585,846</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Finance lease obligations, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_39" contextRef="AsOf2024-03-31" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,987,319</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_40" contextRef="AsOf2023-09-30" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,949,565</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Operating lease obligations, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_41" contextRef="AsOf2024-03-31" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,544,126</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_42" contextRef="AsOf2023-09-30" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,652,949</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Other liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_43" contextRef="AsOf2024-03-31" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_44" contextRef="AsOf2023-09-30" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_45" contextRef="AsOf2024-03-31" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,743,462</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_46" contextRef="AsOf2023-09-30" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,313,360</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Commitments and contingencies (refer to Note E)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td/><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Preferred stock, $<ix:nonFraction id="fid_141" contextRef="AsOf2023-09-30" name="us-gaap:PreferredStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction> par value; <ix:nonFraction id="fid_143" contextRef="AsOf2023-09-30" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,000</ix:nonFraction> shares authorized; <ix:nonFraction id="fid_146" contextRef="AsOf2024-03-31" name="us-gaap:PreferredStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">0</ix:nonFraction> shares issued and outstanding</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_48" contextRef="AsOf2024-03-31" name="us-gaap:PreferredStockValue" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_49" contextRef="AsOf2023-09-30" name="us-gaap:PreferredStockValue" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Common stock, $<ix:nonFraction id="fid_149" contextRef="AsOf2023-09-30" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction> par value; <ix:nonFraction id="fid_152" contextRef="AsOf2024-03-31" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">600,000,000</ix:nonFraction> shares authorized; <ix:nonFraction id="fid_153" contextRef="AsOf2024-03-31" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">54,083,718</ix:nonFraction> and <ix:nonFraction id="fid_154" contextRef="AsOf2023-09-30" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">47,422,304</ix:nonFraction> shares issued and outstanding at March 31, 2024 and September 30, 2023, respectively</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_50" contextRef="AsOf2024-03-31" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">540,837</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_51" contextRef="AsOf2023-09-30" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">474,223</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Additional paid-in capital</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_52" contextRef="AsOf2024-03-31" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">514,809,617</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_53" contextRef="AsOf2023-09-30" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,832,063</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accumulated deficit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_54" contextRef="AsOf2024-03-31" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">501,045,811</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_55" contextRef="AsOf2023-09-30" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">487,091,396</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total stockholders' equity</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_56" contextRef="AsOf2024-03-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,304,643</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_57" contextRef="AsOf2023-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,214,890</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_58" contextRef="AsOf2024-03-31" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,048,105</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_59" contextRef="AsOf2023-09-30" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,528,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="op">CEL-SCI CORPORATION</span></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CONDENSED STATEMENTS OF OPERATIONS</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">SIX MONTHS ENDED MARCH 31, 2024 and 2023</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_61" contextRef="From2023-10-01to2024-03-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,981,044</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_62" contextRef="From2022-10-01to2023-03-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,476,034</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_63" contextRef="From2023-10-01to2024-03-31" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,580,791</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_64" contextRef="From2022-10-01to2023-03-31" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,350,761</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_65" contextRef="From2023-10-01to2024-03-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,561,835</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_66" contextRef="From2022-10-01to2023-03-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,826,795</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_67" contextRef="From2023-10-01to2024-03-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,561,835</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_68" contextRef="From2022-10-01to2023-03-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">15,826,795</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Interest expense, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_69" contextRef="From2023-10-01to2024-03-31" name="us-gaap:InterestIncomeExpenseNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">380,397</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_70" contextRef="From2022-10-01to2023-03-31" name="us-gaap:InterestIncomeExpenseNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">311,852</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_71" contextRef="From2023-10-01to2024-03-31" name="us-gaap:OtherNonoperatingExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,183</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_72" contextRef="From2022-10-01to2023-03-31" name="us-gaap:OtherNonoperatingExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,671</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_73" contextRef="From2023-10-01to2024-03-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,954,415</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_74" contextRef="From2022-10-01to2023-03-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">16,196,318</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Modification of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_75" contextRef="From2023-10-01to2024-03-31" name="cvm:ModificationOfWarrants" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_76" contextRef="From2022-10-01to2023-03-31" name="cvm:ModificationOfWarrants" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">171,552</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_77" contextRef="From2023-10-01to2024-03-31" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,954,415</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_78" contextRef="From2022-10-01to2023-03-31" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">16,367,870</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss per common share &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_79" contextRef="From2023-10-01to2024-03-31" name="cvm:EarningPerShareBasicAndDiluted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.28</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_80" contextRef="From2022-10-01to2023-03-31" name="cvm:EarningPerShareBasicAndDiluted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.38</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_81" contextRef="From2023-10-01to2024-03-31" name="cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">50,228,860</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_82" contextRef="From2022-10-01to2023-03-31" name="cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,513,571</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="op3">CEL-SCI CORPORATION</span></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CONDENSED STATEMENTS OF OPERATIONS</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">THREE MONTHS ENDED MARCH 31, 2024 and 2023</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_121" contextRef="From2024-01-01to2024-03-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,628,535</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_122" contextRef="From2023-01-01to2023-03-31" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,083,488</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">General and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_123" contextRef="From2024-01-01to2024-03-31" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,447,413</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_124" contextRef="From2023-01-01to2023-03-31" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,092,758</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_125" contextRef="From2024-01-01to2024-03-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,075,948</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_126" contextRef="From2023-01-01to2023-03-31" name="us-gaap:OperatingExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,176,246</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_127" contextRef="From2024-01-01to2024-03-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,075,948</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_128" contextRef="From2023-01-01to2023-03-31" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,176,246</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Interest expense, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_129" contextRef="From2024-01-01to2024-03-31" name="us-gaap:InterestIncomeExpenseNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">182,701</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_130" contextRef="From2023-01-01to2023-03-31" name="us-gaap:InterestIncomeExpenseNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,063</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other income (expense)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_131" contextRef="From2024-01-01to2024-03-31" name="us-gaap:OtherNonoperatingExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,758</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_132" contextRef="From2023-01-01to2023-03-31" name="us-gaap:OtherNonoperatingExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,500</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_133" contextRef="From2024-01-01to2024-03-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,244,891</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_134" contextRef="From2023-01-01to2023-03-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,342,809</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_135" contextRef="From2024-01-01to2024-03-31" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,244,891</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_136" contextRef="From2023-01-01to2023-03-31" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,342,809</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss per common share &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_137" contextRef="From2024-01-01to2024-03-31" name="cvm:EarningPerShareBasicAndDiluted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.14</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_138" contextRef="From2023-01-01to2023-03-31" name="cvm:EarningPerShareBasicAndDiluted" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.19</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_139" contextRef="From2024-01-01to2024-03-31" name="cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">52,006,442</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_140" contextRef="From2023-01-01to2023-03-31" name="cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,588,381</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="eq">CEL-SCI CORPORATION</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Additional</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common Stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Paid-In</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Capital</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Deficit</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCES AT SEPTEMBER 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_508" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">47,422,304</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_509" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">474,223</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_510" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,832,063</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_511" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">487,091,396</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_512" contextRef="AsOf2023-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,214,890</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k)&#160;contributions paid in common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_513" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,724</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_514" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">177</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_515" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,730</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_516" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_517" contextRef="From2023-10-01to2023-12-31" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,907</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_518" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">88,573</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_519" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">886</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_520" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">201,421</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_521" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_522" contextRef="From2023-10-01to2023-12-31" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,307</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from the sale of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_523" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,490,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_524" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,900</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_525" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,955,100</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_526" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_527" contextRef="From2023-10-01to2023-12-31" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,980,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation &#8211; employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_528" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_529" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,383,909</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_530" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_531" contextRef="From2023-10-01to2023-12-31" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,383,909</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_532" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="cvm:ShareIssuanceCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_533" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cvm:ShareIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">470,229</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_534" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="cvm:ShareIssuanceCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_535" contextRef="From2023-10-01to2023-12-31" name="cvm:ShareIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">470,229</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_536" contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_537" contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_538" contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,709,524</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_539" contextRef="From2023-10-01to2023-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,709,524</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCES AT DECEMBER 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_540" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">50,018,601</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_541" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,186</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_542" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">505,950,994</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_543" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">493,800,920</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_544" contextRef="AsOf2023-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,650,260</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k)&#160;contributions paid in common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_545" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">27,373</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_546" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">274</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_547" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,211</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_548" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_549" contextRef="From2024-01-01to2024-03-31" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,485</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_550" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">162,744</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_551" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,627</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_552" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">379,243</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_553" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_554" contextRef="From2024-01-01to2024-03-31" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">380,870</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from the sale of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_555" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,875,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_556" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,750</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_557" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,711,250</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_558" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_559" contextRef="From2024-01-01to2024-03-31" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,750,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation &#8211; employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_560" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_561" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,432,540</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_562" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_563" contextRef="From2024-01-01to2024-03-31" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,432,540</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_564" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" name="cvm:ShareIssuanceCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_565" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" name="cvm:ShareIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">717,621</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_566" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" name="cvm:ShareIssuanceCosts" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_567" contextRef="From2024-01-01to2024-03-31" name="cvm:ShareIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">717,621</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_568" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_569" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_570" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,244,891</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_571" contextRef="From2024-01-01to2024-03-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,244,891</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCES AT MARCH 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_572" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">54,083,718</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_573" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">540,837</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_574" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">514,809,617</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_575" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">501,045,811</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_576" contextRef="AsOf2024-03-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,304,643</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (continued)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Additional</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common Stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Paid-In</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Capital</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Deficit</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCES AT SEPTEMBER 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_577" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,448,317</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_578" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">434,484</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_579" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">486,625,816</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_580" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">454,897,093</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_581" contextRef="AsOf2022-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,163,207</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrant exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_582" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="cvm:WarrantExercisesShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">217,752</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_583" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,177</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_584" contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,114</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_585" contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember" name="cvm:WarrantExercisesAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_586" contextRef="From2022-10-01to2022-12-31" name="cvm:WarrantExercisesAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">447,291</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation &#8211; employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_587" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_588" contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,703,931</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_589" contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_590" contextRef="From2022-10-01to2022-12-31" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,703,931</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_591" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">21,331</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_592" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_593" contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,965</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_594" contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_595" contextRef="From2022-10-01to2022-12-31" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,178</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_596" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">40,236</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_597" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_598" contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,221</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_599" contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_600" contextRef="From2022-10-01to2022-12-31" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,623</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2014 incentive stock forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_601" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="cvm:IncentiveStockForfeitedShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares" sign="-">2,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_602" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="cvm:IncentiveStockForfeitedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">20</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_603" contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="cvm:IncentiveStockForfeitedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">11,080</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_604" contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember" name="cvm:IncentiveStockForfeitedAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_605" contextRef="From2022-10-01to2022-12-31" name="cvm:IncentiveStockForfeitedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">11,100</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_606" contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_607" contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_608" contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,853,509</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_609" contextRef="From2022-10-01to2022-12-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,853,509</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCES AT DECEMBER 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_610" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,725,636</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_611" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">437,256</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_612" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">488,904,967</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_613" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">462,750,602</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_614" contextRef="AsOf2022-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,591,621</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation &#8211; employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_615" contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_616" contextRef="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,743,288</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_617" contextRef="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_618" contextRef="From2023-01-01to2023-03-31" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,743,288</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_619" contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">23,627</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_620" contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_621" contextRef="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,629</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_622" contextRef="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_623" contextRef="From2023-01-01to2023-03-31" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,865</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_624" contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">38,562</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_625" contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">386</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_626" contextRef="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,249</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_627" contextRef="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_628" contextRef="From2023-01-01to2023-03-31" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,635</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_629" contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_630" contextRef="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_631" contextRef="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,342,809</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_632" contextRef="From2023-01-01to2023-03-31" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,342,809</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCES AT MARCH 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_633" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,787,825</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_634" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">437,878</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_635" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">490,803,133</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_636" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">471,093,411</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_637" contextRef="AsOf2023-03-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,147,600</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="cf">CEL-SCI CORPORATION</span></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CONDENSED STATEMENTS OF CASH FLOWS</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">SIX MONTHS ENDED MARCH 31, 2024 and 2023</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_162" contextRef="From2023-10-01to2024-03-31" name="us-gaap:ProfitLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,954,415</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_163" contextRef="From2022-10-01to2023-03-31" name="us-gaap:ProfitLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">16,196,318</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_165" contextRef="From2023-10-01to2024-03-31" name="us-gaap:DepreciationAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,993,395</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_166" contextRef="From2022-10-01to2023-03-31" name="us-gaap:DepreciationAndAmortization" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,973,982</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Non-cash lease expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_167" contextRef="From2023-10-01to2024-03-31" name="us-gaap:OtherNoncashExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,383</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_168" contextRef="From2022-10-01to2023-03-31" name="us-gaap:OtherNoncashExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,545</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Share-based payments for services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_169" contextRef="From2023-10-01to2024-03-31" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">547,893</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_170" contextRef="From2022-10-01to2023-03-31" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:numdotdecimal" decimals="0" unitRef="USD">285,722</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Equity-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_171" contextRef="From2023-10-01to2024-03-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,816,449</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_172" contextRef="From2022-10-01to2023-03-31" name="us-gaap:ShareBasedCompensation" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,436,119</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Common stock contributed to 401(k) plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_173" contextRef="From2023-10-01to2024-03-31" name="cvm:CommonStockContributedToEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,392</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_174" contextRef="From2022-10-01to2023-03-31" name="cvm:CommonStockContributedToEmployeeBenefitPlan" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,043</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">(Increase)/decrease in assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_176" contextRef="From2023-10-01to2024-03-31" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">30,996</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_177" contextRef="From2022-10-01to2023-03-31" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,222</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_178" contextRef="From2023-10-01to2024-03-31" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,067</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_179" contextRef="From2022-10-01to2023-03-31" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,434</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_180" contextRef="From2023-10-01to2024-03-31" name="cvm:IncreaseDecreaseInDepositAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">11,884</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_181" contextRef="From2022-10-01to2023-03-31" name="cvm:IncreaseDecreaseInDepositAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,354,723</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Increase/(decrease) in liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_183" contextRef="From2023-10-01to2024-03-31" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">896,939</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_184" contextRef="From2022-10-01to2023-03-31" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,841</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_185" contextRef="From2023-10-01to2024-03-31" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,818</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_186" contextRef="From2022-10-01to2023-03-31" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,515</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">Due to employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_187" contextRef="From2023-10-01to2024-03-31" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">194,363</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_188" contextRef="From2022-10-01to2023-03-31" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,798</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:60px">Net cash used in operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_189" contextRef="From2023-10-01to2024-03-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">9,415,608</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_190" contextRef="From2022-10-01to2023-03-31" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">12,137,820</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM INVESTING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Purchases of property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_192" contextRef="From2023-10-01to2024-03-31" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,650</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_193" contextRef="From2022-10-01to2023-03-31" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,032</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Expenditures for patent costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_194" contextRef="From2023-10-01to2024-03-31" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,211</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_195" contextRef="From2022-10-01to2023-03-31" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:60px">Net cash used in investing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_196" contextRef="From2023-10-01to2024-03-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">64,861</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_197" contextRef="From2022-10-01to2023-03-31" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">165,032</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM FINANCING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Proceeds from issuance of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_199" contextRef="From2023-10-01to2024-03-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,730,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_200" contextRef="From2022-10-01to2023-03-31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Payments of stock issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_201" contextRef="From2023-10-01to2024-03-31" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,218,937</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_202" contextRef="From2022-10-01to2023-03-31" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,010</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Proceeds from the exercise of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_203" contextRef="From2023-10-01to2024-03-31" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_204" contextRef="From2022-10-01to2023-03-31" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:numdotdecimal" decimals="0" unitRef="USD">447,291</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Payments on obligations under finance leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_205" contextRef="From2023-10-01to2024-03-31" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:numdotdecimal" decimals="0" unitRef="USD">867,008</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_206" contextRef="From2022-10-01to2023-03-31" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:numdotdecimal" decimals="0" unitRef="USD">761,223</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:60px">Net cash provided by (used in) financing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_207" contextRef="From2023-10-01to2024-03-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,644,055</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_208" contextRef="From2022-10-01to2023-03-31" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">322,942</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_209" contextRef="From2023-10-01to2024-03-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,163,586</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_210" contextRef="From2022-10-01to2023-03-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">12,625,794</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_211" contextRef="AsOf2023-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,145,735</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_212" contextRef="AsOf2022-09-30" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,672,138</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH AND CASH EQUIVALENTS, END OF PERIOD</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_213" contextRef="AsOf2024-03-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,309,321</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_214" contextRef="AsOf2023-03-31" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,046,344</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CONDENSED STATEMENTS OF CASH FLOWS</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">SIX MONTHS ENDED MARCH 31, 2024 and 2023</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(UNAUDITED)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment purchases included in current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_230" contextRef="From2023-10-01to2024-03-31" name="cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_231" contextRef="From2022-10-01to2023-03-31" name="cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,743</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Assets purchased under finance leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_232" contextRef="From2023-10-01to2024-03-31" name="cvm:AssetsPurchasedUnderFinanceLeases" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,797</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_233" contextRef="From2022-10-01to2023-03-31" name="cvm:AssetsPurchasedUnderFinanceLeases" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease obligation included in accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_234" contextRef="From2023-10-01to2024-03-31" name="cvm:FinanceLeaseObligationIncludedInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">522</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_235" contextRef="From2022-10-01to2023-03-31" name="cvm:FinanceLeaseObligationIncludedInAccountsPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,402</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consulting services paid with issuance of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_236" contextRef="From2023-10-01to2024-03-31" name="cvm:ConsultingServicesPaidWithIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">583,177</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_237" contextRef="From2022-10-01to2023-03-31" name="cvm:ConsultingServicesPaidWithIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">192,258</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued consulting services to be paid with common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_238" contextRef="From2023-10-01to2024-03-31" name="cvm:AccruedConsultingServicesToBePaidWithCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_239" contextRef="From2022-10-01to2023-03-31" name="cvm:AccruedConsultingServicesToBePaidWithCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Financing costs included in current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_240" contextRef="From2023-10-01to2024-03-31" name="cvm:FinancingCostsIncludedInCurrentLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,616</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_241" contextRef="From2022-10-01to2023-03-31" name="cvm:FinancingCostsIncludedInCurrentLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Cash paid for interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_242" contextRef="From2023-10-01to2024-03-31" name="us-gaap:InterestPaidNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">480,044</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_243" contextRef="From2022-10-01to2023-03-31" name="us-gaap:InterestPaidNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">547,765</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See notes to condensed financial statements.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="fs">CEL-SCI CORPORATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO CONDENSED FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SIX MONTHS ENDED MARCH 31, 2024 AND 2023 (UNAUDITED)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_251" contextRef="From2023-10-01to2024-03-31" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true" continuedAt="cont_2a36e6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A. <span style="text-decoration:underline">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Basis of Presentation</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The accompanying condensed financial statements of CEL-SCI Corporation (the &#8220;Company&#8221;) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair presentation of the Company&#8217;s financial position as of March 31, 2024 and the results of its operations for the six months then ended. The condensed balance sheet as of September 30, 2023 is derived from the September 30, 2023 audited financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Summary of Significant Accounting Policies:</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_252" contextRef="From2023-10-01to2024-03-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_253" contextRef="From2023-10-01to2024-03-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_254" contextRef="From2023-10-01to2024-03-31" name="us-gaap:InventoryPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing &#8211;</em> Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_255" contextRef="From2023-10-01to2024-03-31" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_256" contextRef="From2023-10-01to2024-03-31" name="cvm:LeasesPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Leases &#8211; </em>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.</p></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_2a36e6" continuedAt="cont_bcf924"><ix:nonNumeric id="fid_257" contextRef="From2023-10-01to2024-03-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Share-Based Compensation</em> &#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, <em>Compensation &#8211; Stock Compensation</em> (&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#8220;Plans&#8221;. All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_258" contextRef="From2023-10-01to2024-03-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Research and Development Costs</em> &#8211; Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_259" contextRef="From2023-10-01to2024-03-31" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260, <em>Earnings Per Share</em>. Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_260" contextRef="From2023-10-01to2024-03-31" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company accounts for income taxes in accordance with the provisions of ASC 740, <em>Income Taxes</em>, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of March 31, 2024 and September 30, 2023.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_bcf924"><ix:nonNumeric id="fid_261" contextRef="From2023-10-01to2024-03-31" name="cvm:ImpairmentOfLongLivedAssetsPolicyTextblock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impairment of long-lived assets</em> &#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_262" contextRef="From2023-10-01to2024-03-31" name="us-gaap:UseOfEstimates" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_263" contextRef="From2023-10-01to2024-03-31" name="cvm:NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Recently Adopted Accounting Standards</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2016-13,<em> Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;). </em>ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no impact on the Company&#8217;s financial position, results of operations, or cash flows.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_264" contextRef="From2023-10-01to2024-03-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>New Accounting Pronouncements</em> &#8211; The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_244" contextRef="From2023-10-01to2024-03-31" name="cvm:LiquidityDisclosureTextBlock" escape="true" continuedAt="cont_8e1a1e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">B. <span style="text-decoration:underline">LIQUIDITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company&#8217;s lead investigational therapy, to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_8e1a1e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to the Company&#8217;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_245" contextRef="From2023-10-01to2024-03-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="cont_73e30e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">C. <span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Proceeds from the Sale of Common Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In February 2024, the Company sold <ix:nonFraction id="fid_374" contextRef="AsOf2024-02-29" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,875,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_375" contextRef="AsOf2024-02-29" name="us-gaap:SaleOfStockPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2</ix:nonFraction>.00 per share and received proceeds of approximately $<ix:nonFraction id="fid_377" contextRef="From2024-02-01to2024-02-29" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="-6" unitRef="USD" scale="6">7</ix:nonFraction>.0 million, net of issuance costs of approximately $<ix:nonFraction id="fid_378" contextRef="From2024-02-01to2024-02-29" name="cvm:NetofissuanceCosts" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.7</ix:nonFraction> million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2023, the Company sold <ix:nonFraction id="fid_358" contextRef="AsOf2023-11-30" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,490,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_359" contextRef="AsOf2023-11-30" name="us-gaap:SaleOfStockPricePerShare" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2</ix:nonFraction>.00 per share and received proceeds of approximately $<ix:nonFraction id="fid_370" contextRef="From2023-11-01to2023-11-30" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">4.5</ix:nonFraction> million, net of issuance costs of approximately $<ix:nonFraction id="fid_372" contextRef="From2023-11-01to2023-11-30" name="cvm:NetofissuanceCosts" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.5</ix:nonFraction> million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Equity Compensation</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Underlying share information for equity compensation plans as of March 31, 2024 is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_265" contextRef="From2023-10-01to2024-03-31" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><strong>Total Shares Reserved</strong> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Under Plans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_274" contextRef="AsOf2024-03-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">138,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_275" contextRef="AsOf2024-03-31_cvm_NonQualifiedStockOptionsPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,787,200</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_276" contextRef="AsOf2024-03-31_cvm_StockBonusPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,283,760</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_277" contextRef="AsOf2024-03-31_us-gaap_StockCompensationPlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">634,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_278" contextRef="AsOf2024-03-31_cvm_IncentiveStockBonusPlansMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">640,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Stock option activity</span>:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_266" contextRef="From2023-10-01to2024-03-31" name="cvm:ScheduleOfStockOptionActivityTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"><strong>Six Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"><strong>&#160;2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_287" contextRef="From2023-10-01to2024-03-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_283" contextRef="From2022-10-01to2023-03-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_280" contextRef="From2023-10-01to2024-03-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">53,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_289" contextRef="From2022-10-01to2023-03-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">122,332</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_288" contextRef="From2023-10-01to2024-03-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">27,035</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_290" contextRef="From2022-10-01to2023-03-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">45,404</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"><strong>Three Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"><strong>&#160;2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_284" contextRef="From2024-01-01to2024-03-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_279" contextRef="From2023-01-01to2023-03-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_285" contextRef="From2024-01-01to2024-03-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">42,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_281" contextRef="From2023-01-01to2023-03-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">25,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_286" contextRef="From2024-01-01to2024-03-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">27,035</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_282" contextRef="From2023-01-01to2023-03-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:numdotdecimal" decimals="-3" unitRef="Shares" scale="3">4</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On March 1, 2024, the Company accelerated the vesting of <ix:nonFraction id="fid_638" contextRef="From2024-01-01to2024-03-31" name="us-gaap:StockOptionPlanExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,332</ix:nonFraction> stock options issued to directors to vest on April 19, 2024. The Company concluded that the change in vesting of the options should be treated as a modification in accordance with ASC 718. As such, the Company revalued the options as of March 1, 2024 (the modification date) and subtracted any compensation cost already recognized prior to the modification date. This resulted in remaining compensation cost of approximately $<ix:nonFraction id="fid_488" contextRef="From2023-10-01to2024-03-31" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,000</ix:nonFraction> that will be amortized on a straight-line basis over the remaining service period.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_73e30e" continuedAt="cont_8694a6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Share-Based Compensation Expense</span>:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_267" contextRef="From2023-10-01to2024-03-31" name="cvm:ScheduleOfCompensatingBalancesTableTextBlock" escape="true" continuedAt="cont_47a60e"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"><strong>Six Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 15pt; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 27.05pt; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_295" contextRef="From2023-10-01to2024-03-31_us-gaap_EmployeeStockMember" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,816,449</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_334" contextRef="From2022-10-01to2023-03-31_us-gaap_EmployeeStockMember" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,436,119</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_297" contextRef="From2023-10-01to2024-03-31_cvm_NonEmployeesMember" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">370,163</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_337" contextRef="From2022-10-01to2023-03-31_cvm_NonEmployeesMember" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">285,722</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_47a60e"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"><strong>Three Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 15pt; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 27.05pt; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_336" contextRef="From2024-01-01to2024-03-31_us-gaap_EmployeeStockMember" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,432,540</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_335" contextRef="From2023-01-01to2023-03-31_us-gaap_EmployeeStockMember" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,743,288</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_338" contextRef="From2024-01-01to2024-03-31_cvm_NonEmployeesMember" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,777</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_339" contextRef="From2023-01-01to2023-03-31_cvm_NonEmployeesMember" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,864</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Warrants and Non-Employee Options</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following chart represents the warrants and non-employee options outstanding at March 31, 2024:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_268" contextRef="From2023-10-01to2024-03-31" name="cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_299" contextRef="From2023-10-01to2024-03-31_cvm_SeriesNMember" name="cvm:IssueDate1">8/18/2008</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_308" contextRef="AsOf2023-12-31_cvm_SeriesNMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">85,339</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_316" contextRef="AsOf2023-12-31_cvm_SeriesNMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_325" contextRef="From2023-10-01to2024-03-31_cvm_SeriesNMember" name="cvm:ExpirationDate">8/18/2024</ix:nonNumeric>&#160; </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_300" contextRef="From2023-10-01to2024-03-31_cvm_SeriesUUMember" name="cvm:IssueDate1">6/11/2018</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_309" contextRef="AsOf2023-12-31_cvm_SeriesUUMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">93,603</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_317" contextRef="AsOf2023-12-31_cvm_SeriesUUMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.80</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_326" contextRef="From2023-10-01to2024-03-31_cvm_SeriesUUMember" name="cvm:ExpirationDate">6/30/2024</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_301" contextRef="From2023-10-01to2024-03-31_cvm_SeriesXMember" name="cvm:IssueDate1">1/13/2016</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_310" contextRef="AsOf2023-12-31_cvm_SeriesXMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">120,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_318" contextRef="AsOf2023-12-31_cvm_SeriesXMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.25</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_327" contextRef="From2023-10-01to2024-03-31_cvm_SeriesXMember" name="cvm:ExpirationDate">7/13/2024</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_302" contextRef="From2023-10-01to2024-03-31_cvm_SeriesYMember" name="cvm:IssueDate1">2/15/2016</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_311" contextRef="AsOf2023-12-31_cvm_SeriesYMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">26,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_319" contextRef="AsOf2023-12-31_cvm_SeriesYMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_328" contextRef="From2023-10-01to2024-03-31_cvm_SeriesYMember" name="cvm:ExpirationDate">8/15/2024</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_303" contextRef="From2023-10-01to2024-03-31_cvm_SeriesMMMember" name="cvm:IssueDate1">6/22/2017</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_312" contextRef="AsOf2023-12-31_cvm_SeriesMMMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">333,432</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_320" contextRef="AsOf2023-12-31_cvm_SeriesMMMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.86</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_329" contextRef="From2023-10-01to2024-03-31_cvm_SeriesMMMember" name="cvm:ExpirationDate">6/22/2024</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_304" contextRef="From2023-10-01to2024-03-31_cvm_SeriesNNMember" name="cvm:IssueDate1">7/24/2017</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_313" contextRef="AsOf2023-12-31_cvm_SeriesNNMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,087</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_321" contextRef="AsOf2023-12-31_cvm_SeriesNNMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.52</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_330" contextRef="From2023-10-01to2024-03-31_cvm_SeriesNNMember" name="cvm:ExpirationDate">7/24/2024</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_305" contextRef="From2023-10-01to2024-03-31_cvm_SeriesRRMember" name="cvm:IssueDate1">10/30/2017</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_314" contextRef="AsOf2023-12-31_cvm_SeriesRRMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">234,009</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_322" contextRef="AsOf2023-12-31_cvm_SeriesRRMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_331" contextRef="From2023-10-01to2024-03-31_cvm_SeriesRRMember" name="cvm:ExpirationDate">10/30/2024</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"><ix:nonNumeric id="fid_306" contextRef="From2023-10-01to2024-03-31_srt_MinimumMember_cvm_ConsultantsMember" name="cvm:IssueDate1">7/28/2017</ix:nonNumeric> &#8211; <ix:nonNumeric id="fid_307" contextRef="From2023-10-01to2024-03-31_srt_MaximumMember_cvm_ConsultantsMember" name="cvm:IssueDate1">9/2/2023</ix:nonNumeric> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_315" contextRef="AsOf2023-12-31_cvm_ConsultantsOptionMember" name="cvm:SharesIssuableUponExerciseOfWarrantOptions" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">110,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>$</td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"><ix:nonFraction id="fid_323" contextRef="AsOf2023-12-31_srt_MinimumMember_cvm_ConsultantsMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.39</ix:nonFraction> - $<ix:nonFraction id="fid_324" contextRef="AsOf2023-12-31_cvm_ConsultantsOptionMember" name="cvm:ExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.18</ix:nonFraction></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"><ix:nonNumeric id="fid_332" contextRef="From2023-10-01to2024-03-31_srt_MinimumMember_cvm_ConsultantsMember" name="cvm:ExpirationDate">7/27/2027</ix:nonNumeric> -&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"><ix:nonNumeric id="fid_333" contextRef="From2023-10-01to2024-03-31_srt_MaximumMember_cvm_ConsultantsMember" name="cvm:ExpirationDate">9/1/2028</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1. <span style="text-decoration:underline">Equity Warrants</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Changes in Equity Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No warrants recorded as equity were exercised during the six months ended March 31, 2024. The following warrants recorded as equity were exercised during the six months ended March 31, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_269" contextRef="From2023-10-01to2024-03-31" name="cvm:ScheduleOfDerivativeLiabilitiesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_340" contextRef="From2023-10-01to2024-03-31_cvm_SeriesRRMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">17,752</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_343" contextRef="From2023-10-01to2024-03-31_cvm_SeriesRRMember" name="cvm:EquityWarrantsExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.65</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_345" contextRef="From2023-10-01to2024-03-31_cvm_SeriesRRMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,291</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_341" contextRef="From2023-10-01to2024-03-31_cvm_SeriesSSMember" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_344" contextRef="From2023-10-01to2024-03-31_cvm_SeriesSSMember" name="cvm:EquityWarrantsExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.09</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_346" contextRef="From2023-10-01to2024-03-31_cvm_SeriesSSMember" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">418,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_347" contextRef="From2023-10-01to2024-03-31" name="cvm:EquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">217,752</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_348" contextRef="From2023-10-01to2024-03-31" name="cvm:ProceedsFromEquityWarrantsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">447,291</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No warrants recorded as equity expired during the six and three months ended March 31 ,2024. On February 5, 2023, 600 Series TT warrants, with an exercise price of $<ix:nonFraction id="fid_350" contextRef="From2023-10-01to2024-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.24</ix:nonFraction>, expired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No warrants recorded as equity were extended during the six and three months ended March 31, 2024. On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024. The incremental cost of this extension was approximately $<ix:nonFraction id="fid_349" contextRef="From2022-10-01to2022-10-28_cvm_SeriesRRMember" name="cvm:IncrementalCostDeemedDividend" format="ixt:numdotdecimal" decimals="0" unitRef="USD">172,000</ix:nonFraction>, which was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2022. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_8694a6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">2. <span style="text-decoration:underline">Options and Shares Issued to Consultants</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the six months ended March 31, 2024 and 2023, the Company issued <ix:nonFraction id="fid_354" contextRef="From2023-10-01to2024-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">251,317</ix:nonFraction> and <ix:nonFraction id="fid_490" contextRef="From2022-10-01to2023-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">78,798</ix:nonFraction> shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $<ix:nonFraction id="fid_492" contextRef="From2023-10-01to2024-03-31_cvm_ConsultingAgreementsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.99</ix:nonFraction> and $<ix:nonFraction id="fid_494" contextRef="From2022-10-01to2023-03-31_cvm_ConsultingAgreementsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.47</ix:nonFraction> during the six months ended March 31, 2024 and 2023, respectively. During the three months ended March 31, 2024 and 2023, the Company issued <ix:nonFraction id="fid_498" contextRef="From2024-01-01to2024-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">162,744</ix:nonFraction> and <ix:nonFraction id="fid_499" contextRef="From2023-01-01to2023-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">38,562</ix:nonFraction> shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $<ix:nonFraction id="fid_500" contextRef="From2024-01-01to2024-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.22</ix:nonFraction> and $<ix:nonFraction id="fid_501" contextRef="From2023-01-01to2023-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.42</ix:nonFraction> during the three months ended March 31, 2024 and 2023, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No options were issued to a consultant during the six months ended March 31, 2024. During the six months ended March 31, 2023, <ix:nonFraction id="fid_507" contextRef="From2023-10-01to2024-03-31_cvm_ConsultingAgreementsMember" name="us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,000</ix:nonFraction> options with an exercise price of $<ix:nonFraction id="fid_506" contextRef="From2023-10-01to2024-03-31_cvm_ConsultingAgreementsMember" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.61</ix:nonFraction> issued to a consultant expired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the six months ended March 31, 2024 and 2023, the Company recorded total expense of approximately $<ix:nonFraction id="fid_365" contextRef="From2023-10-01to2024-03-31_cvm_ConsultingAgreementsMember" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">370,000</ix:nonFraction> and $<ix:nonFraction id="fid_502" contextRef="From2022-10-01to2023-03-31_cvm_ConsultingAgreementsMember" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">285,000</ix:nonFraction>, respectively, relating to the share-based compensation under various consulting agreements. During the three months ended March 31, 2024 and 2023, the Company recorded total expense of approximately $<ix:nonFraction id="fid_503" contextRef="From2024-01-01to2024-03-31_cvm_ConsultingAgreementsMember" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,000</ix:nonFraction> and $<ix:nonFraction id="fid_504" contextRef="From2023-01-01to2023-03-31_cvm_ConsultingAgreementsMember" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,000</ix:nonFraction>, respectively, relating to the share-based compensation under these consulting agreements. On March 31, 2024 and September 30, 2023, consulting fees of approximately $<ix:nonFraction id="fid_367" contextRef="AsOf2024-03-31_cvm_ConsultingAgreementsMember" name="cvm:ConsultingFeesIncluedPrepaidExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">351,000</ix:nonFraction> and $<ix:nonFraction id="fid_353" contextRef="AsOf2023-09-30_cvm_ConsultingAgreementsMember" name="cvm:ConsultingFeesIncluedPrepaidExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">205,000</ix:nonFraction>, respectively, are included in current assets as prepaid expenses and will be amortized over the remaining service periods. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_246" contextRef="From2023-10-01to2024-03-31" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">D. <span style="text-decoration:underline">RELATED PARTY TRANSACTIONS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the six and three months ended March 31, 2024, no restricted shares of the Company&#8217;s common stock were purchased by related parties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024 (Note C). The incremental cost of this extension was approximately $<ix:nonFraction id="fid_379" contextRef="From2023-10-01to2023-10-28" name="cvm:IncrementalCostDeemedDividend" format="ixt:numdotdecimal" decimals="0" unitRef="USD">172,000</ix:nonFraction>, which was recorded as a deemed dividend. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_247" contextRef="From2023-10-01to2024-03-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="cont_c29046"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E. <span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Clinical Research Agreement</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:right;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $<ix:nonFraction id="fid_472" contextRef="From2023-10-01to2024-03-31_cvm_ErgomedMember" name="cvm:ClinicalServiceTrial" format="ixt:numdotdecimal" decimals="-6" unitRef="USD" scale="6">12</ix:nonFraction> million towards the Company&#8217;s Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808, <em>Collaborative Arrangements</em>. The Company determined the payments to Ergomed are within the scope of ASC 730, <em>Research and Development</em>. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its statements of operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $<ix:nonFraction id="fid_469" contextRef="From2023-10-01to2024-03-31" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="-4" unitRef="USD" scale="5">35.8</ix:nonFraction> million for Ergomed&#8217;s services. This amount is net of Ergomed&#8217;s discount of approximately $<ix:nonFraction id="fid_456" contextRef="From2023-10-01to2024-03-31" name="cvm:NetOfDiscount" format="ixt:numdotdecimal" decimals="-4" unitRef="USD" scale="5">11.9</ix:nonFraction> million. During the six months ended March 31, 2024 and 2023, the Company recorded, net of Ergomed&#8217;s discount, approximately $<ix:nonFraction id="fid_479" contextRef="From2024-01-01to2024-03-31_cvm_ErgomedMember" name="us-gaap:OtherResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.1</ix:nonFraction> million for each quarter as research and development expense related to Ergomed&#8217;s services. During the three months ended March 31, 2024 and 2023, the Company recorded, net of Ergomed&#8217;s discount, less than $<ix:nonFraction id="fid_480" contextRef="From2024-01-01to2024-03-31_cvm_ErgomedMember" name="cvm:NetOfDiscount" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.1</ix:nonFraction> million for each quarter as research and development expense related to Ergomed&#8217;s services.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_c29046" continuedAt="cont_650487"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Lease Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase 3 clinical trial and sales of the drug if approved by any regulatory agency. The lease is for a term of twenty years and requires annual base rent to escalate each year at <ix:nonFraction id="fid_466" contextRef="AsOf2023-12-31" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" decimals="INF" unitRef="Pure" scale="-2">3</ix:nonFraction>%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The San Tomas lease is classified as a finance lease on the Company&#8217;s balance sheet, as well as several other smaller finance leases for office equipment. The finance right of use assets are being depreciated using the straight-line method over the underlying lease terms. Total cash paid related to finance leases during the six months ended March 31, 2024 and 2023 was approximately $<ix:nonFraction id="fid_458" contextRef="From2023-10-01to2024-03-31" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">1.3</ix:nonFraction> million for both periods, of which approximately $<ix:nonFraction id="fid_459" contextRef="From2023-10-01to2024-03-31" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.5</ix:nonFraction> and $<ix:nonFraction id="fid_486" contextRef="From2022-10-01to2023-03-31" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.6</ix:nonFraction> million was for interest, respectively, in each six-month period. As of March 31, 2024, the weighted average discount rate of the Company&#8217;s finance leases is <ix:nonFraction id="fid_484" contextRef="AsOf2024-03-31" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" decimals="INF" unitRef="Pure" scale="-2">8.46</ix:nonFraction>% and the weighted average time to maturity is <ix:nonNumeric id="fid_461" contextRef="From2023-10-01to2024-03-31" name="cvm:FinanceLeaseWeightedAverageRemainingLeaseTermOne" format="ixt-sec:duryear">4.59</ix:nonNumeric> years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On January 11, 2023, the Company was required to deposit approximately $<ix:nonFraction id="fid_473" contextRef="From2023-01-01to2023-01-11_cvm_LandlordMember" name="cvm:FinancingArrangementDepositBaseRentAmount" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">2.3</ix:nonFraction> million to its landlord, equivalent to one year&#8217;s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Approximate future minimum lease payments under finance leases as of March 31, 2024 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_270" contextRef="From2023-10-01to2024-03-31" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" escape="true" continuedAt="cont_54a23e"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Six months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_432" contextRef="AsOf2024-03-31" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,333,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_433" contextRef="AsOf2024-03-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,747,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_434" contextRef="AsOf2024-03-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,838,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_435" contextRef="AsOf2024-03-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,929,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_436" contextRef="AsOf2024-03-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,021,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_437" contextRef="AsOf2024-03-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">255,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_439" contextRef="AsOf2024-03-31" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,123,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_440" contextRef="AsOf2024-03-31" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,247,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of financing lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_441" contextRef="AsOf2024-03-31" name="us-gaap:FinanceLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,876,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of financing lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_442" contextRef="AsOf2024-03-31" name="cvm:FinanceLeaseLiabilityCurrentPortion" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,889,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of financing lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_443" contextRef="AsOf2024-03-31" name="cvm:FinanceLeaseLiabilityNoncurrentPortion" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,987,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases two facilities under operating leases. The lease for the Company&#8217;s office headquarters will expire on November 30, 2025.&#160; The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on February 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. The Company incurred lease expense for operating leases of approximately $<ix:nonFraction id="fid_463" contextRef="From2023-10-01to2024-03-31" name="us-gaap:OperatingLeaseExpense" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.2</ix:nonFraction> million for both the six months ended March 31, 2024 and 2023. Total cash paid related to operating leases during the six months ended March 31, 2024 and 2023 was approximately $<ix:nonFraction id="fid_465" contextRef="From2023-10-01to2024-03-31" name="us-gaap:OperatingLeasePaymentsUse" format="ixt:numdotdecimal" decimals="-5" unitRef="USD" scale="6">0.2</ix:nonFraction> million for each period. The weighted average discount rate of the Company&#8217;s operating leases is <ix:nonFraction id="fid_505" contextRef="AsOf2024-03-31" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" decimals="INF" unitRef="Pure" scale="-2">9.03</ix:nonFraction>% and the weighted average time to maturity is <ix:nonNumeric id="fid_467" contextRef="From2023-10-01to2024-03-31" name="cvm:OperatingLeaseWeightedAverageRemainingLeaseTermOne" format="ixt-sec:duryear">7.35</ix:nonNumeric> years. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_650487"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of March 31, 2024, approximate future minimum lease payments under operating leases are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_54a23e"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Six months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_444" contextRef="AsOf2024-03-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_445" contextRef="AsOf2024-03-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">366,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_446" contextRef="AsOf2024-03-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_447" contextRef="AsOf2024-03-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">277,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_448" contextRef="AsOf2024-03-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">285,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_449" contextRef="AsOf2024-03-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_450" contextRef="AsOf2024-03-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">746,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_451" contextRef="AsOf2024-03-31" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,435,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_452" contextRef="AsOf2024-03-31" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">680,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_453" contextRef="AsOf2024-03-31" name="us-gaap:OperatingLeaseLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,755,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of operating lease obligations - current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_454" contextRef="AsOf2024-03-31" name="cvm:OperatingLeaseLiabilityCurrentPortion" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_455" contextRef="AsOf2024-03-31" name="cvm:OperatingLeaseLiabilityNoncurrentPortion" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,544,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:continuation></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_248" contextRef="From2023-10-01to2024-03-31" name="us-gaap:IntangibleAssetsDisclosureTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">G. <span style="text-decoration:underline">PATENTS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the six and three months ended March 31, 2024 and 2023, there was no impairment of patent costs. The weighted average amortization period for patents&#160;is approximately&#160;<ix:nonNumeric id="fid_424" contextRef="From2023-10-01to2024-03-31" name="cvm:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" format="ixt-sec:duryear">8</ix:nonNumeric>&#160;years. For the six months ended March 31, 2024 and 2023, amortization of patent costs totaled approximately $<ix:nonFraction id="fid_422" contextRef="From2023-10-01to2024-03-31" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,000</ix:nonFraction> and $<ix:nonFraction id="fid_426" contextRef="From2022-10-01to2023-03-31" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction>, respectively. For the three months ended March 31, 2024 and 2023, amortization of patent costs totaled approximately $<ix:nonFraction id="fid_430" contextRef="From2024-01-01to2024-03-31" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction>&#160;and $<ix:nonFraction id="fid_431" contextRef="From2023-01-01to2023-03-31" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction>, respectively. The total estimated future amortization is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_271" contextRef="From2023-10-01to2024-03-31" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Six months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_412" contextRef="AsOf2024-03-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_413" contextRef="AsOf2024-03-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_414" contextRef="AsOf2024-03-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_415" contextRef="AsOf2024-03-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_416" contextRef="AsOf2024-03-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_417" contextRef="AsOf2024-03-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_418" contextRef="AsOf2024-03-31" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_419" contextRef="AsOf2024-03-31" name="us-gaap:OtherIndefiniteLivedIntangibleAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_249" contextRef="From2023-10-01to2024-03-31" name="us-gaap:EarningsPerShareTextBlock" escape="true" continuedAt="cont_37cc54"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">H. <span style="text-decoration:underline">LOSS PER COMMON SHARE</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, common stock warrants and unvested restricted stock are not included in the computation of diluted net loss per share if their effect would be anti-dilutive.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_37cc54"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table provides a reconciliation of the numerators and denominators of the basic and diluted loss per-share computations:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_272" contextRef="From2023-10-01to2024-03-31" name="cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Six Months</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net loss available to common &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_390" contextRef="From2023-10-01to2024-03-31" name="cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">13,954,415</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_403" contextRef="From2022-10-01to2023-03-31" name="cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">16,367,870</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_406" contextRef="From2024-01-01to2024-03-31" name="cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,244,891</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_407" contextRef="From2023-01-01to2023-03-31" name="cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,342,809</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_392" contextRef="From2023-10-01to2024-03-31" name="cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">50,228,860</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_404" contextRef="From2022-10-01to2023-03-31" name="cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">43,513,571</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_408" contextRef="From2024-01-01to2024-03-31" name="cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">52,006,442</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,588,381</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_394" contextRef="From2023-10-01to2024-03-31" name="cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.28</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_405" contextRef="From2022-10-01to2023-03-31" name="cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.38</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_409" contextRef="From2024-01-01to2024-03-31" name="cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.14</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_411" contextRef="From2023-01-01to2023-03-31" name="cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares" sign="-">0.19</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with the contingently issuable shares guidance of ASC 260, <em>Earnings Per Share</em>, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of March 31:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_273" contextRef="From2023-10-01to2024-03-31" name="cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_396" contextRef="From2023-10-01to2024-03-31_cvm_OptionsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,772,993</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_397" contextRef="From2022-10-01to2023-03-31_cvm_OptionsMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">13,893,248</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_398" contextRef="From2023-10-01to2024-03-31_cvm_UnvestedRestrictedStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">147,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_399" contextRef="From2022-10-01to2023-03-31_cvm_UnvestedRestrictedStockMember" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">149,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_401" contextRef="From2023-10-01to2024-03-31" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">15,920,243</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_402" contextRef="From2022-10-01to2023-03-31" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">14,042,498</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_250" contextRef="From2023-10-01to2024-03-31" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">J. <span style="text-decoration:underline">SUBSEQUENT EVENTS</span> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 4, 2024, the Company extended for two years the expiration date of <ix:nonFraction id="fid_639" contextRef="AsOf2024-05-08_us-gaap_SubsequentEventMember" name="us-gaap:ClassOfWarrantOrRightUnissued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,092,470</ix:nonFraction> outstanding warrants.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 8, 2024, officers and directors purchased <ix:nonFraction id="fid_387" contextRef="AsOf2024-05-08_us-gaap_SubsequentEventMember" name="cvm:RestrictedCommonStock" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">58,000</ix:nonFraction> shares of restricted common stock from the Company at an aggregate fair market value of $<ix:nonFraction id="fid_385" contextRef="AsOf2024-05-08_us-gaap_SubsequentEventMember" name="us-gaap:SecurityOwnedNotReadilyMarketableFairValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,620</ix:nonFraction>.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i2">Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Company Overview</span>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body&#8217;s natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">1)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates under development for the potential treatment of rheumatoid arthritis.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this report as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review under the Company&#8217;s future anticipated regulatory submission for approval. None of the Company&#8217;s product candidates have been approved for sale, barter or exchange by the Food and Drug Administration (FDA) or any other regulatory agency for any use to treat disease in humans nor has the safety or efficacy of these products been established for any use. There can be no assurance that obtaining marketing approval from the FDA in the United States and by comparable agencies in most foreign countries will be granted.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">MULTIKINE AND THE PHASE III CLINICAL TRIAL RESULTS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Immunotherapy is a large, high growth market.</span></strong> Immunotherapies use the patient&#8217;s own immune system to fight disease. These &#8220;targeted therapies&#8221; are at the forefront of modern cancer research. A recent Bloomberg report from January 2023 asserted that:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;">The global cancer immunotherapy market is expected to reach USD $196.45 billion by 2030, registering CAGR of 7.2% during the forecast period, according to a new report by Grand View Research, Inc. The rising adoption of immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period. Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth. (<span style="text-decoration:underline">https://www.bloomberg.com/press-releases/2023-01-18/cancer-immunotherapy-market-worth-196-45-billion-by-2030-grand-view-research-inc</span>)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI hopes to participate in this growing market with its lead investigational therapy Multikine&#174; (Leukocyte Interleukin, Injection). Multikine has already been tested in approximately 750 human patients in multiple clinical trials, including a well-controlled, multicenter, global, 928 patient Phase III randomized controlled trial. Multikine is unique among approved cancer immunotherapies because it is <em><span style="text-decoration:underline">given first</span></em><span style="text-decoration:underline">, right after diagnosis and before surgery</span>. CEL-SCI believes that the Phase III clinical trial demonstrated that Multikine caused tumors to reduce in size and/or caused the disease to &#8220;downstage&#8221; within just a few weeks of treatment before surgery. Importantly, patients with these reductions and/or downstages had their <em><span style="text-decoration:underline">risk of death cut in half at five years</span></em> of follow up. CEL-SCI is in discussions with regulators about the design of a confirmatory trial focused on the patients selected as the best responding patients in the prior study. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">What is Multikine and who is it for?</span></strong> Multikine is a biological medicinal immunotherapy comprised of a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment <em><span style="text-decoration:underline">before</span></em> the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikine&#8217;s rationale for use is to incite a locoregional immune response against the tumor before the local immune system has been compromised by the standard of care and/or disease progression.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Multikine target population is treatment-na&#239;ve adult patients with resectable locally advanced primary squamous cell carcinoma of the head and neck (SCCHN) in the oral cavity and who have:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>No lymph node involvement</strong> (via PET scan)</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>Low PD-L1 tumor expression</strong> (TPS&lt;10) (via biopsy)</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">PD-L1 is a protein receptor on the tumor surface that helps the tumor repel the immune system. CEL-SCI believes that patients with tumors having low PD-L1 would be more likely to respond to Multikine because their tumors have lower defenses against the patient&#8217;s immune system. CEL-SCI estimates that patients with tumors having low PD-L1 represent about 70% of locally advanced primary SCCHN patients.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Multikine leads to longer survival with no safety issues.</span></strong> Clinical investigations of Multikine have demonstrated in the randomized controlled Phase III trial (RCT) the following in the target population:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong><em><span style="text-decoration:underline">risk of death cut in half at five years</span></em></strong><strong><em> </em></strong>versus the control;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">28.6% absolute 5-year overall survival benefit versus control (p=0.0015);</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">0.349 hazard ratio vs control (95% CIs [0.18, 0.66], Wald p=0.0012);</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">&gt;35% rate of pre-surgery reductions and/or downstages (p&lt;0.01); and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">low PD-L1 tumor expression (vs high PD-L1 where Keytruda and Opdivo work best).</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There were no demonstrable safety signals or toxicities observed in approximately 750 Multikine-treated subjects across multiple clinical trials. Adverse event (AE) and serious adverse event (SAE) incidences were not significantly different among treatment and control groups. There were no Multikine-related deaths and only two discontinuations. Multikine-related AEs before surgery were local and resolved after surgery. Although the literature reports that some of Multikine&#8217;s components may be toxic when administered systemically (e.g., TNF&#945;, IFN &#947;, IL-1&#946;), these toxicities did not emerge with Multikine, even at doses many times higher than those administered in the Phase III trial, primarily due to Multikine&#8217;s delivery by local injection and dosage.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI published its data as abstracts and posters at the annual conferences for the 2022 American Society of Clinical Oncology (ASCO), 2022 and 2023 European Society for Medical Oncology (ESMO), and the 2023 European Head and Neck Society&#8217;s (EHNS&#8217;s) annual European Conference On Head And Neck Oncology (ECHNO) and the 2023 European Society for Therapeutic Radiology and Oncology (ESTRO) and 2023 American Head and Neck Society (AHNS). These publications can be accessed at <span style="text-decoration:underline">http://www.cel-sci.com</span>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Multikine</span></strong><strong><span style="text-decoration:underline"> works by inducing pre-surgical responses.</span></strong> CEL-SCI observed statistically significant pre-surgical responses after Multikine treatment, and therefore CEL-SCI believes in the following: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Multikine causes pre-surgical responses;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Pre-surgical responses lead to longer life;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#10146;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Therefore, selecting more patients predicted to have a pre-surgical response should lead to much better survival in the target population.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A &#8220;pre-surgical response&#8221; is a significant change in disease before surgery. CEL-SCI saw two kinds of responses in the Phase III trial. First, there were &#8220;reductions&#8221; in the size of the tumor&#8212;a reduction of 30% or more qualified as a &#8220;pre-surgical reduction&#8221; or &#8220;PSR&#8221; for short. Second, there were disease &#8220;downstages,&#8221; (e.g., the disease improved from Stage IV to Stage III) pre-surgery. CEL-SCI calls this a &#8220;pre-surgical downstaging&#8221; or &#8220;PSD&#8221; for short. CEL-SCI&#8217;s 2022 ESMO cancer conference presentation reported on PSR, and CEL-SCI&#8217;s new 2023 ESMO presentation reported on PSD.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Across the whole Phase III trial, PSRs were seen in 8.5% of Multikine patients compared to <em><span style="text-decoration:underline">none</span><strong> </strong></em>in the control group. PSDs were seen in 22% of Multikine patients as compared to 13% in the control group. Because Multikine was the only therapy given to these patients before surgery, it is CEL-SCI&#8217;s strong belief that Multikine had to be the cause of the higher rates of PSR and PSD.&#160; These data are presented visually below. The taller blue columns show PSR and PSD rates in all 529 Multikine-treated patients in the Phase III trial, and the gray columns show PSR and PSD rates for all 394 control patients. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg8.jpg" alt="cvm_10qimg8.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">It was not enough for us to show that Multikine likely leads to PSRs and PSDs as compared to a control group, CEL-SCI also had to test if PSRs and PSDs lead to improved survival. CEL-SCI&#8217;s Phase III trial demonstrated that PSR patients were 72% likely to be alive after five years, whereas control patients were only about 49% likely to be alive after five years. Patients with PSD saw similar improvement in CEL-SCI&#8217;s Phase III trial.&#160; Their five-year chance of survival was approximately 68%. Therefore, CEL-SCI believes that the Phase III trial demonstrated that those patients who had PSR or PSD resulting from Multikine lived longer than those who were not treated with Multikine. It is important to note that these results are from the entire Phase III study population, not from a subgroup. The likelihood of living at least five years is shown in the graphic below for patients with PSR (blue), patients with PSD (orange) and patients who did not receive Multikine (gray). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg9.jpg" alt="cvm_10qimg9.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">CEL-SCI&#8217;s target population</span></strong><strong><span style="text-decoration:underline"> as presented at ESMO in October 2023 can be readily selected by doctors upon diagnoses using standard tests.</span></strong><strong>&#160; </strong>Having shown a potential causal link supported by strong statistics between Multikine and survival benefit, CEL-SCI believes that Multikine should be approved quickly. But recall that the Phase III study&#8217;s primary endpoint of 10% survival benefit was not met. How then can we say that Multikine actually benefits patients? The answer is that while Multikine has shown that it can help patients with PSR/PSD, there were not enough PSR/PSD in the Phase III study population to yield a 10% survival benefit for the whole population. In other words, the benefits from PSR/PSD were too diluted when averaged with the other patients in the study. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None of this changes the fact that CEL-SCI observed statistical significance when analyzing Multikine&#8217;s ability to cause PSR/PSD and that these PSR/PSD statistically appear to lead to a higher chance of living five years or longer&#8212;CEL-SCI simply had to define a target population who would have a larger number of PSR/PSD. To do so, CEL-SCI analyzed Multikine&#8217;s biological mechanism of action, talked to regulators and physicians who knew best, and were guided by the Phase III data, including patient-specific data down to the cellular level. All this of course took time, but CEL-SCI believes it has succeeded and is ready to move forward.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">One of the first things we reported from the Phase III study was that Multikine was shown to work best in patients who were deemed &#8220;low risk&#8221; after surgery, about 40% of the study population. These patients saw a significant 14.1% absolute 5&#8209;year survival benefit vs the &#8220;low risk&#8221; control group not receiving Multikine. It made sense biologically that these patients would benefit most from Multikine, because they tended to have immune systems that were not yet compromised by the disease. &#8220;High risk&#8221; patients, by contrast, typically had lymph nodes invaded by the tumor, and needed chemotherapy after surgery. Because their lymph nodes were compromised, this made it harder for their immune systems to work, and they needed surgery as soon as possible without waiting an extra three weeks to receive Multikine. CEL-SCI initially developed criteria for selecting &#8220;low-risk&#8221; patients at diagnosis&#8212;i.e., those having no lymph nodes invaded by the tumor (N0) or only one lymph node invaded by the tumor (N1) as well as no extracapsular spread as determined by PET scan. CEL-SCI published these criteria at the ASCO conference in 2022. However, after discussions with regulators and physicians, CEL-SCI saw that outcomes could be improved further if the N1 patients were excluded, and only the N0 patients were included in the target population. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI also saw from the Phase III data that Multikine was more effective for patients with low PD-L1 tumor expression than for patients with high PD-L1 expression. This analysis was pre-specified in the statistical analysis plan. Targeting low PD-L1 also differentiates Multikine from other immunotherapies. For example, checkpoint inhibitors like Keytruda and Opdivo appear to best serve patients having high PD-L1, because these drugs work by blocking PD1/PD-L1 receptors interaction; when this interaction (PD1/PD-L1) happens it leads to inactivation/death of the immune cells attacking the tumor. While none of these drugs are currently approved as a first-line treatment before surgery, even if such approvals were to come in the future, the large majority of patients in this group having low PD-L1 would still be expected to need Multikine. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI&#8217;s target population is now directed to patients who present at diagnosis with N0 nodal involvement and also with low PD-L1 tumor expression (defined as tumor proportions score (TPS) &lt; 10). These patients can be readily identified&#160;upon diagnosis&#160;with tests that physicians routinely use in cancer screening, a crucial achievement towards Multikine becoming available for use. For instance, a PET scan should be used to determine the N0 nodal status and a screening biopsy should be used to determine the low PD-L1 expression. Doctors already routinely screen head and neck cancer patients using PET scans and biopsy. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg10.jpg" alt="cvm_10qimg10.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Multikine cut the 5-year risk of death in half in the target population.</span></strong><strong> </strong>CEL-SCI&#8217;s results show that Multikine can cut the risk of death in half at five<strong> </strong>years versus the control group in the finalized target population. Survival increased from 45% in the control group to 73% in the Multikine group, at five years. This means the risk of death fell to 27% in the Multikine group from 55% in the control, shown below.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg11.jpg" alt="cvm_10qimg11.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Another way to see the survival benefit of Multikine in the target population is the Kaplan-Meier curve from our ESMO &#8217;23 poster, shown below. On the vertical axis is the probability of survival and the horizontal axis is time in months. The blue Multikine line is far above the green control line, meaning the chance of survival is much higher in the Multikine group at every point in time compared to the control. These results had a low p-value of 0.0015, which is very significant as a statistical matter. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg12.jpg" alt="cvm_10qimg12.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI&#8217;s physician consultants tell CEL-SCI that the early separation of these two survival curves (e.g., at 12 months) adds validation to the potential positive effects of Multikine.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Another measure of survival benefit is called the &#8220;hazard ratio,&#8221; which compares the chances of dying between two different groups. Here, in the Multikine target population, the hazard ratio was 0.35, which means that deaths occurred in the Multikine group about one-third as frequently as in the control group. It is also important to note that the hazard ratio&#8217;s 95% confidence interval remained far below 1.0. In the case of Multikine, statistically speaking, there is a 95% chance that the hazard ratio would fall between 0.18 and 0.66 if Multikine were tested in the target population in another study. A hazard ratio of 0.66 as the &#8220;so called worst case scenario&#8221; is still below (better) than the hazard ratio required for most drug approvals. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These positive survival outcomes&#8212;increased overall survival, reduced risk of death, widely separated Kaplan-Meier curves with early separation, low hazard ratio, low p-values, low confidence intervals&#8212;CEL-SCI believes were driven by high PSR/PSD rates in the target population, as shown in the graphic below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg13.jpg" alt="cvm_10qimg13.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI relies on all of these data together to support its plan to request accelerated/conditional approval in the new target population without waiting until the completion of another clinical trial.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI&#8217;s regulatory strategy going forward is to seek approval of Multikine following full enrollment of its confirmatory study wherever possible. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">When the Phase III trial was designed, there was no evidentiary basis for excluding either of the low-risk or high-risk patient groups before surgery. Therefore, the study had to include a large percentage of high-risk patients with immune systems already compromised by disease. These subjects generally did not respond to Multikine. CEL-SCI has narrowed its target population as compared to the overall Phase III study population to focus on patients most likely to have PSR/PSD and to exclude the rest. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI acknowledges that efficacy in the target population has not been tested prospectively, but CEL-SCI believes that the data generated to date already presents a compelling patient need in the target population that justifies accelerated/conditional access to Multikine. This is why the conditional approval pathways were created in the first place. CEL-SCI intends to base its request for regulatory approval, in part, on its view that patients should not have to wait many more years before gaining access to the benefits of Multikine PSRs/PSDs and increased survival, particularly given Multikine&#8217;s safety profile and data that mechanistically and empirically supports the target population definition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The benefit-risk balance favoring immediate patient access to Multikine is described below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10qimg14.jpg" alt="cvm_10qimg14.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">An &#8220;unmet need&#8221; is a factor for approval considered by all major regulatory bodies worldwide. In the Multikine target population, there is also a tremendous unmet need for improved survival. The current standard of care provides only about a 50/50 chance of surviving five years, whereas Multikine could increase that survival rate to over 70% based on the Phase III data. Chemotherapy has improved outcomes for some head and neck patients, but chemotherapy is only indicated for high-risk patients, who are not likely to fall within the Multikine target population. Currently available immunotherapies are given after surgery or where surgery is not indicated, in contrast to Multikine, which is given before surgery to patients with resectable tumors. Available checkpoint inhibitors work best on tumors with high PD-L1 expression, whereas Multikine works best in tumors with low PD-L1 expression. Therefore, Multikine&#8217;s target population is underserved, and will continue to be underserved, by current therapies, but Multikine can meet the need for improved survival.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The major regulatory bodies with whom we are working, U.S. FDA, Health Canada, European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) all have conditional approval pathways designed for situations where the target population has not been fully tested prospectively and there is strong data supporting clinical benefit for patients. The reason is that regulators understand that in many cases patients should not have to wait for additional data before being offered the chance to benefit from a new drug. Every situation is different and depends on the specific facts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In May 2024, CEL-SCI announced that based on strong safety and efficacy data from CEL-SCI&#8217;s completed Phase 3 head and neck cancer study, the FDA indicated CEL-SCI may move forward with a confirmatory Registration Study of Multikine in newly diagnosed advanced primary head and neck cancer patients with no lymph node involvement (determined via PET scan) and with low PD-L1 tumor expression (determined via biopsy).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Through this discussion and agreement with the FDA, CEL-SCI has achieved a tremendous milestone for people who are newly diagnosed with head and neck cancer. The survival benefit was so strong and clear in the target patient population that the confirmatory study needs to enroll only 212 people to confirm what was already achieved in the Phase 3 study. This gives the company a clear path forward.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The FDA agreed to a 212-person confirmatory Registration Study based on the strength of the safety and survival benefit data in the selected target population from the prior 928-person Phase 3 study. The confirmatory study will be a randomized controlled trial with two arms: Multikine treatment plus standard of care versus standard of care alone. As presented at the ESMO cancer conference in October 2023, Multikine-treated patients in the selected group had a 73% 5-year survival vs a 45% 5-year survival in the control group who did not receive Multikine.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Generally, patient selection for different treatments in newly diagnosed head and neck cancer is done only after surgery. That presented CEL-SCI with a challenge, because Multikine has to be given before surgery. By analyzing Multikine's biological mechanism of action, as supported by the completed Phase 3 study, CEL-SCI developed criteria for selecting, before surgery, those patients who would have the best survival from Multikine. The FDA accepted the selection criteria and the proposed study design, which now permits CEL-SCI to enroll patients in the confirmatory study.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">CEL-SCI met a very high bar set by the FDA, which requires more stringent analysis for newly-diagnosed patients than for terminal cancer patients. One regulator called these newly-diagnosed cancer patients &#8220;much more delicate&#8221; and explained that the standard for permitting a new study with these patients has to be more stringent, since they are not all expected to die.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">CEL-SCI has been advised by statisticians and physicians that the confirmatory study has a high likelihood of success because a large survival benefit has already been demonstrated in the target population in the completed Phase 3 study. The much smaller confirmatory study&#8212;less than a quarter the size of the prior study&#8212;will focus on the patients who saw the greatest survival benefit when treated with Multikine.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">If approved as a pre-surgical treatment, Multikine should be added to the standard of care for the target population.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">The FDA also acknowledged in the meeting that there is a great unmet need in the target population for improved therapies. This is an important factor that weighs in favor of approval for Multikine.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">CEL-SCI believes that its de-risked value proposition for investors presents a unique opportunity to invest in a Phase 3 oncology company with a large body of data demonstrating not only tumor responses, but also long-term survival, in the target patient population. The goal of our smaller confirmatory study is to confirm these positive results in a prospectively defined target population.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Liquidity and Capital Resources</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since inception, the Company has financed its operations through the issuance of equity securities, convertible notes, loans and certain research grants. The Company will likely continue to generate net operating losses as it continues the development of Multikine and brings other drug candidates into clinical trials. Until such time as the Company becomes profitable, any or all of these financing vehicles or others may be utilized to assist the Company&#8217;s capital requirements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Capital raised by the Company has been expended primarily for patent applications, research and development, administrative costs, the construction and upgrade of the Company&#8217;s manufacturing and laboratory facilities and clinical trials. The Company does not anticipate realizing significant revenues until entering into licensing arrangements for its technology and know-how or until it receives regulatory approval to sell its products (which could take several years). Thus, the Company has been dependent upon the proceeds from the sale of its securities to meet all of the Company&#8217;s liquidity and capital requirements and anticipates having to do so in the future.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company will be required to raise additional capital or find additional long-term financing to continue with its research efforts. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. &#160;However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations. Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since the Company launched its Phase 3 clinical trial for Multikine, the Company has incurred expenses of approximately $64.6 million as of March 31, 2024 on direct costs for the Phase 3 clinical trial and the filing of the clinical study report to the FDA. The Company estimates it will incur additional expenses of approximately $0.6 million for the remainder of the Phase 3 clinical trial and the filing of the clinical study report to the FDA. It should be noted that this estimate is based only on the information currently available from the CROs responsible for managing the Phase 3 clinical trial and does not include other related costs, e.g., the manufacturing of the drug. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company uses two CROs to manage the global Phase 3 study; ICON and Ergomed, who are both international leaders in managing oncology trials. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under a co-development agreement, Ergomed agreed to contribute up to $12 million towards the study where it will perform clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specified maximum amount.&#160; Approximately $11.9 million of the committed $12 million contribution has been realized as of March 31, 2024. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the six months ended March 31, 2024, the Company&#8217;s cash increased by approximately $1.2 million.&#160;Significant components of this increase included net proceeds from the November 2023 and February 2024 financing of $11.5 million offset by cash used to fund the Company&#8217;s regular operations of approximately $9.4 million and approximately $0.9 million in payments on their finance lease obligations.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the six months ended March 31, 2023, the Company&#8217;s cash decreased by approximately $12.6 million.&#160; The significant component of this decrease included cash used to fund the Company&#8217;s regular operations of approximately $12.1 million, which includes the approximate&#160; $2.3 million deposit made to the Company&#8217;s landlord as a result of falling below certain cash requirements per the San Tomas lease.&#160; Other components of this decrease include approximately $0.2 million used to make leasehold improvements and acquire research and development equipment, and approximately $0.8 million in payments on the Company&#8217;s finance leases.&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the six months ended March 31, 2024, no warrants were exercised. During the six months ended March 31, 2023, 217,752 warrants were exercised at a weighted average exercise price of $2.05 for total proceeds of approximately $0.5 million. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Results of Operations and Financial Condition</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company incurred a net operating loss of approximately $13.6 million for the six months ended March 31, 2024. This net operating loss consists of significant non-cash expenses including approximately $3.2 million in share-based compensation to employees and non-employees, and approximately $2.0 million in depreciation and amortization expense.&#160; The Company incurred a net operating loss of approximately $7.1 million for the three months ended March 31, 2024.&#160; This net operating loss consists of significant non-cash expenses including approximately $1.6 million in share-based compensation to employees and non-employees, and approximately $1.0 million in depreciation and amortization expense.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the six months ended March 31, 2024, research and development expenses decreased by approximately $2.5 million, or 22%, compared to the six months ended March 31, 2023.&#160; Major components of this decrease include an approximately $0.2 million decrease in costs incurred to prepare for the potential commercial sale of Multikine, an approximately $1.6 million decrease in expenses related to the Phase 3 study, a decrease of approximately $0.6 million of employee stock compensation expense and an approximately $0.1 million decrease in other research and development costs. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended March 31, 2024, research and development expenses decreased by approximately $1.5 million, or 24%, compared to the three months ended March 31, 2023.&#160; Major components of this decrease include &#160;an approximately $1.0 million decrease in expenses related to the Phase 3 study, a decrease of approximately $0.4 million of employee stock compensation expense and an approximately $0.1 million decrease in other research and development costs. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the six months ended March 31, 2024, general and administrative expenses increased by approximately $0.2 million, or 5%, compared to the six months ended March 31, 2023. This increase is primarily due to an approximately $0.1 million increase in consulting fees and an increase of approximately $0.1 million in other general and administrative costs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended March 31, 2024, general and administrative expenses increased by approximately $0.4 million, or 17%, compared to the three months ended March 31, 2023. This increase is primarily due to an approximately $0.2 million increase in consulting fees, an increase of approximately $0.1 million of employee stock compensation expense related to the accelerated vesting of options for directors, and a net&#160; increase of approximately $0.1 million in other general and administrative expenses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the six months ended March 31, 2024, net interest expense increased by approximately $0.1 million compared to the six months ended March 31, 2023. While the amount of interest paid on the Company&#8217;s lease liabilities remained relatively constant at approximately $0.5 million for the six months ended March 31, 2024 and 2023, the Company earned approximately $0.1 million less in interest income during the six months ended March 31, 2024 compared to the six months ended March 31, 2023. Net interest expense, which consists primarily of interest paid on lease liabilities, remained relatively constant at approximately $0.2 million for the three months ended March 31, 2024 and March 31, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Research and Development Expenses</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s research and development efforts involve Multikine and LEAPS. The table below shows the research and development expenses associated with each project.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Six months ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three months ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">MULTIKINE</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,934,795</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,258,629</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,605,543</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,964,252</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">LEAPS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">46,249</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">217,405</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">22,992</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">119,236</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">TOTAL</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8,981,044</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">11,476,034</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,628,535</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6,083,488</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company&#8217;s clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all of the Company&#8217;s projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Critical Accounting Estimates </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management&#8217;s discussion and analysis of the Company&#8217;s financial condition and results of operations is based on its unaudited condensed financial statements. The preparation of these financial statements is based on the selection of accounting policies and the application of significant accounting estimates, some of which require management to make judgments, estimates and assumptions that affect the amounts reported in the financial statements and notes. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company believes some of the more critical estimates that affect its financial condition and results of operations are in the areas of leases and share-based compensation. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The measurement of the finance and operating lease right-of-use asset and lease liabilities requires the determination of an estimated lease term and an incremental borrowing rate, which involves complex judgment by management. Significant judgment is required by management to develop inputs and assumptions used to determine the incremental borrowing rate for lease contracts. &#160;The fair value of the stock options is calculated using the Black-Scholes option pricing model which requires various judgmental assumptions including volatility and expected option life. The compensation cost is recognized as expense over the requisite service or vesting period.&#160; Performance-based options are valued using a Monte-Carlo simulation model, which requires inputs based on estimates, including the likelihood of the occurrence of performance and market conditions, volatility and expected option life.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For more information regarding the Company&#8217;s critical accounting estimates, see Part II, Item&#160;7 of the Company&#8217;s Annual Report on Form 10-K for the year ended September 30, 2023. The application of these critical accounting estimates has been discussed with the Audit Committee of the Company&#8217;s Board of Directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i3">Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company does not believe that it has any significant exposure to market risk.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i4">Item 4.&#160; CONTROLS AND PROCEDURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Evaluation of Disclosure Controls and Procedures</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">Under the direction and with the participation of the Company&#8217;s management, including the Company&#8217;s Chief Executive Officer and Chief Financial Officer, the Company carried out an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of March 31, 2024. The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and regulations, and that such information is accumulated and communicated to the Company&#8217;s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. The Company&#8217;s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching its desired disclosure control objectives. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">The Company&#8217;s Chief Executive Officer and Chief Financial Officer has concluded that the Company&#8217;s disclosure controls and procedures were not effective as of March 31, 2024 due to the material weaknesses described in the Company's Annual Report on Form 10-K for the year ended September 30, 2023.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Changes in Internal Control over Financial Reporting</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There were no changes in the Company&#8217;s internal control over financial reporting that occurred during the three months ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="p2">PART II</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="ii2">Item 2.&#160; Unregistered Sales of Equity Securities and Use of Proceeds.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the six months ended March 31, 2024, the Company issued 251,317 restricted shares of common stock to consultants for investor relations services. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 with respect to the issuance of these shares. The individuals who acquired these shares were sophisticated investors and were provided full information regarding the Company&#8217;s business and operations. There was no general solicitation in connection with the offer or sale of these securities. The individuals who acquired these shares acquired them for their own accounts. The certificates representing these shares bear a restricted legend which provides they cannot be sold except pursuant to an effective registration statement or an exemption from registration. No commission or other form of remuneration was given to any person in connection with the issuance of these shares.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="ii5">Item 5.&#160; Other Information</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period ending March 31, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span class="atag" style="display: inline" id="ii6"><strong>Item 6.</strong> <strong>Exhibits</strong></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Number</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exhibit</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex31.htm">31</a></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex31.htm">Rule 13a-14(a) Certifications</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex32.htm">32</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="cvm_ex32.htm">Section 1350 Certifications</a></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">31</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="sig">SIGNATURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CEL-SCI CORPORATION</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:50%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:35%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Date: &#160;May 15, 2024 </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">By:&#160;&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/&#160; Geert Kersten</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert Kersten&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Principal Executive Officer*&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">* Also signing in the capacity of the Principal Accounting and Financial Officer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">32</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>2
<FILENAME>cvm_ex31.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>cvm_ex31.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXHIBIT 31</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><strong></strong> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATIONS</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Geert Kersten, certify that: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">c)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">d)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table>&nbsp; <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">May 15, 2024&nbsp;</p></td> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Geert Kersten</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Geert Kersten</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Principal Executive Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>CERTIFICATIONS</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Geert Kersten, certify that: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">c)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">d)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table>&nbsp; <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table>&nbsp; <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">May 15, 2024&nbsp;</p></td> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Geert Kersten</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Geert Kersten</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Principal Executive Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>3
<FILENAME>cvm_ex32.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>cvm_ex32.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXHIBIT 32</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In connection with the Quarterly Report of CEL-SCI Corporation (the &#8220;Company&#8221;) on Form 10-Q for the period ending March 31, 2024 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), Geert Kersten, the Principal Executive and Principal Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(1)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(2)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The information contained in the Report fairly presents, in all material respects, the financial condition and results of the Company.</p></td></tr></table>&nbsp; <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:3%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">/s/ Geert Kersten</p></td> <td style="width:12%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Geert Kersten</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Principal Executive and</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Principal Financial Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">May 15, 2024</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cvm-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/15/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:cvm="http://cvm.com/20240331" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cvm.com/20240331">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://cvm.com/role/Cover" id="Cover">
        <link:definition>000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedBalanceSheets" id="CondensedBalanceSheets">
        <link:definition>000002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" id="CondensedBalanceSheetsParenthetical">
        <link:definition>000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" id="CondensedStatementsOfOperationsUnaudited">
        <link:definition>000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" id="StatementsOfStockholdersEquityUnaudited">
        <link:definition>000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" id="CondensedStatementsOfCashFlowsUnaudited">
        <link:definition>000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LIQUIDITY" id="LIQUIDITY">
        <link:definition>000008 - Disclosure - LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>000009 - Disclosure - STOCKHOLDERS EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>000010 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>000011 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PATENTS" id="PATENTS">
        <link:definition>000012 - Disclosure - PATENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShare" id="LossPerCommonShare">
        <link:definition>000013 - Disclosure - LOSS PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>000014 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
        <link:definition>000016 - Disclosure - STOCKHOLDERS EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>000017 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsTables" id="PatentsTables">
        <link:definition>000018 - Disclosure - PATENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShareTables" id="LossPerCommonShareTables">
        <link:definition>000019 - Disclosure - LOSS PER COMMON SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
        <link:definition>000020 - Disclosure - STOCKHOLDERS EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
        <link:definition>000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
        <link:definition>000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails3" id="StockholdersEquityDetails3">
        <link:definition>000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetails4" id="StockholdersEquityDetails4">
        <link:definition>000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
        <link:definition>000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
        <link:definition>000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
        <link:definition>000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
        <link:definition>000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetails" id="PatentsDetails">
        <link:definition>000030 - Disclosure - PATENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetailsNarrative" id="PatentsDetailsNarrative">
        <link:definition>000031 - Disclosure - PATENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShareDetails" id="LossPerCommonShareDetails">
        <link:definition>000032 - Disclosure - LOSS PER COMMON SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LossPerCommonShareDetails1" id="LossPerCommonShareDetails1">
        <link:definition>000033 - Disclosure - LOSS PER COMMON SHARE (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
        <link:definition>000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <import namespace="http://fasb.org/srt-roles/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd" />
  <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <element id="cvm_SuppliesUsedForRDAndManufacturingCurrent" name="SuppliesUsedForRDAndManufacturingCurrent" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SuppliesUsedForRDAndManufacturingNonCurrent" name="SuppliesUsedForRDAndManufacturingNonCurrent" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_DueToEmployeeCurrent" name="DueToEmployeeCurrent" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ModificationOfWarrants" name="ModificationOfWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EarningPerShareBasicAndDiluted" name="EarningPerShareBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" name="WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantExercisesShares" name="WarrantExercisesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantExercisesAmount" name="WarrantExercisesAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncentiveStockForfeitedShares" name="IncentiveStockForfeitedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncentiveStockForfeitedAmount" name="IncentiveStockForfeitedAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ShareIssuanceCosts" name="ShareIssuanceCosts" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CommonStockContributedToEmployeeBenefitPlan" name="CommonStockContributedToEmployeeBenefitPlan" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncreaseDecreaseInDepositAssets" name="IncreaseDecreaseInDepositAssets" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" name="PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AssetsPurchasedUnderFinanceLeases" name="AssetsPurchasedUnderFinanceLeases" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseObligationIncludedInAccountsPayable" name="FinanceLeaseObligationIncludedInAccountsPayable" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ConsultingServicesPaidWithIssuanceOfCommonStock" name="ConsultingServicesPaidWithIssuanceOfCommonStock" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AccruedConsultingServicesToBePaidWithCommonStock" name="AccruedConsultingServicesToBePaidWithCommonStock" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinancingCostsIncludedInCurrentLiabilities" name="FinancingCostsIncludedInCurrentLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LiquidityDisclosureTextBlock" name="LiquidityDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LeasesPolicyTextBlock" name="LeasesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" name="ImpairmentOfLongLivedAssetsPolicyTextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" name="NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfStockOptionActivityTableTextBlock" name="ScheduleOfStockOptionActivityTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfCompensatingBalancesTableTextBlock" name="ScheduleOfCompensatingBalancesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" name="ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock" name="ScheduleOfDerivativeLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" name="ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" name="ScheduleOfAntiDilutiveSecuritiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IssueDate1" name="IssueDate1" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SharesIssuableUponExerciseOfWarrantOptions" name="SharesIssuableUponExerciseOfWarrantOptions" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExpirationDate" name="ExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EquityWarrantsExercised" name="EquityWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EquityWarrantsExercisePrice" name="EquityWarrantsExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedsFromEquityWarrantsExercised" name="ProceedsFromEquityWarrantsExercised" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncrementalCostDeemedDividend" name="IncrementalCostDeemedDividend" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ConsultingFeesIncluedPrepaidExpenses" name="ConsultingFeesIncluedPrepaidExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetofissuanceCosts" name="NetofissuanceCosts" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseLiabilityCurrentPortion" name="FinanceLeaseLiabilityCurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseLiabilityNoncurrentPortion" name="FinanceLeaseLiabilityNoncurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OperatingLeaseLiabilityCurrentPortion" name="OperatingLeaseLiabilityCurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OperatingLeaseLiabilityNoncurrentPortion" name="OperatingLeaseLiabilityNoncurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetOfDiscount" name="NetOfDiscount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne" name="FinanceLeaseWeightedAverageRemainingLeaseTermOne" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne" name="OperatingLeaseWeightedAverageRemainingLeaseTermOne" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ClinicalServiceTrial" name="ClinicalServiceTrial" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinancingArrangementDepositBaseRentAmount" name="FinancingArrangementDepositBaseRentAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" name="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" name="NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" name="WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" name="IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_RestrictedCommonStock" name="RestrictedCommonStock" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LIQUIDITYAbstract" name="LIQUIDITYAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CommitmentsAndContingenciesAbstract" name="CommitmentsAndContingenciesAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element name="NonQualifiedStockOptionsPlansMember" id="cvm_NonQualifiedStockOptionsPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockBonusPlansMember" id="cvm_StockBonusPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="IncentiveStockBonusPlansMember" id="cvm_IncentiveStockBonusPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNMember" id="cvm_SeriesNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesUUMember" id="cvm_SeriesUUMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesXMember" id="cvm_SeriesXMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesYMember" id="cvm_SeriesYMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesMMMember" id="cvm_SeriesMMMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNNMember" id="cvm_SeriesNNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesRRMember" id="cvm_SeriesRRMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultantsMember" id="cvm_ConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultantsOptionMember" id="cvm_ConsultantsOptionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesSSMember" id="cvm_SeriesSSMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RestrictedStocksMember" id="cvm_RestrictedStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultingAgreementsMember" id="cvm_ConsultingAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OptionsMember" id="cvm_OptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="UnvestedRestrictedStockMember" id="cvm_UnvestedRestrictedStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ErgomedMember" id="cvm_ErgomedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="LandlordMember" id="cvm_LandlordMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NonEmployeesMember" id="cvm_NonEmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>cvm-20240331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/15/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_782496" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_782496" xml:lang="en-US">CONDENSED BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl_24d5cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl_24d5cb" xml:lang="en-US">Current assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_257aa0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_257aa0" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl_7e54f2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl_7e54f2" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SuppliesUsedForRDAndManufacturingCurrent" xlink:label="cvm_SuppliesUsedForRDAndManufacturingCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SuppliesUsedForRDAndManufacturingCurrent" xlink:to="cvm_SuppliesUsedForRDAndManufacturingCurrent_lbl_cdd175" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SuppliesUsedForRDAndManufacturingCurrent_lbl_cdd175" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl_d84bb8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl_d84bb8" xml:lang="en-US">Deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_ae1173" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_ae1173" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_7" xml:lang="en-US">[Assets, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl_351145" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl_351145" xml:lang="en-US">Finance lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_9089d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_9089d7" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_121ba9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_121ba9" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_31a8ca" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_31a8ca" xml:lang="en-US">Patent costs, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets_lbl_27411c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepositsAssets_lbl_27411c" xml:lang="en-US">Deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssets_lbl_12" xml:lang="en-US">[Deposits Assets]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:to="cvm_SuppliesUsedForRDAndManufacturingNonCurrent_lbl_67758f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_SuppliesUsedForRDAndManufacturingNonCurrent_lbl_67758f" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:label="cvm_SuppliesUsedForRDAndManufacturingNonCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:to="cvm_SuppliesUsedForRDAndManufacturingNonCurrent_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SuppliesUsedForRDAndManufacturingNonCurrent_lbl_13" xml:lang="en-US">[Supplies used for R&amp;D and manufacturing]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_103731" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl_103731" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl_14" xml:lang="en-US">[Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_0cb257" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_0cb257" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl_dbff3f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl_dbff3f" xml:lang="en-US">Current liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl_0dd84f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl_0dd84f" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_ba8d02" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_ba8d02" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_DueToEmployeeCurrent" xlink:label="cvm_DueToEmployeeCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_DueToEmployeeCurrent" xlink:to="cvm_DueToEmployeeCurrent_lbl_1e7bec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_DueToEmployeeCurrent_lbl_1e7bec" xml:lang="en-US">Due to employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl_5d3322" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl_5d3322" xml:lang="en-US">Finance lease obligation, current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_041a0e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_041a0e" xml:lang="en-US">Operating lease obligation, current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_320086" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_320086" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_22" xml:lang="en-US">[Liabilities, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_e3a7bd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_e3a7bd" xml:lang="en-US">Finance lease obligations, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_f8ee5b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_f8ee5b" xml:lang="en-US">Operating lease obligations, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl_11cbc2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl_11cbc2" xml:lang="en-US">Other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_3a85eb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl_3a85eb" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl_26" xml:lang="en-US">[Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_65520f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_65520f" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl_5a3396" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl_5a3396" xml:lang="en-US">Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_c3ee52" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_c3ee52" xml:lang="en-US">Common stock, $.01 par value; 600,000,000 shares authorized; 54,083,718 and 47,422,304 shares issued and outstanding at March 31, 2024 and September 30, 2023, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl_dd3f46" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl_dd3f46" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_ad62b4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_ad62b4" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_0b726b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl_0b726b" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_32" xml:lang="en-US">[Stockholders' Equity Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_2a26e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_2a26e8" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_33" xml:lang="en-US">[Liabilities and Equity]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_22fe1b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_22fe1b" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_130cc2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_130cc2" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_76b576" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_76b576" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_040d1b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_040d1b" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_46f8d0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_46f8d0" xml:lang="en-US">Common stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_fc65ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_fc65ff" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_c72bce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_c72bce" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_cacc5f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_cacc5f" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_ecf4ec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_ecf4ec" xml:lang="en-US">CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_327135" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_327135" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl_03b101" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl_03b101" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_fdf4ab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl_fdf4ab" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl_4" xml:lang="en-US">[Operating Expenses]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_c6b1b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_c6b1b0" xml:lang="en-US">Operating loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_5" xml:lang="en-US">[Operating Income (Loss)]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl_742665" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl_742665" xml:lang="en-US">Interest expense, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl_6" xml:lang="en-US">[Interest Income (Expense), Net]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl_35392b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl_35392b" xml:lang="en-US">Other expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl_7" xml:lang="en-US">[Other Nonoperating Expense]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_500210" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_500210" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_8" xml:lang="en-US">[Net Income (Loss) Attributable to Parent]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ModificationOfWarrants" xlink:label="cvm_ModificationOfWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ModificationOfWarrants" xlink:to="cvm_ModificationOfWarrants_lbl_82454b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ModificationOfWarrants_lbl_82454b" xml:lang="en-US">Modification of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_0ebffd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_0ebffd" xml:lang="en-US">Net loss available to common shareholders</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl_10" xml:lang="en-US">[Net Income (Loss) Available to Common Stockholders, Basic]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_EarningPerShareBasicAndDiluted" xlink:label="cvm_EarningPerShareBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EarningPerShareBasicAndDiluted" xlink:to="cvm_EarningPerShareBasicAndDiluted_lbl_2b382a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EarningPerShareBasicAndDiluted_lbl_2b382a" xml:lang="en-US">Net loss per common share - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" xlink:label="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" xlink:to="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted_lbl_bd70d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted_lbl_bd70d6" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_4d376c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_4d376c" xml:lang="en-US">STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_f25d51" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_f25d51" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_3be82f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_3be82f" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_b67252" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_b67252" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl_0b7973" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl_0b7973" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_1facf0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_1facf0" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_32062d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_32062d" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_27841c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_27841c" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_250136" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl_250136" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_WarrantExercisesShares" xlink:label="cvm_WarrantExercisesShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantExercisesShares" xlink:to="cvm_WarrantExercisesShares_lbl_25ac1e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantExercisesShares_lbl_25ac1e" xml:lang="en-US">Warrant exercises, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_WarrantExercisesAmount" xlink:label="cvm_WarrantExercisesAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantExercisesAmount" xlink:to="cvm_WarrantExercisesAmount_lbl_2d05be" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantExercisesAmount_lbl_2d05be" xml:lang="en-US">Warrant exercises, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_6be3e6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_6be3e6" xml:lang="en-US">Equity based compensation - employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl_5144af" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl_5144af" xml:lang="en-US">401(k) contributions paid in common stock, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl_6ba046" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl_6ba046" xml:lang="en-US">401(k) contributions paid in common stock, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_60321d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_60321d" xml:lang="en-US">Stock issued to nonemployees for service, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_a03edf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_a03edf" xml:lang="en-US">Stock issued to nonemployees for service, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IncentiveStockForfeitedShares" xlink:label="cvm_IncentiveStockForfeitedShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockForfeitedShares" xlink:to="cvm_IncentiveStockForfeitedShares_lbl_cdf45c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockForfeitedShares_lbl_cdf45c" xml:lang="en-US">2014 incentive stock forfeited, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IncentiveStockForfeitedAmount" xlink:label="cvm_IncentiveStockForfeitedAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockForfeitedAmount" xlink:to="cvm_IncentiveStockForfeitedAmount_lbl_ffc43e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockForfeitedAmount_lbl_ffc43e" xml:lang="en-US">2014 incentive stock forfeited, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_78a437" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_78a437" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_e95961" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_e95961" xml:lang="en-US">Proceeds from the sale of common stock, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_3d4d01" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_3d4d01" xml:lang="en-US">Proceeds from the sale of common stock, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ShareIssuanceCosts" xlink:label="cvm_ShareIssuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ShareIssuanceCosts" xlink:to="cvm_ShareIssuanceCosts_lbl_387c02" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ShareIssuanceCosts_lbl_387c02" xml:lang="en-US">Share issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_5401ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_5401ea" xml:lang="en-US">Balance, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_ec8493" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl_ec8493" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_156f4c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_156f4c" xml:lang="en-US">CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_b74e55" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl_b74e55" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl_2" xml:lang="en-US">[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_bd4e9d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_bd4e9d" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl_d7028d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl_d7028d" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl_534a60" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl_534a60" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_16e2bd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_16e2bd" xml:lang="en-US">Share-based payments for services</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_8c17f3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl_8c17f3" xml:lang="en-US">Equity-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="cvm_CommonStockContributedToEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:to="cvm_CommonStockContributedToEmployeeBenefitPlan_lbl_913ade" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CommonStockContributedToEmployeeBenefitPlan_lbl_913ade" xml:lang="en-US">Common stock contributed to 401(k) plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl_a6f74e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl_a6f74e" xml:lang="en-US">(Increase)/decrease in assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_696bd7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_696bd7" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_10" xml:lang="en-US">[Increase (Decrease) in Prepaid Expense]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_0ddbc5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_0ddbc5" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_11" xml:lang="en-US">[Increase (Decrease) in Inventories]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncreaseDecreaseInDepositAssets" xlink:to="cvm_IncreaseDecreaseInDepositAssets_lbl_9a2f3d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_IncreaseDecreaseInDepositAssets_lbl_9a2f3d" xml:lang="en-US">Deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IncreaseDecreaseInDepositAssets" xlink:label="cvm_IncreaseDecreaseInDepositAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncreaseDecreaseInDepositAssets" xlink:to="cvm_IncreaseDecreaseInDepositAssets_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncreaseDecreaseInDepositAssets_lbl_12" xml:lang="en-US">[Deposits]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl_7a6572" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl_7a6572" xml:lang="en-US">Increase/(decrease) in liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_c9f7f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_c9f7f5" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_14" xml:lang="en-US">[Increase (Decrease) in Accounts Payable]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_5fdc75" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_5fdc75" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_15" xml:lang="en-US">[Increase (Decrease) in Accrued Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_edbb98" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_edbb98" xml:lang="en-US">Due to employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_16" xml:lang="en-US">[Increase (Decrease) in Employee Related Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_f1c852" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_f1c852" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_17" xml:lang="en-US">[Net Cash Provided by (Used in) Operating Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_e6c7d1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_e6c7d1" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_a629be" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_a629be" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_19" xml:lang="en-US">[Payments to Acquire Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_1e5e43" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_1e5e43" xml:lang="en-US">Expenditures for patent costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_20" xml:lang="en-US">[Payments to Acquire Intangible Assets]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_2967ca" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_2967ca" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_21" xml:lang="en-US">[Net Cash Provided by (Used in) Investing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_9d6654" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_9d6654" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_9643ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_9643ad" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl_da0962" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl_da0962" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl_24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl_24" xml:lang="en-US">[Payments of Stock Issuance Costs]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl_986bd8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl_986bd8" xml:lang="en-US">Proceeds from the exercise of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_8b01e1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_8b01e1" xml:lang="en-US">Payments on obligations under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_26" xml:lang="en-US">[Repayments of Debt and Lease Obligation]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_30474a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_30474a" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_27" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_06771d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_06771d" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_28" xml:lang="en-US">[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_9e1a75" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_9e1a75" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_ea0a68" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_ea0a68" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF PERIOD</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" xlink:label="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" xlink:to="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_lbl_d3a05a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_lbl_d3a05a" xml:lang="en-US">Property and equipment purchases included in current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_AssetsPurchasedUnderFinanceLeases" xlink:label="cvm_AssetsPurchasedUnderFinanceLeases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AssetsPurchasedUnderFinanceLeases" xlink:to="cvm_AssetsPurchasedUnderFinanceLeases_lbl_75f4f0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AssetsPurchasedUnderFinanceLeases_lbl_75f4f0" xml:lang="en-US">Assets purchased under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:label="cvm_FinanceLeaseObligationIncludedInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:to="cvm_FinanceLeaseObligationIncludedInAccountsPayable_lbl_20ae42" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseObligationIncludedInAccountsPayable_lbl_20ae42" xml:lang="en-US">Finance lease obligation included in accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ConsultingServicesPaidWithIssuanceOfCommonStock" xlink:label="cvm_ConsultingServicesPaidWithIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingServicesPaidWithIssuanceOfCommonStock" xlink:to="cvm_ConsultingServicesPaidWithIssuanceOfCommonStock_lbl_713ea2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingServicesPaidWithIssuanceOfCommonStock_lbl_713ea2" xml:lang="en-US">Consulting services paid with issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_AccruedConsultingServicesToBePaidWithCommonStock" xlink:label="cvm_AccruedConsultingServicesToBePaidWithCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AccruedConsultingServicesToBePaidWithCommonStock" xlink:to="cvm_AccruedConsultingServicesToBePaidWithCommonStock_lbl_8fbef2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AccruedConsultingServicesToBePaidWithCommonStock_lbl_8fbef2" xml:lang="en-US">Accrued consulting services to be paid with common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_FinancingCostsIncludedInCurrentLiabilities" xlink:label="cvm_FinancingCostsIncludedInCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinancingCostsIncludedInCurrentLiabilities" xlink:to="cvm_FinancingCostsIncludedInCurrentLiabilities_lbl_20912c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinancingCostsIncludedInCurrentLiabilities_lbl_20912c" xml:lang="en-US">Financing costs included in current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl_99208c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl_99208c" xml:lang="en-US">Cash paid for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_f56e71" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_f56e71" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_b82583" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_b82583" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_LIQUIDITYAbstract" xlink:label="cvm_LIQUIDITYAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LIQUIDITYAbstract" xlink:to="cvm_LIQUIDITYAbstract_lbl_5c47da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LIQUIDITYAbstract_lbl_5c47da" xml:lang="en-US">LIQUIDITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LiquidityDisclosureTextBlock" xlink:to="cvm_LiquidityDisclosureTextBlock_lbl_a2047b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_LiquidityDisclosureTextBlock_lbl_a2047b" xml:lang="en-US">LIQUIDITY</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_LiquidityDisclosureTextBlock" xlink:label="cvm_LiquidityDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LiquidityDisclosureTextBlock" xlink:to="cvm_LiquidityDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LiquidityDisclosureTextBlock_lbl_2" xml:lang="en-US">[LIQUIDITY]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl_9fbb30" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl_9fbb30" xml:lang="en-US">STOCKHOLDERS EQUITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_707ec9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_707ec9" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl_cc3497" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl_cc3497" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_e02570" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_e02570" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="cvm_CommitmentsAndContingenciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CommitmentsAndContingenciesAbstract" xlink:to="cvm_CommitmentsAndContingenciesAbstract_lbl_78869b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CommitmentsAndContingenciesAbstract_lbl_78869b" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_d92b19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_d92b19" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl_44e916" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl_44e916" xml:lang="en-US">PATENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_c11d54" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_c11d54" xml:lang="en-US">PATENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_2" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl_2299ae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl_2299ae" xml:lang="en-US">LOSS PER COMMON SHARE</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl_6b68de" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl_6b68de" xml:lang="en-US">LOSS PER COMMON SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl_2" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl_6a9b0d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl_6a9b0d" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_da5453" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_da5453" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_2" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl_0522a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl_0522a5" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_8056fd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_8056fd" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_83c15e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_83c15e" xml:lang="en-US">Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl_456514" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl_456514" xml:lang="en-US">Supplies used for R&amp;amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl_42d7a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl_42d7a4" xml:lang="en-US">Patents</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_LeasesPolicyTextBlock" xlink:label="cvm_LeasesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LeasesPolicyTextBlock" xlink:to="cvm_LeasesPolicyTextBlock_lbl_1dffc6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LeasesPolicyTextBlock_lbl_1dffc6" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_89d3f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_89d3f5" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_867381" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_867381" xml:lang="en-US">Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl_43e75b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl_43e75b" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl_3cb98e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl_3cb98e" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" xlink:label="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" xlink:to="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock_lbl_f15fe8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ImpairmentOfLongLivedAssetsPolicyTextblock_lbl_f15fe8" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl_ee7db1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl_ee7db1" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" xlink:label="cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" xlink:to="cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock_lbl_3fd17c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock_lbl_3fd17c" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_63373b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_63373b" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl_88468d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl_88468d" xml:lang="en-US">Schedule of equity compensation plans</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ScheduleOfStockOptionActivityTableTextBlock" xlink:label="cvm_ScheduleOfStockOptionActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfStockOptionActivityTableTextBlock" xlink:to="cvm_ScheduleOfStockOptionActivityTableTextBlock_lbl_e8a685" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfStockOptionActivityTableTextBlock_lbl_e8a685" xml:lang="en-US">Schedule of Stock option activity</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ScheduleOfCompensatingBalancesTableTextBlock" xlink:label="cvm_ScheduleOfCompensatingBalancesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfCompensatingBalancesTableTextBlock" xlink:to="cvm_ScheduleOfCompensatingBalancesTableTextBlock_lbl_049035" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfCompensatingBalancesTableTextBlock_lbl_049035" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" xlink:label="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" xlink:to="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_lbl_6737ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_lbl_6737ea" xml:lang="en-US">Schedule of warrants and non-employee options outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock" xlink:label="cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock" xlink:to="cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock_lbl_56a801" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock_lbl_56a801" xml:lang="en-US">Schedule of derivative liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl_3c403b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl_3c403b" xml:lang="en-US">Schedule of future minimum payments under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl_67c25b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl_67c25b" xml:lang="en-US">Schedule of total estimated future amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" xlink:label="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" xlink:to="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_lbl_bb8757" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_lbl_bb8757" xml:lang="en-US">Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" xlink:label="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" xlink:to="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock_lbl_719c9f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock_lbl_719c9f" xml:lang="en-US">Schedule of anti-dilutive securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl_98ea7a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl_98ea7a" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="cvm_NonQualifiedStockOptionsPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonQualifiedStockOptionsPlansMember" xlink:to="cvm_NonQualifiedStockOptionsPlansMember_lbl_213938" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonQualifiedStockOptionsPlansMember_lbl_213938" xml:lang="en-US">Non-Qualified Stock Option Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_StockBonusPlansMember" xlink:label="cvm_StockBonusPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockBonusPlansMember" xlink:to="cvm_StockBonusPlansMember_lbl_f76471" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockBonusPlansMember_lbl_f76471" xml:lang="en-US">Stock Bonus Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl_332166" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl_332166" xml:lang="en-US">Stock Compensation Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IncentiveStockBonusPlansMember" xlink:label="cvm_IncentiveStockBonusPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockBonusPlansMember" xlink:to="cvm_IncentiveStockBonusPlansMember_lbl_23d89b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockBonusPlansMember_lbl_23d89b" xml:lang="en-US">Incentive Stock Bonus Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_56401b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl_56401b" xml:lang="en-US">Remaining Options/shares Under Plans</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_90c7a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_90c7a4" xml:lang="en-US">Options Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_b5d89e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl_b5d89e" xml:lang="en-US">Options Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl_994209" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl_994209" xml:lang="en-US">Option exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_745186" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_745186" xml:lang="en-US">Options Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl_bb6064" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl_bb6064" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl_4c96b4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl_4c96b4" xml:lang="en-US">Employees</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_NonEmployeesMember" xlink:label="cvm_NonEmployeesMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonEmployeesMember" xlink:to="cvm_NonEmployeesMember_lbl_8c8f3f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonEmployeesMember_lbl_8c8f3f" xml:lang="en-US">Non-employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl_8a88e3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl_8a88e3" xml:lang="en-US">Stock Based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl_c59e81" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl_c59e81" xml:lang="en-US">Class Of Warrant Or Right Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl_4300a7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl_4300a7" xml:lang="en-US">Range Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_9557a3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_9557a3" xml:lang="en-US">Related Party Transactions By Related Party Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesNMember" xlink:label="cvm_SeriesNMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNMember" xlink:to="cvm_SeriesNMember_lbl_d039d5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNMember_lbl_d039d5" xml:lang="en-US">Series N [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesUUMember" xlink:label="cvm_SeriesUUMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesUUMember" xlink:to="cvm_SeriesUUMember_lbl_f72e9e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesUUMember_lbl_f72e9e" xml:lang="en-US">Series UU [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesXMember" xlink:label="cvm_SeriesXMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesXMember" xlink:to="cvm_SeriesXMember_lbl_9f3e8b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesXMember_lbl_9f3e8b" xml:lang="en-US">Series X [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesYMember" xlink:label="cvm_SeriesYMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesYMember" xlink:to="cvm_SeriesYMember_lbl_9d1518" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesYMember_lbl_9d1518" xml:lang="en-US">Series Y [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesMMMember" xlink:label="cvm_SeriesMMMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesMMMember" xlink:to="cvm_SeriesMMMember_lbl_05c1f7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesMMMember_lbl_05c1f7" xml:lang="en-US">Series MM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesNNMember" xlink:label="cvm_SeriesNNMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNNMember" xlink:to="cvm_SeriesNNMember_lbl_b664a2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNNMember_lbl_b664a2" xml:lang="en-US">Series NN [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesRRMember" xlink:label="cvm_SeriesRRMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesRRMember" xlink:to="cvm_SeriesRRMember_lbl_0c0701" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesRRMember_lbl_0c0701" xml:lang="en-US">Series RR [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl_7fa693" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl_7fa693" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ConsultantsMember" xlink:label="cvm_ConsultantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsMember" xlink:to="cvm_ConsultantsMember_lbl_e05cf5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultantsMember_lbl_e05cf5" xml:lang="en-US">Consultants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl_cd9724" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl_cd9724" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ConsultantsOptionMember" xlink:label="cvm_ConsultantsOptionMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsOptionMember" xlink:to="cvm_ConsultantsOptionMember_lbl_0ec3d0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultantsOptionMember_lbl_0ec3d0" xml:lang="en-US">Consultants Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IssueDate1" xlink:label="cvm_IssueDate1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IssueDate1" xlink:to="cvm_IssueDate1_lbl_8b035a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IssueDate1_lbl_8b035a" xml:lang="en-US">Issue Date</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:label="cvm_SharesIssuableUponExerciseOfWarrantOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:to="cvm_SharesIssuableUponExerciseOfWarrantOptions_lbl_7de43f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SharesIssuableUponExerciseOfWarrantOptions_lbl_7de43f" xml:lang="en-US">Shares Issuable Upon Exercise Of Warrant/options</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ExercisePrice" xlink:label="cvm_ExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExercisePrice" xlink:to="cvm_ExercisePrice_lbl_b69047" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExercisePrice_lbl_b69047" xml:lang="en-US">Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ExpirationDate" xlink:label="cvm_ExpirationDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpirationDate" xlink:to="cvm_ExpirationDate_lbl_db0ced" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExpirationDate_lbl_db0ced" xml:lang="en-US">Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesSSMember" xlink:label="cvm_SeriesSSMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesSSMember" xlink:to="cvm_SeriesSSMember_lbl_15b7fe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesSSMember_lbl_15b7fe" xml:lang="en-US">Series SS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_EquityWarrantsExercised" xlink:label="cvm_EquityWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EquityWarrantsExercised" xlink:to="cvm_EquityWarrantsExercised_lbl_286632" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EquityWarrantsExercised_lbl_286632" xml:lang="en-US">Equity Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_EquityWarrantsExercisePrice" xlink:label="cvm_EquityWarrantsExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EquityWarrantsExercisePrice" xlink:to="cvm_EquityWarrantsExercisePrice_lbl_03a74c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EquityWarrantsExercisePrice_lbl_03a74c" xml:lang="en-US">Equity Warrants Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ProceedsFromEquityWarrantsExercised" xlink:label="cvm_ProceedsFromEquityWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedsFromEquityWarrantsExercised" xlink:to="cvm_ProceedsFromEquityWarrantsExercised_lbl_1a02aa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedsFromEquityWarrantsExercised_lbl_1a02aa" xml:lang="en-US">Proceeds from Equity Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_c794d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_c794d7" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl_3881ce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl_3881ce" xml:lang="en-US">Plan Name Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_RestrictedStocksMember" xlink:label="cvm_RestrictedStocksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RestrictedStocksMember" xlink:to="cvm_RestrictedStocksMember_lbl_f793ac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RestrictedStocksMember_lbl_f793ac" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsMember" xlink:to="cvm_ConsultantsMember_lbl_d19965" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ConsultantsMember_lbl_d19965" xml:lang="en-US">Consultants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ConsultingAgreementsMember" xlink:label="cvm_ConsultingAgreementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingAgreementsMember" xlink:to="cvm_ConsultingAgreementsMember_lbl_ba090a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingAgreementsMember_lbl_ba090a" xml:lang="en-US">Consulting Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="cvm_IncrementalCostDeemedDividend" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncrementalCostDeemedDividend" xlink:to="cvm_IncrementalCostDeemedDividend_lbl_225cc6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncrementalCostDeemedDividend_lbl_225cc6" xml:lang="en-US">Incremental cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_3d0e65" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_3d0e65" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_lbl_e94bc2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_lbl_e94bc2" xml:lang="en-US">Options issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_7c0a2f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_7c0a2f" xml:lang="en-US">Exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ConsultingFeesIncluedPrepaidExpenses" xlink:label="cvm_ConsultingFeesIncluedPrepaidExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingFeesIncluedPrepaidExpenses" xlink:to="cvm_ConsultingFeesIncluedPrepaidExpenses_lbl_3b1804" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingFeesIncluedPrepaidExpenses_lbl_3b1804" xml:lang="en-US">Consulting fees inclued prepaid expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_2b4460" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_2b4460" xml:lang="en-US">Common stock issued for service, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_4699fe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_4699fe" xml:lang="en-US">Common stock shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl_ed1fb4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl_ed1fb4" xml:lang="en-US">Public offering price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_d6c1a9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_d6c1a9" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_NetofissuanceCosts" xlink:label="cvm_NetofissuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetofissuanceCosts" xlink:to="cvm_NetofissuanceCosts_lbl_143df2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetofissuanceCosts_lbl_143df2" xml:lang="en-US">Net of issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl_d1c9b8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl_d1c9b8" xml:lang="en-US">Amortization Cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl_63147f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl_63147f" xml:lang="en-US">Stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl_a53990" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl_a53990" xml:lang="en-US">Total expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncrementalCostDeemedDividend" xlink:to="cvm_IncrementalCostDeemedDividend_lbl_b18157" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_IncrementalCostDeemedDividend_lbl_b18157" xml:lang="en-US">Incremental cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_78fa5c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_78fa5c" xml:lang="en-US">Three months ending September 30, 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_70adce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_70adce" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_3cb7fc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_3cb7fc" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_1e1871" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_1e1871" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_bec0c1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_bec0c1" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_be444a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_be444a" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_542f36" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_542f36" xml:lang="en-US">Total future minimum lease obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_17bdc5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_17bdc5" xml:lang="en-US">Less imputed interest on finance lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_9" xml:lang="en-US">[Finance Lease, Liability, Undiscounted Excess Amount]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl_1c71cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl_1c71cb" xml:lang="en-US">Net present value of financing lease obligations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseLiabilityCurrentPortion" xlink:to="cvm_FinanceLeaseLiabilityCurrentPortion_lbl_8509b1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvm_FinanceLeaseLiabilityCurrentPortion_lbl_8509b1" xml:lang="en-US">Less net present value of financing lease obligations - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_FinanceLeaseLiabilityCurrentPortion" xlink:label="cvm_FinanceLeaseLiabilityCurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseLiabilityCurrentPortion" xlink:to="cvm_FinanceLeaseLiabilityCurrentPortion_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseLiabilityCurrentPortion_lbl_11" xml:lang="en-US">[Less net present value of financing lease obligations - current portion]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_FinanceLeaseLiabilityNoncurrentPortion" xlink:label="cvm_FinanceLeaseLiabilityNoncurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseLiabilityNoncurrentPortion" xlink:to="cvm_FinanceLeaseLiabilityNoncurrentPortion_lbl_c18864" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseLiabilityNoncurrentPortion_lbl_c18864" xml:lang="en-US">Net present value of financing lease obligations - non-current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_df16f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_df16f4" xml:lang="en-US">Three months ending September 30, 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl_2" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_f7dbc6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_f7dbc6" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_3" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_d3ca56" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_d3ca56" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_4" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_405234" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_405234" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_5" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_ebc1b3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_ebc1b3" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_6" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Four]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_2566a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_2566a5" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_7" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Five]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_97e71b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_97e71b" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_ed879e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_ed879e" xml:lang="en-US">Total Future Minimum Lease Obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_7da79a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_7da79a" xml:lang="en-US">Less Imputed Interest On Operating Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_10" xml:lang="en-US">[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_a1be9b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl_a1be9b" xml:lang="en-US">Net Present Value Of Operating Lease Obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseLiabilityCurrentPortion" xlink:to="cvm_OperatingLeaseLiabilityCurrentPortion_lbl_3e925d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvm_OperatingLeaseLiabilityCurrentPortion_lbl_3e925d" xml:lang="en-US">Net present value of lease finance lease obligations - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_OperatingLeaseLiabilityCurrentPortion" xlink:label="cvm_OperatingLeaseLiabilityCurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseLiabilityCurrentPortion" xlink:to="cvm_OperatingLeaseLiabilityCurrentPortion_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OperatingLeaseLiabilityCurrentPortion_lbl_12" xml:lang="en-US">[Net present value of lease finance lease obligations - current portion]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_OperatingLeaseLiabilityNoncurrentPortion" xlink:label="cvm_OperatingLeaseLiabilityNoncurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseLiabilityNoncurrentPortion" xlink:to="cvm_OperatingLeaseLiabilityNoncurrentPortion_lbl_125b19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OperatingLeaseLiabilityNoncurrentPortion_lbl_125b19" xml:lang="en-US">Net present value of lease finance lease obligations - non-current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl_df9b98" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl_df9b98" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ErgomedMember" xlink:label="cvm_ErgomedMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ErgomedMember" xlink:to="cvm_ErgomedMember_lbl_ca50d9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ErgomedMember_lbl_ca50d9" xml:lang="en-US">Ergomed [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_LandlordMember" xlink:label="cvm_LandlordMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LandlordMember" xlink:to="cvm_LandlordMember_lbl_57ac0b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LandlordMember_lbl_57ac0b" xml:lang="en-US">Landlord [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_NetOfDiscount" xlink:label="cvm_NetOfDiscount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetOfDiscount" xlink:to="cvm_NetOfDiscount_lbl_796839" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetOfDiscount_lbl_796839" xml:lang="en-US">Net Of Discount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl_66ad54" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl_66ad54" xml:lang="en-US">Total cash payment for financing lease</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl_cc42fb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl_cc42fb" xml:lang="en-US">Interest amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne" xlink:label="cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne" xlink:to="cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne_lbl_de0467" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne_lbl_de0467" xml:lang="en-US">Weighted average time of maturity of financing lease</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl_f8bed7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl_f8bed7" xml:lang="en-US">Lease expense for operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="us-gaap_OperatingLeasePaymentsUse" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_lbl_3cf1d9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl_3cf1d9" xml:lang="en-US">Total cash payment for oprating lease</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl_96a8c5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl_96a8c5" xml:lang="en-US">Weighted average discount rate of financing lease</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne" xlink:label="cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne" xlink:to="cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne_lbl_6b9878" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne_lbl_6b9878" xml:lang="en-US">Weighted average time of maturity of operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl_6ede9e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl_6ede9e" xml:lang="en-US">Research And Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl_e37caa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl_e37caa" xml:lang="en-US">Weighted Average Discount Rate Operating Lease</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ClinicalServiceTrial" xlink:label="cvm_ClinicalServiceTrial" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ClinicalServiceTrial" xlink:to="cvm_ClinicalServiceTrial_lbl_7fe334" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ClinicalServiceTrial_lbl_7fe334" xml:lang="en-US">Clinical Service Trial</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_FinancingArrangementDepositBaseRentAmount" xlink:label="cvm_FinancingArrangementDepositBaseRentAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinancingArrangementDepositBaseRentAmount" xlink:to="cvm_FinancingArrangementDepositBaseRentAmount_lbl_d170a2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinancingArrangementDepositBaseRentAmount_lbl_d170a2" xml:lang="en-US">Financing arrangement deposit base rent amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_0cfb93" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_0cfb93" xml:lang="en-US">Three months ending September 30, 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl_2" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_d09125" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_d09125" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_3" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_6663f0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_6663f0" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_4" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_b4ab8e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_b4ab8e" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_5" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_4876cd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_4876cd" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_6" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Four]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_2b1051" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_2b1051" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_7" xml:lang="en-US">[Finite-Lived Intangible Asset, Expected Amortization, Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_5c87fa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_5c87fa" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_8" xml:lang="en-US">[Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_40e64f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_40e64f" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIndefiniteLivedIntangibleAssets_lbl_9" xml:lang="en-US">[Other Indefinite-Lived Intangible Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl_fd76ce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl_fd76ce" xml:lang="en-US">Amortization expense</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" xlink:label="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" xlink:to="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod_lbl_2078e3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod_lbl_2078e3" xml:lang="en-US">Weighted average amortization period for patents</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:to="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl_135e06" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl_135e06" xml:lang="en-US">Net loss available to common shareholders - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl_3cd712" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl_3cd712" xml:lang="en-US">Loss per share- basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" xlink:label="cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" xlink:to="cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted_lbl_42746b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted_lbl_42746b" xml:lang="en-US">Weighted average shares outstanding - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" xlink:label="cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" xlink:to="cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares_lbl_4dd200" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares_lbl_4dd200" xml:lang="en-US">Basic and diluted loss per common share</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_OptionsMember" xlink:label="cvm_OptionsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OptionsMember" xlink:to="cvm_OptionsMember_lbl_f3dd03" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OptionsMember_lbl_f3dd03" xml:lang="en-US">Options and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="cvm_UnvestedRestrictedStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_UnvestedRestrictedStockMember" xlink:to="cvm_UnvestedRestrictedStockMember_lbl_667fab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_UnvestedRestrictedStockMember_lbl_667fab" xml:lang="en-US">Unvested Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_542037" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_542037" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl_7bd659" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl_7bd659" xml:lang="en-US">Subsequent Event Type Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl_ec7c34" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl_ec7c34" xml:lang="en-US">Subsequent Event</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl_9d8d51" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl_9d8d51" xml:lang="en-US">Stock warrants under the extention period</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_RestrictedCommonStock" xlink:label="cvm_RestrictedCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RestrictedCommonStock" xlink:to="cvm_RestrictedCommonStock_lbl_c6f64c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RestrictedCommonStock_lbl_c6f64c" xml:lang="en-US">Restricted common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityOwnedNotReadilyMarketableFairValue" xlink:label="us-gaap_SecurityOwnedNotReadilyMarketableFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityOwnedNotReadilyMarketableFairValue" xlink:to="us-gaap_SecurityOwnedNotReadilyMarketableFairValue_lbl_f5ab51" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityOwnedNotReadilyMarketableFairValue_lbl_f5ab51" xml:lang="en-US">Fair market value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_ShareIssuanceCosts" xlink:to="cvm_ShareIssuanceCosts_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_ShareIssuanceCosts_d">Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement.</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>cvm-20240331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/15/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20240331.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20240331.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20240331.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20240331.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:href="cvm-20240331.xsd#StatementsOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20240331.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20240331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20240331.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20240331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20240331.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20240331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20240331.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShare" xlink:href="cvm-20240331.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20240331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20240331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20240331.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20240331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20240331.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareTables" xlink:href="cvm-20240331.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20240331.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails1" xlink:href="cvm-20240331.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails2" xlink:href="cvm-20240331.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails3" xlink:href="cvm-20240331.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails4" xlink:href="cvm-20240331.xsd#StockholdersEquityDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20240331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20240331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20240331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20240331.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20240331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20240331.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20240331.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails" xlink:href="cvm-20240331.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails1" xlink:href="cvm-20240331.xsd#LossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cvm-20240331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - CONDENSED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SuppliesUsedForRDAndManufacturingCurrent" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturingCurrent" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturingCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_DueToEmployeeCurrent" xlink:label="loc_cvmDueToEmployeeCurrent" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_cvmDueToEmployeeCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ModificationOfWarrants" xlink:label="loc_cvmModificationOfWarrants" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_cvmModificationOfWarrants" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="loc_cvmCommonStockContributedToEmployeeBenefitPlan" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmCommonStockContributedToEmployeeBenefitPlan" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IncreaseDecreaseInDepositAssets" xlink:label="loc_cvmIncreaseDecreaseInDepositAssets" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmIncreaseDecreaseInDepositAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000009 - Disclosure - STOCKHOLDERS EQUITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000010 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000011 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShare" xlink:title="000013 - Disclosure - LOSS PER COMMON SHARE" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000014 - Disclosure - SUBSEQUENT EVENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="000016 - Disclosure - STOCKHOLDERS EQUITY (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000017 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000018 - Disclosure - PATENTS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareTables" xlink:title="000019 - Disclosure - LOSS PER COMMON SHARE (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="000020 - Disclosure - STOCKHOLDERS EQUITY (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails1" xlink:title="000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails2" xlink:title="000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails3" xlink:title="000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails4" xlink:title="000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000030 - Disclosure - PATENTS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000031 - Disclosure - PATENTS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails" xlink:title="000032 - Disclosure - LOSS PER COMMON SHARE (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails1" xlink:title="000033 - Disclosure - LOSS PER COMMON SHARE (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:title="000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>cvm-20240331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/15/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20240331.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20240331.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20240331.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20240331.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:href="cvm-20240331.xsd#StatementsOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20240331.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20240331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20240331.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20240331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20240331.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20240331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20240331.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShare" xlink:href="cvm-20240331.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20240331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20240331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20240331.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20240331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20240331.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareTables" xlink:href="cvm-20240331.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20240331.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails1" xlink:href="cvm-20240331.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails2" xlink:href="cvm-20240331.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails3" xlink:href="cvm-20240331.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails4" xlink:href="cvm-20240331.xsd#StockholdersEquityDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20240331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20240331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20240331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20240331.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20240331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20240331.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20240331.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails" xlink:href="cvm-20240331.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails1" xlink:href="cvm-20240331.xsd#LossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cvm-20240331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - CONDENSED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_9b08a9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_e4afd6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_9b08a9" xlink:to="loc_us-gaapAssetsCurrentAbstract_e4afd6" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0d0ef3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_e4afd6" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0d0ef3" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_1e9b70" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_e4afd6" xlink:to="loc_us-gaapPrepaidExpenseCurrent_1e9b70" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SuppliesUsedForRDAndManufacturingCurrent" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturingCurrent_ed10b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_e4afd6" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturingCurrent_ed10b5" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent_627183" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_e4afd6" xlink:to="loc_us-gaapDepositsAssetsCurrent_627183" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_e55213" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_e4afd6" xlink:to="loc_us-gaapAssetsCurrent_e55213" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_f28999" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_e4afd6" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_f28999" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_3c1f97" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_e4afd6" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_3c1f97" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_77e594" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_e4afd6" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_77e594" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_d1553a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_e4afd6" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_d1553a" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets_12de29" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_e4afd6" xlink:to="loc_us-gaapDepositsAssets_12de29" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SuppliesUsedForRDAndManufacturingNonCurrent" xlink:label="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent_c14760" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_e4afd6" xlink:to="loc_cvmSuppliesUsedForRDAndManufacturingNonCurrent_c14760" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_09bc19" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_e4afd6" xlink:to="loc_us-gaapAssets_09bc19" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_f3dc4d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract_e4afd6" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_f3dc4d" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_844d7f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_f3dc4d" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_844d7f" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_632d35" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_844d7f" xlink:to="loc_us-gaapAccountsPayableCurrent_632d35" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_95e5aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_844d7f" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_95e5aa" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_DueToEmployeeCurrent" xlink:label="loc_cvmDueToEmployeeCurrent_29f3ed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_844d7f" xlink:to="loc_cvmDueToEmployeeCurrent_29f3ed" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_23084b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_844d7f" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_23084b" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_d3a0fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_844d7f" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_d3a0fa" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_930b25" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_844d7f" xlink:to="loc_us-gaapLiabilitiesCurrent_930b25" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent_1055ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_844d7f" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent_1055ac" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_859e33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_844d7f" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_859e33" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent_203ee1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_844d7f" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent_203ee1" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_37dec1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_844d7f" xlink:to="loc_us-gaapLiabilities_37dec1" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_fede3c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_844d7f" xlink:to="loc_us-gaapStockholdersEquityAbstract_fede3c" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_d84003" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_fede3c" xlink:to="loc_us-gaapPreferredStockValue_d84003" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_776f6d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_fede3c" xlink:to="loc_us-gaapCommonStockValue_776f6d" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_b9054d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_fede3c" xlink:to="loc_us-gaapAdditionalPaidInCapital_b9054d" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_8b5a69" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_fede3c" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_8b5a69" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_b28529" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_fede3c" xlink:to="loc_us-gaapStockholdersEquity_b28529" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_d98299" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_fede3c" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_d98299" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_dd5320" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_afec6f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_dd5320" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_afec6f" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_7b457a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_dd5320" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_7b457a" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_66859e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_dd5320" xlink:to="loc_us-gaapPreferredStockSharesIssued_66859e" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_8c3449" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_dd5320" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_8c3449" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_82069d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_dd5320" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_82069d" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_f017cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_dd5320" xlink:to="loc_us-gaapCommonStockSharesAuthorized_f017cc" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_27cb22" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_dd5320" xlink:to="loc_us-gaapCommonStockSharesIssued_27cb22" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_e7b146" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_dd5320" xlink:to="loc_us-gaapCommonStockSharesOutstanding_e7b146" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_76a955" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_fd2c56" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_76a955" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_fd2c56" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_086f47" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_76a955" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_086f47" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_ad5765" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_76a955" xlink:to="loc_us-gaapOperatingExpenses_ad5765" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_a1ca33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_76a955" xlink:to="loc_us-gaapOperatingIncomeLoss_a1ca33" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet_822b39" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_76a955" xlink:to="loc_us-gaapInterestIncomeExpenseNet_822b39" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense_9a29f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_76a955" xlink:to="loc_us-gaapOtherNonoperatingExpense_9a29f4" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_12c782" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_76a955" xlink:to="loc_us-gaapNetIncomeLoss_12c782" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ModificationOfWarrants" xlink:label="loc_cvmModificationOfWarrants_58aff5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_76a955" xlink:to="loc_cvmModificationOfWarrants_58aff5" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_7006cd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_76a955" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_7006cd" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_EarningPerShareBasicAndDiluted" xlink:label="loc_cvmEarningPerShareBasicAndDiluted_4627fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_76a955" xlink:to="loc_cvmEarningPerShareBasicAndDiluted_4627fa" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted" xlink:label="loc_cvmWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted_8455d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_76a955" xlink:to="loc_cvmWeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted_8455d3" order="11" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_cda990" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_efc628" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_cda990" xlink:to="loc_us-gaapStatementTable_efc628" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_5732d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_efc628" xlink:to="loc_us-gaapStatementLineItems_5732d8" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_480d33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_efc628" xlink:to="loc_us-gaapStatementEquityComponentsAxis_480d33" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_642e0f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_480d33" xlink:to="loc_us-gaapEquityComponentDomain_642e0f" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_41eefc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_642e0f" xlink:to="loc_us-gaapCommonStockMember_41eefc" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_3ebb8e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_642e0f" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_3ebb8e" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_f83d71" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_642e0f" xlink:to="loc_us-gaapRetainedEarningsMember_f83d71" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_bbbb5c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5732d8" xlink:to="loc_us-gaapSharesIssued_bbbb5c" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_51212f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5732d8" xlink:to="loc_us-gaapStockholdersEquity_51212f" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_WarrantExercisesShares" xlink:label="loc_cvmWarrantExercisesShares_2265c5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5732d8" xlink:to="loc_cvmWarrantExercisesShares_2265c5" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_WarrantExercisesAmount" xlink:label="loc_cvmWarrantExercisesAmount_376d83" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5732d8" xlink:to="loc_cvmWarrantExercisesAmount_376d83" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_f6c569" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5732d8" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_f6c569" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_ae3c52" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5732d8" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_ae3c52" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_71235e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5732d8" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_71235e" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_e224f9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5732d8" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_e224f9" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_8fa534" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5732d8" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_8fa534" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IncentiveStockForfeitedShares" xlink:label="loc_cvmIncentiveStockForfeitedShares_f06c81" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5732d8" xlink:to="loc_cvmIncentiveStockForfeitedShares_f06c81" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IncentiveStockForfeitedAmount" xlink:label="loc_cvmIncentiveStockForfeitedAmount_01d040" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5732d8" xlink:to="loc_cvmIncentiveStockForfeitedAmount_01d040" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_0c8196" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5732d8" xlink:to="loc_us-gaapNetIncomeLoss_0c8196" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_10455c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5732d8" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_10455c" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_4ee6d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5732d8" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_4ee6d0" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ShareIssuanceCosts" xlink:label="loc_cvmShareIssuanceCosts_6b1309" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5732d8" xlink:to="loc_cvmShareIssuanceCosts_6b1309" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_3c93dc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5732d8" xlink:to="loc_us-gaapSharesIssued_3c93dc" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_178b77" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5732d8" xlink:to="loc_us-gaapStockholdersEquity_178b77" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_348138" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_9586ff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_348138" xlink:to="loc_us-gaapProfitLoss_9586ff" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dfa0b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_348138" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dfa0b1" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_390506" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dfa0b1" xlink:to="loc_us-gaapDepreciationAndAmortization_390506" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense_e3ee11" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dfa0b1" xlink:to="loc_us-gaapOtherNoncashExpense_e3ee11" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_0f2f73" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dfa0b1" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_0f2f73" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_c8b8a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dfa0b1" xlink:to="loc_us-gaapShareBasedCompensation_c8b8a4" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="loc_cvmCommonStockContributedToEmployeeBenefitPlan_f15d34" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dfa0b1" xlink:to="loc_cvmCommonStockContributedToEmployeeBenefitPlan_f15d34" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_60f9ed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dfa0b1" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_60f9ed" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense_ce81ef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_60f9ed" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense_ce81ef" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories_ff0d29" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_60f9ed" xlink:to="loc_us-gaapIncreaseDecreaseInInventories_ff0d29" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IncreaseDecreaseInDepositAssets" xlink:label="loc_cvmIncreaseDecreaseInDepositAssets_eff1b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_60f9ed" xlink:to="loc_cvmIncreaseDecreaseInDepositAssets_eff1b0" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_e70ae4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_60f9ed" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_e70ae4" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable_061531" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_e70ae4" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable_061531" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_03ffdd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_e70ae4" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_03ffdd" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities_30287e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_e70ae4" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities_30287e" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_a2ef6c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_e70ae4" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_a2ef6c" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_f05cff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_e70ae4" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_f05cff" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_2aa71d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_f05cff" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_2aa71d" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_03c28c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_f05cff" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_03c28c" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_d7ba8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_f05cff" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_d7ba8a" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_8e5559" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_f05cff" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_8e5559" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_e7e516" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_8e5559" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_e7e516" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_89815d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_8e5559" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_89815d" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_4835ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_8e5559" xlink:to="loc_us-gaapProceedsFromWarrantExercises_4835ee" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations_8601af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_8e5559" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations_8601af" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_686615" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_8e5559" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_686615" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_679bd5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_8e5559" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_679bd5" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_544020" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_8e5559" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_544020" order="28" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bd4a95" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_8e5559" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bd4a95" order="29" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" xlink:label="loc_cvmPropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_bb50e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_8e5559" xlink:to="loc_cvmPropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_bb50e5" order="30" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_AssetsPurchasedUnderFinanceLeases" xlink:label="loc_cvmAssetsPurchasedUnderFinanceLeases_259c30" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_8e5559" xlink:to="loc_cvmAssetsPurchasedUnderFinanceLeases_259c30" order="31" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:label="loc_cvmFinanceLeaseObligationIncludedInAccountsPayable_539d15" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_8e5559" xlink:to="loc_cvmFinanceLeaseObligationIncludedInAccountsPayable_539d15" order="32" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ConsultingServicesPaidWithIssuanceOfCommonStock" xlink:label="loc_cvmConsultingServicesPaidWithIssuanceOfCommonStock_7f95cf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_8e5559" xlink:to="loc_cvmConsultingServicesPaidWithIssuanceOfCommonStock_7f95cf" order="33" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_AccruedConsultingServicesToBePaidWithCommonStock" xlink:label="loc_cvmAccruedConsultingServicesToBePaidWithCommonStock_41a7e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_8e5559" xlink:to="loc_cvmAccruedConsultingServicesToBePaidWithCommonStock_41a7e6" order="34" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_FinancingCostsIncludedInCurrentLiabilities" xlink:label="loc_cvmFinancingCostsIncludedInCurrentLiabilities_2a16a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_8e5559" xlink:to="loc_cvmFinancingCostsIncludedInCurrentLiabilities_2a16a5" order="35" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_6d6fbc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_8e5559" xlink:to="loc_us-gaapInterestPaidNet_6d6fbc" order="36" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a44b9d" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock_78a318" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a44b9d" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock_78a318" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY">
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_LIQUIDITYAbstract" xlink:label="loc_cvmLIQUIDITYAbstract_781a51" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_LiquidityDisclosureTextBlock" xlink:label="loc_cvmLiquidityDisclosureTextBlock_2bc165" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmLIQUIDITYAbstract_781a51" xlink:to="loc_cvmLiquidityDisclosureTextBlock_2bc165" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000009 - Disclosure - STOCKHOLDERS EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_76f812" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_c2550a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_76f812" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_c2550a" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000010 - Disclosure - RELATED PARTY TRANSACTIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_cb6bb1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_2b32cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_cb6bb1" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_2b32cb" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000011 - Disclosure - COMMITMENTS AND CONTINGENCIES">
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_954f1a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_9e5e52" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_954f1a" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_9e5e52" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_82e0c8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock_56046f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_82e0c8" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock_56046f" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShare" xlink:title="000013 - Disclosure - LOSS PER COMMON SHARE">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_964946" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock_30010a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_964946" xlink:to="loc_us-gaapEarningsPerShareTextBlock_30010a" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000014 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_ee1469" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_ea3d21" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_ee1469" xlink:to="loc_us-gaapSubsequentEventsTextBlock_ea3d21" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_52e90e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_163aa5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_52e90e" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_163aa5" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_4bc71c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_52e90e" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_4bc71c" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock_0d1d53" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_52e90e" xlink:to="loc_us-gaapInventoryPolicyTextBlock_0d1d53" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy_553375" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_52e90e" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy_553375" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_LeasesPolicyTextBlock" xlink:label="loc_cvmLeasesPolicyTextBlock_e581a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_52e90e" xlink:to="loc_cvmLeasesPolicyTextBlock_e581a4" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_6ead95" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_52e90e" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_6ead95" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy_d704aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_52e90e" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy_d704aa" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_cdf7a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_52e90e" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_cdf7a8" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock_efb934" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_52e90e" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock_efb934" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ImpairmentOfLongLivedAssetsPolicyTextblock" xlink:label="loc_cvmImpairmentOfLongLivedAssetsPolicyTextblock_30b148" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_52e90e" xlink:to="loc_cvmImpairmentOfLongLivedAssetsPolicyTextblock_30b148" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_7187ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_52e90e" xlink:to="loc_us-gaapUseOfEstimates_7187ae" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock" xlink:label="loc_cvmNewAccountingPronouncementEarlyAdoptionPolicyTextBlock_134e05" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_52e90e" xlink:to="loc_cvmNewAccountingPronouncementEarlyAdoptionPolicyTextBlock_134e05" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_2f04e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_52e90e" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_2f04e4" order="13" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="000016 - Disclosure - STOCKHOLDERS EQUITY (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_bb2ffb" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock_ff683c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_bb2ffb" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationActivityTableTextBlock_ff683c" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ScheduleOfStockOptionActivityTableTextBlock" xlink:label="loc_cvmScheduleOfStockOptionActivityTableTextBlock_c2fb66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_bb2ffb" xlink:to="loc_cvmScheduleOfStockOptionActivityTableTextBlock_c2fb66" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ScheduleOfCompensatingBalancesTableTextBlock" xlink:label="loc_cvmScheduleOfCompensatingBalancesTableTextBlock_bf880e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_bb2ffb" xlink:to="loc_cvmScheduleOfCompensatingBalancesTableTextBlock_bf880e" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock" xlink:label="loc_cvmScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_d372d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_bb2ffb" xlink:to="loc_cvmScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock_d372d6" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock" xlink:label="loc_cvmScheduleOfDerivativeLiabilitiesTableTextBlock_2cebec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_bb2ffb" xlink:to="loc_cvmScheduleOfDerivativeLiabilitiesTableTextBlock_2cebec" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000017 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_9ab044" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock_e50b50" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_9ab044" xlink:to="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock_e50b50" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000018 - Disclosure - PATENTS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_49f029" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_00ea25" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_49f029" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_00ea25" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareTables" xlink:title="000019 - Disclosure - LOSS PER COMMON SHARE (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_3be2cb" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock" xlink:label="loc_cvmScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_564ec0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_3be2cb" xlink:to="loc_cvmScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock_564ec0" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock" xlink:label="loc_cvmScheduleOfAntiDilutiveSecuritiesTableTextBlock_d7efb0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_3be2cb" xlink:to="loc_cvmScheduleOfAntiDilutiveSecuritiesTableTextBlock_d7efb0" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="000020 - Disclosure - STOCKHOLDERS EQUITY (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_e2bb7a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_93bff5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_e2bb7a" xlink:to="loc_us-gaapStatementTable_93bff5" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_5ccc89" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_93bff5" xlink:to="loc_us-gaapStatementLineItems_5ccc89" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_7e02b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_93bff5" xlink:to="loc_us-gaapAwardTypeAxis_7e02b6" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8830a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_7e02b6" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8830a3" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember_406f3b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8830a3" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember_406f3b" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_StockBonusPlansMember" xlink:label="loc_cvmStockBonusPlansMember_1a699c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8830a3" xlink:to="loc_cvmStockBonusPlansMember_1a699c" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaapStockCompensationPlanMember_7c5a9b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8830a3" xlink:to="loc_us-gaapStockCompensationPlanMember_7c5a9b" order="23" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IncentiveStockBonusPlansMember" xlink:label="loc_cvmIncentiveStockBonusPlansMember_cc51d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8830a3" xlink:to="loc_cvmIncentiveStockBonusPlansMember_cc51d8" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6bcb21" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5ccc89" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6bcb21" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails1" xlink:title="000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_629411" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_900c0e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_629411" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_900c0e" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e2d239" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_629411" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e2d239" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_f879db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_629411" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_f879db" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_67c1c8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_629411" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_67c1c8" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails2" xlink:title="000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_7ff63b" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_60424a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_7ff63b" xlink:to="loc_us-gaapStatementTable_60424a" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_6acade" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_60424a" xlink:to="loc_us-gaapStatementLineItems_6acade" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis_1a63be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_60424a" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis_1a63be" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_88d032" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis_1a63be" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_88d032" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember_5f3cca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain_88d032" xlink:to="loc_us-gaapEmployeeStockMember_5f3cca" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_NonEmployeesMember" xlink:label="loc_cvmNonEmployeesMember_f1c8c4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain_88d032" xlink:to="loc_cvmNonEmployeesMember_f1c8c4" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_4e561d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6acade" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_4e561d" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails3" xlink:title="000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_48808f" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_043b43" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_48808f" xlink:to="loc_us-gaapStatementTable_043b43" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_9fee8c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_043b43" xlink:to="loc_us-gaapStatementLineItems_9fee8c" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_c07b2c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_043b43" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_c07b2c" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_1b9a8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_c07b2c" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_1b9a8a" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_fa5c70" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_043b43" xlink:to="loc_srtRangeAxis_fa5c70" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_ce11fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_fa5c70" xlink:to="loc_srtRangeMember_ce11fb" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_d7b4cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_043b43" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_d7b4cb" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_3d9b3c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_d7b4cb" xlink:to="loc_us-gaapRelatedPartyDomain_3d9b3c" order="60" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesNMember" xlink:label="loc_cvmSeriesNMember_debf4c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_1b9a8a" xlink:to="loc_cvmSeriesNMember_debf4c" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember_0a91cf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_1b9a8a" xlink:to="loc_cvmSeriesUUMember_0a91cf" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember_56b008" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_1b9a8a" xlink:to="loc_cvmSeriesXMember_56b008" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember_178461" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_1b9a8a" xlink:to="loc_cvmSeriesYMember_178461" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember_ce2690" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_1b9a8a" xlink:to="loc_cvmSeriesMMMember_ce2690" order="65" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember_185540" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_1b9a8a" xlink:to="loc_cvmSeriesNNMember_185540" order="66" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_44239d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_1b9a8a" xlink:to="loc_cvmSeriesRRMember_44239d" order="67" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_3ffb7e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_ce11fb" xlink:to="loc_srtMinimumMember_3ffb7e" order="68" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember_92b868" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_3d9b3c" xlink:to="loc_cvmConsultantsMember_92b868" order="69" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_cbd860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_ce11fb" xlink:to="loc_srtMaximumMember_cbd860" order="70" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ConsultantsOptionMember" xlink:label="loc_cvmConsultantsOptionMember_c4b3bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_3d9b3c" xlink:to="loc_cvmConsultantsOptionMember_c4b3bf" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IssueDate1" xlink:label="loc_cvmIssueDate1_363d63" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9fee8c" xlink:to="loc_cvmIssueDate1_363d63" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:label="loc_cvmSharesIssuableUponExerciseOfWarrantOptions_6583bb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9fee8c" xlink:to="loc_cvmSharesIssuableUponExerciseOfWarrantOptions_6583bb" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ExercisePrice" xlink:label="loc_cvmExercisePrice_064361" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9fee8c" xlink:to="loc_cvmExercisePrice_064361" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ExpirationDate" xlink:label="loc_cvmExpirationDate_132290" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9fee8c" xlink:to="loc_cvmExpirationDate_132290" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails4" xlink:title="000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_2366ea" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_ec99ea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_2366ea" xlink:to="loc_us-gaapStatementTable_ec99ea" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_c8fe80" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ec99ea" xlink:to="loc_us-gaapStatementLineItems_c8fe80" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_3af58a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ec99ea" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_3af58a" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_6779e8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_3af58a" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_6779e8" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_b3536e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6779e8" xlink:to="loc_cvmSeriesRRMember_b3536e" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesSSMember" xlink:label="loc_cvmSeriesSSMember_ca55b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_6779e8" xlink:to="loc_cvmSeriesSSMember_ca55b0" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_EquityWarrantsExercised" xlink:label="loc_cvmEquityWarrantsExercised_c386d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c8fe80" xlink:to="loc_cvmEquityWarrantsExercised_c386d3" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_EquityWarrantsExercisePrice" xlink:label="loc_cvmEquityWarrantsExercisePrice_7d680c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c8fe80" xlink:to="loc_cvmEquityWarrantsExercisePrice_7d680c" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ProceedsFromEquityWarrantsExercised" xlink:label="loc_cvmProceedsFromEquityWarrantsExercised_ffeada" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c8fe80" xlink:to="loc_cvmProceedsFromEquityWarrantsExercised_ffeada" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_bc25ad" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_1e2fcb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_bc25ad" xlink:to="loc_us-gaapStatementTable_1e2fcb" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_f075a7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1e2fcb" xlink:to="loc_us-gaapStatementLineItems_f075a7" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_e2ffde" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1e2fcb" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_e2ffde" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_5f56f3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_e2ffde" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_5f56f3" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a46cd3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1e2fcb" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a46cd3" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_86ca46" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a46cd3" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_86ca46" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_5331b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1e2fcb" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_5331b5" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_4b873a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_5331b5" xlink:to="loc_us-gaapRelatedPartyDomain_4b873a" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_34f85f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_1e2fcb" xlink:to="loc_us-gaapPlanNameAxis_34f85f" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_402104" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_34f85f" xlink:to="loc_us-gaapPlanNameDomain_402104" order="60" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_0b0089" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_5f56f3" xlink:to="loc_cvmSeriesRRMember_0b0089" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_RestrictedStocksMember" xlink:label="loc_cvmRestrictedStocksMember_6fc718" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_86ca46" xlink:to="loc_cvmRestrictedStocksMember_6fc718" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember_5b3700" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_4b873a" xlink:to="loc_cvmConsultantsMember_5b3700" order="63" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ConsultingAgreementsMember" xlink:label="loc_cvmConsultingAgreementsMember_7b1b8b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_402104" xlink:to="loc_cvmConsultingAgreementsMember_7b1b8b" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="loc_cvmIncrementalCostDeemedDividend_b8d803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f075a7" xlink:to="loc_cvmIncrementalCostDeemedDividend_b8d803" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9fb563" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f075a7" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9fb563" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_54ac6e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f075a7" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1_54ac6e" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_dce931" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f075a7" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_dce931" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ConsultingFeesIncluedPrepaidExpenses" xlink:label="loc_cvmConsultingFeesIncluedPrepaidExpenses_974b5c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f075a7" xlink:to="loc_cvmConsultingFeesIncluedPrepaidExpenses_974b5c" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_895df2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f075a7" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_895df2" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_32c4bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f075a7" xlink:to="loc_us-gaapCommonStockSharesIssued_32c4bc" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_1cc016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f075a7" xlink:to="loc_us-gaapSaleOfStockPricePerShare_1cc016" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_91824b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f075a7" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_91824b" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_NetofissuanceCosts" xlink:label="loc_cvmNetofissuanceCosts_5024da" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f075a7" xlink:to="loc_cvmNetofissuanceCosts_5024da" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_4cff40" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f075a7" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_4cff40" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense_f19f6b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f075a7" xlink:to="loc_us-gaapStockOptionPlanExpense_f19f6b" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_f643a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f075a7" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_f643a0" order="13" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_8dbd62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="loc_cvmIncrementalCostDeemedDividend_1da4c7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_8dbd62" xlink:to="loc_cvmIncrementalCostDeemedDividend_1da4c7" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_0cc608" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_a42d34" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_0cc608" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_a42d34" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_e0805b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_0cc608" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_e0805b" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_efa739" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_0cc608" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_efa739" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_7ad847" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_0cc608" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_7ad847" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_64faac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_0cc608" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_64faac" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_7a6c32" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_0cc608" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_7a6c32" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_b784e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_0cc608" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_b784e4" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount_7fd8a1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_0cc608" xlink:to="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount_7fd8a1" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability_01d1cf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_0cc608" xlink:to="loc_us-gaapFinanceLeaseLiability_01d1cf" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_FinanceLeaseLiabilityCurrentPortion" xlink:label="loc_cvmFinanceLeaseLiabilityCurrentPortion_891d82" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_0cc608" xlink:to="loc_cvmFinanceLeaseLiabilityCurrentPortion_891d82" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_FinanceLeaseLiabilityNoncurrentPortion" xlink:label="loc_cvmFinanceLeaseLiabilityNoncurrentPortion_0a9d97" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_0cc608" xlink:to="loc_cvmFinanceLeaseLiabilityNoncurrentPortion_0a9d97" order="11" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)">
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_951e8a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_bfe9c4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_951e8a" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_bfe9c4" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b79162" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_951e8a" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b79162" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fe6b0e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_951e8a" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fe6b0e" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_7e9b10" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_951e8a" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_7e9b10" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_470f62" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_951e8a" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_470f62" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_f318fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_951e8a" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_f318fa" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_647366" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_951e8a" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_647366" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_65bee9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_951e8a" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_65bee9" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4bf348" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_951e8a" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4bf348" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_7c2fa1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_951e8a" xlink:to="loc_us-gaapOperatingLeaseLiability_7c2fa1" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_OperatingLeaseLiabilityCurrentPortion" xlink:label="loc_cvmOperatingLeaseLiabilityCurrentPortion_84b454" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_951e8a" xlink:to="loc_cvmOperatingLeaseLiabilityCurrentPortion_84b454" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_OperatingLeaseLiabilityNoncurrentPortion" xlink:label="loc_cvmOperatingLeaseLiabilityNoncurrentPortion_c9e0c8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_951e8a" xlink:to="loc_cvmOperatingLeaseLiabilityNoncurrentPortion_c9e0c8" order="12" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_CommitmentsAndContingenciesAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesAbstract_c7a17a" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_ec18f9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmCommitmentsAndContingenciesAbstract_c7a17a" xlink:to="loc_us-gaapStatementTable_ec18f9" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_dbf2b8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ec18f9" xlink:to="loc_us-gaapStatementLineItems_dbf2b8" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_87f9f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ec18f9" xlink:to="loc_us-gaapPlanNameAxis_87f9f2" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_c3f540" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_87f9f2" xlink:to="loc_us-gaapPlanNameDomain_c3f540" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis_2b1291" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ec18f9" xlink:to="loc_srtTitleOfIndividualAxis_2b1291" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_81d61b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis_2b1291" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_81d61b" order="30" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember_090f61" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_c3f540" xlink:to="loc_cvmErgomedMember_090f61" order="31" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_LandlordMember" xlink:label="loc_cvmLandlordMember_e0a8f8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_81d61b" xlink:to="loc_cvmLandlordMember_e0a8f8" order="32" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_NetOfDiscount" xlink:label="loc_cvmNetOfDiscount_4a4ba6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_dbf2b8" xlink:to="loc_cvmNetOfDiscount_4a4ba6" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments_c69c9b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_dbf2b8" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments_c69c9b" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_f3ff31" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_dbf2b8" xlink:to="loc_us-gaapInterestPaid_f3ff31" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne" xlink:label="loc_cvmFinanceLeaseWeightedAverageRemainingLeaseTermOne_f4662d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_dbf2b8" xlink:to="loc_cvmFinanceLeaseWeightedAverageRemainingLeaseTermOne_f4662d" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_09713e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_dbf2b8" xlink:to="loc_us-gaapOperatingLeaseExpense_09713e" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="loc_us-gaapOperatingLeasePaymentsUse_1babc3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_dbf2b8" xlink:to="loc_us-gaapOperatingLeasePaymentsUse_1babc3" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent_bd229f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_dbf2b8" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent_bd229f" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne" xlink:label="loc_cvmOperatingLeaseWeightedAverageRemainingLeaseTermOne_b20b98" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_dbf2b8" xlink:to="loc_cvmOperatingLeaseWeightedAverageRemainingLeaseTermOne_b20b98" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_fda95d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_dbf2b8" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_fda95d" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_44e683" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_dbf2b8" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_44e683" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ClinicalServiceTrial" xlink:label="loc_cvmClinicalServiceTrial_cfe9ef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_dbf2b8" xlink:to="loc_cvmClinicalServiceTrial_cfe9ef" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_FinancingArrangementDepositBaseRentAmount" xlink:label="loc_cvmFinancingArrangementDepositBaseRentAmount_ddf509" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_dbf2b8" xlink:to="loc_cvmFinancingArrangementDepositBaseRentAmount_ddf509" order="12" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000030 - Disclosure - PATENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_f489b3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3dca9c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_f489b3" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3dca9c" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9a85d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_f489b3" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9a85d0" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d50db9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_f489b3" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d50db9" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7814d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_f489b3" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7814d9" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_77985c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_f489b3" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_77985c" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_bd5218" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_f489b3" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_bd5218" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_5a24ff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_f489b3" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_5a24ff" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_231eeb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_f489b3" xlink:to="loc_us-gaapOtherIndefiniteLivedIntangibleAssets_231eeb" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000031 - Disclosure - PATENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_3000f0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_8febce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_3000f0" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_8febce" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod" xlink:label="loc_cvmFiniteLivedIntangibleAssetsRemainingAmortizationPeriod_249b19" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract_3000f0" xlink:to="loc_cvmFiniteLivedIntangibleAssetsRemainingAmortizationPeriod_249b19" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails" xlink:title="000032 - Disclosure - LOSS PER COMMON SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_306c72" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="loc_cvmNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_a22db4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_306c72" xlink:to="loc_cvmNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_a22db4" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_3f9d57" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_306c72" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_3f9d57" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted" xlink:label="loc_cvmWeightedAverageNumberOfShareOutstandingBasicsAndDiluted_548a39" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_3f9d57" xlink:to="loc_cvmWeightedAverageNumberOfShareOutstandingBasicsAndDiluted_548a39" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares" xlink:label="loc_cvmIncomeLossFromContinuingOperationsPerBasicAndDilutedShares_cda18d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract_3f9d57" xlink:to="loc_cvmIncomeLossFromContinuingOperationsPerBasicAndDilutedShares_cda18d" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails1" xlink:title="000033 - Disclosure - LOSS PER COMMON SHARE (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_f69d90" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_b6052b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_f69d90" xlink:to="loc_us-gaapStatementTable_b6052b" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_250155" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b6052b" xlink:to="loc_us-gaapStatementLineItems_250155" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1522cb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b6052b" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1522cb" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_65fa42" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1522cb" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_65fa42" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_OptionsMember" xlink:label="loc_cvmOptionsMember_478f13" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_65fa42" xlink:to="loc_cvmOptionsMember_478f13" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="loc_cvmUnvestedRestrictedStockMember_4d75fe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_65fa42" xlink:to="loc_cvmUnvestedRestrictedStockMember_4d75fe" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_452e7e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_250155" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_452e7e" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:title="000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_3e76ae" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_ddf3b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_3e76ae" xlink:to="loc_us-gaapStatementTable_ddf3b0" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_9be09b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ddf3b0" xlink:to="loc_us-gaapStatementLineItems_9be09b" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis_995b4c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ddf3b0" xlink:to="loc_us-gaapSubsequentEventTypeAxis_995b4c" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_8eae91" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis_995b4c" xlink:to="loc_us-gaapSubsequentEventTypeDomain_8eae91" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_ff26d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain_8eae91" xlink:to="loc_us-gaapSubsequentEventMember_ff26d9" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaapClassOfWarrantOrRightUnissued_878494" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9be09b" xlink:to="loc_us-gaapClassOfWarrantOrRightUnissued_878494" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_RestrictedCommonStock" xlink:label="loc_cvmRestrictedCommonStock_4d9fc8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9be09b" xlink:to="loc_cvmRestrictedCommonStock_4d9fc8" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityOwnedNotReadilyMarketableFairValue" xlink:label="loc_us-gaapSecurityOwnedNotReadilyMarketableFairValue_70b0a7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9be09b" xlink:to="loc_us-gaapSecurityOwnedNotReadilyMarketableFairValue_70b0a7" order="3" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cvm-20240331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/15/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20240331.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheets" xlink:href="cvm-20240331.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:href="cvm-20240331.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:href="cvm-20240331.xsd#CondensedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:href="cvm-20240331.xsd#StatementsOfStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="cvm-20240331.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20240331.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20240331.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20240331.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20240331.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20240331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20240331.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShare" xlink:href="cvm-20240331.xsd#LossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20240331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20240331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityTables" xlink:href="cvm-20240331.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20240331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20240331.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareTables" xlink:href="cvm-20240331.xsd#LossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails" xlink:href="cvm-20240331.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails1" xlink:href="cvm-20240331.xsd#StockholdersEquityDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails2" xlink:href="cvm-20240331.xsd#StockholdersEquityDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails3" xlink:href="cvm-20240331.xsd#StockholdersEquityDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetails4" xlink:href="cvm-20240331.xsd#StockholdersEquityDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20240331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20240331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20240331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20240331.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20240331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20240331.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20240331.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails" xlink:href="cvm-20240331.xsd#LossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LossPerCommonShareDetails1" xlink:href="cvm-20240331.xsd#LossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cvm-20240331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheets" xlink:title="000002 - Statement - CONDENSED BALANCE SHEETS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedBalanceSheetsParenthetical" xlink:title="000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfOperationsUnaudited" xlink:title="000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquityUnaudited" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_WarrantExercisesShares" xlink:label="loc_cvmWarrantExercisesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantExercisesShares" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_WarrantExercisesAmount" xlink:label="loc_cvmWarrantExercisesAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantExercisesAmount" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IncentiveStockForfeitedShares" xlink:label="loc_cvmIncentiveStockForfeitedShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncentiveStockForfeitedShares" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IncentiveStockForfeitedAmount" xlink:label="loc_cvmIncentiveStockForfeitedAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncentiveStockForfeitedAmount" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ShareIssuanceCosts" xlink:label="loc_cvmShareIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmShareIssuanceCosts" order="15" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000009 - Disclosure - STOCKHOLDERS EQUITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000010 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000011 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShare" xlink:title="000013 - Disclosure - LOSS PER COMMON SHARE" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000014 - Disclosure - SUBSEQUENT EVENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityTables" xlink:title="000016 - Disclosure - STOCKHOLDERS EQUITY (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000017 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000018 - Disclosure - PATENTS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareTables" xlink:title="000019 - Disclosure - LOSS PER COMMON SHARE (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails" xlink:title="000020 - Disclosure - STOCKHOLDERS EQUITY (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_StockBonusPlansMember" xlink:label="loc_cvmStockBonusPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmStockBonusPlansMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaapStockCompensationPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockCompensationPlanMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IncentiveStockBonusPlansMember" xlink:label="loc_cvmIncentiveStockBonusPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmIncentiveStockBonusPlansMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails1" xlink:title="000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails2" xlink:title="000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaapEmployeeStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapEmployeeStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_NonEmployeesMember" xlink:label="loc_cvmNonEmployeesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_cvmNonEmployeesMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails3" xlink:title="000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesNMember" xlink:label="loc_cvmSeriesNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesNMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesUUMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesXMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesYMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesMMMember" order="65" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesNNMember" order="66" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesRRMember" order="67" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" order="68" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsMember" order="69" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" order="70" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ConsultantsOptionMember" xlink:label="loc_cvmConsultantsOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsOptionMember" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IssueDate1" xlink:label="loc_cvmIssueDate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIssueDate1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SharesIssuableUponExerciseOfWarrantOptions" xlink:label="loc_cvmSharesIssuableUponExerciseOfWarrantOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmSharesIssuableUponExerciseOfWarrantOptions" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ExercisePrice" xlink:label="loc_cvmExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExercisePrice" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ExpirationDate" xlink:label="loc_cvmExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExpirationDate" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetails4" xlink:title="000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesRRMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesSSMember" xlink:label="loc_cvmSeriesSSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesSSMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_EquityWarrantsExercised" xlink:label="loc_cvmEquityWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmEquityWarrantsExercised" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_EquityWarrantsExercisePrice" xlink:label="loc_cvmEquityWarrantsExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmEquityWarrantsExercisePrice" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ProceedsFromEquityWarrantsExercised" xlink:label="loc_cvmProceedsFromEquityWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmProceedsFromEquityWarrantsExercised" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesRRMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_RestrictedStocksMember" xlink:label="loc_cvmRestrictedStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmRestrictedStocksMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ConsultingAgreementsMember" xlink:label="loc_cvmConsultingAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmConsultingAgreementsMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="loc_cvmIncrementalCostDeemedDividend" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncrementalCostDeemedDividend" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" xlink:label="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ConsultingFeesIncluedPrepaidExpenses" xlink:label="loc_cvmConsultingFeesIncluedPrepaidExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmConsultingFeesIncluedPrepaidExpenses" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_NetofissuanceCosts" xlink:label="loc_cvmNetofissuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNetofissuanceCosts" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockOptionPlanExpense" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" order="13" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmErgomedMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_LandlordMember" xlink:label="loc_cvmLandlordMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_cvmLandlordMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_NetOfDiscount" xlink:label="loc_cvmNetOfDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNetOfDiscount" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestPaid" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne" xlink:label="loc_cvmFinanceLeaseWeightedAverageRemainingLeaseTermOne" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmFinanceLeaseWeightedAverageRemainingLeaseTermOne" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="loc_us-gaapOperatingLeasePaymentsUse" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePaymentsUse" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseWeightedAverageDiscountRatePercent" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne" xlink:label="loc_cvmOperatingLeaseWeightedAverageRemainingLeaseTermOne" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmOperatingLeaseWeightedAverageRemainingLeaseTermOne" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_ClinicalServiceTrial" xlink:label="loc_cvmClinicalServiceTrial" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmClinicalServiceTrial" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_FinancingArrangementDepositBaseRentAmount" xlink:label="loc_cvmFinancingArrangementDepositBaseRentAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmFinancingArrangementDepositBaseRentAmount" order="12" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000030 - Disclosure - PATENTS (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000031 - Disclosure - PATENTS (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails" xlink:title="000032 - Disclosure - LOSS PER COMMON SHARE (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LossPerCommonShareDetails1" xlink:title="000033 - Disclosure - LOSS PER COMMON SHARE (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_OptionsMember" xlink:label="loc_cvmOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmOptionsMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="loc_cvmUnvestedRestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmUnvestedRestrictedStockMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:title="000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaapClassOfWarrantOrRightUnissued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightUnissued" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240331.xsd#cvm_RestrictedCommonStock" xlink:label="loc_cvmRestrictedCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmRestrictedCommonStock" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityOwnedNotReadilyMarketableFairValue" xlink:label="loc_us-gaapSecurityOwnedNotReadilyMarketableFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSecurityOwnedNotReadilyMarketableFairValue" order="3" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>cvm_10qimg14.jpg
<TEXT>
begin 644 cvm_10qimg14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $& C$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[+HHHH **
M** "BBB@ HHHH 3%9M]J%KI\ DN)O+#,$48+,['HJJ.6/L.:TZP6C6;QA+)(
M,FULXS#G^ R.X<CW(11^%"UW$R[:WSWNX_8+JU4?=:=57?\ 09)'X@5'JFH6
M^CZ/>:M>%A;6D+SRE!D[5&3@?05J=ZY;X@?\DU\2_P#8-N/_ $6:J*4I)";M
M%LR$^*GA^1%DCL=39&&580*01_WU3O\ A:6@_P#0-U/_ +\+_P#%5\7S33).
MZI,ZJ#T#$"H_M-S_ ,_$O_?9KWEEU+S^\\KZY4\C[6_X6EH?_0.U3_OPO_Q5
M'_"TM#_Z!VJ?]^%_^*KXOE&IP('G6[A1N TBNH/XFH?M5QG'VB3/^^:T_LRC
MY_>3]<J^1]K?\+2T/_H':I_WX7_XJC_A:6A_] [5/^_"_P#Q5?%!NYP.;J0=
MOOFC[7, ";IP#W\PT?V91\_O%]=J>1]J_P#"TM$_Z!FI_P#?A?\ XJC_ (6E
MHG_0,U/_ +\+_P#%5\5?:Y_^?J3_ +[-*;J=?O7,@^KFE_9M'S^\?URIY'VM
M_P +2T/_ *!VJ?\ ?A?_ (JC_A:6A_\ 0.U3_OPO_P 57Q=<R7-K(B27P?=&
ML@,<^\#<N<$@\,,X(['(J6:+4;?3+/4I)V%M>&01,)22?+(#9';DBH_LZCY_
M>'URKY'V9_PM+0?^@=JG_?A?_BJ3_A:6A_\ 0-U3_OPO_P 57Q5]JN ,FYDQ
M_OFK6FQ:CJVI0:?8SL\\[%5W3;5& 2223@  $D]@#3>6T5J[_>'URKY'V7_P
MM+1/^@;J?_?E?_BJ/^%I:)_T#=3_ ._*_P#Q5?%]S)-;7#Q#4DN57I-;S%XW
M&,Y!XS4K1:@NCQ:L;AOLDL[VRL)>=ZJK-QZ88<TO[.H^?WA]<J^1]E_\+2T/
M_H':I_WX7_XJC_A:6B?] W4_^_*__%5\4B[G()%U(0.^\U9L5U#4KG[-92R2
MR['DQYN/E1"[')/95)_"E_9]%=_O#ZY5\C[,_P"%I:#_ - W4_\ OPO_ ,53
MO^%I:'_T#M4_[\+_ /%5\93QZA;:;8ZA-<,+>_$A@;S>6V-M;([<U6^U7 '_
M !\2?]]FJ_LVB^_WA]<J^1]J_P#"TM$_Z!NJ?]^5_P#BJ/\ A:6B?] W4_\
MORO_ ,57Q2+N<]+J0_\  S5FS34=0NC;6DDDDHC>7;YF/E1"['D]E4G\*/[.
MHKO]X?7*OD?9O_"TM"_Z!^J?]^%_^*H_X6EH7_0/U3_OPO\ \57Q?;-=73LJ
M7HCVQM)F6;8"%&< GJ3T [GBH?M<V<?:I,^F\T?V=1\_O#ZW4\C[7_X6EH?_
M $#M4_[\+_\ %4?\+2T/_H':I_WX7_XJOC.&'4;C3K[4(YV^SV(C,Q,I!&]M
MJX'?FJGVN;&[[4^/7S#5_P!F4?/[P^N5?(^U/^%H:%_T#M3_ / =?_BJ/^%H
M:%_T#M3_ / =?_BJ^-8X]0DTBZU5)V-K:R1QR-YIR&<,5P._W&JQJMCJ6C7"
MVMY?1-<XS)##<;W@. =L@'W6P1QS^E+^S:-[7?WA];J[GV)_PM'0?^@;JG_@
M.O\ \51_PM+0?^@;JG_@.O\ \57Q5]IN?^?B7_OLT?:;G_GXE_[[-5_95/S^
M\/KE3R/M7_A:6@_] W5/_ =?_BJ/^%I:#_T#=4_\!U_^*KXJ^TW/_/Q+_P!]
MFC[3<_\ /Q+_ -]FC^RJ?G]X?7*GD?:O_"TM!_Z!NJ?^ Z__ !5'_"TM!_Z!
MNJ?^ Z__ !5?%7VFY_Y^)?\ OLT?:;G_ )^)?^^S1_95/S^\/KE3R/M7_A:6
M@_\ 0-U3_P !U_\ BJ/^%I:#_P! W5/_  '7_P"*KXJ^TW/_ #\2_P#?9H^T
MW/\ S\2_]]FC^RJ?G]X?7*GD?:O_  M+0?\ H&ZI_P" Z_\ Q5'_  M+0?\
MH&ZI_P" Z_\ Q5?%7VFY_P"?B7_OLT?:;G_GXE_[[-']E4_/[P^N5/(^U?\
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M7_OLT?V53\_O#ZY4\C[5_P"%I:#_ - W5/\ P'7_ .*H_P"%I:#_ - W5/\
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M<F0?E()R. <^PQD:/#8P?$'5+>);8/$UXFF+<;3#]H!80@[OE/MGC=MS7(X
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M!FM-.@N[K4+&"2>V^UI:O(PE,9R5.-N,MCA<YZ=,UW]Y>6$<#7%G#=7/AG[
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M^=F_#%-\4> =%\::OHFI:[<:C)#H\PN8M/2Y*6LLH(*/+&/OE2..>YZ@UW-
M'/ZMI=YJ3!K77KNQ48S#&%\M_J0 _/\ LN*-"D6.WDTUK5+.XL\!XHN48-DB
M13U(;!Z\Y!SGJ=^LB#_D;K__ *\[?_T.:FG=6)M9W-;O7+_$'_DFWB3_ +!M
MQ_Z+-=1WKE_B#_R3;Q)_V#;C_P!%FG2_B1]13^%GPM<?\?,GUJ+J.>E;-GH\
MFK/JDL=_9V@L;9KIENIO+,P'\$?]YO:JFC1I/XATN&10T<EY"C*PR"#(H((K
MZ]26OD?.V* 55^ZH'T% 50,!0!["O0]4\.:2WB2\\10P>3X6@DGFNHD./*EB
MDV-:*>Q=RFS_ &),_P )J#Q1H>B6>OZWJ6HR36=@VIRVMI9Z="C-\H5G/S$*
MJ+O4 =23VQFA5XMI?UZ%NFT<)@9SCGUI"JM]X _6NMN_"NGZ7IVHW^HZO*\-
MO-#';?9H,F[6: S1M\Q&S@#.<XY R:OW/P\N;;[18NNH+J%O TSSM;J+-G5-
M[1A\[NF0'(P6&,8.:W]M#N+DD<&54C!4'\*"JL,%0171Z1;Z1-X%\3W=]'.U
MU!]E^SR1JIV;G8=2<C) !]JV=>T'1;K6K^WM;J6WU*'2HKY88[=5MQLM8W>,
MMG.\C<V0,9XYZUDZJ4K/^M@Y+JYP953C*@X]:7 SG'-=8_A)6\,WFIPKJ44]
MG9B]?[7 D<4J94$+ABZGY@06&& /3BIM4\)Z/976O:9:ZS=7.I:1;FZ8M;JL
M$B@IN3.[=O <'.,$@CWK3VL=OZ_K4.61Q@55Z*!]!1M7;MVC'IBMO0;33[ZX
M^RS:7JNK7TKA8+33F525Q\S9*L2?08QU)-=+!X+M%&KR6]AJ'B.*VU,Z?;&Q
MF2'>JIN9B2K!FR47"]3G&:QE5C%V8E!O8X**22":.6"1HI8V#(Z-M92.A!'0
MU?U+7-8UD1#5=2GO%B)*+(W"D]3@<9/<]36WI[:7=Z;<Z2-/DMI$6;S6EA5S
M%F0;)6DX<,@^01@?.Q _B-8>MHT6HM#_ &9)IB1(J1PS(5D*CHSYZL>23T[#
M@5NFI/5:@U9;C-.U2ZTM[B2R\M9IH7@\UD#/&K##%#_"2"1GK@FJ)52-I (]
M*]6\0Z;):Z_K]OJNDZ19^'(XYQ;RI';QS(PCS#Y93]X6+[1@YR"<^M9-U"NH
MV4D/A*WT&_T_[(#]A:%5U"(B,&1R6 =W#!FRC,,=L<5A[9;VW_K<MP:T//RJ
MG (!Q2X [5ZM!I-Y]JT0MH>D-X8.F6D^H3S0P*5B:-3-*7'[T-R2"/XL8ZUQ
M.AV5BC7GB#4(C-I&G28CADX-Y,<F*$^Q W/Z*#ZBG&LFG_7],EP:.>(5OO '
MZT$+D$@9'2O1+2UUF7P=H>H:+HVCW#W,MVUV]W;VP5F$PV@^9@A "1\O %.?
M_A'4GO[7PG=:%#<C4)?^0M&KI-!A=BPR2J4"AO,'.UB-IS2]MY?UY]A\AYSP
M/04N!SQUZUW%S]KT#PS?3S:)I]GJ9ULP2Q2V<<RQ)Y <(F\-A<G(P>0>N*Q_
M$,%I)INB:Y:V<5BVI0R^=;P@B,212%"Z _=5A@XZ AL<<5K&I=DN-CG\#CCI
M2;5SG:,^N*6BN@D,#)..3UI J@Y"@'UQ2T4 )M7=NVC/K2X&.E%% ";5W;MH
MSZTN!Z>]%% "  $X &:7 YXZT44 &*0 #H /I2T4 6=/O+C2]2M=0LV5+BUE
M6:(E<@,IR.._-5N-[-@ L<D@=:**/, I J@8"@#TI:* $VKNW;1GUHVKNW;1
MGUI:* !,QRK-&3'(I#*Z\,I'0@CH:TM2U[6M82./5=4N+Q(V+*LC<!CU;'=O
M<\UFT4K)NX7"BBBF 4444 %%%% !1110 4444 %%%% !1110 5O>"_\ DH'A
MW_L)6_\ Z,6L&M[P7_R4#P[_ -A*W_\ 1BUG5_AR!'VU1117S!UG04445YA[
M84444 %%%% !1110 5D6_P#R-]__ ->=O_Z'-6O61;_\C??_ /7G;_\ H<U-
M=27T-7O7+_$#_DFWB3_L&W'_ *+-=1WKE_B!_P DV\2?]@VX_P#19HI?''U%
M/X6?"UR ;E\CO2VES)9W]M>1!3);RI,@;H2K!AGVR*2Y_P"/E_K4VFV+:GJU
MIIL<T4$EU*L*23'"*S' R>PS@5]>K6U/G!;K4KV[-XLEPZ0WER;N6!&(C,A)
M^;;ZC<0#Z&M>;Q=<WMS?OJNEV&I07ET;PV\RNJQ3$!2R%6# $  C)!P/2J^G
M>&-1U)9FC:*$VUPUO="4D&VVQNY=^.%Q&XSZKCN*I-I=RFBV>JMMV7L[P01#
M)DDV!=S >F6"^YSZ4_W;T*]Y%G4?$6HZK:WEO>^4RW=U'=/L3;L*1F-$4#A4
M"G 'L*?>>(&OXI9+O2;"749HA#)J#1L97  &[&[9OP -^W/X\U7L]%O;J^N;
M*2-K.>WM9;MDN(V1ML:%R,$9R0.*CU#39=-%B99$?[;:1WB;<_*KYP#[\5=H
M7L@O+<ETW5WTZRU&Q:RMKRVU"-$ECN V%*-N1E*L"""3['/(J63Q%?2:O<:H
MT</GW%F;%QM.WRS (21SUVC/UK+CM[F9)7M[6:<0KOD\J,OL7U.!P/<UH:AH
M=]8Z]<:-'&U]<P!2WV:-GR"H;( &<?,*34;ZA>5B]<>++BY.HS-I5@M[JEJU
MK>W81S),I !89;"'Y5)V@9(].*K3^([ZXU;6-3>.$3:M ]O. IVJK;<[>>#\
MH]:-+\/W&HZ5J.JR2M:V5AM1Y/L\DNZ1LX0!1QPI))X4=>M4Y=-N1J,EG9QR
MWY5BJO! _P"\P 3A2-W&>XI)0O9#;EN3Z6VBB-_[2N]3L;E7#17%@JO\N.5P
M64AL\A@?PK6U#5O#FOZM>W^I_P!JZ=YMV;B..UV3*RD*.A*A)3MR7&02>G%<
MW!:W5U(T=K:SW$BC+)%&SE1ZD <4D-O<W.\6MK-<&-2[B*,N54=S@<#WI.*;
MO<2;M8W=0\6WUUX@N-6M88K-I=0_M'8!N+.#\@<G[P7GTY9CU-9>I:DVI?9X
M_L\=M;VT9BAAC+,$!8N>6))RS$\FG:CI-QIVKKIC,MQ,R0NOE G=YD:NH ZY
MPX'UI]]H.K:?KUWHLEC/->VLC(Z0Q.V[:<;@,9*\<'%;Q4%:P/F=[D&K:A+K
M&M7FKW4<:7%W(99/+& "?2M>'Q9);2"\M="TFVU,(46_AA=73*E2RH&\L/@G
MD+WSUK 2WN)6*Q6\LC E2%0D@@9(X[X!_(TX6EVULERMI.8')591$VQB.H#8
MP>A_*I<8M68DWN:</B*^@URQU:.. 36EK'9!"F4EA2/R]CC/(9>#]>U5;S5)
M[S3['3_+C@M+%7\J*+."S'+.V226/ SZ*H[556VNFM'O%M9FMD.UIA&3&I]"
MV,"KFI:-J&DP6$U[ R1W]NMU"Q5@"K$C!) YXSCT(]:RM%-!J0W6H2WFEZ=I
MTT<?E:?YOE$+\Q\QMS9_$<5;L=8@MK(6=YH.FZG&K%D:X1UD7/4%XV4LOLV<
M=L506SO&MY+A;.=H8P&>41,40'H2<8 -)':W4T$L\-K-+##S)(D;,L?^\0,#
M\:WM&U@NSH)/&-S=Q746K:1IVII/<K=!95D18F6,1*J"-UPH10 #GI61JFK7
M>L7,<UT(HTAC$,$$";(H(QDA$7L,DGN22222:KPV=Y<*S6]G<3JJEV,<3, H
MZDX'3WJ':WEB3:=C' ;'!/U_$5"A%;#<F]Q**OOI5Q'H7]K2$(GVPV1A92'#
MA ^<>F#CUJ2PT'5=0UVQT5+.:"[O75(EGB9,Y_BZ9V^^*WYEO<5F9E%6IK)X
M+423,T<_GM"UL\3JZX .3D8YSC'7CIR*CFM+RWN/L]Q9SPSXW>5)$ROCUP1G
M%5S(1#14LUM<VXC:XMIH1*N^,R1E0Z^HR.1[BE^R7AM/M@M)_LV[;Y_E-Y>?
M3=C&:+@0T4\QRAG4Q.#']\%3E.W/ISZU(]G>1VYN9+.=( VPRM$P0-_=W8QG
MVHN!!14_V2\^S/<_8Y_(0@-+Y3;%STRV,#.1^=-6VNI+:2ZCM9GMXCB298V*
M(?=L8'XT7 BHJ_I>D:AJVI6FGV=M(TEU*D2,4;8"[;020.!G//L?2HCINH?;
MY;%;&XDN820\20LSKCOC&<4N=;!9E6BI8;:ZNG:.UM9KAT4LR11LY4#J2 .!
M6J/#]R?$6F:']HB\[4!;%).=J>>JLN>_&X9^E9NHEN.S9BT58DL;R(Q[[.<+
M,2L+&)@)<''R<?-^%0A696948A1EB!D*.G/I6MQ#:*FAM;JY$C6MK/.(EW2&
M*-G"#U.!P/K5YM&:.SL+J6\C2.^M9KJ/Y&8@1LZ[3@'DE.#T&1DBI;2"US+H
MJ8VMX+>2X-G/Y,9"O)Y;;5)Z G& 3D=?6IY--N#?FSL5DU"38LG^CPN3@J"?
MEQGC.,XQQQP13N@L4J*GAL[RX65K>SGF$(S(8XF;RQ_M8''XU//ILMOHNGZJ
MTJ-%?/,B(,[E\LJ#GZ[ABBZ"Q1HJ>"TNKD,T%O+)'&0))$C9ECSW8@8'XU;O
M]%O['5=2TY8)+LZ=,\,TL$3,@VD@L3C@<=Z+J]@LS-HK0FT;4(= L]<>!OL5
MW+)%&X5NJ;<Y.,8.X8YYP?2JMQ:W5HZI=VL]LS+N59HV0L/49'(H33V"S(:*
MF6UNGM7NTM9VMD.'F6-BBGW;&!0MI=R122QVD[QQJ'=UB8JBGHQ., >].X$-
M%:&EZ/>ZM?VEK;Q.L=S<QVOVDQL8HW=@HW,!@=1QUJE(ACFDC)R48J2/8XI7
M5[!891113 **** "M[P7_P E \._]A*W_P#1BU@UO>"_^2@>'?\ L)6__HQ:
MSJ_PY C[:HHHKY@ZSH****\P]L**** "BBB@ HHHH *R+?\ Y&^__P"O.W_]
M#FK7K(M_^1OO_P#KSM__ $.:FNI+Z&KWKE_B!_R3;Q)_V#;C_P!%FNH[UR_Q
M _Y)MXD_[!MQ_P"BS12^./J*?PL^*K/5O[+?58O[-L[[[;;-:[KN+>;?/_+2
M/^ZX]:QN<<$@]B.HJ6X_X^9/K4FGV<FHZK9Z="RI)=SI C-T!=@H)]N:^JBD
MKL^=U>AZ!'K6AR12W4M]$MQXLB6SU-0Q'V$JN'E;']^;RY/]T/ZU6L=9TFW\
M8R6:W"?8K'3)-+TVZ$QA02XYF\P E/,<RX?'&\'C&1Q%S97%I,4FB=4\QHUE
M*$(Y4X)4XYZ=J66QF6]NK:U#7JVS,&E@B<J5!QOP1D#Z@5/LX]S3G9Z!!J%K
MYEOH]Q+9V\S6-_''+-JOVLQ&6$JL32D!%5F&0-QP2<XS6'JMQI<::!>75O;:
MQ;II4=F]O%>^6\4T;-NW;,L!SQG@YR*YUM.D30(=9,B>1+<O:A?X@RHKD^F,
M.*KS03V^W[1;RP[UW+YB%=R^HSU'O6T::OHQ.3.PANWOO"UO9^&]5@T&:WO9
M[BYMI+[R"P8+Y4GF''F! &7')'7!W5T6J:OI.H7>OPV-U#=75QJ$5T98]2^P
M"[A^SHHPY&#M<,2A(QNSC(X\O:UN(_+\ZWEB5P&5GC8 J3C<..1[U)+8S"\N
MK>U5[U;9F#2P1.5*@XWXQD ^X%)THMWN-39UVOZ\EWHGB&&&]C2::[LEVV]T
M\@NMD,J22;B%+Y.W<<<G!YSFKGB_Q,RV6HQZ'K6UI]=FN2;27:[H((0C9'.W
M<#[97VKS]8)Y+=[B.WE>!/ORJA*+]3T%6;[39M/@T^:61&%]:BZC"Y^52[+@
M^^4/YBA4HIH7/)IGH^IZKI-]/J\&ES1/<-K$MW(T>K?8!<(R)LD#XPX5A)QG
M(+9 .3C.U'56UJTO(=!U:RTF^&HM<76R]-NMXOE(B3+*P3?AED8K@',FX YK
M@#;SB%IC;RB)" TAC.U2>@)Z#-$EO/%,(9K>6.4XQ&\95CGIP>>:GV,5LQ^T
M;.C\97\5UXXDU"VU".\4QVK?:K<D!V6&,,1T(.X'C -=%J30R>(/$FH0:Y!>
MSWEV)K>*/6?L\;VS,[!V<$$LIV_N\@@-G!KSJ2">&?[/-!+%-D#RW0JV3TX/
M-7;;1KRX74=T9MY-/MOM4D4R,KE=Z)@#&<Y<5HX))*^W_ %S.[T.V\6:_ -.
MU]=%UB/?J-Y92.;:8[IE%FPE.[AB/,X8G&3UZU?L[RXO/&%U?:?X@MQHL^F7
M$=O8"XPT2+:/B P=4*$9W8 XW9YY\O-I=?:?LC6DXN#QY)B;?_WSC-:LOB#Q
M%);2Z?)<299!;2D6ZB=DX C=PN\C@#!//2H='2T?ZV*Y];L[*#6]-2+2M2L5
MMS8VFG1PR6\^KF)%98]LL+VP4E][;CD AM^21SCF/$<QO-#\-W4>I17$4.G1
MVKP?:=TD,JO)N!C)R."OS=#Q6$+-ECNS<-]FEME4F&6-@[DL!CIP0#GYL<>]
M,DM;J'89K6:+S%W)OC9=X]1D<CWIQIQB[IDN;:L>F1SWMOJ/@V^/B:VLM+L]
M+M'N[>6YV[8^3(OD_P#+7>O& &SG!QBJ-E?^<WAV[T/Q#;:)IFG$_:K6:Z\I
MH6\YF=VCZS;XRHX#9QM.,5Q-R-6O9[:*Y@N998K=(X4,+;A"H^7 QDJ!WJCQ
MC/:FJ*[_ -?TQNH>E74E[=>'?#TOAO7H=!MOME_<10S7GV7R4-R2C]<,%'&T
M9([ YJAKSZ3XCM;D:/J%C9V]OK-U<%+F00?N94BQ*B'D@F-OE4$C(&*Y;R=8
MOI=,T1X)V?=Y=G;R1E3^\?)QD9(+'.:36M+71M5ET[[8MV\)*R.D3Q@,"00
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MNH[7Q'-K7B*VU*RU"0?8(([L3;I?/5DE1!_J51 X.0OWMN#5K6KZYU&[N?\
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M1+G6M,\2:1_;WBZWE5Y+E4']IB<QL\#*)&D!(1&8J.6'(R0,9KFO^$+\6_\
M0KZM_P" ,O\ \31_PA?BW_H5]6_\ 9?_ (FL_<U7,M1^]V.FTN\CL]$L=/DU
MBU@UQ8=1AANS<JZP3O)"0QE!(4N@D429X)SGO4]AJS:2NGIJ>L6USK=I9ZD1
M.9UN/(1X,0PM)DAVW[F"Y.W<!WQ7)?\ "%^+?^A7U;_P!E_^)H_X0OQ;_P!"
MOJW_ ( R_P#Q-#5-[R%[RZ$FJZI)J7A+15O=0>\OH+R[!,TIDE2-EB*Y).=I
M;>1[YKG:W_\ A#/%O_0KZO\ ^ ,O_P 31_PAGB[_ *%?5_\ P!E_^)KKC.G%
M63$U)]# HK?_ .$,\6_]"OJW_@#+_P#$T?\ "&>+?^A7U;_P!E_^)KH]K#N1
MRR[&!16__P (9XM_Z%?5O_ &7_XFC_A#/%O_ $*^K?\ @#+_ /$T>UAW#EEV
M,"BM_P#X0SQ;_P!"OJW_ ( R_P#Q-'_"&>+?^A7U;_P!E_\ B:/:P[ARR[&!
M16__ ,(9XM_Z%?5O_ &7_P")H_X0SQ;_ -"OJW_@#+_\31[6'<.678P**W_^
M$,\6_P#0KZM_X R__$T?\(9XM_Z%?5O_  !E_P#B:/:P[ARR[&!16_\ \(9X
MM_Z%?5O_  !E_P#B:/\ A#/%O_0KZM_X R__ !-'M8=PY9=C HK?_P"$,\6_
M]"OJW_@#+_\ $T?\(9XM_P"A7U;_ , 9?_B:/:P[ARR[&!16_P#\(9XM_P"A
M7U;_ , 9?_B:/^$,\6_]"OJW_@#+_P#$T>UAW#EEV,"BM_\ X0SQ;_T*^K?^
M ,O_ ,31_P (9XM_Z%?5O_ &7_XFCVL.X<LNQ@45O_\ "&>+?^A7U;_P!E_^
M)H_X0SQ;_P!"OJW_ ( R_P#Q-'M8=PY9=C HK?\ ^$,\6_\ 0KZM_P" ,O\
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M-T?4*W=?C_D'UJGV9]545\J_\+TUC_H.ZG_X"VO_ ,;H_P"%Z:Q_T'=3_P#
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M;H^H5NZ_'_(7URGV9]545\J_\+TUC_H.ZG_X"VO_ ,;H_P"%Z:Q_T'=3_P#
M6U_^-T?4*W=?C_D/ZW3[,^J?EHX_R*^5O^%Y:Q_T'=3_ / 6U_\ C='_  O+
M6/\ H.ZG_P" MK_\;JO[/K=U^/\ D+ZY3[,^J?EH^6OE;_A>6L?]!W4__ 6U
M_P#C='_"\M8_Z#NI_P#@+:__ !NC^SZW=?C_ )!]<I]F?55%?*O_  O36/\
MH.ZG_P" MK_\;H_X7IK'_0=U/_P%M?\ XW2_L^MW7X_Y#^MT^S/JFBOE;_A>
M6L?]!W4__ 6U_P#C='_"\M8_Z#NI_P#@+:__ !NE]0K=U^/^0OK=/LSZH^6E
M^6OE;_A>6L?]!W4__ 6U_P#C='_"\M8_Z#NI_P#@+:__ !NG]0K=U^/^0?7*
M?9GU317RM_PO+6/^@[J?_@+:_P#QNC_A>6L?]!W4_P#P%M?_ (W3_L^MW7X_
MY!];I]F?5/RTW"_W:^6/^%Y:Q_T'=3_\!;7_ .-T?\+RUC_H.ZG_ . MK_\
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MF,RW&I7"SRQKMV^4C!00G?G.2!TKG*ZX<UO>,Y6OH%;W@O\ Y*!X=_["5O\
M^C%K!K>\%_\ )0/#O_82M_\ T8M15_AL2/MJBBBOFCK.@HHHKS#VPHHHH **
M** "BBB@ K(M_P#D;[__ *\[?_T.:M>LBW_Y&^__ .O.W_\ 0YJ:ZDOH:O>N
M7^('_)-O$G_8-N/_ $6:ZCO7+_$#_DFWB3_L&W'_ *+-%+XX^HI_"SX6N/\
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MKL $<-M()Z#!ZGI7=QZLUU'K4DD%C:II.L6DEB(;>-!:J;AT8 XR5*XSN)Y
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M\#6\OA73H[V]ENYH]2Q;)<2*N%\E&# [8B-Y)X!.<G@5VN5M_B$+R-+>*?\
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M2+R./6?!6B)9V7V'4=/C2^WVR,]T'>5?G8C(( &,$8/-3[?R#V?F>9[E!P2
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MF1)()O.$CB7.[S QW9]<]:0DDEB223DD]2:&&UF4,& )&Y>A]Q25U$!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !6]X+_ .2@>'?^PE;_ /HQ:P:WO!?_ "4#P[_V$K?_ -&+
M6=7^'($?;5%%%?,'6=!1117F'MA1110 4444 %%%% !61;_\C??_ /7G;_\
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2_OD445-V;V1+M3^[1112)/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>cvm_10qimg9.jpg
<TEXT>
begin 644 cvm_10qimg9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %& 94# 2(  A$! Q$!_\0
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M *\HL?AW+:_#_3I_$D.L>(-7ATNSLUM+::&VET]8VCD/D%2@WI(BMN+$GRU
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MX\K&=FTK\Q8G.:K?%+Q%KVJ>(_[7\/WGB:-;O1;2?PFEA'<Q1SWQN3YHE10
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M73=+V:EKG3R@<QVY]9"._P#LCGUQ7GWQ,^.TUV9]#\%S-!!RDNHCY7?U$?\
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M!_.J^U[CF8;(NT?<_7_"@!//W*?+B>1?[RXP?ID\UY#\?I96\%V$)22..2]
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M.D_Y]9/S7_&CSI/^?63\U_QJ:BF,A\Z3_GUD_-?\:/.D_P"?63\U_P :FHH
MA\Z3_GUD_-?\:/.D_P"?63\U_P :FHH A\Z3_GUD_-?\:/.D_P"?63\U_P :
MFHH A\Z3_GUD_-?\:E!R!QCV-+10 4444 %%%% !6/K"S?V>\T&K#2U@S++/
MY:R ( 2<AN .^?:MBLS4]-M=6L6T^\#-;NR,Z*<;PK!MI_V3C!'<9% ''6>J
M>)KZ+3M/74$M;JXLY]1,\EJI8QAU$,;+G .UP6QZ8&.M,3QAK3SZ;J<ENT6F
MSVL%R\26S.K(\3-(WF] RN%4+WR.NX8ZC5M M=6:*2::YMYXD>(2VLIC<QOC
M<A([' ^A (Q5A](L6L;*Q6,QVMDT;11(<+^[^X#Z@$ X]0* ,_P_KT.J1_99
M+@-J42EYD6-D0?,5(0D8=58%-PSROO71LVU"VTMCL.IK#TOP_I^DW\]Y:B8M
M+E5$DA98E+ERJ#L"S$__ %@*Z"@"FL32,'N.@Y6,=!]?4U<HHH *K23;6\M5
MWR'HH_F?04AD>8E8.%[R'I^'K4D<:QKA>IY)/))]Z $CA.[S)6WO^B_2IZ*:
MS*JEF( '4F@!*\<_: _Y$_3/^OX?^BVKUH2S-_JX<KV+MMS^&*\@^/S2GP?I
MF^-5'VX=&S_RS;VKT,M_WJGZG%C?]WD?.5;G@WQ%IOA?Q:FM:AI=QJ+6\9^R
M1QLJK'(>-[9]!D#'J3Z5AT5^CUJ4:\'3ELSY&$W"2DMT6]6UBYU37I=:U9'N
MWNKD37*1MM++N&44]OE^4>G%>AWWQ.\"ZSHMGH5SX'U2WTVU_P!7;6]TL46?
M5@I&X^YSSSUKS&BO*JX&C4Y;MKEVL[6-Z>(E!.VM][E>^MK4W=Q-91RP122-
ML0-EEC)X!/<@5V:^/FTKQSX?UO1]+D31=$M?L5MI[2#=Y3+B1B1QO8G.?85R
ME%9U,%1J?$NEOO'"O.'PG3ZUXDT6Z\)Z?X9\,Z;?66FVMS+>,U_*LDKR/GCY
M> HR?T_&AI/AJSO!_:LDC>>QVC(!"8XXK'KL_#O_ "!X_P#>;^=?*9_S8'"J
M-&35VD_-/5W/L^'80Q6(O6BG9-KR::L1C082.+I_^^11_8$6?^/J3_OD5KR.
ML:-(QPJC)-=79>&;>WT2PU35-/U.^EOT\R*VL8\^6F 0SMVX([]\8/-?DTJ=
M;%-\CVW9^H3Q-'"13J+?9=3SW^P(<X^U/_WR*/[ A_Y^G_[Y%=YX=T73_$/B
M+5[%3<0QV,?G):G"W$@R1MYZ$8P?J*BUK3=+M_"=MK4-O>Z9/+<?9S9ZBH$A
M.XJ6'? ]>F*XU@,0XN2:MK\[.Q#S7#J2BT[Z?*ZN<1_8,.[;]J?/^Z*7_A'X
MO^?I_P#OD5W.I:#I-M=:]I<;7"WVCVD=U+.[#RY R[B ,<52NM)DAMK*..VG
MFOKF+[1-%&I<0QG[@( X8]>:YIX/$4[\W3^K'51S'#SMR]>_I>YR1T"(*3]I
M?C_9%<3+*\S[G/T'85Z?(I7>K JPR"",$&O+*,*Y2YN8Z<3RQY>7J%>N? '_
M )*!=?\ 7@__ *,CKR6O6/@*9!\0+O8@8_V>_!;'_+1/:O>P'^\0]3Y[,?X$
MO0^J:*@\RZ_YX)_W\_\ K4>9=?\ /!/^_G_UJ^]/@ N_^/.?_KFW\JCL?^09
M:_\ 7)/Y"FW3W'V.?]PG^K;_ ):>WTIEB]Q_9MM^Y3_5)_RT]A[4^A/42'_D
M-WW_ %SB_P#9ZT*RH7N/[9O?W"9\N+_EI_O^U7]]Q_SP3_OY_P#6J9;_ '#1
M/14'F77_ #P3_OY_]:CS+K_G@G_?S_ZU,9/14'F77_/!/^_G_P!:CS+K_G@G
M_?S_ .M0!/14'F77_/!/^_G_ -:CS+K_ )X)_P!_/_K4 3T5!YEU_P \$_[^
M?_6H\RZ_YX)_W\_^M0!/14'F77_/!/\ OY_]:IAG SUH 6BBB@ HHHH **X1
MI/%']LSW&BR>5IPG=9/[8F5HI&W;<0[,NHW<#<<>BU9\3:AK45CH]G9P&"^U
M*Z$,@AF4; (WD95D88!.S&[;G!.!G% '945YM,^KZII-E<::-0\G3WN8+ZV_
MM#RIVD1@/]9@AP"K8Y&<C/>FS:AK:W.G:_8M>SZ-)!;O;AI5VR(T; I(I.XR
ML[1@'GKUX.0#TNBN0\+Z^+[&F7!N)+N.)I3<2[=MP!(R.R8.0H<$ $ XVUUC
M%@A*KN/89QF@ >18T+.VT57VM<?ZP%(O[G=OK_A3DB.[S)FWOV]%^G^-6: $
M    X [4M%5GD))CA 9^Y/1?K_A0!))*L8&>6/W5'4U"L3,PDN.W*QCHO^)I
MT<0C)8DNYZN>I_P%6: $/6O&?V@/^1/TO_K^'_HMJ]E;J*\:_:"_Y$_3/^OX
M?^BVKORW_>J?J<>-_@2/FBYF,,.\#)STKU_7M#^'=O\ \)/'I\D8O[.S1A;!
MCMLBK(&D!S\V\2 CKC:U>1NJR+M89%1-:P,/]6*^YQ5"I5E&4)N-NW75'R]*
MI&":E&]SU-/!NCZ3JERTX-Q#Y]_#;I<.C+)#':>9%*,=26/!Z<=*CDTGP_'%
M-<VNE)%:OI>GW4<DLBRI+))-$LNPD95AN8-SWZ"N'\.^$W\1/>QV4UE:I9QI
M)-)=2%% 9MJ] ?XB!6C>?#G5-/TN[U#4FT^RAMY)H\3W&#*T7WPA (]ADC-?
M/S@XSY9U=?Z9VIIQO&&AV&N>&?#NFZEKLU@8;JT;3K^XCD&PQ0S1SA!#&O56
M13U[YXXJ'_A _#,FH7EO'K%U"+*^FL]DDT;M>%;=9E$>%X))(Z-G''/%<AK/
M@/4=!TTZA=26$T4;0K*D$I9X3(FZ/<"HZCTS7-FSMR1^[''M711HU9QO3J7\
MS.=2$96E Z#Q)IMGI'B"XL;&2>2V4(R?:4VR+N4':P]03CH/H*W?#H_XDR?[
MS?SKB5 50H&!7;>'/^0*G^\W\Z^=XI3CA8IN[NOR/L.%6GB)-=G^:+6I1O)I
MD\:#!*D5VMIXIM=:L/"5U;^+AH<^DA$OK*5V7SU4*" O1\[3CKPWM7*G''I4
M0MH/,WB%=W7I7Y+3QDL,I65T[?@?I&*P4<5RMNS5_P =]SJK7Q5X?NOB+XDU
M&29=*NKRU6#3=0DCXC8(59_8D[2,]A3=<U"UU/X?1Z'K.N6FO:XDV8[VT7B)
M,]VP,G&0?7/MFN8DMX9?];&K?6G1QQQKMC4(/:F\PJ.DX\JO*_XO\SA66THU
MHRYG96_!=^Q:TW7-4O-1ATWQ%K@_LU%$MPK1JLEPL?*1%@-SY..">F:FTOQ)
M)J6GZGYNO0Z/K<FJI=F2>1HUDMU"CRE8==H&-O?\:H;%+[BH#>M,\F%W,C1J
M6]<5R4\;5A93][?=_P!;'HSRVC5;<?=VV2M_3-;7KZUU37+^^M<&&5AM91C=
MA0"WXD$UXW7J;?<;Z5Y96>%DYSG*6[=_O.ZO25.G"$=HJWW6"O7/@!_R4&Y_
MZ\'_ /1D=>1UZY\ /^2@W/\ UX/_ .C(Z][ ?QX^I\_F/\"?H?4M%%%?>'P)
M!=_\><__ %S;^51V/_(,M?\ KDG\A4EW_P ><_\ US;^51V/_(,M?^N2?R%/
MH3U(8?\ D-WW_7.+_P!GK0K/A_Y#=]_USB_]GK0J>HT+1113&%%%% !1110
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M @Q=?\](O^^#_C1BZ_YZ1?\ ?!_QJ>B@"'%U_P ](O\ O@_XU*,X&>OM2T4
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M_0M'_P "_P#["GY"\SUJ".1=7NY&4A&CC"MV)&[/\Q5_O7BW_"]T_P"A:/\
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M?*-?6GP:_P"23Z5_OS?^C6H [K[.O_/:;_OLT?9U_P">TW_?9J>B@"#[.O\
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MQG\&1\S9HS3:*_2#Y4=FC--HH =FC--HH =FNR\/G_B2Q_[[?SKBZ['P^?\
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M7?5<-2[J )]]&^H-U&Z@#-\3M_Q3TO\ UT3^=>?EJ[KQ,W_%/R_[Z?SK@"U
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M 1V]*\1_:0FCD\"Z4(W#'^T!_P"BWKW&.-8QM1<"O$/VE/\ D1-)_P"P@/\
MT6]=N7_[S#U.7%?P9'RWS1S3:*_1#Y<=S1S3:*8#N:.:;10,=S76Z"?^).G^
M^W\ZY"NLT(_\2A/]YOYU^?\ &'^[KU7Y'VO"O^\/T?YHULT9IF:,U^&G[)<?
MFC-,S1F@+C\T9IF:,T!<<Q_=M]#6K8-_Q+;7_KDO\JQG/[MOH:TK%O\ B6VW
M_7)?Y5]?D>\OD?&YWM'YE_=1NJ#?1OK[$^)+ :EW57#\TN^@"?=1NJ#?1OH
MSO$K?\2"3_?7^=<&6KMO$C?\2&3_ 'U_G7"%J '%J^P_@C<0I\'=(#R '?/Q
M_P!MGKXW+5]E_ LY^#.C_P"_/_Z.>@#T3[5;_P#/04?:K?\ YZ"IJ* (?M5O
M_P ]!1]JM_\ GH*FHH A^U6__/04?:K?_GH*FHH A^U6_P#SU%2@A@".0:6B
M@ HHHH **** "L75KB\M+![BS:T0I\TDEY(4CC0 DL<#G]/K6U63J-O?W$,:
MZ?J7V"96W;S")588^Z0<?7@CI0!RMQXROET;1KY;>TM([\3&2XN#(\*!" K
MJN=KCY@6QQUJQ<>,I+/Q!;Z?<K:FV\N)II4E.YP\;N98QWC79R??VYM1^'-0
ML]*33]-UY[;+3/<.]LDGFM*Q9F X"8). ,@9Y!J\V@V:Z-IVD0L4M+(11X8!
MFDCCQA"?0E5SZX([T +H>LPZM;[BT*W:<S6T<H=[?).U7'9L=?<'TK=9E12S
M,%4=2:Y?1?#,>C:I/??;GG#(T4*% OEHTK2D$C[QW,>3V_$GJJ *?[Z=NZ0_
MDS_X#]:M*JHH55"J.@%.HH *ADD6-=S?0 =2?:F23;6\N-=[^G8>Y-$<.UM\
MC;Y/[WI[#TH ;L>;#3?*G:/_ !]?I5NBB@!O\5>&_M+?\B)I/_81'_HMZ]R_
MBKPS]I;_ )$72!GG^T!_Z+>NS ?[Q#U.7%?P9'RQFC--HK]"/F!V:,TVB@!V
M:,TVB@!V:ZS0S_Q*$_WF_G7(UU>AG_B4I_O-_.O@^,-<*O5?D?:\)_[T_1_F
M:N:,TS-&:_$;'[ /S1FF9HS2L,?FC-,S1FBPAS'Y&^AJ]8M_Q+K;_KFO\JSF
M/R-]#5NR;_B7VW_7-?Y5];D6\OD?'YUM'YE[?1OJ#=1NK[ ^+)]].WU6W4[=
M0!/OHWU!NHW4 4/$3?\ $BD_WU_G7#%J[+Q"W_$CD_WU_G5;PCX%U;Q7>)Y,
M3Q6F[#2E?O>RCO\ R% &%I>DZAK5\MGI]NTTC=<=%'J3V%?7'PO\,^(-!\,V
M6G7.HL+.#<P0+C<68L<=\9-:'@CX;:5X9L8\VZ^9PQ!Y)/JQ[FO00 H ' %
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MJM_^>GZ&@#R)?@7ILS(M[JSW$(8,8_+ #8]<&O2=%\.Z;H-LL-C"!M&W=@#
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40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cvm_10qimg8.jpg
<TEXT>
begin 644 cvm_10qimg8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %W 9T# 2(  A$! Q$!_\0
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MY'7OQ6!??$'Q;KFHV7BG3[Q=.OKSX;WNJ"".1_L\4RS [PN3\P4'!.><9XH
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M@:UCNV3,B1,<L@/H3VKG)?A3\-9["VT^;P3I#6MM))-!"ULI6)GQOVCL#@9
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M_:K?_GXB_P"^Q1]JM_\ GXB_[[% $U%0_:K?_GXB_P"^Q1]JM_\ GXB_[[%
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M]]BC[5;_ //Q%_WV* )J*A^U6_\ S\1?]]BC[5;_ //Q%_WV* )J*A^U6_\
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MG]Q?RIU% #?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q?RIU% !1110 4444
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MP?RJ6D4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!155ILL5AC,A'4@X ]LT_P VX_Y]3_WV* )Z*@\VX_Y]3_WV*/-N/^?4_P#?
M8H GHJ#S;C_GU/\ WV*/-N/^?4_]]B@">BH/-N/^?4_]]BCS;C_GU/\ WV*
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MG&SN>CA*M2=2TW?0]DJIJ7_(+N_^N+_^@FG^;<?\^I_[[%5-0EG_ ++N\VI
M\E_XQ_=->&CU67;?_CUB_P!T?RJ:J5O+<?98O]%/W!_&/2IO-N/^?4_]]BD]
MP1/14'FW'_/J?^^Q1YMQ_P ^I_[[% R>BH/-N/\ GU/_ 'V*/-N/^?4_]]B@
M">BH/-N/^?4_]]BCS;C_ )]3_P!]B@">B@=/2B@ HHHH **** "BBB@ HHHH
M ***ADF6/ P6<_=0=30!(S*BEF8!1U)JK^^N#W2'\F?_  'ZT1PL[B28Y(Y5
M!]U?\3[U<H :JJBA54*HZ 4ZBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "@]**#TH ^*O'/_)0=?_Z_Y_\ T8U9ECH^K:M'))I>FW=\D7#M
M!"SA?J0*T_'/_)0=?_Z_Y_\ T8U6_A[IZR:R-6O/$D5K8Z;.+B/36OT@DO+@
M ;0 [ !>F6/;@=Z^X^L2H86$H]D?'2@JE9Q?=F'8Z#KFJ1S2:;H][>+ =LAA
MA9Q&?0X'!]JC@T?5KJRN+ZUTNZFM;7_72QPLR1^NXXXKMO"MO<7'CC4_$VM>
M(K*V%E?27B:3!JD:"[N6P0%)8+Y8R 7YSC'K5+0_&5Y#K\^AZI9VD=Y/J%W(
MM_'?!+6W^T+B9G RLJJN2N".<"L_[4KW:A%.UO\ @^ILL-"RYG:YQTMK=006
M]Q/;R117*EX79<"50<$KZC((S7->(?\ 66WT;^E>SW%UX'\1>&+C4U^RP^1:
MW-M;B6Z*7-H(2JV<<<.?F#C+,<'ECR*\8\0_?MO]UOZ5UT<7]8IRYDTU_F8>
MR]E46M[F'7VK^SK_ ,D:L_\ KZG_ /0J^*J^U?V=?^2-6?\ U]3_ /H5>1FO
M\'YK]3V,%_$^1Z]534O^07=_]<7_ /035NJFI?\ (+N_^N+_ /H)KY='LLEM
M_P#CUB_W1_*IJAM_^/:+_='\JFH>X(****!A1110 4444 %%%% !1110 53N
MII;>VEFCMY+IT7*Q18W.?09('YFKE9FJ'4O[+N6T?[/]OV'R/M)(C#>K8&<4
M 8*^+84AN%N-+NHM2@N8[3[#N1F>210R;6#;<%3DDGC!STJ.;QM:6]D)O[.N
MGN(VG%S;#9NMQ  9226P<!E(P3D,,55M_#NL+I,+?9[5-2MK]-1:62Z:4WLF
M"K[V\M=F5.!@$+@#&!5V'PKYVEWS:M9VEWJ5S=2WJ1L6,43LH54W8!9=JJ&X
MYYXH W+/45U"\NDMU8QVSK&9#C:[%0Q [\ C/OQV-:U<!;^#[^U\2V-Y#=1F
M* QN]PS,)LA7\U N-I$COO)SUSP<#'?T 5))F9S%" S#[S'[J_XGVJ6*%8P6
MY9V^\QZFI%544*JA0.PIU !1110 4444 %%%% !1110 4444 %%%% !1110
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MUJR6I'J4+!FS]Y1CO7JNE^--:O/C1JO@F\TVVMM-M])BU*TG28O-.'D*'>.
MF"K#;R>,YYP-BX^'_@F^724O/">DS)HX T]7LT(M0"" @Q\HR <>HJ>/P3X/
MA\7OXNC\-V*>('SNU$0CSSE=A^;K]WCZ4 =-1110 4444 %%%% !0>E%!Z4
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ML+3$S!=H (&.&//S"N]KYA^ O_)1Y_\ KPE_]#2OIZ@ HHHH **** "BBB@
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MQ_Z,:N<S7Z;@?X$/1?D?&5?CEZCJ*;FC-=YD.KN? /\ J=0_WD_D:X3-=UX
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MY\;OAW87LMG)KC2O$VUGAMW="?9@,'ZCBKITJE7^'%OT(E4C#XG8].JA<_\
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MU;_OM:/-N/\ GU;_ +[6K-% %;S;C_GU;_OM:7SI\?\ 'HW_ 'TO^-6*#TH
M^%?'C$_$?Q(67:?[2N..O_+1JYK-='\0#_Q<GQ+_ -A*X_\ 1C5S.:_2L%_
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MP1],2[J-U1;J-U %76F_XD5[_P!<S7G)->@ZRW_$CO/^N9KSLF@#V#]GD_\
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M5\F?LZG_ (NA<?\ 8.E_]#CKZSH **** "BBB@ HHHH **** "BBB@ HHHH
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MKRLU_P!VG\OS1VX+^+'Y_D=7NHW5%NHW5\*?2$NZC=46ZC=0!6U=O^)+=_\
M7,UP!-=WJ[?\26[_ .N9K@>6.!R: /8OV=]S?$ZXVN4_XETO(Q_?C]:^L?)E
M_P"?J3_OE?\ "OBOX<V/BNW\0"[\-RR6UU(AA:15SA203G\A7UMX8T_7+6P1
MM;U22[G(YSVH WO)E_Y^I/\ OE?\*/)E_P"?J3_OE?\ "IJ* (?)E_Y^I/\
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MUO%&_P!Y40G"C^7;%==10!RUKX0TN&&TAEDN[U+6.:!/MDYES'*%#*V>HPH
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MFS:^)UJ:![^WO/+'R6JAV<D8QE3&4_X&AKLO!GP^T/P,UZVCRW<AO GF?:)
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MU&WE0-+,!\ZQ;@0=O=B,9R.<'&E<^%5OX0NH:M=7,_V&YT]YV5%9UF*Y8@*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cvm_10qimg10.jpg
<TEXT>
begin 644 cvm_10qimg10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" #O B0# 2(  A$! Q$!_\0
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M1/\ P3C_ .+KV6B@#QK_ (7Q+_T1[XB?^"<?_%T?\+XE_P"B/?$3_P $X_\
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M ,53Y)=OQ%[6/?\ !GRGH4U]X;\"? W7-2T'5Q:^'-0U&'45CL9'D@9BP7Y
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MM7+>&;G3C)_PCJZ5;:@SHVV,#<&>13CG9Z#/K]+_ /"2S_\ 0M:M_P!^D_\
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M_P!"UJW_ 'Z3_P"*I<DA>UCW_!G1;A1N%<Y_PDT__0MZM_WZ3_XJC_A)I_\
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MA";5(]2;0;=;Q)GN/-7<I9W?S&+8.&R_S8;(SVJ(?#CP:MC]@7P_ MN)EG5
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MO?@G_L&I_,T4 <W\2_\ DY;X-?[^I_\ HA:]M)P"3TKQ+XE_\G+?!K_?U/\
M]$+7M<G^J;Z&@#S#_A?7PC4LI\80@JQ4_P"CS=1Q_<IW_"_OA'_T.,/_ (#S
M?_$5\/Z!I<VO>+-.T&&<0/J-\+596&0A=\9(KK=7^'T-O8ZO=^'?&%IX@;1Y
M1'J5M%;2036Z[]GF!7^^H;@D&O0^K4U;FEN>3];JN_+%67F?6?\ PO[X1?\
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M-6[6%XR_Y$#Q%_V#;G_T4U ')? 7_DWOP3_V#4_F:*/@+_R;WX)_[!J?S-%
M'-_$O_DY;X-?[^I_^B%KVN3_ %3?0UXI\2_^3EO@U_OZG_Z(6O;&7<I7U&*
M/S9\(ZK:Z'\0=$UJ_P!_V2PU-+B;RUW-L63)P.YKN;[Q9X)T%?%-UX7O=4U;
M5/$Q,,DMS:K!%9P/,)) !N)=CC / KU@_LHZ3O=E\;7X#,6Q]DC.,G/K3O\
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MD:>PY/<F@#?MK@7-G%<>7)%YBAO+D7:ZY&<$=C5NBB@ HHHH **** "BBB@
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MT/&O_P#@PD_QKT[4M4^&MUK>MZ?J%OH4.@V.I:7+;2V$06::)N+H[E^9U_O
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MF'*BA_9&E_\ 0-M?^_*_X4?V1I?_ $#;7_ORO^%7Z*.9ARHH?V1I?_0-M?\
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M1^)O_)-]7_W8_P#T8M=='_J5_P!T5Y#_ (:]7^A[*_B/T1-67<3222FUM?\
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M1@DA5$,<\O\ K&X'1NZGCVJ>Z^)GBZ[US2]<D\0I%>:26:R$$,<44!;[V(U
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M7<,8HE 55)]<#)]R:=.513]YZ!5C%P]R.IR]%+NA_P"?B/\ .E!C;.V56([
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M>F,$BM'2_A'\?-%TI]+TG[-:6;[ODCU"+*;AAMC%=R9'7:1FL+_AG'XK9_Y
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MVLIM6NDOTU#3OM,]] JQGRH6"DJPR<'(P2*3C0Y;QA?[QQJ5^;EE.W7H6?\
MAJ3XA9Q_9_A[/_7";_XY1_PU)\1?^@;X>_[\3?\ QRI]'LUNK7P#I-EX+LK[
MPUK%M,^I33V"M)#%]HD'F-<@91DC .<]O>N.\!^&='_X61X9F76]*UBTN=4,
M/]F_,\_E_. 9$*[<84'J>HJ8QHV;<-O,;J5KI*>_D=5_PU'\1/\ H&^'O^_$
MW_QRE_X:D^(G_0.\/?\ ?B;_ ..5Q_@'P;:ZM\0X=%\6>'=<^SWDCI L$30J
MIR?F=B,A ,=.Y%>>74$MI>S6T\,D,D3E6CD4JRX/0@\BMU1HRDXJ)C*O7C%2
M<MSW/_AJ3XB?] WP]_WXF_\ CE'_  U)\1/^@=X>_P"_$W_QRO!OPH_"M_JE
M'^4Q^N5OYCW@_M2_$3'_ "#/#_\ WXF_^.5]1^!=<OO$_P /=!\17\<4=UJ-
ME%<R)""$5F4$@9).*_.4=#7Z%_"#_DBG@W_L%0?^@"O-QU&G24>16O<]3 5Z
ME5RYW>UCKKNZ@L;.:\N&V0P1M([>B@9-<-X1T7^VKJ'QWKL)EU*YS)91MP+.
M YV*H]2#DD^M:OQ(E:'X<:VR'!>#R\CT9@I_0UT=G"MM8V]N@PD4:H![ 8KS
M5[L.9;MV^1Z+]Z=GTU/%_P!H+_7>%?\ KI=?^BUKQ,JV?NFOK#QAX%T7QLMD
MNLM=*;)G>%K:<Q$%A@YQUX%<O_PHOP;G_CZUG_P.;_"N&K0E.7,CY/-LFK8W
M$>VIR25DM3YXVL5'!K=M_%&K6-CI$&FYLY]-CN(1,C;O.29]Q!!'&.,>X!KV
MK_A1/A'_ )^M9_\  ]O\*;_PHOPB!S=:R!_U_M_A6:P]1;,XZ.1XBA?V<DK^
MIXY9^*'MTLH;K31=V\6EMI5Q%YY0S*6W;PV/E;./6I_^$PC8);R:#']B&GMI
MK01W3@^5O#(P8@G<,<^OM7IVF?"/X?ZSIUOJ&EZMJES:7(+0R)J#8D ."1D<
MCCK6A_PHSPAT^U:QG_K_ &_PK3V57NCL668I*W.ON_ \>A\6&.31KEM'4WFF
MV9L6F%PV)8O+9%^7'RD;L^]1W'BJ^O-#M]!O+%9=-ATU+(0F0C9,F=MPAQPW
M.".A'%>R?\*+\'_\_FL_^!S?X51U3X1_#_1;$7VJ:MJEI;F6.$227[8WNP1%
MZ=2S ?C2]G5[H?\ 9N*LUS*SW\SR+7/$5QKD6JQR6/D?;Y+>0L)"WEF.+R\=
M.<]:TV\<7TU[J+3V,R6M]-'<B.TOG@DBD6-8R-X'S*P49!%>KM\#?!J*6:ZU
MC &3B^8_TJIIOP?\ ZSI=MJFEZIJMU97*"2*:/4&*NI[]*/95=[F*RG$J3DI
M*[_KL>(:I?7&J:E<:A/OWS-G#R-(5'0#<W)P..:J;6_NFOH;_A1O@_=_Q]:S
M_P"![?X5YW\3_ .D^";/1KK1[G4&>[NV@E6YN3*I7RF;H1UR!6,L/-)R;/)Q
M605H1E5E).UV]SSK[IKL/ /@&Z\>:@TTWF6WA^W?;<7*G:URPZQ1G_T)ATZ#
MGHWX?^ [SQUJ322M):^'[9]MS=+PUPPZPQ'_ -";MT'/3ZEL-/L]+T^#3]/M
MX[6TMT$<4,8PJ*.@ JZ%"_O2/2R;*-JU9:=%W\V+I]C9Z;I\%A86Z6UI;H(X
MH8UVJBCH *\W_:"CDD^!7B!(HWD;]Q\J*6/^N3L*]6]*/:O1B^5I]C[>4>:+
MB?F)]ANL_P#'K<?]^'_PKH]#\6>//#=@^GZ#KFL:=9L2WD1*^Q2>I4%3M/N,
M5^BVTT[ ]*[WC7+244SS8X!1=XR:/SET_P 6>/=*T^6QTW7-:M;>:X-TZ1B0
M$RDY+YQD$D9///>JMQJ_B#4KRQEUMM0U2&SN&N%A=9(^7DWR;65<J6;G(Z'F
MOTEQ28'I2^M_W$7]1_OL^$/%OQ(OM?\ "=QX?LK/Q"RWD\4\]SJURUS)'Y>2
MD<6U%P 3DL<L<#-<O>^,?B!J+V+WVNZO.UC,MQ;L8V!25?NR'"_,P_O-DU^C
M&*,"ICBE%64$.6"<G=S9^>G@WQ1<>$]?U'Q-)I>I7NORP2I:W"[D2.24$/)(
M-N7ZY &.17$R1R1R'SA()3\Q$BE6.>_-?IZ?6OC_ /:6T^^U;XR:!I>FV<EY
M?7>F)%!;Q+EI&,TG _J>@'-:T,7S5-5:_P"AS8C!<M/W9-VZ>IX/INFZAK&J
MVVE:59R7M_=.(X8(AEI&/\AW)Z <FOMOX0_"&Q^&^C_;K]4O/$MVF+BY RL"
M]?*C_P!D=SU8^V (O@_\']/^'.E_VEJ7EWOB6ZCQ<7(&5MU//E1>WJ>K'VP*
M]EJ,5BG4?+';\SIPF$5)<TOB_(=320H+,< =2:=67X@_Y%?5O^O.;_T UP'I
M!_;&DY_Y"EG_ -_U_P :?_;&D_\ 06M/^_Z_XU^8^G6*W8M+6VL1<7$^Q(XT
MCW,['   [DFNWO/A/XNTM;9K[P];HD]S%:,4GBD^SRR,%190C$QDD@?-7=]5
M6G-)(\OZX]>6+=C] /[9TG_H*6?_ '_7_&C^V='_ .@I:?\ ?]?\:_-/5=(;
M1M9O=)OK2!;JRG>WF" ,H=#A@#WY%4_)MO\ GUC]?NU7U2_VC-YA;1P/TY_M
MC1O^@K9_]_U_QI/[8T;_ *"MG_W_ %_QK\Q_)MN/]%CYZ?+UH\JU_P"?6+U^
MZ*/JG]X/K_\ </TX_MC1_P#H*6G_ '_7_&F-K&CR*5;4K-E/!!F0@_K7YE>5
M:_\ /K%_WR*/)M?^?6(=_NU7U/\ O#^N_P!T_34:KHPQC4[(8&!^^3@?G3O[
M8TK_ *"EI_W^7_&OSETWPC=ZMI3:I;VUFED+Z'3WDGD6,)+*,IG/1?5N@K*O
M+"&QO[FRE@MGDMI&B=HL.A*G&0PX(XX/>I6#3=E,IXVRNX,_3#^V-)_Z"MG_
M -_U_P :7^V=)_Z"MG_W_7_&OSGTWP/JVJ/H2VNDP!->F>WT^21E5970X89[
M8/K6%<6<-M<S6\UK"'B=HVPHQE3@\_45*P=W93$\?97<&?II_;6D_P#04L_^
M_P"O^-']M:3_ -!2S_[_ *_XU^8_DVW_ #ZQ_P#?-'E6O_/K%Z_=K3ZC_>(_
MM+^X?IM_;&D_]!:S'_;=?\:^6?VD-2L_^%F>%;F"]#I'8R9EM91OA;S00ZD'
MA@<$'VKYO\FV_P"?6/\ [YIZK&F?+A5">ZKBMZ6!]G-2<KD5<;SP<5&U_,^V
MOA3\5O\ A(?)\+^*KB-=;5,VUV,+'J2 =1V$@'WE[]1QD#VBOS;T76?)V6=Y
M)(L2N'BFC8K);N#E71NH(/>OKKX3_%C_ (2#R?"OBFXC77 F;6[&%CU-!W'8
M2 ?>7OU'<##%X3D]^&WY&^#Q?.O9SW_,]OK"\9?\B!XB_P"P;<_^BFK=K"\9
M?\B!XB_[!MS_ .BFKS3U3DO@+_R;WX)_[!J?S-%'P%_Y-[\$_P#8-3^9HH Y
MOXE_\G+?!K_?U/\ ]$+7MQZ5XC\2_P#DY;X-?[^I_P#HA:]NH _,/5?^0[J?
M_7[<?^C6J.SM;F_O(+&R@:>ZN)%BBB099W8X"CW)J35/^0[J?_7[<?\ HUJU
M/!>L1^'_ !]H&M3S&""SOHI9I%7<5CW#?QW^7-?5Q;5)-=OT/D)I.LT^YB3P
MR6US+;7$9CFA<I(C=58'!!^AJ+*^M>Z+KW@^[U8SZQXNTR62P\6C6'N?LLC?
M;+0HH"( G)7;@@X'4\U)'X^\-V3VFFPWFES:<=/U07(:Q5Q+<F:1[0$E,D<H
M1VYYK#ZQ+I$U^KQ_F/&V\2^(6TO^RV\0:DVGE/*^RF[<Q;/[NW.,>U0WNL:M
MJAM_[2U:\O?LZA83<7#2>4!V7)X_"O8K?QCH-]&;N'7M,T?Q;=Z)8Q_VQ<V(
M,44Z2/\ :(V 0A79=GS!<$#&>:S?&WC/PS-X9U:R\&_8XGO]8D,N+,*[VYMX
MP[ID?NT>56.!@CVIQJ7DER?U]PW3M%OG/+;G4KZ\5DO-0N;A7E,[+-,S@R,,
M%SD_>( R>IQ4;74S6B6;7,K6T;M(D)<E$8]2%Z G S]*]@\$^+/!>E_#VQL[
MIK**[@DNFU:TO-P&I*P_= 8B<N,?* &3:>?>I=-U_P -WND^&M%M;ZR?Q%]K
MT];Z7[+_ ,?EL+CY+57(Y>,%-QP-X&,G;4NM9M<NP*ES)/GW/(EU[7%TK^R5
MUN_&G8V_9!<N(L9SC9G&,^U5+>ZFL[F*ZM+F2VN(FW1RQ.4=#Z@CD5]$7OB;
MPCIOC".'Q#KFDZD]IXAG>VCAT[RQIMH(Y4:&7Y!D%R@"_-TSGFL'PEX]\.MX
M>6?69M/@U/[9-+JD5Q'Y4>H0; L2*J0N&4 %=@*8//O4JL[74!NBN:SF>5MX
MQ\7-,LS>+-8,JJ5#F^EW '!(SNZ<#\JJM#JFK0:CK<TCW?V<HUU<33 OESA2
M=QW-DCMGWKUBU\3>%_\ A!]#ADU;2K2:RN;=X]/\AY8)@)2[?:D,6]2H(!='
M.\8XK3NO%OP]75+VZUC4X]:CG.G236XB$P0)<LTL<4@C0R*$*DY )'RY-7[;
ME^&!7L>9>],\$RF.M)7O3>,O"MOJ%I<:QK^D:_JL2ZF\5];Z?LAC@> BWMW4
MH-Q\SD#!V],UYOXXUZU\1IX:U%9H)M5_LE(M3>*$19N%D?[P  SLV<BJA6<G
M;EL85*$81;4KG'>M?H7\'_\ DBO@W_L%0?\ H K\].:_0OX/_P#)%?!O_8*@
M_P#0!7%F.T?F>AEF\OD3_$W_ ))OJ_\ NQ_^C%KL(_\ 5+_NBN/^)O\ R3?5
M_P#=C_\ 1BUV$?\ JE_W17EO^''U?Y(]=?Q'Z(EHHHK(V"LK7+!M5\/:EI<<
MYMWO+:6W65>L9="N[\,YK5HH ^<-5\/WBWWPWLU\'W\7B?2)-/CO);:U=HF@
MB.UMEX#LB10&=EQEP0M=+\0_ OCC4/%_]L>#[B-K9C%J$MO<7CQ+)<0C8(,#
MI'*I0L>QB']XU[510!\[7'PM\?6_BS3_ "-:N;BTCCL_)U-+H"2QE1B]RQ5S
M\PD=B< $,#M. !65'\(_B=/I=Y;W&I-%J)D@,EVURDL5](MZDOV@H>2R(I(#
M;>NWI7T]10!\_KX%\?6^J^%KA+$7UUI5P5N[FXU'=;W0^T;WNMF0Z3.O(P2
M?D(VBO2?AQH>H^'_  3%9ZI&+>\EN;F[DMT8,MOYT[R",$<':& XXSFNWHH
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MZO:S1I:7+2R7D?GAC)*!_J]HRQW]\UT</[+?Q&C@2,WV@L54#/VB7_XW3_\
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M Q73:MK'@EDTI_$VJ:=J1TSQ)%*6:^BO9/L+*R[OW<:@1[@C&,9VCTZ5A_\
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M3>_!/_8-3^9HH^ O_)O?@G_L&I_,T4 <W\2_^3EO@U_OZG_Z(6O;J\1^)?\
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M]/CT:]UQKJ_MK'2X[V'48[A$$UM=PN%AA.,C]YYD9[_Q8Z5YAU%=Q)J/B1O
MUSX93PYJ2M?WHOM0OGAN))+QUSL!!7"XR2<<DXS7-?V#K/\ T!-3_P# *7_X
MFNJG.U^>2_ YJU.]N2+^XS.:2M/^P=9_Z FI_P#@%+_\32_V#K/_ $!-3_\
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M]J+_ )]?AU_W^N__ (F@#VJBO%?,_:B_Y]?AU_W^N_\ XFCS/VHO^?7X=?\
M?Z[_ /B: /:J*\5\S]J+_GU^'7_?Z[_^)H\S]J+_ )]?AU_W^N__ (F@#VJB
MO%?,_:B_Y]?AU_W^N_\ XFCS/VHO^?7X=?\ ?Z[_ /B: /:J*\5\S]J+_GU^
M'7_?Z[_^)H\S]J+_ )]?AU_W^N__ (F@#VJBO%?,_:B_Y]?AU_W^N_\ XFCS
M/VHO^?7X=?\ ?Z[_ /B: /:0 !@# I:\5\S]J+_GU^'7_?Z[_P#B:/,_:B_Y
M]?AU_P!_KO\ ^)H ]JHKQ7S/VHO^?7X=?]_KO_XFCS/VHO\ GU^'7_?Z[_\
MB: /:J*\5\S]J+_GU^'7_?Z[_P#B:/,_:B_Y]?AU_P!_KO\ ^)H ]JHKQ7S/
MVHO^?7X=?]_KO_XFCS/VHO\ GU^'7_?Z[_\ B: /:J*\5\S]J+_GU^'7_?Z[
M_P#B:/,_:B_Y]?AU_P!_KO\ ^)H ]JHKQ7S/VHO^?7X=?]_KO_XFCS/VHO\
MGU^'7_?Z[_\ B: /:J*\5\S]J+_GU^'7_?Z[_P#B:/,_:B_Y]?AU_P!_KO\
M^)H ]JHKQ7S/VHO^?7X=?]_KO_XFCS/VHO\ GU^'7_?Z[_\ B: /:J*\5\S]
MJ+_GU^'7_?Z[_P#B:/,_:B_Y]?AU_P!_KO\ ^)H ]JHKQ7S/VHO^?7X=?]_K
MO_XFCS/VHO\ GU^'7_?Z[_\ B: /:J*\5\S]J+_GU^'7_?Z[_P#B:/,_:B_Y
M]?AU_P!_KO\ ^)H ]JHKQ7S/VHO^?7X=?]_KO_XFCS/VHO\ GU^'7_?Z[_\
MB: /:J*\5\S]J+_GU^'7_?Z[_P#B:/,_:B_Y]?AU_P!_KO\ ^)H ]JHKQ7S/
MVHO^?7X=?]_KO_XFCS/VHO\ GU^'7_?Z[_\ B: /:J*\5\S]J+_GU^'7_?Z[
M_P#B:/,_:B_Y]?AU_P!_KO\ ^)H ]JHKQ7S/VHO^?7X=?]_KO_XFCS/VHO\
MGU^'7_?Z[_\ B: /:J*\5\S]J+_GU^'7_?Z[_P#B:/,_:B_Y]?AU_P!_KO\
M^)H ]JHKQ7S/VHO^?7X=?]_KO_XFCS/VHO\ GU^'7_?Z[_\ B: /:J*\5\S]
MJ+_GU^'7_?Z[_P#B:/,_:B_Y]?AU_P!_KO\ ^)H ]JHKQ7S/VHO^?7X=?]_K
MO_XFCS/VHO\ GU^'7_?Z[_\ B: /:J*\5\S]J+_GU^'7_?Z[_P#B:/,_:B_Y
M]?AU_P!_KO\ ^)H ]JHKQ7S/VHO^?7X=?]_KO_XFCS/VHO\ GU^'7_?Z[_\
MB: /:J*\5\S]J+_GU^'7_?Z[_P#B:/,_:B_Y]?AU_P!_KO\ ^)H ]JHKQ7S/
MVHO^?7X=?]_KO_XFCS/VHO\ GU^'7_?Z[_\ B: /:JPO&7_(@>(O^P;<_P#H
MIJ\R\S]J+_GU^'7_ '^N_P#XFJFIVO[3&I:/>Z9<6_P]6.Z@>!V6:[R%92I(
M^7KS0!U?P%_Y-[\$_P#8-3^9HJY\/]!U#P7\-_#_ (7OLS76G6:0RO;ONC+#
+KM+,IQ^ HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cvm_10qimg11.jpg
<TEXT>
begin 644 cvm_10qimg11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %T B0# 2(  A$! Q$!_\0
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MH GHJ'S8]H;<,')!SUQ2B6,R&,2*7 R5SR!]* ):*** "BBB@ HHHH ****
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MNZ* /+_A?H^I> ?@S8V_BCS9;ZUCFO+BWM4:8P[W:3R8U7).T$* /3CBN?\
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MX=/T^&!K*WA+7<R *APF<YQEL9S@>M=]10!\_>%=%M/A_I?CC4M-T+7+_P
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M8EFW <==\?IF/P5U[1+/1[_5]1U*#[/:VUG:23L6WK\QV*0H7[W..G%>NT4
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M)-#*)2\K.I.1[8 []>U=)9^)I)O"-[KSVF?LV_%LI_>KMXQ(/X6[D=A7.?\
M"<1^;N_X0G4-VW9G^S9,[?3[O2I%^($BM(R^#]44R\N182?-VY^7FF(DN-<U
M;4M;TO2VDME07L9N);21C'*AC9P@/J"O([\5:\6:[?PW3Z=9M';+ ]J\DCN1
M+*'F VQ@=>!SGUK,A\=+;HJ0^"M2B4,74)IT@ 8]_N]:?-X\6XECEN/!>I2R
M1'*,^GR$J?8[>* 'GQ]>?V?<WCZ?# HR;<2EB6(9AY9 YW?+G/3\J9=>)M:U
M)A]D>VMXS<V#6Z!V#L)0K$.>Z\D''I31XVADE;=X)O0TS@NTFGN 3V+$K^M=
M]#96I6&9K*%)511P@^3'( /L: ,S2]6DU319WFDAM;R+SHY K\*49DWC/.W(
MSS7 0R74G@Z^T_\ MBW6YL;R)YKQM3?R;T;-Q59.JG'51T->HM::?;RR7C6\
M,;LGEO)M )7.<'\237(ZQXDTG3?^)3;>$[N]B1M^(M-9H,^HPN,T 9EUJ%\O
M]G:M!?7<-I>VL>^TW$R01L N,D[<D]&/.23VKKG\2:+;?8KZZO!;07-ONB\T
M$$C(KEY/'1E1TD\&ZHZR *P:PD(8#H#\M96L>)YM4E@?_A'=9MQ"I0*NGRXQ
M^524>GZ;JVG:Q;M<:;=Q74:,48QMG:P[$=C6E7A$.J:EINI#5M&TO6(;W $B
M/ITOEW2C^!^.OHW4?2O6?#>OP^)-#CU2&UN+1BS1R6]S&4DAD4X96'L::)-Z
MBBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 1CO7-Z\ WB'2%8 CRI^#_VSKI!WKG-
M>_Y&+1_^N4_\XZJG\1C5^#[BW]CMO^>*_P#?(I5L[8,/W*=?[HJEK&L0:+8-
M>7"&2*+#3!&&](^[A>K =P.:;H6KKKFG_P!I0VYBM96S;LS@M+'C(<@?=SV!
MYQ6]SD<5:]C3T;_D$K_OR?\ HQJU>]96C?\ ()7_ 'Y/_1C5J]ZYG\3.V'PK
MT0ZBBB@T"BBB@ HHHH **** "BBB@ HHHH **** "N=\0?\ (<\,?]A!O_2>
M:NBKG/$/_(<\+_\ 81;_ -)YJ .CHI**BX["T4E%%PL+124F:+B*-Y(F^&%W
M"H3O<D_PC_$XI?M$TW%K%A?^>LG _ =34[6UO)<+.\8:11M!/.!4].X%1+-%
M<23,9Y1_$_0?0=!5RDHI7 6BDHHN M<WX2_X]]8;UU6Z/_C]='7.>#^=.U!O
M[VI71_\ (AJDP.DHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %8FL^(+#0VM4O!.\EVQ2*."%I&8@9/ ]JVZX
M7QQ9WEW;6IL--O[C48MYM+FSF6/[/*1@%\G[OKUXH UKSQ5HMGK,6DW-PT=S
M*%/,;;(RWW0[8PI.. >M%CXJT74I$%K<.[/,(50QL&8D;@P']W SNZ8KE+[0
M]>FO;S39K'SQJT]G=2WZ$>7"8@GF @\YRGRCON]JD.DZ]IFOIJ6@Z+##%/*T
M8B*@E$WC);)^7<,G(Z *,4 >ET444 %%%% $5<[KW_(Q:/\ ]<I_YQUT5<[K
MG_(Q:/\ ]<I__:=5#XC&K\/W&#XUATY(;?49M,M=0F@D42QN5\PQ$-@#<0,%
ML9]LT?#^S>PTB]M!);30I.I22V"A"Q12X&WC:&R!WP*U/$>C3:MI\8LI+2WN
MHI4D\RZA$D;*N?D8=P<GZ59T&SGLK!XK@Z<7,A8?V?%Y<>/<>M;=3GE\+-'1
MO^02O^_)_P"C&K5K*T;_ )!*_P"_)_Z,:M6L'\3.FG\*]$.HHHI&H4444 %%
M%% !1110 4444 %%%% !1110 5SGB+_D-^%_^PBW_I/-71US7B/_ )#?A?\
M["+?^D\U)@;^:7-1;J-U9FA+14>ZEW4 /HIFZC=0 ^BF;J-U 6),T9J/=2[J
M!6'YHS3-U&Z@"0'D5SO@SG1;EO[U_<G_ ,BM6^I^85@>"?\ D6BW]Z[N3_Y&
M>KB)G2T4451(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 1=S7.ZY_P C%H__ %RG_P#:
M==%W-<YKW_(Q:/\ ]<Y__:=5#XC&K\/W',?$"XD8:9I\C:5]G>X27RM0OO(6
MY*YS&5[C'/ID"M3P;<Z?-I]Y!I]CIUE]GN-DL>G2"2/<5!SN P3@BF^,["2\
MTRVDM[6T,Z2X-W<01RFV3:WS#?P,G )[ DU#\/VN6T:Z\YY98?/'E2R6BVQ;
MY%W (H P&R,]ZUZG/+X#K-&_Y!*_[\G_ *,:M6LK1O\ D$K_ +\G_HQJU:Q?
MQ,Z:?PKT0ZBBBD:A1110 4444 %%%% !1110 4444 %%%% !7->)/^0SX6_[
M"3?^D\U=+7,>)O\ D+>%_P#L)-_Z3S4F!L[J-U1;J-U9EDNZC=46ZC=0!-NI
M=U0;J7=0!-NHW5%NHW4 2[J-U1;J-U $NZEW5#NHW4 6%/SK]:PO O/A*)O6
MXN#_ .1GK8C;]XOU%8O@//\ PAEKGO-<'_R.]7$3.HHHHJB0HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%U;5]/T/2+G6-7O([.QM5WS
M3RMA4'3^>!CN:VJ\C^+GVJ+2XUO/'6G^'='N)K>)([BP6:4W F4I(K-(H^5M
MC'@X"DF@#J]!^(7A/Q1J1T_1=0FN+D(9"KV<T0VCKRZ =_6NQKRKPGXDO)_&
M<&BW'Q(T?Q0T]K+-Y&EV*+Y80J-SNLK[?O8 (Y_"O5: "BBB@ HHHH ****
M"BBB@ HHHH B[FN<U[_D8M'_ .N<_P#[3KH^YKG->_Y&+1_^N<__ +3JH?$8
MU?A^XYSX@:IIEMIMO:7DT9E$BS"UGCD,5R.5",RJ0#D@@'N!FD^',OVC0KB9
MKB-Y/.2*2&/>5@9(E4C+@')QDX&.:Z#7M-FU&R@-MJ'V"XM)UN(9F4,@89&'
M4]002/;K4>@Z?-9B]NKK4TU&\O9A-/+$ L:D*%"J 3@  =>36W4YY?"S9T;_
M )!*_P"_)_Z,:M6LK1O^02O^_)_Z,:M6L'\3.FG\*]$.HHHI&H4444 %%%%
M!1110 4444 %%%% !1110 5R_BG_ )"OA?\ ["3?^D\U=17+>*_^0MX8/IJ+
M?^D\M)@:.ZC=46ZC=699+NHW5%NHW4 2[J-U1;J-U $NZEW5#NHW4 3[J-U0
M[J7=0!+NHW5%NHW4 3QM^\7ZUF>!5_XHFQ]VF/YRO5U6^854\"_\B-ION'/_
M )$:JB)G2T4459(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5PGQ(AM5\#37$NC6&IRQ7%N(5U"'S(8':=%$K <[4SN('4+CI7=UR7CZ?
M6;?P+J$F@?:/M@\O+6L0EF2(R*)6C0\,XCWE1Z@4 >;?#G7]93XE7/AG4;GP
M\\L:W:75KI.FFUGMVAE58WE^8_)(K;E]?>O=J\4^%WB'4-9UN"WLIM8O[.U2
M]CO[W5;-HF=1./LN7=%+R;-W X"]><5[70 4444 %%%96J:I:Z3ILE]>/M1.
M H^\['@*H[DG@4 :M%>=1^.M4O-(L;K3]'A>YDL9-1N89YBHBB1MNT$ Y<\^
MW!J6U\;7UYJ!AM](.RZ1?L)?<-Q;!!<XQMVDMQG 'O0!Z!12#.T;NO?%+0 4
M444 1MT-<YKG_(Q:/_URG_\ :==&W0USFN?\C%H__7*?_P!IU4/B,*OP_=^9
M@>/6CFT>"/R$NI+6YBN&MIU<PS+R-K;0<]SCU S5WP7<6]SHTTEMI%KI:"<C
MRK9"JL<#YB"!S5KQ#K5QHMC:SVL$,LMS<I;*UQ-Y449;/S.W.!QCCJ2*N:7<
MW]U:M)J/V'S0^!]BF,J8]R0.?:M>IA/X2YHW_()7_?D_]&-6K65HW_()7_?D
M_P#1C5JUB_B9TT_A7HAU%%%(U"BBB@ HHHH **** "BBB@ HHHH **** "N7
M\6?\A#PW_P!A _\ HB6NHKEO%W_']X<_["!_]$2TF!-NHW5%NHW5F62[J7=4
M.ZC=0!/NHW5#NI=U $NZC=46ZC=0!+NHW5%NHW4 3;J-U0[J-U $V[K]#4?@
M;_D1=*]XB?\ QXTA;Y&_W3_*G>!_^1$T?WMP:J(F='1115DA1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7F7Q1\/ZO<Z%=ZYH6N^);6^M
MTC46NDW6T>7Y@\QUBQ\[A"Q [E0*]-KS3QMX^UCP;JVU_!^HZII<HM5M[JPA
M,W[QYMDJO@Y4A2A7CYB2,T <_P"!;Y9OB%'_ ,(_KWC#7=(_L]_MC:ZLJ16\
MNY?+V^8B%G(W9 !P!FO:ZY+0?&4>O:H;)?#?B'32$+^=J.G-!%QVW'OSTKK:
M "BBB@ K,U'2M-UBW2WU*SCNHT;S%609"MV/UYK3HH \\C^';6.F6=GI.K?8
M9([:6SN)!"&$T,C;CP3PP/0U=U3P:M];);Q7QA6VCCAM4*DI'&JX*G!!.3@D
M_P"RM=M10!1L+5K+3;:S:=[@PQK&99/O/@8R?>KU%% !1110!&W0USFN?\C%
MH_\ URG_ /:==&W0USFN?\C%H_\ URG_ /:=5#XC"K\/W?F9/CF-9_#L4$\>
M;%[F,7DJPB9X(N<NJX/.<#.#@$GM4/@6&.#3+Z&S5I=,6Z_T.YDB\M[A-HRQ
MX&<-D!L#(%0^-+>\DGT[[/IVF7<%U,EO/]MGDC9C\VQ4">YSGZ]JL^#;=K2U
MU2U:.RMS%=[3:V;NX@.Q>&9^23U],&M>IA+X6=5HO_()7_?D_P#1C5J5EZ+_
M ,@E?]^3_P!&-6I6+^)G33^&/HAU%%%(U"BBB@ HHHH **** "BBB@ HHHH
M**** "N4\8?\?OAO_L(G_P!$2UU=<GXR.+OPY_V$3_Z(EI, W4;JCW5D^)M9
M;0/!^LZ['%YSZ?9RW*Q]F*J2!^=06:TUU;6^W[3=0P;NGFR!,_F:>KJRAD8,
MIZ,IR#7RK\,/A;9?&+PQ)\0_B1KVI:K=W]S(L5M!<>6EN%./P]@.@Q7J<@\-
M_L]_#;4[^2_U+4]--T&M;:XDWR!V&!$K>G!.?K3L!ZQNHW5Y+I?Q8UBW\7^'
M_#OCKP<?#C^(H]VFSQW0G5FX^20 ?*W(_.N<;X_:[-IWBG4M-^'<EW8^&+IH
M;ZY-X$01JVW(XR6[X["BP'OVZC=7S]XW^+WB=M:^&\'@G13-9^)=E\HEF6-K
MH?\ /OG^$ GD]^*UM>^-FK>&O%VD^%-4\"S/K6I6'VE+.UN/-?SR6"0@@8(.
MW);L*+ >V;J;)-'$ADFD2-!U9V"@?B:\8C^,OB*]UC2?"6F_#^5_&5W;O=76
MFW%T(H[*-20"SD=2!G'H1ZUR?Q&^(]KX^_9T\9Q_V?-I&LZ/=0VFH6,C[C"_
MF@9##JIVG\C18#Z4#A@&5@0>00<@TNZL#PBW_%">'L\G^SK?K_US%;>ZD YV
MQ%(?]AOY5:\$?\B%H?\ UZ1G]*H2M_H\O_7-OY&M'P3_ ,B#H7_7E%_Z"*I"
M9T%%%%42%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=\
M0CK0\#:E_8+78N_W>XV0S<"'S%\XQ?\ 33R]^WWQCFNQK!US5(M!T:?5KBUN
MKJ"WPTB6L1ED5<@%@HY(4')QS@'K0!YK\/;BQ_X3@0^"[KQ/=:$+.0ZD=;-R
M8DGW+Y?EFX&[S#\^X+QC&><5[17':/XZT7Q%XB?2?#K2:M!##YMQJ5L-UI"Q
MP5C\SHSD'.U<X'7%=C0 4444 %%%% !1110 4444 %%%% $;=#7.:Y_R,6C_
M /7*?_VG71MT-<YKG_(Q:/\ ]<I__:=5#XC"K\/W?F5/%%C?7VD1'2XMVH6\
MRS6[B98C$PR-V6!!&"01W!K.\$M=F+6%U:,KK"WH%XS3++O.Q=A&T *-N,#K
MZU5\?PWDEG8[M2MK73)KF.&;[3;&18B<_O"P8$#L.V2,U-X!2."QU6S@DM+F
MWM[W;'=6D/EQS@HI/<[B#P3D]*UZF$O@9V.B_P#()7_?D_\ 1C5J5EZ+_P @
ME?\ ?D_]&-6I6+^)G33^&/HAU%%%(U"BBB@ HHHH **** "BBB@ HHHH ***
M* "N2\:<77AS_L(G_P!$2UUM<AXV_P"/CPY_V$3_ .B): (=U1W$,%W:36EU
M$LUO.C1R1MT=2,$'\*;NHW5!1X/:_!?XA>"=1O%^%?Q#CT[1KN4R?8+^/?Y1
M/IP0?3/!]:WKSX/ZOXD^&.J>%_&WC:;6=6O;I;V*_P#+PEK(HPJJO]WDY^M>
MM;J-U 'DUC\-?&&N>.O#7B3XB:]IMW%X77_0K?3(60SR<?O)"W3[H.!Z57TG
MX0ZOI_@'XB^')=7M'G\5W4MQ!*H;;"&[-_\ 6KV'=2[J /&]4^#_ (@D\,?#
MTZ'KUE:^(_!D81)9XRT$_3/N.GZUJVGP\\33?&#P[\0M>UG3[NXT_3&L[I((
MBF^0[\,@/0#</?BO3]U&Z@#S3Q1\/?$'_"TH/B9X%U>QM-<^R_8KJVU*-G@G
MCQ@'*\@X _(5S+? O4&^&'B[19-?M[GQ+XINTO+V],92!2KEPBCKCEN?>O<=
MU&Z@"MHEF^E^'=-TN5UDDL[6.!G7HQ50"1^5:&ZH-U+NH 6X?%G<'TB?_P!!
M-;7@U=O@70U]+*+_ - %<]>MC3;H^D+_ /H)KI?"@V^#-%7_ *<XO_0!30F;
M5%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\T^)V
MCZ+#I,_BS4_[5=K40PNMKJUQ:11QM*%:1Q$P&%#EB<$X6O2ZX7Q]-'HV@:GK
MUYKVJV%BL,,$GV*6-/LH\X;IU+J>0&^;K\J\#- '!_#&WT?3/%\,>@:-/::!
MJ4-W)I,O]K7,YECCD4/,\$AV*LA;<C#G'7[U>[5YGX-7P^?$.[2?BQ<^*IS"
MW^A2ZG;7 "\?/MC4-QQ[<UZ90 4444 %%%% !1110 4444 %%%% $7<USFO?
M\C'I'_7*?^<=='W-<YK_ /R,>D?]<I_YQU5/XC&K\/W&5XV;.BQV[,S03RA+
MBWBD59IX\'*ID\\[<@<D9Q47@4ZA_8++?0RVR(8UAMIPHDB C4,"H^Z"V2 >
M>?>J?BOPWJFJ:M<W%KI-AJ,<VFFSB-W-L:UD+,=Z\'!Y'(P>*V_"FFS:3H2V
M=QIL-C*&RWE3F8S' S(SGDL3ZUMU.>7P,W=%_P"02O\ OR?^C&K4K+T7_D$K
M_OR?^C&K4K!_$SII?#'T0ZBBBD:A1110 4444 %%%% !1110 4444 %%%% !
M7'^..)?#O_81/_HB6NPKCO'7#^'3_P!1'_VA+0!0W4;JBW4;J@HEW4;JBW4;
MJ )=U&ZHMU&Z@"7=2[JAW4;J )MU&ZHM]&Z@"7=1NJ+=1NH CU%\:1>G_IA)
M_P"@FNR\-KM\):0OI9Q?^@"N%U5\:)J!_P"G:3_T$UWV@C;X9TM?2TB_] %-
M"9I44450@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KGO
M$FJ:1H^@37VM1B33U>-)0T8=5WNJAF!X"@L"2>  3VKH:XOXBW$%MX O_M&D
MVNJI,\-L+6]X@9I)4C5I, _(I8,>.@H W+'3] MY_.TNRT^*8K]^VC16*_51
MTK8KY_\ A>UO8_$MM-D\,>#=,O/+O;=VT.%UN87@E5") Q^5'!# XYXKZ H
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MX% 'M^1G&1GKBEKSKP1J$?V^73;O[6^HK$$S/SMCCP G7@C<"2>I)QTKT6@
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MC=45% $NZC=46:7- "_>U#2U_O:C;#_R*M?0]?.\1_XF^B_]A.U_]&BOHB@
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M:_\ HP5]$5\\V8W>(=!7UU.W_P#0J^AJ "BBB@ HHHH **** "BBB@ HHHH
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G 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cvm_10qimg12.jpg
<TEXT>
begin 644 cvm_10qimg12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %G G # 2(  A$! Q$!_\0
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MR P]JM5-FG9@%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_K5WM6/;R26^MSVLFTI.#.C!N>, @BEL1LS:HHHIEA1110 TKD8-4O[(TO\
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M_3.?6JC4E"ZCL1*C1F[R;^[_ ()B'X?^'TU&ZO56V2XO5\N:3RUWSJ/X6/\
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M'_\ A.O!OA&>1M<\1V>F:EXHOH]4U&WTM;BZM8T+;)$3821,Y&YL,!@;0,T
M?8-%?-VCZK\6/$$GPXTNZU_5='343JK7E\-/C6:>WA:,VK2JRE8G=<YZ=3QF
MOI'MZT %%%% !1110!7FMX+A0MQ"DH!R Z@XK+2SNK6\N)-/@MA!-M.TDIM(
M&#P!6Y2<4FKB:N9OF:Q_SQM?^_C?X51TW4-5%RUOK=O:6\C!GC,$I8%0P SD
M#GFM^H)K6VN-OVBWCEV]-Z@XI6?<5GT8[[3;_P#/:/\ [Z%'VFW_ .>T?_?0
MJ'^R]/\ ^?*#_OV*/[+T_P#Y\H/^_8IZAJ)'?6<Q<1W4+E#M;;(#@^AJV&#*
M,<@]Q6;#H.CVYE:WTVVC,S;W*QCYF]:ALX-4LK..UCCM72/(4EV'&>.U*[ZA
M=]3;Q163)-JT<3R&&T(52V/,;M^%7;6;[39PW&W;YB!L=<9%.XT[EFBBBF,*
M*** "BBB@ HHHH **** "BBB@ HHHH X?7]!TRXUK2I)]/MII);C#O)"K%OW
M;=21S760PQP0K'#&J1J,*JC  ] *R]:_Y"VC_P#7R?\ T6U;6.:B*2DSIJSE
M*$$WI9_F344459S'(W>@^('U6^NM/\3&SBN6C98OLJOY97AN3ZBIQH_B7^W?
MM9\5$V6S;]F^R)U]<UTU%7[27EM;9"LCGK_3-?N+8)9^)#:R!U;?]E1L@'D?
MC56]T;Q1/=F2U\6FVBVJ/+^R(>0<DY]Q75T4U5DNB^Y?Y!8Y&ZT/Q9+#>K#X
MN,+RN&A;[&A\I1U'XT^#1O%$<%XDWBXRR2@"%_L:#RCC&<=^:ZNBG[:5K67W
M+_(+&);Z?K4=K''-KGFRJH#/]G4;CZU/]BU7_H,?^2ZUJ8I:CVDGT7W(+&':
MV.L0ZTUU<:U]HLC%M%KY"KAL_>W"MNBBI=V[C%HHHH **** "BBB@ HHHH *
M*** "BBB@ K&\/?\>EW_ -?DW_H5;-8WA[_CTN_^OR;_ -"H V:*** "BBB@
M HHHH **** "N ^)$<TNB6,4,+W7^FHTELL;2K,@!R'13N9>A./:N_KSGQAX
M3U_5/$T6L:.-,>2.*)8I+R21'MF23>2FT'[PX- '1>#;1K'P?86[SW$Q52<W
M$;1LN6)V[6Y '09[ 5TE4=/:^:QC;4HX8KLC]XL#%D!]B0":O4 %>*WGC[Q5
M%XAUBRDN(;"WCNFBCD:W$BVD:]&?G.7.  ?7BO:JKM#"V_=$IWXW9 ^;'3-
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M4W*46G9;/34]/$TJ,:-.I"2<I)W2OIKH;X;<H8=Z6LU;C5%4#^RTX'_/P/\
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M+I=UXBU/X96&L6&M36O]AZK<Z8T<>L7%VU_=B>(I);2')GW!7C5'.T!R<\4
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M&]'_ * U=-Z5S&OP^7=^'8\YV7@_] :NG]*M;L]>7\.%^S_,DHHHJS(****
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M //Y!_WY/^-5VM]>_M"U==0MOLBD^?'Y)W.,<8.>*/D%_(VZ***905C>'O\
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MBB@ HHHH **** "L;P]_QZ7?_7Y-_P"A5LUC>'O^/2[_ .OR;_T*@#9HHHH
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MA_\ 7Y_[3:NB'6HCNS:I\,?1_F244459B%%%% !1110 4444 %%%% !1110
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MTH Z&BN>M]:U"[=DM+.RN&7[PBOE8CZX%6?MFO\ _0%B_P# H?X4 ;%%<_\
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M %%%% !1110 4444 %%%% !1110 4444 %8WA[_CTN_^OR;_ -"K9K&\/?\
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M+V:\#^&A=3J4DER-\@/4$]2*C6WTE+%K%8_"RVC-O: !0A;UQTS74_V+H_\
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M>T?^UTOOL=F$6(P>7Y*\L6S^=:7]BZ/_ - FS_[\+_A0 ?VUH_\ T%K/_O\
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MY/-;O]L:/@?\3:S_ ._Z_P"-4[KP_H\UY;3"SLXQ;L7=?)7D%2.:N_V+H_\
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M'(/S=C5J'1-'C@CC.F6;%5"Y\A><#Z5<AAAMXEAMX4AC7HB*% _ 4 6****
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M$O-.U#6;Z\T=M+DNG51&MP)8Y0N?WG4G<223GM@=JZ/7+::\\/ZA:0QO))-
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M@1,N%], %,CZF@#V9YH8PQDE1=N-VY@,9Z9IRR(Q*JX)&,@'.,]*\5O?A_\
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M+C\PR;5#D;=V.<>E2=1SR* /(M/\>:]=""W:XTC^T?MOE&V#!Q.C8($;JVW
M3)9NQP,<UZ]61_8.A_N?^)19_NF+Q_N%^1B<DCC@YK7H \B\3?%+4M,\3ZIH
M6F:7@VL*".:YC90TAD56?)PIC4-UR,GO7H6@ZC+JWANRU)G4RSQ!F**5!/?
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MN56(Y /<4EUI>G7P9;ZQM[E3C<)HE<''3J.U6HXHX8DBA18XT 5548  [ 4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cvm_10qimg13.jpg
<TEXT>
begin 644 cvm_10qimg13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" &F ;T# 2(  A$! Q$!_\0
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M=@P/7K5G4_@[H^LGQ1)J&N:I/<>)=,MM+O9SY08K","083 =NIXQSP!7J5%
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M0S0[F64#=A=NYN!@<]*X*YOTO6EM/#^O:GXC\-QWVAS"[OI'G,=X=07S$5V
M/^K"LR=$./NY(KT?XH!7\.Z3#<?\@Z77-/2]!^Z8C<+@-_LE]@/L: %_X5O\
M/-3\30>-F\)V<VK2,ERMU)&R[GQE9#&<+O']XKN%7+CX:^![NQU2QNM AEMM
M5OQJ=Y&SOB>Y!!$A^;@Y X&![5YI\3->N+/4O&JZIXHU70IK#2EF\/PV4\D"
MW+F)S))\@_>L) %(.0H .!G-;7VC4CX@\=ZW=7VOWL>A0P2V>F65PT:R$V*N
MP51]]F8G@Y /.,T >QUBZIJFGZ/%!-J%PEI#-.ELLKYV^8YVHI/;)( )XR0.
M]>'^%]2\6ZY_PD^F>'?$DEPRZ3:ZIIK1:A<7J+=+*Y,1GF52P?8J.H^4 G@'
M-;]OJS^,O@[XV\::TUQ;Z-K-C,^GV5R<?9;:*$JK[>TC2!WR.?N>@H ]KHK,
MT-KQ_#FF/J.1>M:Q&?/7S-@W?KFM.@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@"E>V=MJ.GW.FWUNEQ:W,;0S12#*R(PPRD>A!(J+3=/@TO3+73;42BW
MM8UAC\V1I&VJ,#+,23QW)S6E10 4444 8E]HMCJ.J:=J5Y"TMQIKO):@NVV-
MV7:7VYP6"E@"0<;CCK6W110 4444 %%%% !1110 5C:SI-AKFC7FDZI:K=6E
MW&8I8FR RGW'(/H1R#R*V:* .3U3P3HNM20'5'U&YABB2%[9M0G$$ZJ<CS8P
MX60YZE@<]\UUE%% &9?6L.H:?<V,F_RYXVB?RW*-AA@X8<@X/4<BL^;POHMY
MX?LM FL?^)58F$Q6BNRIB(@QJP!^9054[3D' SFNCHH **^>?&_B'QYK7Q8U
MOP[X#U#5X9M*CTVV@2UA5K-;B27S9Y+EV4A56WVC;D$D\ FO3?B$OQ";2K;_
M (5^]BLOF'[9YV/M!BX_X]]_[O?U_P!9\M '<T5X_P"*--\4ZG^SMJVG>'?^
M$@_M^:W90FJ2HM^Y\[,J[D.P%D#A=O&"N*R?A?\ VAX7&L&Q\&>(].\,ZMK<
M-OH^FW41,NG1FW'FSRJ[DQPF53W/)SCF@#W:BOC_ ,.^#?B9'9ZU#INB^(-*
M\2'P_J5OK.H74["+5;YY@;=H'+D,VS=AP!M!QFIE\&Z]-X&\4C2O#_BC0/#3
M7^F3V6A7-I-<R7;QQL+I)(5E$GDNY0DAQDKF@#ZZHKS3X,Z+XDT'X6:?8>*%
ME@OO.FECM9'+M:P-(QBB)+,1M4C@LV.F3BO2Z "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBH99ECPO+.?NJ.IH >[K&A=V"J.I-5PU
MQ+\T>V).Q=22?PR,4V.%F<2W!#,.50?=3_$^]7: *^R[_P">\?\ WZ/_ ,51
MLN_^>\?_ 'Z/_P 55BB@"OLN_P#GO'_WZ/\ \51LN_\ GO'_ -^C_P#%58HH
M K[+O_GO'_WZ/_Q5&R[_ .>\?_?H_P#Q56** *^R[_Y[Q_\ ?H__ !5&R[_Y
M[Q_]^C_\55BB@"OLN_\ GO'_ -^C_P#%4;+O_GO'_P!^C_\ %58HH K[+O\
MY[Q_]^C_ /%4;+O_ )[Q_P#?H_\ Q56** *^R[_Y[Q_]^C_\51LN_P#GO'_W
MZ/\ \55BB@"OLN_^>\?_ 'Z/_P 51LN_^>\?_?H__%58HH K[+O_ )[Q_P#?
MH_\ Q5&R[_Y[Q_\ ?H__ !56** *^R[_ .>\?_?H_P#Q5&R[_P">\?\ WZ/_
M ,55BB@"OLN_^>\?_?H__%4;+O\ Y[Q_]^C_ /%58HH K[;O_GM%_P!^C_\
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M_P"@BK;_ .K/TJII/_($L/\ KWC_ /017-T-^I=HHHH&%%%% !1110 4444
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M2;E_O#\Z /)/CY_R3^T_Z_T_]%R5\Q-YVY!;IOD+#:F,[CG@8[YKZ<^/A!\
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MV6V_Y]X_^^14U% $/V6V_P"?>/\ [Y%'V6V_Y]X_^^14U% $/V6V_P"?>/\
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M9;_\]#_WR?\ "K-% %;[9;_\]#_WR?\ "C[9;_\ /0_]\G_"K-% %;[9;_\
M/0_]\G_"C[9;_P#/0_\ ?)_PJS10!6^V6_\ ST/_ 'R?\*/MEO\ \]#_ -\G
M_"K-% 'C/Q\N(I/A_:!7R?[03C:1_P LY*^9LU].?M _\D_M/^PA'_Z+DKYB
MK[?(/X7S9\QF7\?Y(7-&:2BOISS!<T9I** .>UX_Z9%_US_K616MKW_'[%_U
MS_K637B8C^)(]&E\"/KS]F.XBC^&6H!GP?[3?L3_ ,LXZ]R^V0?\]#_WR?\
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MDWD$,WEOMXQ@#'?/:NFT.2.71+:2&ZN+N,J=LUS%Y4C\GJNU<?D* -:BBB@
MHHHH **** "F,ZQH6=@JCJ3399EBP,%F/W5'4U!'"SN)9\,PY5!]U?\ $^]
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MI532?^0)8?\ 7O'_ .@BKG:F*JH@51M4#  X KEZ&W4DHHHI@%%%% !1110
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M9MRW['K8:E*I%6/9?@#XNT+PG\/;FRU^XEM+BXOFGC3R';<A1 #P#W4UZ_\
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MNI\-0ZC;Z'''J7G"7S93&L\GF2)$9&,:NV3E@FT$Y/U/6N@HH BDB24 2#<
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M_GZE_P#'?\*/)D_Y^I?_ !W_  H GHJ#R9/^?J7_ ,=_PH\F3_GZE_\ '?\
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M["OBZO\ $EZL^@I_ BCI_P#Q\ZE_U\_^TTJ_52VMS#+=2,P/G2^8,=AM4?\
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M_P!5'))C+A.V:]X\&?#G3?#5LCR1K)<]V//-=K]MM_[S?]\-_A1]MM_[S?\
M?#?X4 6  HPHP*6JWVVW_O-_WPW^%'VVW_O-_P!\-_A0!9HJM]MM_P"\W_?#
M?X4?;;?^\W_?#?X4 6:RM9U1M-LGEBMI+B0#A47-7/MMO_>;_OAO\*/MUO\
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MU6.=V<\-G'/3%;,.O7#:K?M<ZQ#8V^FD(-.6$/+<H(5?>,G<<[CM"_W>YS@
M[ZBO(X/$NJ:E9W-GJ%Y%<Q'[!>0NCQEU#W2+M81G [<9)Z\FNX\2WFH6JZ7!
MIMS';2WE\ELTKQ^9M4HY.!D<_** .DHKS&R\2>)&\22VLA2XBM+F2UDA9H(V
ME5%.'"[O,WL0& "[<'CUK.7Q%J(N'UW^VK6]NSH37?EPQJ$M-TL1*D DD#GE
MN>#0!Z_17GFI^+IO[3OK73M3M4MA<6ML+S D2U\Q7+,W."?E4#/ +#/I5.^N
MKR#6-2F;Q4EY&NAF18Q'&$NRIG!Q@]1@9V_I0!Z?17G+^)M2AO#MU"UC%K<6
MEHFEF,&2[258\R YW?\ +1L8&/W9SWPV/7/$4,,6H?VA:RI>7%[;Q031"*.,
MQ><8V:3.?^60![8/;% 'I%%<CX/U:;4H+R&\NWN+NUD59 T4:A-RAL!HV96'
MOG/K774 %%%% !17EMC8ZE?>+M0O+&WGB:UUAC-J)NSL,*HI: 1;N<YQR !G
M.<BG3>(O$UOH.AWCWR3/K*AC(D4,2V^(]VU3(P4EO]H_PG ] #U"BN2TG6-<
MN-+M6O=+B+/ SR7L=S$;=6&[&<,3S@9QD#)YXK!T[Q9JB6ZC4M2C:Y6ZM!=9
M2+R8HY693LD1B"I(P-V&'&>M 'I=%>>VNNZMK6N_V?INKV\-LUS=J)XHUE)2
M(0;0#G&<R-D\UDS>*M5N+9IGU2T87=K?N^FB,;K7RD;:&.=V<CYLXYZ8H ]8
MHK@;77KA]6O&N-9M[.WT_8HT\0AI;E/)63>,G<<EB%"_W>YS6!'XEU34K*YL
M[Z\BN876QO(75H_,0-=(-K",X&1CC)/7DT >NT5S'B;4KK3XK"WM[R*P^VW0
MMWO9E#+ NQFS@\9)4*,\9;\*X_3]=O;>PCM(/$%K:0DZA>'49HU9+ADNF&Q1
MG:!@[C@YP1C% 'J]%>83>--8C,+21Q0D6]OJUQ&T9S%9&,"8#_:#YP3VJ277
M?$DFFWNHQZI! MCID6I&'[.&\W>96"$YX&Q5''.><T >ET5YIK&N:NVJZIIL
MFI"*.>&XALX[1(Y1D0%QO.[S$D!#=5V\ =36?>>)M4TWP]IJZ?X@BN[E-.-\
M\TPA2.10!A"Q/)!R,*,\\D9% 'K=%><3>*-0FU0R)JUI9(E[96JZ<8U:2X2;
MRBSY)STD8# _@.?:.SU77+J*.WT_4H;!5M;RZ8BW$NYDN64#D\#'7],4 >ET
M5Y?<^+M6FC^UQZI;Z<8H[%ELS&K-=>?L+,"QS@;BHQW4YS6MHVN7\WBZXTO4
MKY6\PSFW@MUCDBV(X .]6+JV",AP.<XZ4 =U1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !5=8XX]VQ%7>2S8&,GU-6** *<EG9S6GV6:UB
MDM\ >4Z I@=..E21PQ10K#'&J1*-H15PH'IBK%% &>FFZ;';/:QV%LEO)R\2
MQ*$<^XQ@U)#:VT.WR;>.+;G 10,9QGI]!^0JY10!S5OX=L8=7FU6:6:[F<.H
M281[4#XW#Y5!;@ ?,6..*V6L[1[J.Z:UA:>,;4E,8+*/0'J*N44 9T6GZ? I
M6&Q@B4\D)$H!YSV'KS]:MM''(5+JK%3N7(S@^HJ:B@"F;&S:]6]:SA-R!M$Q
MC&\#TW=:CCT^QA:1H;.",R9WE(U!?/7/'.:T** ,Y-.T^.W>VCL;=('7:T:Q
M*%8>A&,$<TUM-TYEA7[#!M@!6(>4N(P1@A>.,CTK3HH I_9+4W$=P;6(SQKL
M238-R#T!Z@4TVMN8MI@C*@DA=HP,YS^>3GZFKU% %6VM+:S@$%I;16T8Y"1(
M$7/T%6J** "BBB@"%8XX]Q2-5WG<V!C)]34$EG:36GV6:UBDM\ >4Z I@=..
ME7:* *\<,4,*PQ1K'$HVJBKA0/3%0)INFQVTEK'I]LEO)S)$L2A'^HQ@U?HH
M HQ6EK#M\FVBBVYV[$ QG&<8^@_(5D6_AVQ76I=4FFFNIG#A4F6/:@?[P^50
M6X&/F+8'%=+10!3:SLVNH[EK6)IHAM24Q@L@] >HJ./3K"$%8;&WC!Y(2)1G
MG/IZ\_6M"B@"M<6\%U"T%Q"DT3_>CD4,K?4&H7T^QD5(9+&!XD;>J-$I56]0
M,<'WJ_10!6\B%V9FA1F9=C$J"2OH?;VJ,V\+%E,";64(PVC#*.@/MR>*NT4
M4UL[..\>\6UA6X<;6F$8#L/0GJ:A&E:;M1?[/M=J,65?)7"D]2..">]:5% '
M-W7ANSNM:MM0FN)R+<HT=N @C!0Y7G;OP#@XW8R!Q6RMM;H?EA1>"O"@<$Y(
M_$\U;HH YV_\-V>I7]O=7#3"* (%M4$8C.UMPYV[@,@<!@#@9%:T-E9V\\MQ
M#:PQ2S<R.D85G^I'6KE% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 >!^.OB[X@\,^.=0T2QCL6M[<
MH%,L3%N45CD[AW)KL=4U[6&TSPGJUG,R/+;-?75O$/EN%6)7=,?0MCWQ70ZA
MX'\):MJ,VH:EX?L[J[F(+S21Y9L  9/T 'X5HKH^GQRZ=)' (SIR-';*A(6-
M2H7&/3  KJK5:4Z<(TXVDMWW.6E3J1G*4Y73V\CC-/\ $VJ17VMZQ<227%K<
MK836=G*=@@BFF:)3C&0Q4*Y![G%7]<UVZDU^'386:W6TU:RC9XY"#,LB,Q4C
MTXZ=ZWK_ $'3=0DOFNK=G-_%'#,1(PXC8LA&#\I!8D$<YQZ57@\)Z/!-YV+F
M:8W$5TTLUP\C-)&"$))/H>G2N4ZC#T77=?FN=.&L""2.XU>ZM8GMYW5AL\_A
MUV@,H" #\">15#1_%5Q<>$]0CAWWATNTN9;Z=[@I(KYD*1H>3G Y;H, #)R!
MU\/A?2[?4Q?1BX#+<M=I$9V,4<K!@S*F<#.]B?<U$?!VAM;)%]GDCV6\UJ62
M5@SQ2Y+HQS\PRQ(ST/(Q0!D7GBS4K5;UK/2H+FVTNP@OKAIKHB1D=7)5?E.6
MPAY) -,U#Q\EKX@GL;>S2:&UECAE7<_GR%U5B8U"%2%#@G+#.#[9Z-_#>ER1
MW\+0L4O[5+.?YS\T2JRJ!Z'#MS4+>&-/DU$WBS7D!8KYB6]U)$DVT *752 3
M@ 9[@ '- '2UPWC/Q9=>&[RVAA$3"6/<=ZD]R/6NYK,O]#TC5)$EU'3X;IT&
MU6D7) H Y*3Q/J6H>#=.NK69+6YU'4(K'[0B@^2K/@L <C=@$#/&2*OW7G>%
M;>-K6\OM4FOYX[2W@OKC<BR-GYB^TL!@$D<].!DUI3>'])FT631OL*"P;DPK
ME0#G(((Y!! ((Y!%5?\ A%=-:REMYYKZ[,A1A+<7DCR1%#N0HQ/R$'G(Y]<T
M 4)/%6I)&MN=+MSJJ:HFF21_:#Y(+1^8) VW.-I'&,]15)?$WB>^\2Z78VMO
M9V[I-=V]Y"\K%)&C"$,K;,XVN".G)(/2NBMO#.DV\%O"D<K^3=_;O,DE9I'F
MP5WNQ.6.#CGL!Z4V;PKI$MR+K;<0W NGNQ+%.R.'=0KC(/W2%&5Z<4 97_"6
M:M]GFO/[*M_(-\^G6J?:6WS3>?Y2LWRX1.I/4\<"FOKFH7'B+2--NT%G=VNJ
M&"Z2WF+13*UI)(A!(!(Z<$<%?H:W9/#NER:1-I+1L;6:9K@CS&#+(TGF;E;.
M5(8Y&.E5[7PQI=G-;S1I-)/%<&Z\^29GDDE,9CW.Q.6^0X / XH Z>BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
..**** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418758067280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CEL-SCI CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000725363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,159,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-11889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-0916344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">8229 Boone Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Suite 802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Vienna<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">22182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">506-9460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CVM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418758194592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,309,321<span></span>
</td>
<td class="nump">$ 4,145,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">696,648<span></span>
</td>
<td class="nump">520,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SuppliesUsedForRDAndManufacturingCurrent', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="nump">2,489,284<span></span>
</td>
<td class="nump">2,248,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">16,129<span></span>
</td>
<td class="nump">4,245<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,511,382<span></span>
</td>
<td class="nump">6,918,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right of use assets</a></td>
<td class="nump">8,251,453<span></span>
</td>
<td class="nump">9,131,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">1,598,879<span></span>
</td>
<td class="nump">1,698,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,113,284<span></span>
</td>
<td class="nump">10,188,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patent costs, net</a></td>
<td class="nump">180,482<span></span>
</td>
<td class="nump">197,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">Deposits</a></td>
<td class="nump">2,319,101<span></span>
</td>
<td class="nump">2,319,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SuppliesUsedForRDAndManufacturingNonCurrent', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="nump">73,524<span></span>
</td>
<td class="nump">74,669<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">30,048,105<span></span>
</td>
<td class="nump">30,528,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,015,969<span></span>
</td>
<td class="nump">2,009,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,219,399<span></span>
</td>
<td class="nump">1,049,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_DueToEmployeeCurrent', window );">Due to employees</a></td>
<td class="nump">751,607<span></span>
</td>
<td class="nump">557,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligation, current portion</a></td>
<td class="nump">1,888,767<span></span>
</td>
<td class="nump">1,771,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligation, current portion</a></td>
<td class="nump">211,275<span></span>
</td>
<td class="nump">197,431<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,087,017<span></span>
</td>
<td class="nump">5,585,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligations, net of current portion</a></td>
<td class="nump">8,987,319<span></span>
</td>
<td class="nump">9,949,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligations, net of current portion</a></td>
<td class="nump">1,544,126<span></span>
</td>
<td class="nump">1,652,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">15,743,462<span></span>
</td>
<td class="nump">17,313,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.01 par value; 600,000,000 shares authorized; 54,083,718 and 47,422,304 shares issued and outstanding at March 31, 2024 and September 30, 2023, respectively</a></td>
<td class="nump">540,837<span></span>
</td>
<td class="nump">474,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">514,809,617<span></span>
</td>
<td class="nump">499,832,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(501,045,811)<span></span>
</td>
<td class="num">(487,091,396)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">14,304,643<span></span>
</td>
<td class="nump">13,214,890<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 30,048,105<span></span>
</td>
<td class="nump">$ 30,528,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_DueToEmployeeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_DueToEmployeeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SuppliesUsedForRDAndManufacturingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SuppliesUsedForRDAndManufacturingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SuppliesUsedForRDAndManufacturingNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SuppliesUsedForRDAndManufacturingNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418844374480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONDENSED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">54,083,718<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">54,083,718<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418756122864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 4,628,535<span></span>
</td>
<td class="nump">$ 6,083,488<span></span>
</td>
<td class="nump">$ 8,981,044<span></span>
</td>
<td class="nump">$ 11,476,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,447,413<span></span>
</td>
<td class="nump">2,092,758<span></span>
</td>
<td class="nump">4,580,791<span></span>
</td>
<td class="nump">4,350,761<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">7,075,948<span></span>
</td>
<td class="nump">8,176,246<span></span>
</td>
<td class="nump">13,561,835<span></span>
</td>
<td class="nump">15,826,795<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(7,075,948)<span></span>
</td>
<td class="num">(8,176,246)<span></span>
</td>
<td class="num">(13,561,835)<span></span>
</td>
<td class="num">(15,826,795)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(182,701)<span></span>
</td>
<td class="num">(159,063)<span></span>
</td>
<td class="num">(380,397)<span></span>
</td>
<td class="num">(311,852)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="num">(13,758)<span></span>
</td>
<td class="num">(7,500)<span></span>
</td>
<td class="num">(12,183)<span></span>
</td>
<td class="num">(57,671)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,244,891)<span></span>
</td>
<td class="num">(8,342,809)<span></span>
</td>
<td class="num">(13,954,415)<span></span>
</td>
<td class="num">(16,196,318)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ModificationOfWarrants', window );">Modification of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(171,552)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common shareholders</a></td>
<td class="num">$ (7,244,891)<span></span>
</td>
<td class="num">$ (8,342,809)<span></span>
</td>
<td class="num">$ (13,954,415)<span></span>
</td>
<td class="num">$ (16,367,870)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EarningPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding - basic and diluted</a></td>
<td class="nump">52,006,442<span></span>
</td>
<td class="nump">43,588,381<span></span>
</td>
<td class="nump">50,228,860<span></span>
</td>
<td class="nump">43,513,571<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EarningPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EarningPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ModificationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ModificationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418751824000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,448,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2022</a></td>
<td class="nump">$ 32,163,207<span></span>
</td>
<td class="nump">$ 434,484<span></span>
</td>
<td class="nump">$ 486,625,816<span></span>
</td>
<td class="num">$ (454,897,093)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantExercisesShares', window );">Warrant exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantExercisesAmount', window );">Warrant exercises, amount</a></td>
<td class="nump">447,291<span></span>
</td>
<td class="nump">$ 2,177<span></span>
</td>
<td class="nump">445,114<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">1,703,931<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,703,931<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">50,178<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
<td class="nump">49,965<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, amount</a></td>
<td class="nump">91,623<span></span>
</td>
<td class="nump">$ 402<span></span>
</td>
<td class="nump">91,221<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncentiveStockForfeitedShares', window );">2014 incentive stock forfeited, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncentiveStockForfeitedAmount', window );">2014 incentive stock forfeited, amount</a></td>
<td class="num">(11,100)<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
<td class="num">(11,080)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,853,509)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,853,509)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,725,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2022</a></td>
<td class="nump">26,591,621<span></span>
</td>
<td class="nump">$ 437,256<span></span>
</td>
<td class="nump">488,904,967<span></span>
</td>
<td class="num">(462,750,602)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,448,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2022</a></td>
<td class="nump">32,163,207<span></span>
</td>
<td class="nump">$ 434,484<span></span>
</td>
<td class="nump">486,625,816<span></span>
</td>
<td class="num">(454,897,093)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,196,318)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,787,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2023</a></td>
<td class="nump">20,147,600<span></span>
</td>
<td class="nump">$ 437,878<span></span>
</td>
<td class="nump">490,803,133<span></span>
</td>
<td class="num">(471,093,411)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,725,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2022</a></td>
<td class="nump">26,591,621<span></span>
</td>
<td class="nump">$ 437,256<span></span>
</td>
<td class="nump">488,904,967<span></span>
</td>
<td class="num">(462,750,602)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">1,743,288<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,743,288<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">54,865<span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
<td class="nump">54,629<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, amount</a></td>
<td class="nump">100,635<span></span>
</td>
<td class="nump">$ 386<span></span>
</td>
<td class="nump">100,249<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,342,809)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,342,809)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,787,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2023</a></td>
<td class="nump">20,147,600<span></span>
</td>
<td class="nump">$ 437,878<span></span>
</td>
<td class="nump">490,803,133<span></span>
</td>
<td class="num">(471,093,411)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2023</a></td>
<td class="nump">13,214,890<span></span>
</td>
<td class="nump">$ 474,223<span></span>
</td>
<td class="nump">499,832,063<span></span>
</td>
<td class="num">(487,091,396)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">1,383,909<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,383,909<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">48,907<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">48,730<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, amount</a></td>
<td class="nump">202,307<span></span>
</td>
<td class="nump">$ 886<span></span>
</td>
<td class="nump">201,421<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,709,524)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,709,524)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from the sale of common stock, amount</a></td>
<td class="nump">4,980,000<span></span>
</td>
<td class="nump">$ 24,900<span></span>
</td>
<td class="nump">4,955,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">(470,229)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(470,229)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,018,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2023</a></td>
<td class="nump">12,650,260<span></span>
</td>
<td class="nump">$ 500,186<span></span>
</td>
<td class="nump">505,950,994<span></span>
</td>
<td class="num">(493,800,920)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2023</a></td>
<td class="nump">13,214,890<span></span>
</td>
<td class="nump">$ 474,223<span></span>
</td>
<td class="nump">499,832,063<span></span>
</td>
<td class="num">(487,091,396)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,954,415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,083,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2024</a></td>
<td class="nump">14,304,643<span></span>
</td>
<td class="nump">$ 540,837<span></span>
</td>
<td class="nump">514,809,617<span></span>
</td>
<td class="num">(501,045,811)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,018,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2023</a></td>
<td class="nump">12,650,260<span></span>
</td>
<td class="nump">$ 500,186<span></span>
</td>
<td class="nump">505,950,994<span></span>
</td>
<td class="num">(493,800,920)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">1,432,540<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,432,540<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">53,485<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
<td class="nump">53,211<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, amount</a></td>
<td class="nump">380,870<span></span>
</td>
<td class="nump">$ 1,627<span></span>
</td>
<td class="nump">379,243<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,244,891)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,244,891)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from the sale of common stock, amount</a></td>
<td class="nump">7,750,000<span></span>
</td>
<td class="nump">$ 38,750<span></span>
</td>
<td class="nump">7,711,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="num">(717,621)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(717,621)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,083,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2024</a></td>
<td class="nump">$ 14,304,643<span></span>
</td>
<td class="nump">$ 540,837<span></span>
</td>
<td class="nump">$ 514,809,617<span></span>
</td>
<td class="num">$ (501,045,811)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncentiveStockForfeitedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncentiveStockForfeitedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncentiveStockForfeitedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncentiveStockForfeitedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantExercisesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantExercisesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantExercisesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantExercisesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418756184352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (13,954,415)<span></span>
</td>
<td class="num">$ (16,196,318)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,993,395<span></span>
</td>
<td class="nump">1,973,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash lease expense</a></td>
<td class="nump">4,383<span></span>
</td>
<td class="nump">9,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share-based payments for services</a></td>
<td class="nump">547,893<span></span>
</td>
<td class="nump">285,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation</a></td>
<td class="nump">2,816,449<span></span>
</td>
<td class="nump">3,436,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommonStockContributedToEmployeeBenefitPlan', window );">Common stock contributed to 401(k) plan</a></td>
<td class="nump">102,392<span></span>
</td>
<td class="nump">105,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase)/decrease in assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(30,996)<span></span>
</td>
<td class="nump">180,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="nump">240,067<span></span>
</td>
<td class="nump">170,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncreaseDecreaseInDepositAssets', window );">Deposits</a></td>
<td class="num">(11,884)<span></span>
</td>
<td class="num">(2,354,723)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase/(decrease) in liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(896,939)<span></span>
</td>
<td class="nump">102,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">59,818<span></span>
</td>
<td class="nump">111,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Due to employees</a></td>
<td class="nump">194,363<span></span>
</td>
<td class="nump">37,798<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(9,415,608)<span></span>
</td>
<td class="num">(12,137,820)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(51,650)<span></span>
</td>
<td class="num">(165,032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Expenditures for patent costs</a></td>
<td class="num">(13,211)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(64,861)<span></span>
</td>
<td class="num">(165,032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">12,730,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="num">(1,218,937)<span></span>
</td>
<td class="num">(9,010)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">447,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payments on obligations under finance leases</a></td>
<td class="num">(867,008)<span></span>
</td>
<td class="num">(761,223)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">10,644,055<span></span>
</td>
<td class="num">(322,942)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">1,163,586<span></span>
</td>
<td class="num">(12,625,794)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</a></td>
<td class="nump">4,145,735<span></span>
</td>
<td class="nump">22,672,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
<td class="nump">5,309,321<span></span>
</td>
<td class="nump">10,046,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities', window );">Property and equipment purchases included in current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">176,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AssetsPurchasedUnderFinanceLeases', window );">Assets purchased under finance leases</a></td>
<td class="nump">20,797<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseObligationIncludedInAccountsPayable', window );">Finance lease obligation included in accounts payable</a></td>
<td class="nump">522<span></span>
</td>
<td class="nump">1,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ConsultingServicesPaidWithIssuanceOfCommonStock', window );">Consulting services paid with issuance of common stock</a></td>
<td class="nump">583,177<span></span>
</td>
<td class="nump">192,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AccruedConsultingServicesToBePaidWithCommonStock', window );">Accrued consulting services to be paid with common stock</a></td>
<td class="nump">165,000<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinancingCostsIncludedInCurrentLiabilities', window );">Financing costs included in current liabilities</a></td>
<td class="nump">46,616<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 480,044<span></span>
</td>
<td class="nump">$ 547,765<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AccruedConsultingServicesToBePaidWithCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AccruedConsultingServicesToBePaidWithCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AssetsPurchasedUnderFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AssetsPurchasedUnderFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommonStockContributedToEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommonStockContributedToEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ConsultingServicesPaidWithIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ConsultingServicesPaidWithIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseObligationIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseObligationIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinancingCostsIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinancingCostsIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncreaseDecreaseInDepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncreaseDecreaseInDepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418756062704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A. <span style="text-decoration:underline">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Basis of Presentation</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The accompanying condensed financial statements of CEL-SCI Corporation (the &#8220;Company&#8221;) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#8217;s annual report on Form 10-K for the year ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair presentation of the Company&#8217;s financial position as of March 31, 2024 and the results of its operations for the six months then ended. The condensed balance sheet as of September 30, 2023 is derived from the September 30, 2023 audited financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Summary of Significant Accounting Policies:</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing &#8211;</em> Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Leases &#8211; </em>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Share-Based Compensation</em> &#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, <em>Compensation &#8211; Stock Compensation</em> (&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#8220;Plans&#8221;. All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Research and Development Costs</em> &#8211; Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260, <em>Earnings Per Share</em>. Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company accounts for income taxes in accordance with the provisions of ASC 740, <em>Income Taxes</em>, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of March 31, 2024 and September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impairment of long-lived assets</em> &#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Recently Adopted Accounting Standards</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2016-13,<em> Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;). </em>ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no impact on the Company&#8217;s financial position, results of operations, or cash flows.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>New Accounting Pronouncements</em> &#8211; The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418756961312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LIQUIDITYAbstract', window );"><strong>LIQUIDITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LiquidityDisclosureTextBlock', window );">LIQUIDITY</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">B. <span style="text-decoration:underline">LIQUIDITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company&#8217;s lead investigational therapy, to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to the Company&#8217;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LIQUIDITYAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LIQUIDITYAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LiquidityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LiquidityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418756336976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">C. <span style="text-decoration:underline">STOCKHOLDERS&#8217; EQUITY</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Proceeds from the Sale of Common Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In February 2024, the Company sold 3,875,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $7.0 million, net of issuance costs of approximately $0.7 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2023, the Company sold 2,490,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $4.5 million, net of issuance costs of approximately $0.5 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Equity Compensation</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Underlying share information for equity compensation plans as of March 31, 2024 is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Total Shares Reserved</strong> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Under Plans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,787,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,283,760</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Stock option activity</span>:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"><strong>Six Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"><strong>&#160;2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">53,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">122,332</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,035</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">45,404</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"><strong>Three Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"><strong>&#160;2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">42,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,035</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On March 1, 2024, the Company accelerated the vesting of 234,332 stock options issued to directors to vest on April 19, 2024. The Company concluded that the change in vesting of the options should be treated as a modification in accordance with ASC 718. As such, the Company revalued the options as of March 1, 2024 (the modification date) and subtracted any compensation cost already recognized prior to the modification date. This resulted in remaining compensation cost of approximately $260,000 that will be amortized on a straight-line basis over the remaining service period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Share-Based Compensation Expense</span>:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"><strong>Six Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 15pt; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 27.05pt; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,816,449</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,436,119</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">370,163</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,722</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"><strong>Three Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 15pt; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 27.05pt; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,432,540</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,743,288</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">151,777</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">136,864</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Warrants and Non-Employee Options</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following chart represents the warrants and non-employee options outstanding at March 31, 2024:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2024&#160; </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,603</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">333,432</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,087</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">234,009</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">7/28/2017 &#8211; 9/2/2023 </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>$</td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">1.39 - $2.18</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">7/27/2027 -&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">9/1/2028</p></td><td style="width:1%;">&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">1. <span style="text-decoration:underline">Equity Warrants</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Changes in Equity Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No warrants recorded as equity were exercised during the six months ended March 31, 2024. The following warrants recorded as equity were exercised during the six months ended March 31, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,752</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">418,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">217,752</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">447,291</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No warrants recorded as equity expired during the six and three months ended March 31 ,2024. On February 5, 2023, 600 Series TT warrants, with an exercise price of $2.24, expired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No warrants recorded as equity were extended during the six and three months ended March 31, 2024. On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024. The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2022. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">2. <span style="text-decoration:underline">Options and Shares Issued to Consultants</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the six months ended March 31, 2024 and 2023, the Company issued 251,317 and 78,798 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $1.99 and $2.47 during the six months ended March 31, 2024 and 2023, respectively. During the three months ended March 31, 2024 and 2023, the Company issued 162,744 and 38,562 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $2.22 and $2.42 during the three months ended March 31, 2024 and 2023, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No options were issued to a consultant during the six months ended March 31, 2024. During the six months ended March 31, 2023, 5,000 options with an exercise price of $11.61 issued to a consultant expired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the six months ended March 31, 2024 and 2023, the Company recorded total expense of approximately $370,000 and $285,000, respectively, relating to the share-based compensation under various consulting agreements. During the three months ended March 31, 2024 and 2023, the Company recorded total expense of approximately $152,000 and $136,000, respectively, relating to the share-based compensation under these consulting agreements. On March 31, 2024 and September 30, 2023, consulting fees of approximately $351,000 and $205,000, respectively, are included in current assets as prepaid expenses and will be amortized over the remaining service periods. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418756925120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">D. <span style="text-decoration:underline">RELATED PARTY TRANSACTIONS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the six and three months ended March 31, 2024, no restricted shares of the Company&#8217;s common stock were purchased by related parties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024 (Note C). The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418754432768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">E. <span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Clinical Research Agreement</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:right;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $12 million towards the Company&#8217;s Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808, <em>Collaborative Arrangements</em>. The Company determined the payments to Ergomed are within the scope of ASC 730, <em>Research and Development</em>. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its statements of operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $35.8 million for Ergomed&#8217;s services. This amount is net of Ergomed&#8217;s discount of approximately $11.9 million. During the six months ended March 31, 2024 and 2023, the Company recorded, net of Ergomed&#8217;s discount, approximately $0.1 million for each quarter as research and development expense related to Ergomed&#8217;s services. During the three months ended March 31, 2024 and 2023, the Company recorded, net of Ergomed&#8217;s discount, less than $0.1 million for each quarter as research and development expense related to Ergomed&#8217;s services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Lease Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase 3 clinical trial and sales of the drug if approved by any regulatory agency. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The San Tomas lease is classified as a finance lease on the Company&#8217;s balance sheet, as well as several other smaller finance leases for office equipment. The finance right of use assets are being depreciated using the straight-line method over the underlying lease terms. Total cash paid related to finance leases during the six months ended March 31, 2024 and 2023 was approximately $1.3 million for both periods, of which approximately $0.5 and $0.6 million was for interest, respectively, in each six-month period. As of March 31, 2024, the weighted average discount rate of the Company&#8217;s finance leases is 8.46% and the weighted average time to maturity is 4.59 years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On January 11, 2023, the Company was required to deposit approximately $2.3 million to its landlord, equivalent to one year&#8217;s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Approximate future minimum lease payments under finance leases as of March 31, 2024 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Six months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,333,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,747,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,838,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,929,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,021,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">255,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,123,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,247,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of financing lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,876,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of financing lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,889,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of financing lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,987,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases two facilities under operating leases. The lease for the Company&#8217;s office headquarters will expire on November 30, 2025.&#160; The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on February 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. The Company incurred lease expense for operating leases of approximately $0.2 million for both the six months ended March 31, 2024 and 2023. Total cash paid related to operating leases during the six months ended March 31, 2024 and 2023 was approximately $0.2 million for each period. The weighted average discount rate of the Company&#8217;s operating leases is 9.03% and the weighted average time to maturity is 7.35 years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of March 31, 2024, approximate future minimum lease payments under operating leases are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Six months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">180,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">746,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,435,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(680,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,755,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of operating lease obligations - current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(211,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,544,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418756965872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">PATENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">G. <span style="text-decoration:underline">PATENTS</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the six and three months ended March 31, 2024 and 2023, there was no impairment of patent costs. The weighted average amortization period for patents&#160;is approximately&#160;8&#160;years. For the six months ended March 31, 2024 and 2023, amortization of patent costs totaled approximately $17,000 and $20,000, respectively. For the three months ended March 31, 2024 and 2023, amortization of patent costs totaled approximately $8,000&#160;and $10,000, respectively. The total estimated future amortization is as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Six months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">54,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">180,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418756915440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER COMMON SHARE</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">H. <span style="text-decoration:underline">LOSS PER COMMON SHARE</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, common stock warrants and unvested restricted stock are not included in the computation of diluted net loss per share if their effect would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table provides a reconciliation of the numerators and denominators of the basic and diluted loss per-share computations:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Six Months</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net loss available to common &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(13,954,415</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(16,367,870</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,244,891</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,342,809</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">50,228,860</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,513,571</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">52,006,442</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,588,381</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.28</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.38</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.14</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.19</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with the contingently issuable shares guidance of ASC 260, <em>Earnings Per Share</em>, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of March 31:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,772,993</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,893,248</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">149,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,920,243</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,042,498</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418756059008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">J. <span style="text-decoration:underline">SUBSEQUENT EVENTS</span> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 4, 2024, the Company extended for two years the expiration date of 1,092,470 outstanding warrants.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 8, 2024, officers and directors purchased 58,000 shares of restricted common stock from the Company at an aggregate fair market value of $80,620.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418758327200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Supplies used for R&amp;amp;D and manufacturing</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing &#8211;</em> Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Leases &#8211; </em>The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Share-Based Compensation</em> &#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, <em>Compensation &#8211; Stock Compensation</em> (&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#8220;Plans&#8221;. All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Research and Development Costs</em> &#8211; Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260, <em>Earnings Per Share</em>. Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company accounts for income taxes in accordance with the provisions of ASC 740, <em>Income Taxes</em>, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of March 31, 2024 and September 30, 2023.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ImpairmentOfLongLivedAssetsPolicyTextblock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impairment of long-lived assets</em> &#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Recently Adopted Accounting Standards</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2016-13,<em> Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;). </em>ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no impact on the Company&#8217;s financial position, results of operations, or cash flows.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>New Accounting Pronouncements</em> &#8211; The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ImpairmentOfLongLivedAssetsPolicyTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ImpairmentOfLongLivedAssetsPolicyTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418758225152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of equity compensation plans</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name of Plan</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><strong>Total Shares Reserved</strong> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Under Plans</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,787,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,283,760</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">634,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">640,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfStockOptionActivityTableTextBlock', window );">Schedule of Stock option activity</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"><strong>Six Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"><strong>&#160;2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">53,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">122,332</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,035</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">45,404</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"><strong>Three Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"><strong>&#160;2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">42,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,035</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfCompensatingBalancesTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"><strong>Six Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 15pt; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 27.05pt; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,816,449</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,436,119</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">370,163</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,722</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"><strong>Three Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 15pt; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 27.05pt; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,432,540</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,743,288</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">151,777</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">136,864</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock', window );">Schedule of warrants and non-employee options outstanding</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">Shares Issuable upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;">of Warrants/ Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2024&#160; </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93,603</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">333,432</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">200,087</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">234,009</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2024</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;">7/28/2017 &#8211; 9/2/2023 </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">110,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>$</td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">1.39 - $2.18</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">7/27/2027 -&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;">9/1/2028</p></td><td style="width:1%;">&#160;</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock', window );">Schedule of derivative liabilities</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,752</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">418,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">217,752</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">447,291</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfCompensatingBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfCompensatingBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfStockOptionActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfStockOptionActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418756968880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum payments under finance leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Six months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,333,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,747,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,838,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,929,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,021,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">255,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,123,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,247,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of financing lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,876,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of financing lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,889,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of financing lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8,987,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Six months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">180,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">746,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,435,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(680,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,755,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less net present value of operating lease obligations - current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(211,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations - non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,544,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418756993328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of total estimated future amortization</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Six months ending September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">54,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">180,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418756984528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock', window );">Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Six Months</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net loss available to common &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(13,954,415</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(16,367,870</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,244,891</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(8,342,809</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">50,228,860</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,513,571</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">52,006,442</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">43,588,381</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.28</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.38</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.14</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.19</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock', window );">Schedule of anti-dilutive securities</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,772,993</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,893,248</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested Restricted Stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">149,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,920,243</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">14,042,498</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418758337056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">138,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember', window );">Non-Qualified Stock Option Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">15,787,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_StockBonusPlansMember', window );">Stock Bonus Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">1,283,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Stock Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">634,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlansMember', window );">Incentive Stock Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/shares Under Plans</a></td>
<td class="nump">640,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_StockBonusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_StockBonusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_IncentiveStockBonusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418756334640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited</a></td>
<td class="nump">42,000<span></span>
</td>
<td class="nump">25,500<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="nump">122,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Option exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options Expired</a></td>
<td class="nump">27,035<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">27,035<span></span>
</td>
<td class="nump">45,404<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418864261968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock Based Compensation Expense</a></td>
<td class="nump">$ 1,432,540<span></span>
</td>
<td class="nump">$ 1,743,288<span></span>
</td>
<td class="nump">$ 2,816,449<span></span>
</td>
<td class="nump">$ 3,436,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cvm_NonEmployeesMember', window );">Non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock Based Compensation Expense</a></td>
<td class="nump">$ 151,777<span></span>
</td>
<td class="nump">$ 136,864<span></span>
</td>
<td class="nump">$ 370,163<span></span>
</td>
<td class="nump">$ 285,722<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cvm_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cvm_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418844260976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 3) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOptionMember', window );">Consultants Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">7/28/2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">7/27/2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">9/2/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">9/1/2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNMember', window );">Series N [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">8/18/2008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">8/18/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUMember', window );">Series UU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">6/11/2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">6/30/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember', window );">Series X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">1/13/2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">7/13/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember', window );">Series Y [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">2/15/2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">8/15/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMMember', window );">Series MM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">6/22/2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">6/22/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember', window );">Series NN [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">7/24/2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">7/24/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssueDate1', window );">Issue Date</a></td>
<td class="text">10/30/2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfWarrantOptions', window );">Shares Issuable Upon Exercise Of Warrant/options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">10/30/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IssueDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IssueDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SharesIssuableUponExerciseOfWarrantOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SharesIssuableUponExerciseOfWarrantOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesUUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesMMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesNNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418758341344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details 4)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised | shares</a></td>
<td class="nump">217,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised | $</a></td>
<td class="nump">$ 447,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised | shares</a></td>
<td class="nump">17,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised | $</a></td>
<td class="nump">$ 29,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesSSMember', window );">Series SS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised | shares</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised | $</a></td>
<td class="nump">$ 418,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EquityWarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EquityWarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EquityWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EquityWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedsFromEquityWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedsFromEquityWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesSSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesSSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418846587808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Oct. 28, 2023</div></th>
<th class="th"><div>Oct. 28, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncrementalCostDeemedDividend', window );">Incremental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">3,875,000<span></span>
</td>
<td class="nump">2,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,083,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,083,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,730,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetofissuanceCosts', window );">Net of issuance costs</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 234,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember', window );">Consulting Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1', window );">Options issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ConsultingFeesIncluedPrepaidExpenses', window );">Consulting fees inclued prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,000<span></span>
</td>
<td class="nump">$ 136,000<span></span>
</td>
<td class="nump">$ 370,000<span></span>
</td>
<td class="nump">$ 285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember', window );">Restricted Stock [Member] | Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="nump">$ 2.42<span></span>
</td>
<td class="nump">$ 2.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,744<span></span>
</td>
<td class="nump">38,562<span></span>
</td>
<td class="nump">251,317<span></span>
</td>
<td class="nump">78,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncrementalCostDeemedDividend', window );">Incremental cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ConsultingFeesIncluedPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ConsultingFeesIncluedPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncrementalCostDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncrementalCostDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetofissuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetofissuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of options issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418756980512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative )<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 28, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncrementalCostDeemedDividend', window );">Incremental cost</a></td>
<td class="nump">$ 172,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncrementalCostDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncrementalCostDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418862836864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Three months ending September 30, 2024</a></td>
<td class="nump">$ 1,333,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">2,747,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">2,838,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">2,929,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">3,021,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">255,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease obligation</a></td>
<td class="nump">13,123,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest on finance lease obligations</a></td>
<td class="num">(2,247,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Net present value of financing lease obligations</a></td>
<td class="nump">10,876,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseLiabilityCurrentPortion', window );">Less net present value of financing lease obligations - current portion</a></td>
<td class="num">(1,889,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseLiabilityNoncurrentPortion', window );">Net present value of financing lease obligations - non-current portion</a></td>
<td class="nump">$ 8,987,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseLiabilityCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseLiabilityCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseLiabilityNoncurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseLiabilityNoncurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418864526256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details 1)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommitmentsAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Three months ending September 30, 2024</a></td>
<td class="nump">$ 180,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">366,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">287,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">277,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">285,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">294,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">746,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total Future Minimum Lease Obligation</a></td>
<td class="nump">2,435,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less Imputed Interest On Operating Lease Obligation</a></td>
<td class="num">(680,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Net Present Value Of Operating Lease Obligation</a></td>
<td class="nump">1,755,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_OperatingLeaseLiabilityCurrentPortion', window );">Net present value of lease finance lease obligations - current portion</a></td>
<td class="num">(211,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_OperatingLeaseLiabilityNoncurrentPortion', window );">Net present value of lease finance lease obligations - non-current portion</a></td>
<td class="nump">$ 1,544,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OperatingLeaseLiabilityCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OperatingLeaseLiabilityCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OperatingLeaseLiabilityNoncurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OperatingLeaseLiabilityNoncurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418756597376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetOfDiscount', window );">Net Of Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,190,000<span></span>
</td>
<td class="nump">$ 11,900,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Total cash payment for financing lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne', window );">Weighted average time of maturity of financing lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense for operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Total cash payment for oprating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate of financing lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.46%<span></span>
</td>
<td class="nump">8.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne', window );">Weighted average time of maturity of operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 7 months 2 days<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research And Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted Average Discount Rate Operating Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.03%<span></span>
</td>
<td class="nump">9.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvm_LandlordMember', window );">Landlord [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinancingArrangementDepositBaseRentAmount', window );">Financing arrangement deposit base rent amount</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ErgomedMember', window );">Ergomed [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetOfDiscount', window );">Net Of Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research And Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ClinicalServiceTrial', window );">Clinical Service Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ClinicalServiceTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ClinicalServiceTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinancingArrangementDepositBaseRentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinancingArrangementDepositBaseRentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvm_LandlordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvm_LandlordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ErgomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ErgomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418846423184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PATENTS (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Three months ending September 30, 2024</a></td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">22,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">19,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">54,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIndefiniteLivedIntangibleAssets', window );">Total</a></td>
<td class="nump">$ 180,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418756007760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod', window );">Weighted average amortization period for patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418844353600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted', window );">Net loss available to common shareholders - basic and diluted</a></td>
<td class="num">$ (7,244,891)<span></span>
</td>
<td class="num">$ (8,342,809)<span></span>
</td>
<td class="num">$ (13,954,415)<span></span>
</td>
<td class="num">$ (16,367,870)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Loss per share- basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted', window );">Weighted average shares outstanding - basic and diluted</a></td>
<td class="nump">52,006,442<span></span>
</td>
<td class="nump">45,581,381<span></span>
</td>
<td class="nump">50,228,860<span></span>
</td>
<td class="nump">43,513,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares', window );">Basic and diluted loss per common share</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418756073936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">15,920,243<span></span>
</td>
<td class="nump">14,042,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember', window );">Options and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">15,772,993<span></span>
</td>
<td class="nump">13,893,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember', window );">Unvested Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">147,250<span></span>
</td>
<td class="nump">149,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm140418756755568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event<br></strong></div></th>
<th class="th">
<div>May 08, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Stock warrants under the extention period</a></td>
<td class="nump">1,092,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_RestrictedCommonStock', window );">Restricted common stock</a></td>
<td class="nump">58,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityOwnedNotReadilyMarketableFairValue', window );">Fair market value | $</a></td>
<td class="nump">$ 80,620<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_RestrictedCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_RestrictedCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityOwnedNotReadilyMarketableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the not readily marketable security or category which has been determined by management based upon fair value methods, including pricing of similar securities and valuation techniques and is included in the schedule of financial condition or the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 820<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481753/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityOwnedNotReadilyMarketableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MZW2M\F&[]!W*M;R+HWM>[1*'S:21R;SZP,C>H&P!"*"GT3< ?;_JZ6;^I)5
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M8[7- JX+U/T%8_*YH1?R9N,6_ 502P,$%     @ +8*O6!PL^:&S!   1!(
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M6 N!_GTEA#J^% 4T%T?C?P!02P,$%     @ +8*O6*JIF6>:"@  >4T  !@
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M6Q+F&C[XY#L3PU=?K[C!(6[8RAZOO.%+K?\0G.8-,?G.Q*#Q A;ZEK)'0,1
MRQY$T5;V(*%#98_0N"'<N/'D)6$!44#-3*KFG.G(,'^,U<J00)L#FC^$FS^\
M+ F[^Y@Z,P6R/2EF8 '.:Z>9+[7^8= T(MPTXF5)6" PP7AB5D<"L@F-S2(;
MU:+$7']#PFPIJ5E$N%G$QY*PNXO)&8G<I(B49\ TKV3B2ZU_&,Z>EW:3B8\U
M80%A09VY%2V8*8G<I8 [Q#"U.*5F,90A<;:DU&0BGDXF B&3F'+%8^"!\>%G
MIA$Q<!T8T5]_F!H/A!L/_ORBL+N#R3,/>30BB05<%/;:;>9+K7\4-"L(-RO\
M^45A 8OWN+,-S#P(#IW!IKV8'B'4#,R00-O<T[ @!AZC'KDH+&!)/X])#+<U
M'P.=TW"D5H8$VGZX01?IT<@B?0*DNR6GSKL(*=!Q2/?:;^9+K6^\YH%HY$ZE
M"9 >P0K? NE() KI6)P%TI%0*Z0OSGZUJOU1,C6R3X4J,[?R5C4.G\?J:%>'
MW_DZO&G*^^Z'K#Z635/NNI=W,M_(J@U0?[\MR^;[F_:WL4Z_MG;U?U!+ P04
M    "  M@J]8,VG2XLP'  !Y(   &    'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;*V:;7/B.!+'OXJ*N]I*JI;!DOR83:@BX.Q2M2&YD,R^-K82?..G]4,R
MV4]_+1MLL&0-<\6\F#&FU?S5<O>O)<_U1YI_*[:,E>A['"7%S6A;EMG59%+X
M6Q9[Q9<T8PE\\YKFL5?"Q_QM4F0Y\X)Z4!Q-B*:9D]@+D]'TNK[WF$^OTZJ,
MPH0]YJBHXMC+/V]9E'[<C/!H?^,I?-N6_,9D>IUY;VS-RI?L,8=/D]9+$,8L
M*<(T03E[O1G-\-6<.GQ ;?$U9!_%P37B4]FDZ3?^81G<C#2NB$7,+[D+#_YY
M9W,61=P3Z/A[YW34_B8?>'B]]WY73QXFL_$*-D^CO\*@W-Z,[!$*V*M71>53
M^O$'VTW(X/[\-"KJO]%'8VN9(^1719G&N\&@( Z3YE_O^RX0!P/ CWP V0T@
M_0'ZP "Z&T#KB3;*ZFDMO-*;7N?I!\JY-7CC%W5LZM$PFS#AR[@N<_@VA''E
M=/ZP6KBKM;M Z^?9LWOOKI[7Z.$.S6?K/]#=GP]_K='%RVKVLE@^NXM+-$8O
MZP6Z^/?E]:2$7^<^)O[NEVZ;7R(#OV2B^S0IMP5RDX %Q^,GH+J53O;2;XG2
MX;V7?T$4_XJ(1G2)GOGIPZE"#FTC26M_]"R1E,6O\:_+_?-\OBHRSV<W(TC8
M@N7O;#3]Y5_8U'Z33?Y,SHY"H;>AT%7>IRLH/U%:%+))-B/->B2O,>_3,::.
MH>O8N)Z\'\Y 9FEBQZ38;BV/Y!FM/$.Y4K/@OY!84(O* I4I%",_3?PP8BC9
MZ>9W^;7O%5M4%2Q 88*@<N9>&29O3>D)RY 55[(9&N=<QC,Y.XJ3V<;)5"[C
M@H%3/_2:>IL$R(O3O S_J6_(9MZX,PY6##L.A=7MK:S,SJ*.3>3K:K5Z+?5C
MER;C>LDB!H4=L>_ NH+)A%J" )W:M*=2-(+'U)!+M%N)ME+B>NOE;,RY$Z#,
M^VR>08 QXFL7^DR:,K8@Q- MV^GK%<V(;5AD(*A.J]A1*G;_KL+R<R?93V,>
MT\$'P)%(P*:N.SVIHAW5J8FQ(]>*M8YFFE+M/(UC>%@!F_XW4)N4>;BI2E .
M&:UK^.+;)<HB3ZI]Y_GHJ00R.*2G76IG:#H=T'Y 8JPL2Q?+Q,_YDWLY"5AS
MQ>N.5Q2LE%>:G<,SE9IS>3N>/NFF3Y1+]YBSS N#?=I*,V'GXC#V8ZHYCME?
M(]$.VQH9R@7<,1XKN3E=5UD60>%OJ, 3]^D7+\Y^6]3U,?:2ZA7H4.6 ":E^
M*B:(#@VWU=<OVF$+'C%]0'\'9JPF,Y3TM A+>7!U,;@8V[;>%R>Q(Q1*$AE*
M@0[,6$WF?09,+O89<,E3( J]31@-$Q>?%;GG\G8<@PZZ6$W=F>^G%<<"\,';
M1%)^89&@8]LQ'=HOM!)#*&JVC@=6JD,M5K,65.85^T&VB@0U'/N@>]MI%,TP
MQ@8>0"WN6(O5L%U4C-=]%F=1^LD&-(K4Q ZPJ ]7B1VU+&>@$\4=7;$:KZM3
MVDRI<)&A8P>::%,3XBNQQ 13RR::7#[I>$LT]::GV]S</3W<H^7JJ[M^7JY^
M1[/Y\_+K\GGIKJ4I2Y0<_]F4/9>WXRATY"9*-$X?J]S?0K$J4/J*LIPO8?E9
M$X%!]Y3Q+D\: RPNC(%-0^LMH,R.F]$!G)&.N43-7)=G;Q "L%C3AF9>"6*A
M<RKDC" 2 &-*,.Y+%NV&GK6.O43-7B%5PN2=%2>D"A%I.C9UVQ1$2^R4<>ZP
M2_2?2I.[Y6JVFI^2)DJ<_W2:G,G;<10ZNA,E.:'#2WW& GC2\C1&85%47N(S
MGC/^0=LN#8,A5FEB40W^]-=0M!QZ\#HB$S61'_<;-5#:["Q:[<.)(B$T%%W8
MM?5[/9FEH^$AU1VAB9K0Q]$NMWQ#S'(_+.J(?WAY[B4#VD4@"V&6[*"A 70&
M^@K2,9NHF=W%&E"XB<*W>J\)_782L!R]ADD=]GJ#+]<N<GILFY8F4%%F:)F8
M##6QI$,Z.1'I0(+W,(!:M?E$%[NB=;F;PPE52\0VUF OK1G]XQ2)Y9@2XN@#
M=8MV>*?J[?3*?0:DSY_<V=I%%PNWN;J$>\VQYFRU:"[<_[PLO\[^Y&>>TI--
MR9X9F]2P^QLWB2&DC4D,RQG8^]".TE1-Z4'%OZ);]_?E:L7K\<,=>G2?E@\+
MZ31$$.M8-RS:7Q&)(2&F!4W70,-(.V13-;(5LW#AKEJ_2&4#ML_ [[Y^R?Y9
MTW23ZD.K<'!*KJ;XH[0]0EG;0H6)'U5!0WB_RG/^[<$&4#HO$=S]@B4QP99I
M#9W:T [M5+VCGM7',ZW^X.1*1<5M--$LIX\'B=D &F@'8JH&\=VAN(,R>Q1[
M[X1]*!5I:Y#^@9G$".O:4&WJJ$S55)X#%JJH;O_VAZ>H/D#Z",OM3W475"2P
M85-L"4LA.[<FQ!C*Z0[5]+3-M"^9$FQ@-^Q@8C^<C&0W#3VLT"C]V.YX,AW!
MJ9K@=RW?ZN;H_\IGD<VZ:6(!%J+9D/H.WE0-[WD-;AYMOAT*DY)!)RS=O>T<
M';Z?TFTHDOWC,HF=H5N6V3_>F!R\Q(U9_E:_VRY0G83-2]'V;OO^?%:_->[=
MO\57\^8M>.>F>2E_[^5O(313$7L%E]H7"T*7-^^YFP]EFM6OBC=I6:9Q?;EE
M'M0S;@#?OZ9IN?_ ?Z#]WP;3_P%02P,$%     @ +8*O6/DQJWW3"   *A4
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MKQT,'_XRERZBJ_EKV-S%Z"K^N<)[GO(D@.?T$M]>D('-Y]'K_P!02P,$%
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M!SL48R 8E,E/>5_J<&3P>O43@W4Q6"?<.5!"^4$&N;ET=B<<[X8W_I%23=8
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M4AH;60(5!N"C$8]&[#3<D8T4G4V'FV5NF"R5PG=XA7N<RL2E:VRJ+BX+.F+
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MH:G7V>&:/BY0F@1ZOA1"[P*SP/YS9?@_4$L#!!0    ( "V"KUCH5X,!60(
M $\%   9    >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;'U4;6_3,!#^*Z>
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M80]E8Q3^9>AGEE_O-AMR?[TF5W>WMW??R.;F<GU-/CS0)P[ZXSPP&,-:!N6
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M"VO*++! ;2.'S$+Z(Z?$AF86UIA9*A3R?"RI+5TP"]/,PHYBEH_P#5Q8I/9
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M:0Q*LT%I#BC-Q>VJ*NZU7Q#Q9'%&OQ7G2^(,2S(!*(G3!^V!1@AUM$W?;<N
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MV*GVR\+^1D"Y!'N^E=*< E>@_3$E?P!02P,$%     @ +8*O6$S"!]H0 P
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M#-#O8\[5<\<4#E7=%_T%4$L#!!0    ( "V"KUAF=S?<,P4  *DA   9
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M%GLH[P+5Z/Y#7UTD9&M:D8*C#)8RE-6[DL)8-9RKC:"EGCX+*N0LT\M4WF>
M*0?Y?4FIV&]4@.:&%/P&4$L#!!0    ( "V"KUBM5+_]0 ,  )P+   9
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;*U6;6_:,!#^*U8V39VTDO>7,HA4
M"%,GC1:!NGYVR4&B)C&S#73_?G82LI"YB&U\ =NYYSG?<V?[!GM"7U@"P-%K
MGA5LJ"6<;_JZSI8)Y)CUR 8*\65%:(ZYF-*USC84<%R"\DRW#,/3<YP66C@H
MUV8T') MS]("9A2Q;9YC^G,$&=D/-5,[+,S3=<+E@AX.-G@-"^"/FQD5,[UA
MB=,<"I:2 E%8#;5;LS_QI7UI\#V%/6N-D8SDF9 7.?D:#S5#;@@R6'+)@,7?
M#L:099)(;.-'S:DU+B6P/3ZP?REC%[$\8P9CDCVE,4^&6J"A&%9XF_$YV=]!
M'8\K^98D8^4OVE>VGJ6AY99QDM=@L8,\+:I__%KKT (('C7 J@%6%^"\ ;!K
M@'VN!Z<&..=Z<&M &;I>Q5X*%V&.PP$E>T2EM6"3@U+]$BWT2@M9)PM.Q==4
MX'CX[6&Q0+/)'(T?IM.'>[2XNYU/T%4$'*<9^XBNT>,B0E?O/PYT+MQ)D+ZL
MJ4<5M?4&M8VFI. )0Y,BAEB!CT[CO1-X7839Q&H=8AU9)PFGF/:0;7Y"EF$Y
MBOV,SX?;JG#^S_ODG[T?B6$WB;=+/OMO$J]*<D7CJ&GD-=9G&[R$H2;N*09T
M!UKXX9WI&9]5"E^2++HDV>1"9$>Y<)I<.*?8PWOQ'F2$,81WXM3AYPP0)VA)
M\EQ<I2S!%!*2Q4"9.([B5DR7"!<QBM-LRY4':U2Y\TIW\J78A=>^Y3C!C3G0
M=^U\* P#V[$"X^;8,%(8FO:-ZSBF>VPY45EZMN<'OM%8'JGD-BJYIRM6*K0!
M6BERIA+N):OWDF31)<DF%R([RHO7Y,4[6;U/Y6,,L:A>H**WJ/+#D.A*&!?I
M28OUN75;.7);M>/*AL=QK$[=_FGHN&Y@VD&GP",%HV%90> 9G;)5,-JN:;N^
MJ:Y:OU''/ZG.J!MW==)E';</N$J-BMAOGR2C9SH=*=16W?.KM+*"C@A**SOH
M**"WVHT<Z+KL\Y@(9UOPZ@%J5IM6\K;LH#KK([,_-A7KD6@]JT[Q-WW5MXI7
M<)T6#&6P$JZ,GB\21JM>L)IPLBF;G6?"1>M4#A/1/@.5!N+[BA!^F$@'34,>
M_@)02P,$%     @ +8*O6 HF G.M @  ZP<  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S,N>&ULK55=;]HP%/TK5B9-F[0U(1^D=! ):*=.&@,1=7V8]F"2
M"[&:V)GM0/?O9SLA Q30)O&"/W+/\3F^^-[ACO$7D0%(]%KD5(RL3,KRSK9%
MDD&!Q0TK@:HO:\8++-62;VQ1<L"I 16Y[3I.WRXPH58T-'L+'@U9)7-"8<&1
MJ(H"\]\3R-EN9/6L_<:2;#*I-^QH6.(-Q""?R@57*[ME24D!5!!&$8?UR!KW
M[J:ACC<!WPGLQ,$<:2<KQE[TXDLZLAPM"')(I&; :MC"%/)<$RD9OQI.JSU2
M P_G>_;/QKORLL("IBQ_)JG,1M:MA5)8XRJ72[9[A,9/H/D2E@OSBW9UK.]9
M**F$9$4#5@H*0NL1OS;W< !0/-T MP&XIP#_#,!K )XQ6BLSMNZQQ-&0LQWB
M.EJQZ8FY&X-6;@C568PE5U^)PLGHZSR.T>)AB:;SV6S^#<6/X^4#>G</$I-<
MH-Y[]!&)#',00UNJ\S3*3AKN2<WMGN'NHQFC,A/H@::0'N-MI;,5Z^[%3MR+
MA#/,;Y#7^X!<Q_4[]$S_'>Y=D..U=^<9/O\,WYA*DI*\TG]$%$-2<2))]T75
M1($AT@]K&_6"@7:A=&P/'70$^H[O^H/;-O!(J]]J]2]JG9?ZU0B$:8J>,>>8
MRDZA%UET2;D3)4Y@9*F:(8!OP8K>ONGUG4]=Z;@2V9'AH#4<7"LY04=RPM =
M#$Z3TQ'HW0X\US^3G'ZKM7]1ZQ/=@I"0HJ4:.$GT-)8L>4$_9E"L@/_LDGV1
M\W]3=26R(_MA:S^\5JK"CN<1NH%SDJBNL,%A6*W3/JB;!?"-:2<"):RBLJY*
M[6[;L<:F4)_L3U0GJQO/7YJZ#:J:LR'JW>6P5I3.3:A$\;JUU O)2E.=5TRJ
M6F^FF>K&P'6 ^KYF3.X7^H"VOT=_ %!+ P04    "  M@J]8!6ZXD"X"  "5
M!   &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q]5%]OFS 0_RHGU(=6
MV@JA29I5!&EI4VT/K;*P=,\.7((5@ZE]A%3:AY]M*,JVI"^VS[[?GX.SHT:J
MG<X1"0Z%*/74RXFJ.]_7:8X%T]>RPM*<;*0J&)E0;7U=*629 Q7"#X-@[!>,
MEUX<N;V%BB-9D^ E+A3HNBB8>INAD,W4&WCO&TN^S<EN^'%4L2TF2*MJH4SD
M]RP9+[#47):@<#/UO@[N9D.;[Q)>.#;Z: VVDK64.QM\SZ9>8 VAP)0L S/3
M'N]1"$MD;+QVG%XO:8''ZW?V1U>[J67---Y+\8MGE$^]B0<9;E@M:"F;;]C5
M,[)\J13:C="TN:-;#]):DRPZL'%0\+*=V:'[#D> <'(&$': T/ENA9S+!T8L
MCI1L0-ELPV87KE2'-N9X:7]*0LJ<<H.C.%G-DOF/U?SY)\Q?S)C Y0,2XT+#
M,U.*V6]V!9\AJ=<:7VLL">9[,T8^&77+X:>=TJQ5"L\H/;$W"":?( S"(:R2
M![B\N *=,X7Z;S+?E-#7$?9UA(Y]>*X.DND.&FNY) UUF:$"RA'P0,:N;8 *
M%9?9*>,M]<A1VR[>QX/@2SB\#2)_?\+33>_IYD-/2]2D>$J802J+PEC0UN4I
M!S?_.1A-@N",_K#7'WZH_\BX,KVB=N9N[YFH$7[#Q2GUEF9\I#X)QN&_ZOY1
ME]D+^\34EI<:!&X,+KB^-?95>PG:@&3E&F\MR;2Q6^;FW4!E$\SY1DIZ#VPO
M]R]1_ =02P,$%     @ +8*O6/;EFCT; P  2!$   T   !X;"]S='EL97,N
M>&ULW5A=3]LP%/TKD1D32!-I&AJ:T53:*B%-VB8D>-@;<ANGM>38F>.REE\_
MWSA-/_!%C(<-EJK$OL?GW&/[!D<=U68MV,V",1.L2B'KC"R,J3Z&83U;L)+6
M9ZIBTB*%TB4UMJOG85UI1O,:2*4(^[U>$I:42S(>R65Y59HZF*FE-!DY[T*!
MNWW),Q(EYR1P<A.5LXS<G;S_N53F\EW@[D<?CHYZ=Z>7A_&3!C@EH5=T\ S1
MLQZN:S%,.MF7W@P_MEH=]Q@C7WC(6Z:CA>VZC4>%DMOEBXD+6%U:LN">BHQ,
MJ.!3S8%5T)*+M0OW(3!30NG V'VSB2*(U \.CEP/MK35*;E4NLGM,KB_TW;X
M ;#I@4$N1&>P3UQ@/*JH,4S+*]MI!C?!1U#0MF_7E74XUW0=]0=D2VAN-LE4
MZ9SI+DU$-J'Q2+ "[&@^7\#=J"H$T!A5VD;.Z5Q)VGC8,-J&E9TQ(6Z@WG\4
M>]JK8F?'>K!?LFM:0VW3R;@.Z.^J.>U=V=Z+=(.*WROS>6FG(YL^%"B[UJS@
MJZ:_*CH#F'J$J].J$NM/@L]ER=SDGYUP/*(;7K!0FC_8;% J,QM@F@3W3!L^
MVXW\TK2Z92NS*:=5@7ONOT'/?W>=YTPR3<6N:5O[KWF57^PXOOA7EIO_*H>&
MO1[;0^RUFQR\!9/)6S#Y.FLR;(^=G;-M[V3KH@&\063D.[R)B&W28+KDPG#9
M]A8\SYE\=,!9>4.G]C5Q3]^.SUE!E\+<=F!&MNUO+.?+,NU&7<-"M*.V[:\P
MO2CI7E]L+BYSMF+YI.WJ^;1I!K9AL[87$ Z1J^;R(QC'87X$,"P/Y@#C.!:6
MYW^:SQ"=C\,P;T,O,D0Y0Y3C6#YDTGRP/'Y.:B__3-,TCI,$6]')Q.M@@JU;
MDL#7KX9Y P:6!S+]V5KCNXU7R--U@.WI4Q6"S12O1&RF^%H#XE\W8*2I?[>Q
M/,# =@&K'<COSP,UY>?$,>PJY@U[@G$D33$$:M%?HTF"K$X"'__^8$])'*>I
M'P',[R".,02>1AS!'( '#(GCYAP\.(_"S3D5;G\[&?\&4$L#!!0    ( "V"
MKUB7BKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] A
MB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:
MU;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]
MVR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::
M1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$
M%     @ +8*O6'3^FTE0 P  $A<   \   !X;"]W;W)K8F]O:RYX;6S%F%UO
MFS 40/^*Q5/WL@1(TP\UE2B0!BV!#)-*?9H<XC16 4?&;;?^^AFRK*9+K_;B
MYHG8CN#XVM?']M4+%X]+SA_1S[*HZI&UD7)[V>O5^8:6I/[*M[12+6LN2B)5
M43STZJV@9%5O*)5ET7/Z_6&O)*RRKJ_V[YJ+GE[@DN:2\4I5-A5WC+[4;^U-
M$3VSFBU9P>2OD=7^+JB%2E:QDKW2U<CJ6ZC>\)<)%^R55Y(4.!>\*$:6O6NX
MHT*R_)]JW$!F9%FW-9(L4Z) 1M:PKUZX9J*6[3_:]Q/%^$S5GW>E)\G'K)!4
M!$326\&?MJQZ:%ZC>M'3NM'&8?_<!?%2_$\8^7K-<AKP_*FDE=S%4="B :SJ
M#=O6%JI(24>6SY^I:/JC/A"M=GV3"DJ+E+ADJD%$JQ;/($H2!V&,PP#=>%,O
M]D.$)V&888W. >B<X]"ADSD1M-(@70#2_2Q(G'E9. MC!9B,43(/4R^+-,@!
M #DP"]E%PUGB?YLDTR!,,0J_+W3(4P#R]#B1]#T\0>.I!CD$((=F(6\\'+54
M\S3$BE -<1(C+U;0B]G,TR#/ ,@SLY#32 UJ$&7W&LXY@'-N>O:]FV\=L L
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MH01!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M
M(:M (:M (:M (:M (6N*0M84A:PI"EE3%+*F_TG6#ZV7?_T/L%V36JKFX,^Z
M'ZVS+U!+ 0(4 Q0    ( "V"KU@'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ +8*O6+U1RO_O
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ +8*O6)E<G",0!@  G"<  !,              ( !S0$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  M@J]8S$=/:<D%  !_'P  &
M            @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ +8*O6*V$IDB)!@  .1H  !@              ("!#0X  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( "V"KUCK+4 ES0(  ,0)
M   8              " @<P4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    "  M@J]8'"SYH;,$  !$$@  &               @('/%P
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ +8*O6*JIF6>:
M"@  >4T  !@              ("!N!P  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( "V"KU@S:=+BS <  'D@   8              "
M@8@G  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  M@J]8
M^3&K?=,(   J%0  &               @(&*+P  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ +8*O6$?G5=S@!0  )PT  !@
M     ("!DS@  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M "V"KUB=R="M-0D  ,$:   8              " @:D^  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    "  M@J]8Z]:)<RL#   %!P  &0
M            @($42   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( "V"KUB<$JOAFP@  &07   9              " @79+  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ +8*O6&ZIL=7E @
M* <  !D              ("!2%0  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    "  M@J]8,7[*A \$  !."0  &0              @(%D
M5P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( "V"KUC7
M @1DB@(  )@%   9              " @:I;  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ +8*O6/UC![(2!P  1A4  !D
M     ("!:UX  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "V"KUC>C,K.F (  '0(   9              "
M@3MT  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ +8*O
M6,E?2=K8 @  4@H  !D              ("!"G<  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    "  M@J]8@[RAV=X"   X"@  &0
M        @($9>@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( "V"KUAEH6X;TP4  #8K   9              " @2Y]  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ +8*O6$-C:7C< @  5PD
M !D              ("!.(,  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    "  M@J]8^]U.I]4&   V.@  &0              @(%+A@
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( "V"KUA_#*[T
M)@(  *0$   9              " @5>-  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ +8*O6$S"!]H0 P  D D  !D
M ("!M(\  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  M
M@J]8<^GZ32@#   #"@  &0              @('[D@  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( "V"KUAF=S?<,P4  *DA   9
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M970S,RYX;6Q02P$"% ,4    "  M@J]8!6ZXD"X"  "5!   &0
M    @(&;IP  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M "V"KUCVY9H]&P,  $@1   -              "  0"J  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ +8*O6)>*NQS     $P(   L              ( !
M1JT  %]R96QS+RYR96QS4$L! A0#%     @ +8*O6'3^FTE0 P  $A<   \
M             ( !+ZX  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( "V"
MKUB,WU^M;@$  -T4   :              "  :RQ  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( "V"KU@&5T)WCP$  ' 5   3
M          "  5*S  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     J "H
*70L  !*U      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>99</ContextCount>
  <ElementCount>224</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>28</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedBalanceSheets</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedStatementsOfOperationsUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StatementsOfStockholdersEquityUnaudited</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000008 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LIQUIDITY</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000009 - Disclosure - STOCKHOLDERS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000010 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000011 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000012 - Disclosure - PATENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PATENTS</Role>
      <ShortName>PATENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000013 - Disclosure - LOSS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShare</Role>
      <ShortName>LOSS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000014 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000016 - Disclosure - STOCKHOLDERS EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquity</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000017 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000018 - Disclosure - PATENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsTables</Role>
      <ShortName>PATENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/PATENTS</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000019 - Disclosure - LOSS PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShareTables</Role>
      <ShortName>LOSS PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/LossPerCommonShare</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000020 - Disclosure - STOCKHOLDERS EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails1</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails2</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails3</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetails4</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquityTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative )</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/RelatedPartyTransactions</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000030 - Disclosure - PATENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetails</Role>
      <ShortName>PATENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000031 - Disclosure - PATENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetailsNarrative</Role>
      <ShortName>PATENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000032 - Disclosure - LOSS PER COMMON SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShareDetails</Role>
      <ShortName>LOSS PER COMMON SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/LossPerCommonShareTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>000033 - Disclosure - LOSS PER COMMON SHARE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LossPerCommonShareDetails1</Role>
      <ShortName>LOSS PER COMMON SHARE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/LossPerCommonShareTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cvm_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/SubsequentEvents</ParentRole>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0540-CurrentFiscalYearEndDate-Registrant-Value] In submission type 10-Q, CurrentFiscalYearEndDate value, --12-31, should match the Entity Registrant Fiscal Year End Date "09/30" on record within EDGAR. cvm_10q.htm 1</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 17 fact(s) appearing in ix:hidden were eligible for transformation: cvm:NetOfDiscount, cvm:OperatingLeaseWeightedAverageRemainingLeaseTermOne, cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesOutstanding, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward -  cvm_10q.htm 1</Log>
    <Log type="Warning">[dqc-0043-Incorrect-Calculation-Weights-In-Operating-Cash-Flows] The concept IncreaseDecreaseInInventories is included in the calculation of NetCashProvidedByUsedInOperatingActivities.IncreaseDecreaseInInventories is a credit balance type concept representing a natural cash outflow in the reconciliation of net income (loss) to NetCashProvidedByUsedInOperatingActivities. A credit balance type concept should always be assigned a negative one (-1) calculation weight as it is a deduction from net income (loss) to reconcile to NetCashProvidedByUsedInOperatingActivities.IncreaseDecreaseInInventories has been incorrectly provided a positive one (+1) calculation weight in the extension taxonomy. Correct the calculation weight to negative one (-1) and input the value as a positive amount if it is a deduction of a non-cash income or gain, an increase in an asset, or a decrease in a liability. If the value is an add-back of a non-cash expense or loss, decrease in an asset, or an increase in a liability and IncreaseDecreaseInInventories is the correct concept, input a negative value. Rule Element Id: 7488. https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd 1957, 4602</Log>
    <Log type="Warning">[DQC.US.0043.9873] The company has reported the concept ProfitLoss as part of the cash flow statement. This income item is being deducted from the value of operating cash flows in the calculation defined by the filer.  This implies that the resulting operating cash flow calculation excludes this income item from cash flow from operations.  If  ProfitLoss represents income from discontinued operations then the element NetCashProvidedByUsedInOperatingActivitiesContinuingOperations should be used as the total rather than the current total element of NetCashProvidedByUsedInOperatingActivities. If the item is an income item and is being deducted because the value is negative then consider changing the sign and weight of the element. - https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd 4602, 9356 - https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd 4602, 9356</Log>
    <Log type="Warning">[DQC.US.0099.9533] The following elements are in the presentation linkbase of http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited but are not included in any calculation relationship in the filing.

AccruedConsultingServicesToBePaidWithCommonStock, AssetsPurchasedUnderFinanceLeases, ConsultingServicesPaidWithIssuanceOfCommonStock, FinanceLeaseObligationIncludedInAccountsPayable, FinancingCostsIncludedInCurrentLiabilities, PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities

All elements appearing in the face of the financial statements should be included in a calculation relationship somewhere in the filing. Items not included in the financial statement calculations but included in the presentation are referred to as parenthetical items. These usually appear as a referenced item, or as a value in parenthesis describing that the value reported includes another specific amount.  These values should be reported in a seperate link role for parenthetical items.

This rule will produce an error irrespective of a fact value being entered for the item(s) listed above.

If the item is an additional disclosure in the cash flow statement then make sure that is included as a child of one of the following abstract items: {nonCFabstracts} - cvm_10q.htm  - cvm_10q.htm </Log>
  </Logs>
  <InputFiles>
    <File>cvm-20240331.xsd</File>
    <File>cvm-20240331_cal.xml</File>
    <File>cvm-20240331_def.xml</File>
    <File>cvm-20240331_lab.xml</File>
    <File>cvm-20240331_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="cvm_10q.htm">cvm_10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cvm_10qimg10.jpg</File>
    <File>cvm_10qimg11.jpg</File>
    <File>cvm_10qimg12.jpg</File>
    <File>cvm_10qimg13.jpg</File>
    <File>cvm_10qimg14.jpg</File>
    <File>cvm_10qimg8.jpg</File>
    <File>cvm_10qimg9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="377">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cvm_10q.htm": {
   "nsprefix": "cvm",
   "nsuri": "http://cvm.com/20240331",
   "dts": {
    "schema": {
     "local": [
      "cvm-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cvm-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cvm-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cvm-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvm-20240331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "cvm_10q.htm"
     ]
    }
   },
   "keyStandard": 171,
   "keyCustom": 53,
   "axisStandard": 10,
   "axisCustom": 0,
   "memberStandard": 8,
   "memberCustom": 20,
   "hidden": {
    "total": 22,
    "http://fasb.org/us-gaap/2023": 13,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://cvm.com/20240331": 4
   },
   "contextCount": 99,
   "entityCount": 1,
   "segmentCount": 28,
   "elementCount": 298,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 377,
    "http://xbrl.sec.gov/dei/2023": 30
   },
   "report": {
    "R1": {
     "role": "http://cvm.com/role/Cover",
     "longName": "000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://cvm.com/role/CondensedBalanceSheets",
     "longName": "000002 - Statement - CONDENSED BALANCE SHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://cvm.com/role/CondensedBalanceSheetsParenthetical",
     "longName": "000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
     "longName": "000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
     "longName": "000005 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)",
     "shortName": "STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-09-30_us-gaap_CommonStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2022-12-31_us-gaap_CommonStockMember",
      "name": "cvm:WarrantExercisesShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
     "longName": "000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "longName": "000007 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://cvm.com/role/LIQUIDITY",
     "longName": "000008 - Disclosure - LIQUIDITY",
     "shortName": "LIQUIDITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "cvm:LiquidityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "cvm:LiquidityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://cvm.com/role/StockholdersEquity",
     "longName": "000009 - Disclosure - STOCKHOLDERS EQUITY",
     "shortName": "STOCKHOLDERS EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://cvm.com/role/RelatedPartyTransactions",
     "longName": "000010 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://cvm.com/role/CommitmentsAndContingencies",
     "longName": "000011 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://cvm.com/role/PATENTS",
     "longName": "000012 - Disclosure - PATENTS",
     "shortName": "PATENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://cvm.com/role/LossPerCommonShare",
     "longName": "000013 - Disclosure - LOSS PER COMMON SHARE",
     "shortName": "LOSS PER COMMON SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://cvm.com/role/SubsequentEvents",
     "longName": "000014 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://cvm.com/role/StockholdersEquityTables",
     "longName": "000016 - Disclosure - STOCKHOLDERS EQUITY (Tables)",
     "shortName": "STOCKHOLDERS EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesTables",
     "longName": "000017 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://cvm.com/role/PatentsTables",
     "longName": "000018 - Disclosure - PATENTS (Tables)",
     "shortName": "PATENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://cvm.com/role/LossPerCommonShareTables",
     "longName": "000019 - Disclosure - LOSS PER COMMON SHARE (Tables)",
     "shortName": "LOSS PER COMMON SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://cvm.com/role/StockholdersEquityDetails",
     "longName": "000020 - Disclosure - STOCKHOLDERS EQUITY (Details)",
     "shortName": "STOCKHOLDERS EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "20",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://cvm.com/role/StockholdersEquityDetails1",
     "longName": "000021 - Disclosure - STOCKHOLDERS EQUITY (Details 1)",
     "shortName": "STOCKHOLDERS EQUITY (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfStockOptionActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfStockOptionActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://cvm.com/role/StockholdersEquityDetails2",
     "longName": "000022 - Disclosure - STOCKHOLDERS EQUITY (Details 2)",
     "shortName": "STOCKHOLDERS EQUITY (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31_us-gaap_EmployeeStockMember",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31_us-gaap_EmployeeStockMember",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://cvm.com/role/StockholdersEquityDetails3",
     "longName": "000023 - Disclosure - STOCKHOLDERS EQUITY (Details 3)",
     "shortName": "STOCKHOLDERS EQUITY (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_cvm_ConsultantsOptionMember",
      "name": "cvm:SharesIssuableUponExerciseOfWarrantOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_cvm_ConsultantsOptionMember",
      "name": "cvm:SharesIssuableUponExerciseOfWarrantOptions",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://cvm.com/role/StockholdersEquityDetails4",
     "longName": "000024 - Disclosure - STOCKHOLDERS EQUITY (Details 4)",
     "shortName": "STOCKHOLDERS EQUITY (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "cvm:EquityWarrantsExercised",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfDerivativeLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "cvm:EquityWarrantsExercised",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfDerivativeLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://cvm.com/role/StockholdersEquityDetailsNarrative",
     "longName": "000025 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)",
     "shortName": "STOCKHOLDERS EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-10-28",
      "name": "cvm:IncrementalCostDeemedDividend",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-29",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "000026 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative )",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2023-10-28",
      "name": "cvm:IncrementalCostDeemedDividend",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails",
     "longName": "000027 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails1",
     "longName": "000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "000029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "cvm:NetOfDiscount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "cvm:NetOfDiscount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://cvm.com/role/PatentsDetails",
     "longName": "000030 - Disclosure - PATENTS (Details)",
     "shortName": "PATENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://cvm.com/role/PatentsDetailsNarrative",
     "longName": "000031 - Disclosure - PATENTS (Details Narrative)",
     "shortName": "PATENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://cvm.com/role/LossPerCommonShareDetails",
     "longName": "000032 - Disclosure - LOSS PER COMMON SHARE (Details)",
     "shortName": "LOSS PER COMMON SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-03-31",
      "name": "cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://cvm.com/role/LossPerCommonShareDetails1",
     "longName": "000033 - Disclosure - LOSS PER COMMON SHARE (Details 1)",
     "shortName": "LOSS PER COMMON SHARE (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-03-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://cvm.com/role/SubsequentEventsDetailsNarrative",
     "longName": "000034 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2024-05-08_us-gaap_SubsequentEventMember",
      "name": "us-gaap:ClassOfWarrantOrRightUnissued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-05-08_us-gaap_SubsequentEventMember",
      "name": "us-gaap:ClassOfWarrantOrRightUnissued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r380"
     ]
    },
    "cvm_AccruedConsultingServicesToBePaidWithCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "AccruedConsultingServicesToBePaidWithCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued consulting services to be paid with common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r380",
      "r461"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r300",
      "r406",
      "r407",
      "r408",
      "r445",
      "r462"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r202"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization Cost",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r145",
      "r237",
      "r403"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r25",
      "r27"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "[Assets]",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r74",
      "r92",
      "r115",
      "r117",
      "r119",
      "r121",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r214",
      "r218",
      "r229",
      "r277",
      "r323",
      "r380",
      "r392",
      "r414",
      "r415",
      "r451"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "[Assets, Current]",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r77",
      "r92",
      "r121",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r214",
      "r218",
      "r229",
      "r380",
      "r414",
      "r415",
      "r451"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_AssetsPurchasedUnderFinanceLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "AssetsPurchasedUnderFinanceLeases",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets purchased under finance leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://cvm.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets",
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r47",
      "r90"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS",
        "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r47"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetails4",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Axis",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetails4",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightUnissued",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock warrants under the extention period",
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ClinicalServiceTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "ClinicalServiceTrial",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Service Trial"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_CommitmentsAndContingenciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "CommitmentsAndContingenciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r130",
      "r131",
      "r366",
      "r413"
     ]
    },
    "cvm_CommonStockContributedToEmployeeBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "CommonStockContributedToEmployeeBenefitPlan",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock contributed to 401(k) plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r406",
      "r407",
      "r445",
      "r460",
      "r462"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r311"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Common stock shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r36",
      "r311",
      "r329",
      "r462",
      "r463"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $.01 par value; 600,000,000 shares authorized; 54,083,718 and 47,422,304 shares issued and outstanding at March 31, 2024 and September 30, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r279",
      "r380"
     ]
    },
    "cvm_ConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "ConsultantsMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants [Member]",
        "verboseLabel": "Consultants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultantsOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "ConsultantsOptionMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "ConsultingAgreementsMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultingFeesIncluedPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "ConsultingFeesIncluedPrepaidExpenses",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting fees inclued prepaid expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultingServicesPaidWithIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "ConsultingServicesPaidWithIssuanceOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting services paid with issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositsAssets",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deposits",
        "label": "[Deposits Assets]",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r28"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_DueToEmployeeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "DueToEmployeeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to employees"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_EarningPerShareBasicAndDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "EarningPerShareBasicAndDiluted",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share - basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LOSS PER COMMON SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share- basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LOSS PER COMMON SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r111",
      "r112",
      "r113"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation Expense",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 2",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r69",
      "r81",
      "r82",
      "r83",
      "r93",
      "r94",
      "r95",
      "r97",
      "r102",
      "r104",
      "r114",
      "r122",
      "r123",
      "r159",
      "r195",
      "r196",
      "r197",
      "r211",
      "r212",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r245",
      "r287",
      "r288",
      "r289",
      "r300",
      "r351"
     ]
    },
    "cvm_EquityWarrantsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "EquityWarrantsExercisePrice",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Warrants Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_EquityWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "EquityWarrantsExercised",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ErgomedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "ErgomedMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ergomed [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "ExercisePrice",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "ExpirationDate",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of financing lease obligations",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r244"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligation, current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "cvm_FinanceLeaseLiabilityCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "FinanceLeaseLiabilityCurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less net present value of financing lease obligations - current portion",
        "label": "[Less net present value of financing lease obligations - current portion]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future minimum payments under finance leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligations, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "cvm_FinanceLeaseLiabilityNoncurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "FinanceLeaseLiabilityNoncurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of financing lease obligations - non-current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total future minimum lease obligation",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three months ending September 30, 2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest on finance lease obligations",
        "label": "[Finance Lease, Liability, Undiscounted Excess Amount]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "cvm_FinanceLeaseObligationIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "FinanceLeaseObligationIncludedInAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligation included in accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total cash payment for financing lease",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r242"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease right of use assets",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average discount rate of financing lease",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r379"
     ]
    },
    "cvm_FinanceLeaseWeightedAverageRemainingLeaseTermOne": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTermOne",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average time of maturity of financing lease"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_FinancingArrangementDepositBaseRentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "FinancingArrangementDepositBaseRentAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing arrangement deposit base rent amount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_FinancingCostsIncludedInCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "FinancingCostsIncludedInCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing costs included in current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year One]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Three months ending September 30, 2024",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Thereafter",
        "label": "[Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five]",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Five]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Four]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Three]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "[Finite-Lived Intangible Asset, Expected Amortization, Year Two]",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent costs, net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r262"
     ]
    },
    "cvm_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average amortization period for patents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r333"
     ]
    },
    "cvm_ImpairmentOfLongLivedAssetsPolicyTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "ImpairmentOfLongLivedAssetsPolicyTextblock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived assets"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockBonusPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "IncentiveStockBonusPlansMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Stock Bonus Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockForfeitedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "IncentiveStockForfeitedAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2014 incentive stock forfeited, amount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockForfeitedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "IncentiveStockForfeitedShares",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2014 incentive stock forfeited, shares"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncomeLossFromContinuingOperationsPerBasicAndDilutedShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShares",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted loss per common share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r293"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "[Increase (Decrease) in Accounts Payable]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "[Increase (Decrease) in Accrued Liabilities]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "cvm_IncreaseDecreaseInDepositAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "IncreaseDecreaseInDepositAssets",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deposits",
        "label": "[Deposits]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due to employees",
        "label": "[Increase (Decrease) in Employee Related Liabilities]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplies used for R&amp;D and manufacturing",
        "label": "[Increase (Decrease) in Inventories]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Increase)/decrease in assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/(decrease) in liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses",
        "label": "[Increase (Decrease) in Prepaid Expense]",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "cvm_IncrementalCostDeemedDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "IncrementalCostDeemedDividend",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental cost",
        "verboseLabel": "Incremental cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/PATENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "PATENTS",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r258",
      "r259",
      "r260",
      "r262",
      "r370"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PATENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense, net",
        "label": "[Interest Income (Expense), Net]",
        "documentation": "The net amount of operating interest income (expense)."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest amount",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r88",
      "r89"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplies used for R&amp;amp;D and manufacturing",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r73",
      "r75",
      "r124",
      "r125",
      "r126",
      "r257",
      "r371"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payments for services",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cvm_IssueDate1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "IssueDate1",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue Date"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LIQUIDITYAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "LIQUIDITYAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LIQUIDITY"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LandlordMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "LandlordMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Landlord [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "LeasesPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Future Minimum Lease Obligation",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year One]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Five]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Four]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Three]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Two]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Three months ending September 30, 2024",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less Imputed Interest On Operating Lease Obligation",
        "label": "[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "[Liabilities]",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r92",
      "r121",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r215",
      "r218",
      "r219",
      "r229",
      "r310",
      "r372",
      "r392",
      "r414",
      "r451",
      "r452"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "[Liabilities and Equity]",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r59",
      "r281",
      "r380",
      "r405",
      "r411",
      "r446"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "[Liabilities, Current]",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r72",
      "r92",
      "r121",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r215",
      "r218",
      "r219",
      "r229",
      "r380",
      "r414",
      "r451",
      "r452"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LiquidityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "LiquidityDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/LIQUIDITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIQUIDITY",
        "label": "[LIQUIDITY]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r162",
      "r256",
      "r286",
      "r302",
      "r303",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r367",
      "r368",
      "r374",
      "r375",
      "r376",
      "r381",
      "r416",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r162",
      "r256",
      "r286",
      "r302",
      "r303",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r367",
      "r368",
      "r374",
      "r375",
      "r376",
      "r381",
      "r416",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458"
     ]
    },
    "cvm_ModificationOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "ModificationOfWarrants",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Modification of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "[Net Cash Provided by (Used in) Financing Activities]",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "[Net Cash Provided by (Used in) Investing Activities]",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "[Net Cash Provided by (Used in) Operating Activities]",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "[Net Income (Loss) Attributable to Parent]",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r49",
      "r60",
      "r70",
      "r78",
      "r79",
      "r83",
      "r92",
      "r96",
      "r98",
      "r99",
      "r100",
      "r101",
      "r103",
      "r104",
      "r108",
      "r115",
      "r116",
      "r118",
      "r120",
      "r121",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r228",
      "r229",
      "r285",
      "r331",
      "r349",
      "r350",
      "r373",
      "r390",
      "r414"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss available to common shareholders",
        "label": "[Net Income (Loss) Available to Common Stockholders, Basic]",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r98",
      "r99",
      "r100",
      "r101",
      "r106",
      "r107",
      "r109",
      "r110",
      "r115",
      "r116",
      "r118",
      "r120",
      "r373"
     ]
    },
    "cvm_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss available to common shareholders - basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NetOfDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "NetOfDiscount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Of Discount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NetofissuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "NetofissuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NewAccountingPronouncementEarlyAdoptionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "NewAccountingPronouncementEarlyAdoptionPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Adopted Accounting Standards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NonEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "NonEmployeesMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-employees"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NonQualifiedStockOptionsPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "NonQualifiedStockOptionsPlansMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Qualified Stock Option Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options issued",
        "documentation": "The number of options issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "[Operating Expenses]",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "[Operating Income (Loss)]",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r118",
      "r120",
      "r373"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease expense for operating leases",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Present Value Of Operating Lease Obligation",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease obligation, current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "cvm_OperatingLeaseLiabilityCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "OperatingLeaseLiabilityCurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net present value of lease finance lease obligations - current portion",
        "label": "[Net present value of lease finance lease obligations - current portion]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease obligations, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "cvm_OperatingLeaseLiabilityNoncurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "OperatingLeaseLiabilityNoncurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of lease finance lease obligations - non-current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePaymentsUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePaymentsUse",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total cash payment for oprating lease",
        "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right of use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Discount Rate Operating Lease",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r379"
     ]
    },
    "cvm_OperatingLeaseWeightedAverageRemainingLeaseTermOne": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTermOne",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average time of maturity of operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_OptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "OptionsMember",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options and Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "[Other Indefinite-Lived Intangible Assets]",
        "documentation": "Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash lease expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expense",
        "label": "[Other Nonoperating Expense]",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Expenses",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of stock issuance costs",
        "label": "[Payments of Stock Issuance Costs]",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expenditures for patent costs",
        "label": "[Payments to Acquire Intangible Assets]",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "[Payments to Acquire Property, Plant, and Equipment]",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name Axis",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r147"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r311"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r147"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r311",
      "r329",
      "r462",
      "r463"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $.01 par value; 200,000 shares authorized; 0 shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r278",
      "r380"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r127",
      "r128",
      "r369"
     ]
    },
    "cvm_ProceedsFromEquityWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "ProceedsFromEquityWarrantsExercised",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Equity Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss",
        "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r78",
      "r79",
      "r86",
      "r92",
      "r96",
      "r103",
      "r104",
      "r115",
      "r116",
      "r118",
      "r120",
      "r121",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r213",
      "r216",
      "r217",
      "r228",
      "r229",
      "r275",
      "r284",
      "r299",
      "r331",
      "r349",
      "r350",
      "r373",
      "r377",
      "r378",
      "r391",
      "r401",
      "r414"
     ]
    },
    "cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment purchases included in current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r276",
      "r283",
      "r380"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r65",
      "r68",
      "r282"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Axis"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r160",
      "r162",
      "r189",
      "r190",
      "r191",
      "r255",
      "r256",
      "r286",
      "r302",
      "r303",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r367",
      "r368",
      "r374",
      "r375",
      "r376",
      "r381",
      "r384",
      "r412",
      "r416",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r160",
      "r162",
      "r189",
      "r190",
      "r191",
      "r255",
      "r256",
      "r286",
      "r302",
      "r303",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r367",
      "r368",
      "r374",
      "r375",
      "r376",
      "r381",
      "r384",
      "r412",
      "r416",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r249",
      "r250",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r328",
      "r330",
      "r358"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions By Related Party Axis",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r249",
      "r250",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r328",
      "r330",
      "r358",
      "r450"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r296",
      "r297",
      "r298",
      "r334",
      "r335",
      "r336",
      "r355",
      "r357"
     ]
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on obligations under finance leases",
        "label": "[Repayments of Debt and Lease Obligation]",
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r204",
      "r459"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "cvm_RestrictedCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "RestrictedCommonStock",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted common stock"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_RestrictedStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "RestrictedStocksMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r57",
      "r280",
      "r290",
      "r291",
      "r295",
      "r312",
      "r380"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r93",
      "r94",
      "r95",
      "r97",
      "r102",
      "r104",
      "r122",
      "r123",
      "r195",
      "r196",
      "r197",
      "r211",
      "r212",
      "r220",
      "r222",
      "r223",
      "r225",
      "r227",
      "r287",
      "r289",
      "r300",
      "r462"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering price",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfAntiDilutiveSecuritiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "ScheduleOfAntiDilutiveSecuritiesTableTextBlock",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of anti-dilutive securities"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfCompensatingBalancesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "ScheduleOfCompensatingBalancesTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfDerivativeLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "ScheduleOfDerivativeLiabilitiesTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of derivative liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of the numerators and denominators of the basic and diluted per-share computations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of equity compensation plans",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7",
      "r31"
     ]
    },
    "cvm_ScheduleOfStockOptionActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "ScheduleOfStockOptionActivityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock option activity"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants and non-employee options outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://cvm.com/role/PatentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of total estimated future amortization",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_SecurityOwnedNotReadilyMarketableFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecurityOwnedNotReadilyMarketableFairValue",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair market value",
        "documentation": "Value of the not readily marketable security or category which has been determined by management based upon fair value methods, including pricing of similar securities and valuation techniques and is included in the schedule of financial condition or the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "cvm_SeriesMMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "SeriesMMMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series MM [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesNMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "SeriesNMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series N [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesNNMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "SeriesNNMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series NN [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesRRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "SeriesRRMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetails4",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series RR [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesSSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "SeriesSSMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series SS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesUUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "SeriesUUMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series UU [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "SeriesXMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series X [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "SeriesYMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Y [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining Options/shares Under Plans",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option exercised",
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r167",
      "r186",
      "r187",
      "r188",
      "r189",
      "r192",
      "r198",
      "r199",
      "r200",
      "r201"
     ]
    },
    "cvm_ShareIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "ShareIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issuance costs",
        "documentation": "Amount of expense for amortization of deferred issuance costs associated with an own-share lending arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SharesIssuableUponExerciseOfWarrantOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "SharesIssuableUponExerciseOfWarrantOptions",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issuable Upon Exercise Of Warrant/options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "label": "[Shares, Issued]",
        "periodEndLabel": "Balance, shares",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r13",
      "r69",
      "r81",
      "r82",
      "r83",
      "r93",
      "r94",
      "r95",
      "r97",
      "r102",
      "r104",
      "r114",
      "r122",
      "r123",
      "r159",
      "r195",
      "r196",
      "r197",
      "r211",
      "r212",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r245",
      "r287",
      "r288",
      "r289",
      "r300",
      "r351"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetails",
      "http://cvm.com/role/StockholdersEquityDetails2",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetails4",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r114",
      "r261",
      "r292",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r332",
      "r333",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r351",
      "r385"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF STOCKHOLDERS EQUITY (UNAUDITED)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/LossPerCommonShareDetails1",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetails",
      "http://cvm.com/role/StockholdersEquityDetails2",
      "http://cvm.com/role/StockholdersEquityDetails3",
      "http://cvm.com/role/StockholdersEquityDetails4",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r114",
      "r261",
      "r292",
      "r301",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r332",
      "r333",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r351",
      "r385"
     ]
    },
    "cvm_StockBonusPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "StockBonusPlansMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Bonus Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Compensation Plan [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) contributions paid in common stock, shares",
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued to nonemployees for service, shares",
        "verboseLabel": "Common stock issued for service, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r35",
      "r36",
      "r57",
      "r294",
      "r351",
      "r364"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) contributions paid in common stock, amount",
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued to nonemployees for service, amount",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock, amount",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r35",
      "r36",
      "r57",
      "r300",
      "r351",
      "r364",
      "r391"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity based compensation - employees",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r35",
      "r36",
      "r57"
     ]
    },
    "us-gaap_StockOptionPlanExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionPlanExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options",
        "documentation": "Amount of noncash expense for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets",
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "label": "[Stockholders' Equity Attributable to Parent]",
        "periodStartLabel": "Balance, amount",
        "periodEndLabel": "Balance, amount",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r39",
      "r40",
      "r51",
      "r313",
      "r329",
      "r352",
      "r353",
      "r380",
      "r392",
      "r405",
      "r411",
      "r446",
      "r462"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "STOCKHOLDERS' EQUITY",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r91",
      "r146",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r226",
      "r354",
      "r356",
      "r365"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r253"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type Axis",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r253"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r253"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://cvm.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r254"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SuppliesUsedForRDAndManufacturingCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "SuppliesUsedForRDAndManufacturingCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplies used for R&amp;D and manufacturing"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SuppliesUsedForRDAndManufacturingNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "SuppliesUsedForRDAndManufacturingNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/CondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cvm.com/role/CondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplies used for R&amp;D and manufacturing",
        "label": "[Supplies used for R&amp;D and manufacturing]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r410",
      "r449"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_UnvestedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "UnvestedRestrictedStockMember",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Restricted Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r63",
      "r64",
      "r66",
      "r67"
     ]
    },
    "cvm_WarrantExercisesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "WarrantExercisesAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercises, amount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WarrantExercisesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "WarrantExercisesShares",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercises, shares"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted",
     "presentation": [
      "http://cvm.com/role/CondensedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding - basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WeightedAverageNumberOfShareOutstandingBasicsAndDiluted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240331",
     "localname": "WeightedAverageNumberOfShareOutstandingBasicsAndDiluted",
     "presentation": [
      "http://cvm.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding - basic and diluted"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "940",
   "SubTopic": "820",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481753/940-820-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r399": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0001654954-24-006411-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-24-006411-xbrl.zip
M4$L#!!0    ( "V"KUAP&OY#6 X  $^)   0    8W9M+3(P,C0P,S,Q+GAS
M9.U=W7/;-A)_OYG['WAZN73F9%E6DFL\3CNT)#>:RI(JR4WRU*%)2,*4 E0
MM*W[ZV\!?HB? BFG%6^.?4A%["ZPNS]PL0 !^.;'EZUK/"'&,24?6]V+RY:!
MB$T=3-8?6QYO6]S&N&5P81''<BE!'UM[Q%L__O#WO]W\H]W^<CL?&P-J>UM$
MA-%GR!+(,9ZQV!B2=&]Q@5B['7#_ZK=S;5Q=]"XNOX_*;RT.4I0H&2!V(\H
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M98[=W7?T.CLXM#E!GTCT=4/?CHPK( 8*6["?VKMF;?91NWO5[G4O7HC3HM8
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M$F,^DO0DTFRBY<RQSNB:<0AD?L<63;Z2JDX_\A8@% 9<4\V)!]:Z92HOB"6
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M!%NLG_>-?T?_>=!]\)__ U!+ P04    "  M@J]8&8U2AWI   !I1@, %
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M<'[\W=L>]5FEX$]P8>:$0A0%A]!"C=HCBU540PF>G8<ER"P*^9?/C]_]F<J
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MZKJ/!/!L+Z@0ITUMSP>CA0EDE@9:Y&16D;U>D5$U)-4KZ0YR65YSDNH3O'*
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M37<>E< Y_H/(F[M!)F[!%G6AW8MT2<:A*B(V]B5"M W<"65EQH@I'B4]\GI
M-%UPX\84Z[-K$?9VNU3U6FLK#R-;@-+R^4 C>DU)M-:F9<^H&[V>IV?2#DW(
M.M4.M:Q'2FV!Q)A^UW2'8LE@7UX;RVNS= M#:Z'L/1.9-V=;@>?=0JD-7=;_
MU&S#9FY=68H?F%7'WJ&J\^PJ_]0&,_<2#;$"4C-@^PZ^?V;T_0$<C8&3-=V;
MD8)RDV..J-%-F#:&M!-:HI@2Q*ZPPB9=,VMNFW 6=B[^4KS8Z5[FIX?-9W!S
M]\OZ\>GF[F>PNGJZ^>7FZ6;]J&>+\CX)PGT*5M8_#VZ(<)EQ[XO?21!<O/)M
M$F"Y)R*\=I;73B*31LO^\X@O6?OZZ(5.ERJ:N2W\4G@.QO:*IU@1R7*Q3VS0
M4W>4&M!]0[1Q,[>N*J4W3%6R=[@TP#.UP5P:?E,C9"&;F &IG0M +5U0^AZ-
MZ5D;E I[X\>X(.[60^6#66DE5C%HBB:]![V?X8JJ49?"X,F^I^W&AS!)4;G'
M'_3CNGPK>GR/J!6;5HE63],=%4<F1 PV@"KE3D[J@.D;M;O F<B=-XUEM;.<
MS2U5&8/:[B[4@J_=77!3"\;O+E0T<^O*,G,QU@5[OZV%UPEST]V%HS'S=Q<^
MN3[TK0YV%RH-:2>T1#$EB%UAA45$VK/9U(3 A7/QU^TN?+JY6]U=2>\NJ$I1
M1+-"?L)\.-TGSES($\U+ZO64)C22*T0ASU&U$FO<V60,3;CLW1!N=?;/8]['
M0O9/K:O)Y!J[, 6GC#Q+[@$'RUGOITG-UY#U@$NMEL[@<3M%Q]</9#)V*EU!
M5K5<@[K0L6[LC'0C$T8P.93BA2*F&7MD(]4$5%7W+"SK^XK/34JXR[**GJ%)
M!%TT*A7EF8=?S+:VJ@@>V0&I&FE])NKT'5!"P"])#A,M8]$#VA^[T#7:DHW;
M*[AWR9*>Q&ILMI[[0M-8<!M/7ILES]@.AJCWU9W\.-46OGC4\D%P4@('WT8A
M<.AT&K$42;I'L.;MW;K.5'H=I30>F1">U09S:1P\&2&.B)BAIRW4 CB9,&K+
ME+,Z/6]MSO+&#R;SB>E;IK7@A5NF^^P&U"'=@')2>\9OH%8T>NNJ,W._J0,N
MCPP.SZK$W'0#]6A,;@.UQ_8E(,G_R#GU&_2(1WU 41RZ%IZ"D!^P>\[_0T:2
M/6U2C+==?TV2.>,_O.):00]X.K-V',3?BU2+@"6 F,WGRIX1K?69.BN@Y'?7
M3^#F[NIAO7I<@^^OU^Q//^!_8YGQ5W?7[ _KOS[?_+*Z)6GS-3M>/0S6VH8J
M!X#_)QW$R(1ENZYREP8S8OJ"#6>9+UR T\<!$R%3\,(_YC48*L"Y6G$!CMA
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M$4L^L4]N2]_@AL,KH3=$AO&HTNFTLJ1P_Z-]07,[(\W-L!G.TAX[)BQNSRX
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M%K^2]F&#ATG8U8\8]OY E6Q9&^NVZ@:U4)"&Q_9Z3-#*FR>I_P+3N@PXI^W
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M<OU_32^@.9XG2M*HMGN*"5B_T*)A7JX[>8BHFO?OZH87:JD]\&3+,T9Z]#5
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M"9S:MI8E5""]8G@;_=+/<M_N7#IS1=@&Q2^KL**6=]M1@*<9AE*J[RLX9_H
MY1N7>ZK3;$P816V.WQY36>7M0MAQ-]4CXAM1>SJW_-1]9&=0H0N0;6@[XA8Z
M:,$D&BIQXF+/-G_^P'G B.]1["#6:,KF<8#M*HK%.Z!N@(=%"ZB]W%<8+&#=
M;[KVXP!;D6R+MY34X:[K 96O;\HJ?4;Q R8O)LWS+'1OT1L*HE<"N_GJ:^P+
M/!=:^MC>+NWA]0IP'?A2['/:MAT):!HRS ]QA;8 >P&_DAO<P'=@L$_@OXE]
M&%18<2DM@>,A"XWMVFL"TR_5;XT$1ZJ^'<N>W*+7*/%3D@?U ?]8Z7UWD&@8
MN@/7]72)MU&ZL\S6!B$_CXY[#(OX>59FGU2E<Z>-^]DF<]CHDV=R".4,)JUO
M!VB6)"A-EBC=U5G'9/\EBMSO?A TIWQM,PJ6K$W+YI?-S$_1G?^&W/,Y%S-^
M[Z_4]JDK^PX.5->!%N_L6'VX6B5-#$:9\88DMZ-"JYR9/<8%%C1U5Q!7 %Y+
MKI(HXXU8;D< EC2=[8<#KBZYMB!/#UYKZYP6XPUH[H"[,3-HEP'!U)0U][^7
MU1DUQAOOW!YY8S+2#N.!Z=0R1:FVR'-9G1!CO.'0'8 WY3_M,!ZP75V1!5$C
M<UU516*,-UJZI2P3!0'18+"%3O<?&^A0T3Q!M&_<!,@ZPHRW3&5F UA@P=BK
MID:#@:2A-U!4&2%!?*&&6SVMH+?. BM"09Q3]6-=\)@J-^DA^X6)C5$CJ6*Z
M>$+4763?SO7]@.DAVQ'$YZ<3+Z@;F1%T+R?5*EM-U<%Q,*@7)[<KB%UIN.DP
M%E TRY;'*//2.=J?$.=>K5<[;.^B),%SV1?8)74+:\P^ROEQ>[=:KR?W\X<L
M:'>UG*S_.GN8\S4"S6%,:)WD!9^;C]>J'IC9AC,=UMU^$6+*(T+TV1LF$0E1
MVD2%ZL;/48 70O(%)KY#/"/\8)M2:[/OG-J[#0>@HK@V[UP(K-0O;;7^N/DZ
M_I\C/IME^P5;,0!0/<O5>>?B[L;FCDA[!0=0]^R9]\IR2V)R5EXVF]4V3?!1
M3RZ*;&))TX[M.!C0-1-R+Q?6D26E[=N7",.''QQ/$U)U?I=@8(NGL/=CBD("
M]@QG-MV*&N_=QP.."V53$+>^WIP>@ [G$0O\WT6TA/JJVNYAU"V1ODA/(\^P
M7(MWWHQVZ4QL0](50=1!C72EWH85@$:>QT31)5DO1;T(D3P@IW ]-\I0N.<Q
MF>&CUB4'*I9'U\C9QG[JHV0GUB)W=QJ_O&[3O?*A=-*_TP>H3XMRP8\"65<4
M1Y#-VV:17(,FG).VT&?(DL:EJ2<P= ]J@N36N08G6RPA"I4NDI4Q>Z;596,X
M:0*TJ>G)@H0M,!.N]'"E8[J V_QC^(82_.I]P/^,?8>\?XGZHH[>M5V YDYU
M3Q!5>7?ZLV$L.<B+<.XQ'PA-R8@'&1YHNH*F@JR'F@?3)>[.,PJ<Z_RN)DFN
MMW:"_MB2X+8W5KNF=BY/KA^_K.>_/LZ7F\G\;R)9.,_1-<N453V BJ8&+*U5
MH65*U_546Q!W\T:ZLLB4.:"1RY26C23ATN"<4IA5ILRA<)<IS];7!G^J7AZL
MZ  L2[<U03Q36S&G <^!0\+PITD J^P"3 21,!D=&^C.RJPS:&*QJ_+)3\>S
M?PI[GF*($CO03'$61IT!RYG$R51[$\ D67F_D2=6F*[B!V*Z>@S])-E2;7S[
M?K7=@#DU-4L0ZWO-A4/E%ANRX7V6CI)@P<I/%Y"I3;'0:'G<JP*T)7HC&K[)
M\/9"V?OJ>XC<990^((CEM?=O,/X'EDWP??H5^O'?8%!78XE]##"5; D*XL[0
M=M]T@'ENYZX66/=_(?^P88+^[?\#4$L#!!0    ( "V"KUA3!P]D*[\  (((
M"@ +    8W9M7S$P<2YH=&WLO6MWXDBR+OS]_ H=SYZ9JK6$K1LW5[7/HFS<
MS3NV\1@\T[V_]!*0V)H6$BT)5WE^_1N1*8' PB L00KEK+UGRB"4EW@B,FX9
M\?7__9C8T@OQ?,MU?OJ[>JK\72+.T!U9SM-/?V_U+CN=O_^_B__S]3F Q^!1
MQS^W?OQT\AP$T_.SL^_?OY_^&'CVJ>L]G6F*JI]9CFTYY-=O#S<G\\>#Y.<7
MCYX%GNGX8]>;F %, ]]4K2A:1:O%7E+QR7#I1?#WZ9/[LO$]C8JN1N\9SCP/
MEO<Z?Q&=3?2FZ%OXH::'/UD:\KM.9ZXVF\VS'[@ET7M_^%;2@YJBJ&>_WM[T
MAL]D8E8LQP],9TCFOX*)_[%^ /PV>O3-D[%M5_0S_'I@^HLWP[?6.\^_F0E\
M.PJ6=R5\N'K&OEQZU$I\M,8>M:)'1\1*WFCX(K['Y\YLDCS94>"=!:]3<@9/
M$,\:SG_@.EO\QG4J*[_SR'CMKM3.X-LYX'S7T-3Z>UO(GHA^,/,KGFN3!5[&
MIC^@3T??+*UXZ,Z<P%N'0_;ET@]F@;=V,LTS^#9ZT/>""BX_82;SKY;>#/NU
M\H/D[83?*!5%K6AJ;*C$098G[E>>3'.:N"_XQ?*VO"R("O\^';H3_-Y0=.#A
MBZ_/Q!Q=? VLP"87\/7OJO+G*;#AUS/VT=?_6ZE<N4,@N1-(EQXQ S*2!J\2
MRH9;TP^(5ZE<?)V0P)1PC KY<V:]_'1RZ3H!_*+2AU6>2$/VUT\G ?D1G%$F
M/[OX>L:&'KBC5\D/7FW"OJ^8MO7DG/]GY@?6^/7+&'Y[KBK30 JL"?$EAWR7
M/'=B.C#WD?42_7)D^5/;?$44DR]I7O/E1+)&/YW@>JXZ_X*76C_.<6+$8_^T
M1B/BT'_"J^\8]"7'G."8Q#IO.[!/KY>P.L^T.\Z(_/@'>0U7_"-X0-ZXAG&0
M(!45:1VXN/D51:<B%(>V?KQ4ZHJJG%PH\)^Z5M5K^M>SI0'7C]\"PHR0.->V
M^;3]N$R@X]C!^< %5C*=L6FCL(O-".!!/]QZ,I=4V ?7EC\T[=^(Z;6=T14@
M9J?]T$XN*A55@X^W'C\"*IO /7SKCJ[A,W^G">@G%__4=AP;%[_[R,;)!7ZS
M9NQKSQSB61P.'O+\^3V(6@+[/^H%[O"/>]/K>KT V?5?ICTCL!F]9]-;(47+
M[X[C<Y@Y%OOBL7=U3Y^'!8S(T)H #GXZZ=Q=+\VS"I ]5>;TB2:6:J)LE-8L
M>'8]Z[]DM.4$WTY.69I:#;<0_Y/!Y#J^/ULS,;VB-"NZDF)B==BS#.;4G06H
M;J!.F=&.-?8SL?0[UDP_L4MW,G&=O3&"INS$"+%9;L4%J;<.U(J+FA+^YZ.3
MRQQQ&DCXJJ$T]+K:R'MRZ;<.I+]1-S1-5XR4DZ-O_@:6PPBF.26.3RVGE@>&
MU!/!(^+;Z^*1>_,5/VI]-[T1F]+]S!L^XU?7KD<_WOX(V7IQ1GJ6VLNJ#%2&
M=UY5E=-5Z;%5Z:E75>-T55H,@>E7E>(8!*OD_(X$W?$5J%9HQNTP'1#CZ^<"
M)Y^J-JF0/,U]4K^CD=7VGMP)&=V2R8!XVTZSN<TTEQ53G&5W2CR@O_-T0X"F
M_R;6TS.<A:T7^/2)/)"):3G1EWWB3;I.LKJ>R)J+V8%LO;@W?JO?:E?;J:TX
MM97)P ]@.[ICBIV81 >86D._!;:$9<^"U<,Q"R9#2]BH5ANJWD@XQ,^6[4"J
M]!!G2/R+K^@D.O>I*PK&D:A_Z1Q-^Y].?&LRM=$;1#][IFX26'0ELKU/?_@C
M:@:OO)+^Z;O @_@7]3J=A^NE,W[G (@>)]0HC?ZR1OCWV"*>1&=*$EU^EYU_
M+!N@JS^^B#Y:?ON46EG17T R+T"3[V(QQ>AWB^_FTQQ%CX8K6 S!OHG^C@8Y
M6]J.I-U9*"/HIOP]E(B_]V8#G_PY@ZFW7^"_0L;+>;_"99,GE*_LSQ$,]F-J
M6T,KG(,TLN!;ZBE>B._ER:(/I?7#\D\NUCS WO3U+'& ^:;-Y[$%&9DO,[A8
M[.1\?>$WZ2FS020^.B_$!^9^@/\&J1&$1@7?E&K!&T8HE*P7TB/#F6<%%O';
M/X;V; 3')ZP8#^!90,_?[KAM>BAK_<@&^?::_ )&;920[^Y*EA1?8EQM>\;5
MLV+<]6)-P(,S>!Q"KF^0'MTI;J%?<C@L[4*9I(,@__[(?T#N7]'QU8K*R'\#
M=H+M>B,^Z>][P7D?@VG=<0?LF1=K-#/M!=66)Y\CV>C>;<FUN+6Y<^VR%<P9
MU>8^;MMT[L!B71!L:=K'R&8)IKZ@UR9Z&=OSU[Z4(D$O_K48^F_T0!;6=1.N
M(*]#?H[F2U!M9C8Z,EM/'J%N;,X5OK?07K\&3L[]O9PC@I)%.V$,3!U=4%*K
M8#""+XD53G'+W<$59"G/8Q(+_HW!$+YV)YSBEO(<5Y"9*YZ?'8EYM5<6N;M7
M>Q%OX(0IEEWW<9SGYKI?\3Z&<C NZDWN)7SNSIGD35I[6&P]\0=B8V[3/3#T
M:Q]S]5G4TO_V&O_FS<%EYG]>'4+#7D[W$=K&KE&_< .SE(]"_?L(058TN@_+
M\G56EI#E0I87PXH42!5(Y<M*7J<?BP.O,/KCAHB5H&318EGK*"E.#W%Z\(74
M^.FAL9@*A6,/7D3\AP>^L7AIFSZ8>O\V\9)!T/4>,+-[0<'E1?!P9&B9AZV2
M!0U;>:]W!.2+%G%4W+?P4N-5X]]]+_C]UG*LR6Q2I",!<XP>\'8/HQG^N;2*
M(Y/9RYY\+1/'R H05LC.<NOX)'X&)(HOKX"$$F<D/U2XNSL"*D2+*"P5;F^/
M@ K1(@I+A=^.@ B_%9P&OQX!#7XM. T>'X^ "-$B"DN%HSB8BT&#=YP"U,(T
M?QR#A1E?Q9%9F ?W2VQ"D/!1" 3MC"!A,Q\)^82Q76CR"2N]T.03YGV!B2?\
M @4FGG H%)I\1Z&U'#/QDI/#[URG/9G:[BLAG-J8\0IIUL@RO=>>B84W:/[2
M@H)O%Y(C&;G+G!9D/(JT8D'&H\@I%F0LV-GXEHQ1E=%H^04H3?@.+:-'$E9S
MC 1-$J^"H(46M&^U5T'0(]-C!4&+J-$FW ;O.$.<\@M;\S?7F?EX9XES58BV
M15@4YD;UY_V%9$G&/*Z%KU!F7C<=UQ)O(H%+*A1IYMRW?B4%HPUUHQ6<68Z!
M1T+C[9\ST\8-8G?DPAJ\Q:3*%JLI&(TB.?9  M-RR"BZ \DW:6B[,OQ-^\\9
M=I<$J>4Z\*>_+-*2%U50"K5&(PO!9MKWIC7J.)?FU I,^R@(]>[:"DJO6 NV
MHZ#1F_7P3I<MC",A]8II)FU!6B$N2T)H(6>+1-#ENQ=\E0/-ZX*).&VXNWZR
MAD+BT"@6O83LY^\:%S^B_0,-&[0LM9>$W1%GPF%BX_LDK3A,2D)H<0H5B: K
M%="%(.:U)/HJA80\+1:]A%CDABXZ'PKY\B(SC;ZLYK$)<9X!#'.ED!#GQ:*7
M$.<'ILL6V;M"ZA4ZC_<]T@IQ61)""SE;)(*&AZ7&C=,[=O)H&4=?-.&[SE@W
MR)M"XM H%KV$[#\P79);C7 BVG>]/ZAE' M)V!UQ)ARL2<O>2"L.DY(06IQ"
M12+H7)6@40,.CJFE<SG;4(8F@K:9:T[Y4D@<&L6BEY#]!Z;+>@\A!Z+]X.ZV
M]25I>-N= ]9W2;@MP]ON'/3J"8>*4M8Y'_R0/=\;MU78-^X6B9/:;9$SQV(K
M?.Q=S9<U(:8_\\B%Y;N&IM;/X;OHY]%7T=_X^S?OHKV,_3>O"SF/?IGJ?3#^
M_<H[1]8+[%C\R;O9A'AFX'H[KN+-[_'#*^*X$\M)>NVVJUEZQ=GR[-];]#V\
M:,T63N&?[V_@F?7C'.;ESKPA\=F?S\0<47#!X!=?IY(?O-J T.ON7;_2Z_QO
M^UQ2E6GP1:(?7+=N.S>_G4L!J$&^Y)#O$@AZT_DBW;8>?N[<G4O*],<7"8%4
M,6WKR3G_S\P']+Y^.;GXVU_4FO)%^GHVO?@:F .;1".- 7D5W_HO.5?AQ]^M
M4?!\KBK*7V&1P< = = #F%XPBI[_UGVX:C]4OG7[_>[MN52=_I!\U[9&7T[.
M8!7TV?>>U]X^?Q:.<T;GE?\FT#W(>A L:40\&..K'WBN\W3Q>-?IMZ^D7K_5
M;_>^GH6?[F?L7OOR\:'3[[1[4NON2FK_>OE+Z^[GMG39O;WM]'J=[MV>)_1O
MTW\&$S9P'5FZ.KT\E32E:C3SG<1AR/[5GYI. F\UIL')Q77WX5;Z"ESON X5
M;-90"B7_ QF_5SGS1'),/+E&Q#J_<H<S-$VP),T)%4K6CY=*O5ZKGUS #_])
MY<IB!-A=G-/%$>SV8I!/MZ;WA]1UR.><R9H5L?XY \V6>/;K YFZ7G BC5UO
M8@9(.X (&9X/7-<>F+;M@C3\L436!NYILV[4OJQ2EFWUV_^6_OG8>NBW'VY^
MDQ[:]]V'OG3_^-![;-WUI7Y7 NG0!Q$@J;K4?9#4JO1I]%GJ7DO]7]I23'+,
MI4;KLH]?JTW=*"YTYA2]=CTI>";2GQ%!)*:*26!0D%%VW'E/W]IF5LH2N<]'
MZ+& %S^/S-=7 IJ*LT1O4&0!W<-G25=E"0=YR]!Y;E#WH2 L11N74<=;:IZJ
M*R%/&=OS5/^A==?K4,X13+4Z2,15P9PF$5N-X1W2[\O_D0)WY:/38]@$]#%:
M/KHGI6L+-&R %#HM/PSX-K4X\97LC4M(5M%L52NJVF@T]R(H$C=UR:08N![8
M-!70.H:@])TK7Q)^C:K1.4[CS< 3TWNRG(I-QL&Y.0O<Z ,/>XNP3YB54@,C
M11H2VYZ:HQ$,]-.)$C=:HMD\$_I#%2R5DW<,DX%M#O^0U(5Y<FAE,2/8/) G
MRT>V#.[@FR7H: #9]DVE=]D!R^ !1%JK3TV#+=3'LV"TR7J+K0?WC/XY-B>6
M_7J>3/)S!2FT-:A6WI^ L:V1U*AFB:2_*/0_,2RQ48SJ7_-%53: Z3A#UX/S
ME-9^I=&52W?F!-[KI3LB;\]8'Y^8>NX+OF=9DZGK*!-M>-7(311-%$6+?8R<
M#_EN4PQ@*^,?%QW[YH].Z+T<4EHF'![&R44#7M!4:[J1K&8N&'T]'^1.+(I"
M"50,%W0,3_K/S+/\D45;UDI6'*YQJNX50KD/]JGST/LLA67//6F9LJ&FL:UD
M+I)VM;KGV?!&:S3RB.^'_W-C.41=XHLJ\(6F-:5OKNL0^.^935Y,;[3*(7)6
MNMW;^6A+\ZF=7/1F%O! 0]'V:PTNJ2CT@1$9AMQV/@.3V;-AMID)K7 '+N&?
M7:_O?E\^3^HG%_^RB..8>1.""IRN=P_'&LB7E*=> V>)BH;U9IX93_/>A7G8
M_VM-V=$<FT/SY$+3U$8"6$)E+G]6#><HN6-IZL$N6E/3EL@/,IQA[7_X&*07
MQFCV(#2XX)!/'Z8]<D7+(^8JM1N@K=85?976GS^.MAMW:-KWSR $WRH/#; \
MJTJMTC1JR@%AMK!O_N[#8S:9XG0EA\Y71O7 GJ%.+YFP<[ %(U)8R"T.W!YP
MD6<%%OS.H^LG'AE)TYGGSV CT+T"3U#-0-4^#3XC#Z)WIC4,SGGQ":PWW]!>
MBP<B\[?,])Q-CKX5V"CQI+8Y?)9HT]3U]D_.UL6'S9_<-PO,1>37WNMDX-J?
M_,]BJ]9-$#TZ<UBU?PR?3><)/G"D?S];\,G#7#3P8,I]^# *A=ZKJ@TH0RT=
M1AISO\+::8[G>^Z&8S$,/[RA(:<Q1EO:373<_.LV.30BMO(=;$9,R'RMJU8#
M@6_?&@P- SCYMU[[C;'0HO]K.L=HUR\&Z3@C=&,0:? J#9_)\ ]I@K'][\^$
M.GM0;UGH>-(G];/T;/K2V+)!XS%M&Q0@#/ZA(O3GS$(U"+2? 0D?@'?.-2$=
M/4AJ%0-SH3X44Z/FTA-T)/P: W/2"+Z%DP@?G7ID2.BYI&H2#=[ZTB=X'Y!8
M\F<@;/UG%^/)4=@K>#:#U;E_-Y=GB5-D/P[7\%DRG9'T2<,EPMP!)_#UX#^P
M 'R</@F_P4F$K\$PJ$_G0.=H^H'45*21^>J?9F5J7LX\#T9A(5:4%F#YSOPE
M_%9/+GY#2VX%OF'2@G3G2O-8:_&#?%O U5N0'*$*))Q800 T!^MDB$$4>(%M
MOTKDA7BO4@=ED#FD1O&5&9@L=KB"YL4[$"%3L/M7]/V'&?S(4*J(78#<S&:.
MP5ZE+WW"?:E_T73M-'P@>+9\F+PYA9$_9X)R;SW*V=3G\Y[#F/B?,P-I; ]Q
M"T/,+H&T)D"Z3J8"&$S)-CV0?N80C"U,N 7:(8W @C:=Q$\EV,5*XA?^!- -
MHWB1R "R3J:F\XKR%]X&4@N]8T_2D^=^#YZC;T]!'!,ZM1$96PY-(J#>H[_]
MI:%IRI=U$Z1?JU^BQ]X\$'XO1P^LG5[T(D1J^.R:J49/6@[C.]!(*UITJ,1/
MD@)8V_L.EBXL(Y!^ 4K"<"(#-PC<R9*]M&,(^0:1PK8FA@;V 87$>HM2RW->
M<0&3.'JNN]+B>BLVV*71Y[E-*,,D'>\2]OC)]5X3# #Z$-WX8?C0BBU0!UL@
M2;!N$S_/EUJU\/; O@;M,3G-L#H7UNS/4 [O=3X9(80NZ]O,MQSB^RE2%AOK
MTX!W\>Y\/#OGK56>V3MSIV4[^5PO(IZBI?Q,5W+)%I(&5\VUJ;!'[G<8OZ.,
M8N H486VQDDF'C7L0%0[+C7&9CY39&%8EE6>D!8+NC".9;_BX-\M&!HU9%R!
MB[KIB^53T>^8SM R;=1[,0L+'\:+A"/3&_D2!J"MT;K(C_[)_)RDE)Z6W-+Q
MGT%YG=LDGX!\U." ;01]?LD/]+YR#^8K6)19F; ]G%5Z]FVNSV2?V[2U/5(Z
ME1FRWR"?EF\PAH;U$"=A &*M7OW7;%2RC\:F<MZ..Q<,>GH-5^K. BJS@+2E
MWQ:\#<1#-"X,EN6MR>4?L[FF?C]82ESPKA0&>.O47E2#81B-073YKI8SFXS<
M8$2&%NCM)U+X#_^GD\[=]8F$U[KI@.$]^+A@QO080U:K3;FIUR/9',UV74"R
M"!M_:[Y*S>AFVN$UQ"QOLR?<3D][^WUU#S8?B,G78#YX-@[Q-(+/IX-G;[%=
M*3PM_?:O_4KG[JI]UV>$B.W(%O)J:CZ1RL CYA\5<PRX.9=,^[OYBJ4BMI9^
M;V9]%!;(FEM (<',P 0)%(XXLORI;;Z>@V)*<PBI> &A=7+1;WV[:>,%PDN8
M Y"H)QWC+>]HA^Y;#WVI(UUW[EIWEYW6C03"M_MP&UY7VON"#Z#CLK?4WWAD
M W>:A=K4"<A$4D_WY==9D:*K.EASXS*S9L5[D%9'YT7+_IWK-^;+P!S^\>2Y
M,V=4&>*5K_._#(>$C,>Y[=@:_UQ&#/'5E)X]5.S^,O!1679&Q$&'S#?3-ITA
M <N&D,"7S$!:OJHO?9HYYFQD!63$DCEZ9!JPVH6Z0A_1OYZ9VWCO\X:\OB-9
MQ_0_N9'U+/RO,D+-G<:A-B]L29T*W2EA5PH6Z3Z^]2/*T6!>QA4H(OP0<'%,
M<@*^5<.!$_ 5S! 3XAEY1D_%- '\CA25;:I\LDV993;Y<SW\J'_IV;7!/O Q
M94BM?Y%8E>)CD.$U/L&8$\#+B.WA>#VV+TW_6;JVW>]'H8\TRH-EH8_DRC-C
M'T-? 3P9N-*">:[G@?P%&T7>K6BRX9_\<8>JE(<]/B#J]P4Q2PL==MKIC@#)
M9 JWIF,^423_W9>N+'\X8Z7/4,RW'--^]2UZ4BR@C^S DF#PF0?BS^Q5/9T7
MQ#?Y1/Q'->V]X4,/(:H?#J(PA7]B3I0% A?OUB#FX ,[^ALA:[M8I=N7S($[
MHZZ\/T@@/5C^'[P 4<] ])Z5658:(1"-PP'1H%HT'.ZV3T%X[[E#,IK1 O5'
M [)C/=]C2Y3@(XRQ_G2BG>0,GBBD.0?1% Y<%@7M,-"\*<;XH:4=*_4.(7%X
M4,]P#H].K#1,S[0)5;5"_U/LYC.*I$>?UI&@DHF,N)%+JI!+7"&[&B*[>D!D
MPQRZ-+6[X[ \/5KV4>!5N)$.QQ>UD"]J!^0+F$/[Q[,UL (AO@LEOHOL[?2M
MIY.+'KS:#'BR9S3N\I(+E/B[H2Z^]"8Q.(D$6MI,NBSRA;^220R;+$^6$@'C
M57@[P(ED(S[(-3Q6RR'F!Y?(IFUN:]/F4S]UZ_1GFH^7U+5@47%T*[0??N&7
M762B7OM*^M:Z:=U=MJ7>+^UVOW?01-3HA=^?K8!00))SR7&_>V8F1T?"@)'
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M*ES8JUXB'YO:GLGI.KM<#[MSG0\F\M1UN:IM5G9X2-(6".8&P<FQ[UVNF66
M8$.NU8IQ)X:GM@B'YR5N6.8X$Y=*.G*92,RG>LJN&?"8W[!R-NIP-H[<V< F
MBY,@RY)*FX;+I-A2JOR&C]EINB(K1@,,M?27^G2A+QX-XE)E-WP8<54-$QTW
MWS/@ 7%"OQ.'?SDV6I"89WF2KWYWTVE]Z]QT^IUV3VK=74F]?O?R'[]T;^#D
MZ?U=:O_SL=/_C8?=$S MPT8+$O,LB8YI#P38RK#1@L0\RY-\-9NH$81MF0/+
MM@*+<-,-0L#RZ#=:D)@[R7.(<KZLZ4UK.(2)!+XT-5^Q=3 /6Y<P,J<="%)E
M+D=;?<]V^J,E&F5%K<K-+2+2')!/ &<%.*FRW[(%CB8K2E.N-PI^(>00%7/G
M(M.;$=&48G_<DJZV&2//S4*W_K"DU=2FK#>%I.5DY-R;H*2K<Y8]WA2C*5<;
M(DUY1P%]-2-2X$ID,K7=5R($=/X,LU6-(LS3!-+TW79(F(\F9%95N:;P5R2F
MI"/G#K*MRA)E#;)JM2YKAKBEMZ,H7JX?YPY@,!/W3YZ7!YZZ'G[ "8B/F'U2
M)?#%JWI%FLWKA_6:1J,AUVM"8G,R<NZ02Y7!EP_DZG6 7=%O61].E5XM+5<8
M"2XN4"$#IJIXM%P@+"L6U%15UNK%:,\B@,L+<%/53<H'N%B?P] W.V%X *Y(
MF^);E3JVY99QY#*1F$?M5(K^GVFFRTV&8IE4/.P?ST#]^.&<*NLAN[A(558:
M=5E1A?^ DY%S!UJJ+(DL@59M5.6&<3P9$D<&/&XA?VS++>/(92(QCWI>BB@2
M*]"+G2ZX]D7R!^*/'\VI4K(27?MWKC/\: /*)BB$NBH2LS@9.6_4&:D2LW)"
M75-N8GI6;;-+FVMI?KB<@/4Q)2'/#\99J;K,K7&X?YRW5+EJ&%PV*RCIR+GC
M+E6ON1QQ5ZMJ*->YPUU!-/1N\$P\?KVP(JB*O):N11U2-.93RX#)M*JL*.DK
M;(E,@#*#-EV/NU*#5GB'^=:6CFVY91RY3"3F4?>, O_<JIK\8?+C9W"J--+8
M\;OSH5N5ZX8N&S71D(V3D7.'6*J$SRP@AH$#7=9KFU4[KL6N4./$&2]&%B0N
MG!IWZ4XF5H#=C7W:3@REO^4\$6>('<<^>61,/+S%?^<&1&I_YF$C!6++L-&"
MQ-P)):'D"+")D06)"Z?DB)8%)8=E24<N$XEWU63.!#I*@(Z2CEPF$O.H>JQ<
MEKVG[A2/X)CN\ ]9^I^U/9?79(*N\<3/7]S#]]Z;7M?K!69 1O\R[1FY)U[O
MV?3(ED[ZSMWULIO^GO[:/[E03I6WA1BDJ>E)+SC.%VG]<I*3GK9:#AN]-0N>
M70_V?[1#K"%:@*8HB6DDDD\?D,SY(.^M)3E(LB8.E[26CN_//K2.]2NPZ*NI
M*\^=!7X _["<)Q[XDV=!^/' 6?(=V:TP07ET&0S_)9X[,OWG=V-G%>Y"9B4=
M.7=P)=_RVDIX'@^X>+Q6LW*^8S %Z+;Y<$]%4/967D_V:O+5@362+[:6#(_U
M&CO6/WZT5U/E9K]9S(?/]:HA*PU=KJN-M^O (WW]Q%/EYV8_<:,N&YHFZPDE
M'M_73"0SD&Y-;_@LZ:HLX5[3)WID&I#)@'B2KM"/=5F"ETP)O/.%V*^<2/[C
M/7.JR7<\-W-"PH&3HN2'H<@-7526X63DW$&6RLC-"F1&W9 U3><.9 5P8+1&
M(POWRK1!-[!&%<N1AN;4"DR;$\0>,:^DTK,6A+H'.G6<2T:EG>6R:L@-I2G7
M1-4O7D;.'6^I/'89X\UH-D$/T&2E5G Q?1@[M#4<SB8S&\U$V.6Q-;0"3E ;
MOK!4=RH_K66Q9*-MC4A_((%I.634-CT'#"<_1N0K1N,=N4WR8;8_G51 S"O8
M]*HJ-]0/UEM.T^[QLX E9[!,OF>T1O+O 98&UAMMJK+>W%R0)&M8[JJ4'YFV
MP:V><VS++>/(92(QC]IC=)F7QBV>77M$//_O$OES9@6<.5I+=4"O/9]3Y1_T
M8D1M4Y+N?%?30/^^7#,VVV0\E.$0>.4%K\F%ZM?HDQGB59<U]%LUC[!LC- T
MA1HB1A8D+IZFV>VW;J2;3NM;YZ;3[[1[4NON2N+_@L[*.:G#.3ER9P.;[.9=
M^)]TQ_*;X3(YEU/E+,:*?;2<47:GM*[(BM&0525];T)=:)5'@\54&7$Y8K&J
M-62MFEYC/ 06Q>5MH4Z48Z,%B7F6)R"Y;9B<\]-)<[Y#&[3'Z^Y=O]+K_&\;
M;&V<LD0_N&[==FY^.Y=6)RW=MAY^[MR=8XC[BQ0[5H8$C@P/WMPC!#8F@%\%
M+AXD(^+X9"2-:>\)B_HVS8#0,C>G*PL^"P;NZ!7_UX0S+?LY_F?F!];X]<O2
M?M.QHH$&K@=G%Z6OY3R=*Y2 E)1O1@DAH2A_A?,2$#DU1YA%BV<9O)0M))&"
M)W$T/T\'S]YB/N_3_N0=U6-@ RYB3B.IW_ZU7^G<7;7O^FPGDHBE;S5DC!)3
M\XE4!AXQ_ZB88WC'N63:W\U7'Y[; KSAV\CDXJLI/7MXVO\%5 :P12@1W+%T
MB9H'0./KF0DOP@>YAD?LUS89!SG"Y>!\_17'CV!K!N;3?"(CRY_:YNNY9#FV
MY9 3JDJZTY.+R_9-I7?9D2Z[#_?=AU:_T[W[>H:OV1XL'"S\LHM,U&NC;=SJ
MMV^!H7I2]UKJWK?9FGI%6DVO\ZMT"Z_XI2>U85U7^(O+7Y93_E'=+]*:/CW>
MM1ZO.OWVU><44BA';6'?.M'SB.E$<U)H^]:/]JY_BBW>M^9YO&R370 N$DEQ
MF.1Z)@>>ZSQ=H.2&DY7]D;2UB5&UTO#L,=!7YY6^AQ08!W="'.XT*+'GIS2;
MOJ4G()_PX*(I)?DQ11^.?\[#GI08#F+3N>)!;JZ"/A"?T'O[:+N/R NQW2GZ
M5WG8OH21LPR(9A?VK*U<@+Z&M=&PIZI4%#5PW[L-Q+:_Y8RN%IO?9D+S(YV\
M\0;0VR(.'%)48&D%2UHBEK08EO0]8DE59:->DQ6=/S#QF!FU(EU_)@XH0C85
MKN9H8CD6V&$FUC[ABR=$@C-RGKZK% _)#(S76B+R!WG/D*L-1:XW/WB+LT2R
M7> 8<6SL>H+DAF.]"CBN%0/'/"KMT=4N]XU=+?B//_ZK[GJ.S-TF(</MWH]/
MEZLU56[HZ;-QQ=%19NC6=CTZLH-N56YH-=!ZB@%=D;S+EV_QJ/V))1VY3"3F
M4_M<Q'-LU^=,Y^0/D!^OW5.K?UB%[#A#=T)N@%P?+MR30ILL>NFHHP13X\-*
M799@VEZ_VUO!)Z&7B4-;C"Q(7#B]K(.Y?L0/(G>@#,_Q&KKG!I<9G*C-7=6S
MB&#L0 U])7=DU^**%WI#D?5FBFK.0B_C!D5U95>]+',4J:#=5S4N%;*<#=O@
MF7B1].0$>&5T2*]GDIU3JRAI[US'7?%,[^R8UF2U\<&:>065O@**%(H[9V9E
M#<5J7:[5]U_;6Y2VXULE.;;EEG'D,I&83Y40]&@1Y=B/ ;1SPB70*-OX1K-J
MR(8JXAN%A-'.^8X9PZ@FJ\V:K"=T_3R8(;TW3^2M.[+&\%I*&7<L?3<]SZ2U
M>+@ 81D-F;7\DCH_<?@R.8\3N#O^=TC>7%I2\Y#7)=#*C=F=.B=Q6[CN(N/K
MJES=PE-Z4--;A+.%729&%B0N7#@[,KTE\\6T;%H\D=8!Q8;1K/]\6!^:ARU<
M>TX7J9#W^E-WYPS$):.J%1&R[\;Z?H=4_&;ZUG"?UON[U;X+:M$?)?AVSEC<
M._C WJ_5Y4;]@Z7FA4I8O)'+I"^4=.0RD9ASE7!*O"5-4/K;7QJ:JGZ1!BC(
M6?DBRYX%9,3#9G)7;F;]69LZEQ'=*V&;Z'OB]9 8]##%NC., EL>JYV[Z^6#
M]9Z^S(^=K\JIEJ\W74!D,T0:J1,5]PL1G:. R]["U/^FTR CL)6)9SZ1)>'H
M2^XL\ ,0BGAGKVB2DIOS_<.AED;J[$7DG(BT+4;9N]ED0+SN.+1A*'V["_+N
MQEAQDR9DJ8NJ(FM:0V[4-ALSI4+)$>,S=4KC(?%IZ'(5[Z)ND?K(M?(LC'%A
MJ8F1!8GS2(T\?$,=T<,-*5&0'F[&5D/&*"%ZN(D>;EOV<--%$S<>5]/_Y:'=
M%FW<\E:^N>PQ=G:8*8H]X:COD6BDE?K@$XW22D)?T2CM\*;O6TN_-/V"Q*9S
MY6K91_T1T2B-,SB(3>>*!T6CM"*FDJR+-ZI:<D#<J"CJ(3JE&7)-:\C5-(5M
MRR"&B@*FY.BU'@/3/ENEU62EH<M&(T4V$H_B571*$W=R-W)><N6.+<1X3BVF
M--DPZK*A?K ^6XF$NP R!7)R[9 MCI#<@*PT-;E>W7R(\ !D'O5VT2NM4 R8
M7(QDBY,DLXY3=5FI5^6F40R6$]#E!KK)A4FV.#LR@VY#5NLU63-JA8"N2)+E
MR[UXU"[%DHY<)A+SJ7V*7FG[+?^H:LFE2M*HD!E6@=Q>FSR::ZM'!:;DTB-I
ME+H,P;2]?B<JB11XY#(=VB4=N4PDYE,O$[W2#G2B)A<8V4(]R[K-E=K0Y+J2
MXO*P4,SX@9&>7(1D"\4L<QA5F[)2VQQI/+Z:(ZQ;FD7W4?H4RM'/G$!0^*;C
MW+)SGE7F;=/TPD0S!7QYJ?FNZCNG=F6-W[I<5=(7]Q2MU@H^<IGLM9*.7"82
M\ZE/\MEJ31S![ C>.<<SV[9:=5DS#+G1W'^_4P%&?L"X<YYFMF!LR+JAR0VE
M*31"H2X<K[I0TI'+1&*^-4+1 2C%D9M/$Q95WSDU>]]=6'97$44'(%[!MW-R
M];[!M[M*N-<.0$(E%/J"&%F0N+@JH>@ E%=J1>H$ZOWV=U&-\J3L<(N1U'G1
M>\;(9O7K$*I6OJ)1] #B*'5M/>ND3H \:!,@35:4FFP8FYO<EPHF1PQ0(W5J
MY:&[ #7 Z&Z(+D"< I9;5CFVY99QY#*16'0!XJ3-"Q*0DO(XNP!5MQHR1HG2
M=0'*L?A\JJXZY,^-377R8^FEYC>]?O?R'[]T;P!]/6I<UK]([7\^=OJ_Y3N+
MU48ON0W$70^H7$\V+ENS',>*Q1:7>HNW;G>2HRQK@9Q!"]FT!9T$*X@MSL4F
M.]Y#.MG6R*:U4RU/N<><D1)-^A%LR?,)=6]:HTK'$43BF4BMX7 VF=GFNK"A
M()0XY JRPOT><KGV+V2!,2EI,T5'RD)2M#5Q9\F=I01!"TG02W-J!<G&MZ!H
M(2EZ1<;6T!(\>CP4I5U#.*.G:/M;ANZ78M/%IHM-%YLN-OUXEL[GA8%OK9O6
MW66[)[7Z4J]]WV_??FL_2+HB2YCCR\.^\036U"[839G6567E%DW+[XY9=G6S
MHBN_AU>8?X]=5;XEF%:]>L>9N7PZOC_[6"IU738T3=:5%!>LRH"#U9'Y[']<
M59H9H2EV)[[]Y\P*7G?NIUTW9$U+41I9H(D;-*G*5FA:I))@R*[CA*ZMW)'5
M;,H-74M7>%N@BYL+I%55W0I>#R0P+8>,PINC?LZX6EPA-1IU66FJLM[,M]F.
M ,L6HDA[#ROY"1E5ES45"PEM+OC,M3TAKI;MW38XMN66<61!XJ,?69#XZ$<6
M)#[ZD<M$8CX=R8:B?OKC,YLK:NJ>-9BAGNQ+4],:298S+T6S-O5: #9+BRFY
M6+]>495%"0]5J^AJ2K<@\S%?S3Q6QLER1\QYW)Y,;?>5D&_$(6,KN+=-YP..
M:+4NUS7AA.9DY/S1NJZ:?_9H_9=IST@V8&4N@GI=P)2/D?.':7(![/=@FMX[
MGC]DC89<U_GS:)5TY/Q1NZYR]GK4IG"Z[PK7_Q+/'9G^\[M(K0B0\C%R_B!-
M+CF; -+#"<VFPM]1SV>)9DH3R:)$P7I/L&,D)(6/^R_YQ'NQAH03=!\S7ZTK
MTYN7'<@^OW:]'B/Q+BVV(BNPT9"K=1'>YV3D_+&:7!<W-RLP"ZC2LZ'12)$B
M4 :H'#%(M76U<?=@ V8&6$U194/CKUYN24?.'[3J 4S #6@5!F"11LX?HEH>
M!F"&$A/3X@MN_^TM&GCON3#4"&P]^$X*GHGDFZR0JX@"[I6I]AT%O"/?Z5<?
ML?HTV6@JLJ((#S4G(^</TSV'_SZ"4G8:&')3X).7D?/'YP'C?A_&*D"U6I55
M 5=>1LX?KH<(^*W!J;#RBC1R_M#,)<R7A8QL\*ER\AG?8[>JL'<@P=XRDREQ
M?)-2.FHK. _W<8+LXO-4A8.UE''D_&7B_D*T5%I&G5?)Z#+&N>+8+N[(^4,T
M?60V,P-H&[BF2->5]88.QGN*[L!E0- 18U=/'[#]N#4D9.RQC9P_3K>.T0KI
M690X&-U]F@=I.D/LQNX'PB 2!E&Q1\Y?$FZ="K#9(,+&Y)0+.R$37B(/BH.X
MN"/G7YE*3Q\UW\K:V0:+NQ2JJBNRIJ4XDHM>I*IX6%L/M?21[_>-$R'OCFWD
M/<B[K</;1R#)^ RHW)% LEV?,^-@0\\.#M@@@ZXB:\V)Q#8?99(\943!>B&9
M/JEB8Y0&N+[C#-T)N0'6S^6,%A@6&(YA>.OLB]W". +/ L\YX/D=S35]Z'R[
MV,X[2-Y!KZW)=:4I5[<H:/4NO@MJMPNL,JQN'4,_5C#R&:.)M\"Y:E^&'7!4
M'CO@K.!4!YR.W-G )MRRTILI9J+'&.LZ4Z3-DLJF:TY5D16U(=>4S1>J5UE*
M%_K+.B1GV8I@/ZA<U]!BE]R]3-H75!5%5K>H32%0><2H7-<ZXZ/I>ADAM"HW
M07XVF^G5$8'2PJ%TO79LZ%O!]'#=@)JZW !QVM0VWQ%Y%ZC'8<05"73K,6>\
MA[D<NPII<@UDGE;[()1X3*W+N=-04=ZY NNB3+LH[Q3;*[:WN.\4VRNVMQCY
MZZ*K"U_I@D9RII914=0HA@#_UGGMZJ+595W4\^5EY/S1FIPRDP=:LZ[VKM5%
M\R%.1LX?ILE9,>_!E,>N+E7L52Q*^G(R<OZH34Y]>0^UHJL+EU Y9I FY[PD
M@/1P0M-H5+G#(Y^7%$17%U[XJII<TR(_.S#+KBYJ39/KAM"O.1DY?[ F%[;(
MS0S,K.:[*M<T_BJ^EW3D_&&:7'5@+V9@9I#5ZTU9,X2+C9.1\P=M<JF"?*U
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MM]DR^5H%>S=#Q!:7<HLW:K]SB9.?+%OX# 2=!"N(+<[E[M+Q'M+915XCB;2
M22U/N<<\^%)O;0%#P9:<G%#HRZYT'$$DGHG4&@YGDYEM!F0D""4.N2*O<+^'
MG)8G5[+D!BEI,Q.3@DK#I86E:&OBSIQ $/1H"!K&Z 5%CX:B5V1L#2W!H\=#
MT;[+'X<>4@\[>)[JX93L,J4JB4T7FRXV76RZV/0]G=R\7)_IM>_[[=MO[0=)
M5^@5&HV'?>,)K*E=L)OS&.N)>8Q:16E6=&7OUV$,73:,AJQOD=)=*ARLCIQE
MOFR6:&IDA*;,\F4-W9"-AF@#7$@T-;="TX&NGQB-FES3,*N_)M#%+[K67QMI
M*%O!ZV#71HPJWK.NRTHS1:?=@EX1X00LZ[&BOH>5_(2,KLEJ39<UA3]]:-=*
M:$<N[;BQ#8YMN64<69#XZ$<6)#[ZD06)CW[D,I&83T?ROTW/,YU (C^(-[1\
MT3EP#T91<FLDK:(J44DR^+>V=:.%D(3MB(*A4WAW;[*F8F=.C3O3J:0CYP_(
MY!Y(F0&294'N:LN#*5_GSXPOZ<CY8S&Y"\U[6-RZ"TBVN#2,JJRJ(D3"R<CY
M(S.Y/\U[R-S<-&0;2(K&(44:.7\<)C>O2<!AGK*O+FM;U++EVL82?=N/F'U$
MF\)BTV^]^$MNF[23L2)Z"I=QY/PAFMRTYL,VS"$Z#]<576[J_)WT)1TY?^PF
M-ZO9W<H1,K:,(^>.TV9R#YIWK" A/3\>B_KX3 Q%_?3'9THZSQK,<#=\:0IG
MGF0Y:!MAE1]_;94?P4)9LE!R:YP\-&D666J'5NXWXI"Q%=S;YBZLM8A2R3J'
MK%72D?-':X91TVV.@FS RB)8:HI,Y#* Y9AAFCZ6FIGMER%DC:;<K%4%:OD8
M.7_4IH^Z?MSJVPA78?(5:>3\0;IU /9 0K.JR&I]<T,ZKHV]O07%*$TDBQ(%
M6X+ CLVC8+C_DD^\%VM(.$'W,?/5U@'EC.Q ]OFUZ_48B3^2JV@HLJ:+FZ2<
MC)P_5O<<_<L"JDRA5D0^+2<CYP_2 \;_,@-L4Y4U3;C7.!DY?\P>(NZW :S"
M_BO2R'E#M*;D$O++4F#6-/X<O7Q>.],4U9 L!VNV6B^$1?QPW\?$6M>30/!2
MAE5<:DJ&P3_,+^Y$M*3?7T>4_.A=M$59%TU6%*4\!5V."FL97WA<@[4/I;3'
M@"905DR4Y11YRQ]QJBHK#8$ZCE&W'G19!\Y2HDV82$4:>0]",'6,;"_B3<U9
M=>,SQ'5' LEV?<XN=6UHZ,$!0V30<F3M-;#$'B!EDD%E1,%Z<9E#Z!.X'N2I
M.R$WP/JYG-8"PP+#,0RG#XFFBC8)/ L\YX#G=W38].'3[4)1[R!Y![6V+C>J
MNEQ5FA_#=T&->8%5AM6MPZ;'"D8^XTOQ_CA7[<NP/8[*8WN<%9SJ@-.1.QO8
MA%M6>C/%3/08=5U?@;3I7)FUU*EK5;FV17+A*DOI0G]9A^0L^Q3L!Y7K.ACL
MDF2846N>NJQ5!2I+C4IM*U0>K,5/0VXJAMRL;:[;*5!:>)2NUXY5?2N8'JY5
M4$V3ZU5%KFV1G/TN4(_#B"L2Z-9CSG@/<_D)/:TF5VD*X.:<:1YD'D]MB(KR
MSA58%V7:17FGV%ZQO<5]I]A>L;W%R+T7Y8A%.>*RC)Q[ JB:G'"G5Q0U"@#!
MOW51CIASH!PS1).3G-Z#*+_EB U=UAK\U5@IZ<CY8S<YN>D][(IRQ+RBY9AQ
MFIRSE(!3(3UY<D:*<L3\L%!R*E4>FG0NY8AUN::)/H6<C)P[6K7D8A2YV7U9
MEB,6]=)X&3E_F":7>=B+[9=E94T#A.OFW-928>>849M<,")?JT^4(SZJD?,'
M:7*]B0^:?-D*S0:'-=SY#(J)<L3<\%5R28W\[, LRQ'K#;E:$Y5>.1DY?ZSN
M.?J76;%"O2%L0$Y&SA^D!XS_909855%DS1 F("<CYP_:0P3^1#WB(QHY?XCF
M$O/+5&+6](+;?Z)65WFJ+(A:70(%[XG;'.+#HK:1P/ ^,:RGCQJ+6ET"SX?&
M\_H;WGKZ^/(A:G4U9-W0Y(:HU55JK&X=53Y6,/(9>HO7ZKIM/5S^$A7JTKD6
M^:4MU*4G5_5('^C(KE!7HRXWM,VN#AX*+Q0$R86K^Z$GU_W8+?R66:&NQA;]
MH 4JCQB5U:U0>:A"74T%]!!=5O7-?>L$2@N/TG=4X]I6,#U<H:ZZ*BM-73;4
M#U97.@X+KDB@6X^Y^GN8R[%0ER*K1EVN;=&2A@>91VVVLV#@CE[Q?TV@0FR0
MZ^Y=O]+K_&\;C$,<1:(?7+=N.S>_G4NKXZ!Y]7/G[ER"D;Y(,6+]9^8'UOCU
MR]+P60^"/8:(!V/T"($-"^!7@8L0&!$'2Y&,+<=TAI9IP[AF0";PN'^:RTP2
METNW-AIHX'J -$I=$'3G"B4?)>2;44) *,I? <_ 15,3#G/G"9$'+V5T2[2Y
M3^(<^#P=/'N+^;QOK9^\(QL&-ECR,0^*U&__VJ]T[J[:=WVV$TDDJ6\U9(P2
M4_.)5 8>,?^HF&-XQ[EDVM_-5[#'MHGTAF\CDXNOIO3L(6_^!1C\Y*)/B>".
MI4N4# " KV<FO @?/# WO ^/V*]M,@YRA(MKPZAP*C;GTGJ#5R9K[OV*XT>P
M-0/S:3Z1D>5/;?/U7+(<&]2$$RKKA^.3B\OV3:5WV9$NNP_WW8=6O].]^WJ&
MK]D>+!PL_+*+3-1K7TF]?JO?O@6&ZDG=:^FRU?M%NK[I_KM7I-7T.K]*M_"*
M7WI2&]9UM>QZ,R33&:WXX/A?TZ?'N];C5:??OOJ<0@KE:*7LVQWX/&)ZW)P4
MVMO$IWSMLKT;@F*+]YVF=;QLDUTT*A))<9CD>B8'GNL\7:#DAI.5_9&TM8D1
MI=+P[#'05^>5OH<4& >/OQWN-"B3"[:LF\YGW)[/E.E<'*(9^MK5VKHTE$7+
M."/9!WKON6,KR"0'1=7E9M60#37%_8""^L[Y!T1R(8%X#\$U3O$L 5&3U69-
MUM44U>&.I%$[HY:%;NA(7VF-T =(/=#HH_8(T&=HV01^SV0>+1$ _QZ:_K,T
M0^^UY4CNE'AF8#E/$N[<BQ58Q#_G5#H>.E/I. _JDHY<)A+SJ(LM23"=3ON*
M3$%J6:RN/_IRS8D+ _^7?L##/O(,V \'M]7:NL(0&Y6\..%:SJ@5(]ONA5^;
M35W6F_S=!2WIR/G#+[GDPQ8J93[PJX.YT>"O+ [WVBB3Y7>N4Z&*IDU,GTCD
M!Y:"%I6H\N>B=34H-@KQ;O!,/" ;4JW-R+5SCJ:L-S9G9Y:*\,<,N>2:$EL(
M[@PAUY2K!G^Z0D$4;WHMI<*::TW-5^9#B!40Y-5=>DQ,M*Y2P$:YC9>13&=(
MNF.:;PH*T+]-SS.!A+&"+%WOTC:MR<Z%6:I&76XTA4SG9.3<X5A/OO2_A4S?
M"QRU1E6N:T(YWU'>LV3TRMMNBIS ^Y@9:UWQ@8UR/MO&.IK<4&NR(:H3\C)R
M_LA+CN%N(=*S19XN&WI-5E7^D%<0;?TRUN)IT06*E0 />T--;5/(\OPY:ETU
M_;6R?/@R.8_=YKY<$*_O9EA%7U4T66_RIQZ5=.3\@9A<?OX=T;XW(%9EQ>#/
M;"R(GOZIXPP]])]_/H--IO_"G U $PE$ED:I0O@E';E,).9>_31HGMF]1VBS
MT3"D)WS#^6=;UM=U0]CL' X/D*OP^.@X(?D^%FY9Y&#JBMQLINC+4?2$W.+!
M:CVJDD/%V_AX\T'5A=I09$VX=7>5S+W9=&I;\#Q-[L7XW</?S,GTRQ5-IH.?
MS\:PH;1X/R<8+SYWO2.TU[5:V$%H=YP7(+/K6;NW5M ,159J*9H]"TG-CZ1.
M#@[O)*DS@)):5V1#-XHMI@^G0%^1J>M;@5"<\Y?!C76UZ]_UT+YEFI!D+>IX
M^?B])55N-%*PCY#$'"$J.7Z[P=6:-Z(T6:\:<EU+X6D]QHMPS&L:;?;9I\AI
M^AF]IK9E#BQ;7' KG5^MI".7B<0%T?Q:PR%,)/ QR19+\_&P=3QC-(OS.G6,
M?KWI%)'OGE'OXTTUFC6YJ:?(@Q&*(#<F>2-UR#UO7-&LCX:QN=@TU\+Y<-Y3
MH((W(R*NM4<>VOG"<2(/(?5N%DK^SE<=FG(C3461,D#AF$&X\[7C/$&HJJI<
M35/HB$=9?D 7ZXQ@-BP),]DXD^6EZFVWGO%VOJG\EO&BE,4'8IM!-@S8-&2]
MEK[%C.@M6FI,[WP5>A^8UNMRO9F^M]<A(+VKS7"<S,4-#QVG]["D(Y>)Q-SK
MK;5Y>=J-Y1EYV,^2'OSO^)EWKM\ -+\$DM][[HLU(J-OKX] ^X[3C2C?FA/^
MPP[G)A;/E6O*!W6 @KJA!5(I4IL[EW;8(U)535:Q%:V6ON'=7AN."]53Z"5B
M9$'B@JF>)Q>+!G#2]4/W5NK<_:O=ZX,<E5J7_<Z_.OU.NR?2I,J$TY*.7"82
M<Q^)9PF<]S-O^&SZ\ -W+$T]M(&#5WJ'B?PYLZ98GI"'W>09MEG8";OW? E+
M2/;=UA (YI'[D(982B)H.:-V1,:=8_2J7*MN-@V*;K$>)ZYV;QV3.Z[46E56
M]!074/.V+P]798I>Y1U9P<PCK!;LU,3FUD ZG[>K2\*QPQ@K.25Q%X'=<0+3
M>;(&-OG0!15LV:6IFS,2A;>QX*!<C\GD%+]=A/W[F/PO\=R1Z3^_"\>*B'T7
M1Q/A5@<ZMN66<>0RD9A[A7--[-MR7H@O8M^\G/'O*)X[EZ=:$U'L1)3/,*)8
M,^1&3:BB98;ISO6N]@C3;3T0(NI]9".722,IZ<AE(C&/2N?;J/=UYZYU=RFB
MWN7%:4E'+A.)BQ+U]EP0@R-?&L/#DA6VT<(0^##6\(.'#>49N1FXK'?.Y(XH
MB+]8M$&+M5G8.8RBR75=D14E1<B[#%@X7A1JRLY9VBE1F%'@A&NA?K@H>A3%
M0C'.&C;-!3N'@?0",]):MX^F[-QQ+R)>V,HR8J9+)-SNC>4UM2$W=5&(N9A@
MVKF)7AY@:LJ*FF\67"%UY^"92.0'\8:63_7G[V$#6DY06GS^6,\>.U?;BVLM
M8</@=DC"?#(]2D7X8X;<SH7XMH?<]A+9,.JRUBQX#3X>U&5'<@<P%.TTZ\,F
MCX@GC2V':LXV%DCA3)J+&"OCQIU+^CV0Z5Q#NB(#3.>^-*=68-HW2.[N @V[
M\F:C5I<5<?>]U/#<N=A?_O"LU\ VW**"OXC\']G(98K%E'3D,I&8>U5S)=UT
M&F9U28-7Z5.8>_HYU#5%\BDG1_KZ$WWG*J)KDOJN(\)_.*GO0E7DFF'(2G5S
M'5\>[IT(4/.CI^Y<1S1W5,=:_VJ:W#1$JJK09HY8FRGIR&4B,8\**^BG[;[4
MN;M\:+=Z;>G359O]ZS-\)M$LUM;=%?M'^Y^/G7^U;MIW_1X/N\DS;#-0-W=.
M#L-3&?\?:U2\F#9ZDAZ('WC6," C_*+EC)8_B#UY3SS+':W6"&__&-JS$1SJ
M\(]GTWDB#V9 VN,Q&>Y> $-6:[I<;=2XBV"4=.3\4QK4G3/-"@'II9JB-:TJ
MUYOYMMX5ZBG?+'-LRRWCR&4B,9_JZ5H=5):^M7_NW-WAI:KNM73??NATKWC8
MQY(ZF=:?^RMYL2V_.V9G?;.B*YF>]3MGT\BJ 0>V+ORG MJIH*TE0EOC"-H:
M**-U+'(O^C$5C\NX8:;CU'A*.G*92%PXI;8-GQ9#G=7A1!VYLX%-=HNR_4^Z
M _S-<-F<X'KB"9Z';W7G&M2RKC1E74M?4TH7RNGQ -589T5Q U15D16C)NO&
M9K\G#T@5JJ;00\JQT8+$/,L3$.LV3,[YZ:0YWZ$-:N=U]ZY?Z77^MPU&.DY9
MHA]<MVX[-[^=2ZN3EFY;#S]W[LXE3%"58H?.$*0]\>#-/4)@8P+X5>#B*3,B
M#N:GAKFII@WCF@&AMQ).5Q9\%@S<T2O^KPDG7O9S_,_,#ZSQZY>E_:9C10,-
M7&]$/$I?RWDZ5R@!*2G?C!)"0E'^"H<I(')JCC &B&<9O)0M))&")W$T/T\'
MS]YB/N_3_N0=Q61@ RYBGBFIW_ZU7^G<78$IP'8BB5B-K8:,46)J/I'*P"/F
M'Q5S#.\XETS[N_GJPW-;@#=\&YE<?#6E9P]/^[\$[O#DHD^)X(ZE2U1+Z+5G
M$UZ$#W(-C]BO;3(.<H3+P?GZLGU3Z5UVI,ONPWWWH=7O=.^V)CD/T^\B*_3:
M5U*OW^JW;]%"1N-X45VO2*OI=7Z5;N$5O_30R(=%P2\N?Y%T59;0XJ1]IU"C
M+]*:/CW>M1ZO.OWVU><4LB3',W_?FLWSB&DV<U)H^]9R]JY%BBW>M_YXO&R3
M7:PN$DEQF.0H^+[Z@><Z3Q<HN;^>A7\D;6UB4*TT/'L,]-5YI>^61D<^(8S>
MX_W]#57)6C=2[_*7]M7C31N5L[ON784J:+%.OW=77%= 7O%2'.Z@*;%KJ#2;
MSF=$\CZQ^ZTTG7?(M1Q,F&8-<X8SS\-O;<L<6#:'5Y9S"?-D&,S1DU/AW[G=
M,7R9G$<TBC<@G;<P[H3TZ3B7C#HW"^*(NF9EP55R"=)WKEADB*L4@<)Z3:X;
MFRO0<"V:]U2$\N2"=:&<B^)1 8J4<<\GJ5N.(Y\P0D2<,7I$,K#[[H369MH]
M1U.1Z\T4A7J%Q.4'2:F;C.^ I(*>V'QJNM=QN1DK_KBDX9K#(4P.I:[YBL$D
MP12IF")U@W!DBC@#+,K<+?2/5DB3>T:2G=/IM,V51#@@K0#5*JA2=_C>(ZA4
MV5#X@Q6?^NREZ_@SF_;;]8GW8@T)BEEK)'VW@N>B]2/BE5E2=\I%9EE0IA<2
MYA[H\F\@2Z9=AJH-75;K0M\M)+!2][;=([#4IB9KU<T7W;B6PWM3A.'H\V8$
MLTC>RN/ E08D)I6%)-Z989(K[&UR-3#:O.6;OON-1+R3!<=@%VC1[:V8R$HN
M$;7)]5!R9/&I$\_+9K)N;2+:EB6C&#M%V^8DH9VS\@B#&#6YIHH":(6$U$Z!
MMETA53+_[Y%#6MR^$B,+$A^)ZK;4\(&E7E[29@]H.H,,!P4N(![Q QXVL$#G
M:^H ?73SO1/N-YHR=V3G^K1& R^SIRC@609A4Q3PI([)9PR>JE&7Z[7-Q>2*
M(D"/',;BM!8C"Q*+B@>BX@&G%0^::2](EJ[B0>[WX+XBOT9P, /S:<ZX(\N?
MVN;K.5@ZMN60$Z:'^6N*#^!K+I8OU.4^][MNO]V3^EUI44\@O(V&5]?FE07V
M/*M-Y0#PTAQJJM+2'?L\IYB(+*;"WLTFQ+.&"QV[FNP W<) ^V;ZEM\=WX.>
M#5M"T[%:SJ@'$[#&<  X09B2!5+J'F3$T")^'T;Y9M-@%/&'YA3>%G@SPF9@
M.3,R:H&.CG_\KIEZC=1R.#D6F],ZE1@WA /0A\ :<#VZF'.:GD]9X>);J]>A
M%2ON']H]O"J)3$ IVWN\A9%^P^]ZG9_O.M>=R]9=7VI=7G8?[^BER?ON3>>R
MT^[->69?%,]@D/G_&]6U(VZ]AX@7%+IQQ&2\*=O,=_\[U'\F-!%Y DM]9;'!
M]_04>C!%,M?UIN%>2I\">,_?_M+0-.7+)7L9_4O]\EDR/0*VJSD;@;XXHG?_
MAJ"'F19F0S/;%]^ GX]=-T"%20)Y/[1=?^;AVO 1VWY=BE?B<*;CS&!RB=.<
M>F0*X\[SK+T1S?>C>2;FG/?A,7BI-;5AF"?B$(^. ]^3:; 8Y]&A$^_AV^D&
MM*B<@F/;?"'2@!!'<B=6@,],9QZF&@6H\.%/O1F^&I?FD:>9S7IJXROPRQX9
MSCP:B:%/1$UB) R,6[X/CYY*_WZV0!L PH*R02]+AK\-]QA&MRWR@AKFLQG0
M;^);-V5HQET'&I@C\N<,UH"3FYA_$/IXG 2+QX$($LS!)B8J<C(^Z1/F9K0F
MFR#B/[LS>X2Y/: <L>BRZ_QGYC /"B4!CISX6]P(IC*O4CN&*K7^Q8^H#W1V
M/=@61[J&=0"'5/Y!7:+XDU=B>A)Q\"4]I.AD0#Q)5^C9IY\>-U]WV*ZY4\O!
M70?8+$ D,_:)<_V"/S<0%P] 9%W@%  4CL<^_X0?P"A@%0Z?*=S@#S-D7J 2
M)AC@0(X9 #0_4T(O<3D9$M\WO5=*/5,:FY87 9*A<QGY<QPL9CEU?8N)$LIB
MMZ8',UFJ?$19DF!."GW"PO^9$B]DRP@VOO5#FL RGY&K@+DI@DXEE)2+S1F8
M-I4H_C,A03CB6Y!)<*K (6.]X'8"(4.^?_-8M/GK3<.C!>K5C JD!4( $7@7
MG&Y7C#KT?)@A>"3;^G-FP8:]PK!DY%,XP\>PU_YL !L'LAUV$,OC F4&[BQ(
M%B T#OX:VN94Q4,ZFM*3&YZ#<$PYC.Z)K#!RJ9P,!96$XCC.$50B3]#@"S&W
M0 !,"7B/,$C#M&=.>"(&KZ<2J+H #9@5LL>,G@,H ^_P7/QVY&#85E_KS283
ME!7(= NE7EIH]5*DUI\?5HM;9]GL''H*ZRJO]I_#U;ZN,V'V1SXR89%)9%;Z
MC]@<)>K$H.RG?I'FC]&V]23V&*8*6WX0Z694)0,ZSQQO7DN:_0CX8D2HT*<O
M K7#"RJ@H4Q0>I-7./"\/T VCP$W/F/C2&NB0P"8?'J,/0./PAA,J@"K@3H5
MLC!3%^%% 2IJKW"XP7&PN",-LP+UCG(ZGK8>(?-S@Z8VKRXM=/(M88(G4":'
MM+8 972Y_]Y&TSI^PY\?7"X5'YE/D&)2BD"YID )2&@/Q1 JDB#3,7N2Z2\$
M%!0X%1"1,Q^E#E4? L]$J5]!425-2/#L E1>0*8#KJQ)^#09SVR W NS*,;P
M#P2-#[J\0_560"R]3_;L@BIM3:8>O"%4D>&HBX],7TT'1@: ?X>*4L)H8Q)]
M:>+E8"E4>"C/A%_0&ZMX"$U! 6.G[@0/)L(NM#+U+CSY8*M)J%6]?3=.D_R8
M,FV),@ZP,^:@@2KUWCZ_6.0[K@K4. G,%5P1,.> &NAX*!*<+>ZL-:9';GQ0
MMCFP6S!W&(=S=DM]@74100:4!*[WRA%[]6;3J8VF[(R:#H"LA[^9D^F7JQ!"
MSFQL#E&, I>$[,9X;_Y#)!V])C*A'G#0AR>^] ?HRHB%9ZJ^ X/ TVCO)2ET
MZP=<J)&GR^,ELC6=R+/I/1$Z9 ABU UAU%?FSO"981I[,>=@2[[8NEVNB^D\
M64 25E#@VD)WR V:- Q^!Q7J9A@B69+B]$-&-[ 2J'E):6I.K0#>\M_0"V5.
M $GTKVV$=Y*$A1&&;P2L%\K1)W-9Y$[9M#ZI=2;@/Y]*H9&.0C^0F/?'I_X.
M,GQV7-M]>L77N6C>2$/+&\XF:-W@W2DFX^BO0;F8T6'?#B9+YA1.#M"DT.VS
M9)RX,5'-WH!;,J5]C*GISC8G],UYZ(,:P;G0<L*AJ<!&4RTZ'4$+_V\DZ1='
M3VBQ@0H&Q@SJYI'R-K;=[_YB!ZD%N&PDS?SE$T5F)B!^C88[AH1"@U^F$XRK
M8DALSZ.>C7![8B]BNB L<+;PIZTNZGODPF(NM3&89 3/OP$)OJ/#;_F I<Z*
MMP/1">-<ER?#NZC8Z5HO*RG"T8'$)C07"E1$Q&V >?4-/*MPO9A %5KM\.<+
M2'KJ+J(&?.@C\%P[#DT+$S+!]D3';ZC1R-(4=6!DQX5>0^6'&6,N7!_R.8E<
MON$<J%%B1CXL5G1)FDU9W1 X":E+.+Z(\)'(G^X1D#F$NBAD8-CA,P@Q#^9D
MFP,THD%CB,T*P>F.P7(FJU-],1E:V83AS+Q=*%I^5 PJYO> 8Y#.&0]+BPHK
M8!8@'HI"JJQ1I_-"N;R&+\"* O9EVN_0M(?4.8[>'UHQ)78-*7(^LS%"#6_%
M-\Q^1-58IFF&NJ3INPXH$Z_S#9I[R:,-_&Z! 4A^$&]HP1O\&2BWX4!LHRUL
MZ8X[ QL+>^BYWW&2'BYH%ECL+$%PA"N(+3.^!IS-@)F,SANON_EB6C95><*Y
MX3U8%#:4("-*2T##!-63N)(^=T"A;6 Q0H 80[='L#)7T'H6QC'[L0R:]!C@
M,8HAC=5&@.,='5WX+*6.JD56+9XQ(&29N,61/3*VF?P.U[7D%0TMF+D"A2"G
M.^RO3@;WAX8<3 PPF':RA#R\Q"QU@HRJ'$6&S,?3T@"&H</8G.<$Q_,"$C(&
M!L-Q4S-.UI^YR14/ME#/>V"HD&\H6U"D 9_1.76G8<I#QT'Z@;*.KAG_\ H[
MG6Z%SE>*3WA9@X]_P^PR&A0"4>W3WS-9:GXWO1&5'1.0(C./F7$Q7<R<AUJ?
M/#.4I4D!8:HPHQ#UH_!LJW<IU=6&+%&/9GPVT13IO>6$)7P*@^#A&Z(@>!A&
M6-(3::&#^;EF^8M3)&Z1?$-FK?2&SRZ&DL.3%C1Z>I%WXHZ(S=Z]_!S] N0S
M'.QH_L");KDS7_K/;/04GF8@4F:3:&QZGE(%U<5SF,9%J&\FTL_#<='$8,/%
M"3%\0ZYEFV"#>67Z\R-B;FG1F8-V3Z)R$7CXH&-VH9<<>2@DKN8]PQ;-.3F$
M'F-QB?*U+-VY3N6?,W@'U4:3GG@+V.5OOKD. (1^Q*QCY\V0BT<H!H!>X>/4
M<V.C*@ /@[KE80C+8ZH1<YM$N2'T!R%3@#4)',U>L4BEH!8KQDL'KXE>'LHU
MZ!4EWK&'1OOKEK^D#*/B!&SE^+#G>-;)\U W^K^ TY<,T^7?4WT8*$U ;W1?
M,7YAOE(K OA6#CVL,E.21P3=*9&B!Y8+FMOA2\-("THE$CU!A2U\/U>NY[P]
M_X0^S\R!A13TL5P,%<L1YV/0W0HS9QS[55Y2X)$UF!1"0WLAU)BV21?+IA63
M;.$,42A&5<!&H(.#F0"V?Y@6-"3SU262@$E!S_+_J(PQ\!-=P6.V06P>JZK_
MXVD/?NO1$^LU?#I8VC%V6,U/)JHG8^:.'7EMYE(Y[O%Q0_,0=G-,8EZOT,X-
MG;+4/*)N3'<XG'EL%0LO3!@(B*CAD3 #@_%P:,!2T$2/T,F&"49Q;\Z 1KG1
M747/%80D)16R^-R'/UILC8G_9]JO81[>LP6[C$E6,>ML0$!*6"Y,NK/J^I^?
M9)%C]NW)R4[$T-[V%T%C!-3:PRQNNB ?ARH'<@ES"LU-%IJ?QO*:F,LK]&.9
MP<+)'#X0U=HHQ3&V:  <<F,$&%9@&O=C_3'#?!0K2%O\<-.A1T'ISP;_ 52R
MZ!H5*#+N/+6_D?E9M(#*KYB@H9]B9@\E&-I?%"Y1(A)J)Z@B43A$AV$(CN^8
MB[)&(PUEP$(=]4/ER)1N4?V7+DW/AHE:DS!9D%WO#>N7^<B^'O,QF $Z-**4
MP/B"AIY%(2G%$TL8HP<N:GYOU34JX >Q>-U"5L]]G&\ULCA^#V^;K[.L4I?&
MBBPK0"[!%#*PHJX(J#4N]9"UV18=WI**ID>A&IN@1.M^+-M32\^.8L^R0D!+
MH5K3CP5J;Q>)IR:MZ>1+EZ"Z4[D\?VG7>S*=*%00V3^7#]UY G#X;L95P^CW
M@<?RJ6:CU\43\_-@4;6303N,V7B$QNY"/H)!:"@C\H!%: V/;M<GT0HQYC>D
M?H/P#$4FL F=,AQ23V&Z(IW-J=2>H]X,Z]?!2+'-BLD4#%@SL]'T0^\6O,.B
MR;?NDT=C$FYLM&7_+3L:_-A;T(<Z'STZ?L*#(SQ_X2\6AJ>GS<)K_80BU,.3
M,LH^#M\*K$W3S?YPW.\.[_R:7'!L"WYMFYX#HM2_)Q[U,G 4B[B#@^0&PTHP
M-XG5/9/H')?9="E%*?(%X-AA4&J*8<"P2.(S\X._\66@WT&K*<QS$6T)'7<Q
MX*F$]QV&80ZN/:,9WVL'^6[Z2QH;JC[ ;329-_K1,G_%?QY::I$U]YWZ]Y"Q
MX(1!MG-F-!,V5H@7?^4O*8\C%L5?L, 2$\WU\JF+WD"FB]%E(3^PU\DAQT0Q
MB_C;XV4G(V5#AI,3O0WTW%M18*@0B_\&CGT\S^%'U(I%>XRJN:M1"A0"LT4R
M<^+.LRV/O%UA ":RH<,(Z3PVB8FNE6BEG/-U+75]M$4" @JOOOF#(X9F<Y)@
M4L1?S\-+(4:+_23 GZ1P0AHA*[\9468I4O ^Z3_ '_[(8O<K:*;4*6@$D0L&
M'HB2HYS14E0JRH )W70XR]!XP1]A/!)T/D(53U W/6LP"R(67X3$_:68>$*B
M]"+ZS4+N/O,*6,R7MVYJS(5A82C1GS+'$IW5P(P4B3#W)C0N\3O*170T6$JH
MFF^[#W.%G>GCQ#&9)0N_\J@4CANW*.YHXCA\S9*5&'5"1J?I'?%CVJ71R0G>
MEO)>E_8NP6Q&BH!P1#4(Y $) CNZ?4#@=\. Y;UN7A55:$)[%R<V7\FR<Y9>
MPXK//F[EAR*,B1^Z)_.@9+(B8U)#)PQLVK;[G0*<ZDFCV3!,ITB8?)2/PI(R
MV-AHL]-L_S_0IT@S.ZBO:[Y+; 6G4@M@:]N)(^/AM4CR>@)+R _63F+MO9%U
MMX>2(I3QT)"(4>X[1JF*&.7[,<I-D<A:ZCO7F/W3F:=/=<<WKO-$TP/#!D3S
M4WMP\%-[D>2%J?LPSXI-KV8Q_E^)0;);KK%[9C_F3\X3XJ39E-T"2,K4ED$L
M@?Z-!ZJ\G.E\2L]VO:; KBZ"=,P9_V9>$I8XF3*9%R9'4WTBMAC'#N\FT$Q"
MFJ@1RR9<R1P$K7?(,E6B?)/E\WF>9+(ZCT]T(I_#.TU,S8U.*P3PZ9L]>W.I
MBSJDT?)_>B+T<Y;Z&"9=H5H[GY[U/K&8K6TNTV4^@W"K_#!W:''(+*6/I]LM
MPI06$D8,%O.C_NCP0=?SE[]D/UJ.6< A'"J%\]VC@0GZE$/C+O/KD'*DF437
MB-DYNYRSF#JC,7QT\!KS)*R!P3+M,>Y#,.B."YC[-7FW/7:^;?7HD^XX\@;Y
MAY1=CRSE<#Z7MU8'N_(^-R\3KRRRN]CH3Z/7F=#NH/&HGUNM^X4@BETWCZZ*
M+SQK-#8<B[@PJ<4TTP6T_/!B]L+Z77O=.UB]BQR[%ARYUF/#>V3A)%Q,="YR
M!AB#0T<7:,W,JQ>%6T)NI_,?1G-?,"7&=&AH(<#U+L5R%@Y!?RG[/U9( +94
MQJ7C90.: 4FO+\CT-AF]JB&Y Q_C4$.4'S+S*YHV/+'J=XC?#$(1,;_J$Q5)
M6,K,3A*-<IBTBI?F%L*/F@=ODRO761+,W\"241(4:SC!6' YND[-I'<8%*.Q
MKSG-8+4VV$"SI^<XLD8N84E_B\(+83$#)MKC5A*37;%06PQOZW".-$6/*+M.
M!?,=L=@._EZFC!#+.EUD^FZU:>NY@09_*#Z6#IO@W532Q8XO(KOSC-:U5Q?C
MX9E%X!-IM<BV6<H5B*YJT5>O,1J9<14+C_(NVE/?641U]8Y\CQ4 \ES'G87Y
MMFW3LU];([9G'#F<'@C:.(!\.C<@=>RJ<P\]F>CM".V+8PXG=QSI_YL!0VF*
M6F-*U?6<_Y.V1/KFPO_,HU+7K=ZW>5@JS#5)_-GCE&9CW+FG=*B*JLM(AMAH
M'<<'&#!Q,[<90)!:S-4/J_S4=Z> 55VK?3Z7;ID6%^FSRT]B]9+$%R^R"1^C
M>2PR"BFY8]\L#G S)A5#_8T6U6"6Q))RP.3 YZ6 ]>)B%(T.S^]>#DB\H@P3
MO^B]#A7&%3]6F!$6.:^ ^9S17#HO3WL*QOY<2-+08WBU:*'#LEQ!=B<JUJ]D
MH;U$=[5CSX79%S1'/>; &[*]CTP29[38N.4[&-2#-O!<$Q,./.I(@X_FUPI8
M[D!X(S%T \[3^D^7EHAN*.:]0S\F'NN]]B50P09!+J-2':9?^ECIB-Z?P'>&
MT0F0^_34H?Y9T(V :LS#."!@^CM494?7A70%0H)ZJ=0J>JG4IAS+[(R*]T0Q
M!=POJN6@<S+^6I@Y(FC=5%;RKW!E4SSE@L@WB@(JA,9WR0\Y*O7D-6W'R;?G
MV]P=!BY](7/9+<_;C.1HC$I1*L;$';&4$H\$GKMP/V.2':LPPU 6 CL\+9C+
M?O&V9Q-+&5$,,Z=M4B[9V^HU<KQ"S>)^J4S-U/G-.=Z/Y9WO-J\_FD-/$D>'
M,LQUJ>3(TFS7AX4P#RX2-"A(;5H?B1WOX9FT5*(L_E86LXU4YTAA#E9@2!7H
ME1_2'!\:H#3GFG0,G-2@7U^8=A^.[IW19NS4"OHFJB)T-;<W4]2 ;!#55#/"
MVYJ%?]N^!N1-YY^/G:M._[=C+>2XRC]S/2%FJH0).C[>E:1XGE^:G)?V,H<L
MB2WDD^A:(+LC30*,SL7N7M/C?6BQ2Y[#F%>!&L;4RF)AJ^?9A%Z^F\SH+VEZ
M$QK6F+OCO_K 2G)T_3O,E AENK<F,0M,YA$8CA;>EZ!G#UV:3,4&('(X=P:
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MM=V-P>$S&<VH3$VL0]?"S G8&>I(61^S?]_;%5N53<;!.]XO=AFF@D^=F[/
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M$_T$6 #K&!GCL(9R5;(&<SGR@)7C(T+;\L')(&+I]<^-TP;8&L1N@>=9 Q)
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M7?!:PQEO#3Z+D@%N'5?X\:('#T8+3]!.7#+";I2 9<'3WH;NU.(I<P]8-A_
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MR,CU9I/I&,P$;''G4 ,.4V6.0X'.XJF&9Z*QWS)LPJR:X0)RJ[$*Q IMSHK
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M4DD7YZ>$A'@0<Y+3K6>:'C)B'CMRWW-?+]9?*W<F=6-X<"*6''H2FZ%8MB[
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M$9E?BQ&+>T%I]^-0S+L@-I-]@]S*@/5V='X*4H$$M!X7%%T7=M:ZG+@>2++
M%XUK3H 32)1ME+MJM@!*KI?E5BF&!C;4,=G37!$/2Y9S 2CA<>4#42**E(^(
MHTXFOXSCYVSOM9HMN7CJ?*)?P3XL7H0,CJDSR,!CM&7^GV)8:%/)@N3)%*6K
M)98]I;I?T3Z_*W&3/0>'?U,SEC9LJJ%<)TX7H!Q ]+4IV .!_ZP0SWAB\#?'
M?TB;&#5]5&!ATDNRL53B#14M)-4O"TH Y,A9ZU2NK,!BI4S])%H*K8K1F2(Y
M1,+M"873)/JI;,J#,?62J.@$BRZ#PN>6%V#LNI<#7\*-5* TYR"9-&>E$EY6
M'9OLJD01C&T(HH%#G?DCAAVP=R'_A])>AKD0=@L#K!\"OIL*^!X? K[K4FSR
MUP?=]GJZ[5>9BE8@FQ+T(V (@]3S4](X*O,72MT#-&FI19Z"E%DTE7M*W"GY
M+&U:Z;Z,L1C3?]!09;*H:AP'*HN4U8U?9F4X6O_V/&84P2QIP'=:A8SFJ F?
M3*[X.>P4L]#A7X(/JR%D<0HRTB*P69P=UK9D-0P1#4$X]NFUI:@E(C)#7>24
MJR2MS+$2&6_$3O<I>E=QE):\*S,\K_6*2KZ^K$#<F5DM+(O I88-_M3>Y$"8
MS#,/HTT76Y>*<#B8VJ"8%(6I!VA#P6>"/\DC9E(6!=<"O 7L8> ^CED)N!3D
M2Q)<M51P*0I7J"T<:R! S$R0 _OPG#1NI[4H1$[AL?D B<A*42\<+0^G-&(H
M1V&*8=SHV]3C*GSE*BOCEAUYY%.&>Z++D&8V1P>B#-:*E)'9PS"-R.5Z?&>F
M,B489-5A/VS7.;#U@:TWRM9(H!1YM^Q'63"G6DI<B9BA@9',BQY1)(S%0Q:0
MG% 3HT@9$;+,K^ 1C[5X$BTK ^L^K]MDCI' JIIX/IKPF)/BXD7+@4=U"2B#
M+!S%%,8. [7JDYS8#==_11ZVJN&C[^AF!8.*4>.N%6=L"A7,HY+-<D#Y@P@X
MB(!-B("K40X7*S.02YOM60H4;=MIC6LA]"/AC<L0,@[$?"#F]1.S<L:HQ"<M
M'59* \L.&""!]9=LCB29K-<!52J93*E"G"+UR>)<V%;:!BH*G 3 *EP:^6Y4
M$D>NKDR=TTCJ@Z@_<,=6K+ULP3L-:7>H=@M3N@39P4$*-R5X_Q%3F&&DU[XG
MOOLGPGM0C ;^P6CH_%7J_%7V5R 'D\MTGP@LL?F'H4/J-"6\;F7I,49M+)!3
M*0VMAG-R11%Q.0*BU]!+U(J_GTM^LBGX$'#W$ *_5%N$HN=(YCOC;(>M1#VA
M[68K521^X%SMMV=5P(LB;7T"RG%M5V3$SD&$(B3.G1/!78"+H!/V&S^1OLLI
M+0P.*N""<\$&Z.<@^A;5=E"3P]0)1;%4K&H14$5%B2PCQ;!*C/W5PR0$&D1>
M -HD?A\0"FK,+=72:1O"7RS7IPI%*P3GYR&T5!G4N>)'SY,EFGIUG^R!@3W'
M<G$$5QK1('B"<)7?YX2^",#*EKOL3))!2)CQW-=(_?=#^!CQ-ZAG&]DLT^P(
MJ_Q"W9$$OTHH1 (H0"Z<D"RQ+@M;.(B'L$Z1:C\S_9U\RKCV1V?L#CV'ABG0
M0B(JV\$Z1G@3PZ"![1!%;A3KKTJ+A02UB@#79-M3*#?8<R5W9NG [SJQDC..
MP2F"D^=J)(0V%05V%-^;3BF6AD1LIE3'I6J*-N"6[(GKBQPZ511&L9AS,B0%
M(.8BX^^2*="LK1SO_(7 [A(TM)+0%24PGC5 H8,R'/Z <%RNJ(0LT)?.!7;@
M<!$B,(@[='%#6"@(1$$S>C2T*NP7)9+GYEU*2%*/ ](P;-_Q"7#4"FDP&N=I
M2(\2GLUP[+,ZQ!6AC5I#V#\$8*6GN2K9')7U7G$'K.=Q:[(LYWPGP5?0,XNM
MKYB#H)Y#+C0G<-HD*HH?$5ZA&X6-$2:M2%,,J0I(E1U$%N<X\;6I]*&9%UC+
MF[);X8*\C+0OXQ^NL%*GKM"I8S&$)(NQO">U9CGQ2TC! J0$F\V1"?524GEN
MV##AXG&E?TIMH%3.L<W"DIS;9*FM3["C,QIA[QK3OS;+AM\J7R4$8XX\@.>_
MTHP(40,L[$CT^(,DQN:-3"E%EBBR;\S^32!J4_!.U(9CO! +'G-\RY#Z U)L
MY._ICI1.K(H_./R>I@=1M.#+)DY(@,G<[4PE[T)C@NX!W<43*;-\,TFB.+O0
MG-;3.=.4Z\3OT3I!;+)D*;!V9E]1@H6K9+DJ<9,#)D"A:;"L1+8PF'#5_ /V
M;P4*M4]*+0FS $!Y"N0.!DD'VA(D2>16D!HL=>.";88094.HF0F,KIA:-KA'
M9F1-,E#)H=:D$R4#C"<1#I<=)(-8]-64R1=]%I,D>0IE,7@ ? 97NM4Q"M]W
M6<[)H2SGE?T-G;4]"T3:6#@8TB//RM-L_*EH), S&3F-3+^(\=RR(WO_>MRI
M'V.ILR<0$-#X)U73;II4NV\0VCVB^+.QIV1UQ9IDP<3(];AO@K6*_!([YSQ[
M2D:@015D+3HG8@E.C@K).-J*KCOG;*FA[4@NEJ'9[!0$8\VKOXJU\#HZ<RK]
M#$)1;@<%I"PWI<$\["7ZL,@)1RF')7USRI([O[N)9"S%E>#_0%_6@\2.G;,I
M921+L [VYD+'HZR5L.,9;Y$BKAGK7)P#][;LFQF7(!EA[2P=,!K&>*8"K=<+
M!I:7S4A^,*[.;Z[I5"_#!_!C[;1G<A 0P#<(0]^25IYC86N2Z$CBRU*1->G/
M[,.9?B'^0O.LIAM6J@/#E,>EE6J3M>D.<%P;@Y#_%9$^!?/*"1BQ ISA5C0I
M%, V0=;1V-,)']TA \DYWWB8)+=V8<7&@X?CT![@UUF FK31 Z\T#&:6A^@2
MUFS"_;"\,,M(QPE-+) VR<2P)@'X?A+;J9<50\UF_4QM10H2L%S=&!E.WZ<Z
M!-E11]X=N["<WBM(Y?V@F N6+IRB_R807@V.4F3W:Y9:D$,K&FLP(H-97A4T
MZ^J4Q2WUM7  ^@)P[3[#E(C91Z)_6XWWPA!:T:N^#AZ=B9H^C'3ST1F$"?H\
MI#13APZ>C*30U4AA)$JO:/ERG,HH$:HGOTEV.$+=%"_JO+-Z)]7BZ&7F56)*
MB@0!P[0M5) ;RG FC9P'IAC 10G_8(^ RQ8FM_8<<K.=.>362DT/>7#4_E5&
M=(KFY!-3FELC8<"2FG))JCV>WQ.EOBU_7ZSXKZUZ6U&+[5#2A.<P"HNG$"@"
MBO."4!0B<&X%EX*0 0P>3%"A(J)-F\M$D::B3*</+N\]7&;$9"A/\(8LE1)F
MS1]<D>I3&2M/<X(Q-GK\.$"\!DX):]&L(2VL,@)*@7P9"RUCM-,YC%8XN0S;
M25[['CD.!+R/K=@A93GD)$8,\L"]88QB<<Z%DS5/NJVJAV$7D\59?>IIXHG;
MZN\8'>>,#;!!H\L.1( A%*4$RCP.)=[W0S$OFA"\$WE4.)*;;*3H(RM .+=S
M&7#<H_2@[CXH+]LJ2;>52>1VB7_Z#'>(.I62YQ/N3L17H*L9/_!K)&F5HYR.
MW,XMJ*V)20Q@CL&1J;&?2CAY?J20#IW)U MFCLC*X#O4)Z7B$%A(?S0HDQ!L
M:$NEB," #F/W7_R!6*FN.%<]XY-4Z:7E;#33=]XAJQ=O[*B;VM6O^:B;JQSU
M/O#B,CJF6JO+JYMGWK52,6]B/J?5^M$L0(8^HY\DD7TF<)F%C!I_GEVC?5W$
MYQ2OQ#1E<ZJ7=*9#,K0<BDRZ:)'$XCMURM7?J0Y.1I+$,>0:O:ST1_,#=E@J
M(>@<?AM@'YS.&.)U(O%8?%"S=)$RUE5Q^71N^Z&X-69X5MZ]E!V:>7;HE+##
M<ZM8@2'X!V4DVM@@B7:^+Q+]OE-AIX=4V"Z(L&?UN4 !9U[+5B;IQEBE"-,T
M*8FP[@H*7920J\!AI!58V9Q;GR\&M)BCG*!%<)/2]K.TKY1))OU)0H[,.1>6
M)-^?KGLYJ70RI-(\64G;K4@MK46HQ5R"5!948CF5J>&>&U@O+@+<P90=?P8[
MP%QQ$$HO!3TIH>+72,7RRO:-D)^/DCDQYQ>Q6E_>TGRZ34]V:='VQQ@!UNGF
M*=5%55+R[5/+M:L"FYQ'\%RN\7')^!+#T8BDN-:>2D9IC&@\)Z2V:)"$Z*00
MO<?!5OC:.<=";:.NG^X,SA.Q=>V%[V7YD[TNN4=3C>(3@894-)2=>^&,S>4/
MN;5\F(2..;>=?>#")6*>J8U^H=GHET(F[6><4Q]Z7N$T<G&J!*W,-1%\NNS=
M]KG,AWT+S@KA5#<Q1/Q99Q1<@P!#6K++VK'@VT#0.!'F#:(.<NM8#;_UDY7$
M@?P@)+^ /F%OZK2[DC.U4:2FL1L[M&OG)X2_":VU=-"5O%!ZA#8> !Q#X"%W
M_></QS^HM= AG150HP9!' >34@=O@S,#&-+SYWY. 8!0X#^\[FD>KF^QZ[LO
M:,%=N,!7[)A]-8HIC^ND$9WER4<GPBV0DC*5=H&"#A>Z9Q=Z$ GKI:#6-B@(
MW:BYQ'/;N[BXNOY5W]N'@X1X2_?;/MSO7M_O@7_W^WYWEG^K%?Z'@37\B@CH
MOEW#]I+PI[\,AXXS&F42I-N&Y__\Y=/]U>]7UY?5@,_-'U^!.>2;RVFP?#U_
MS5/\:)2A^,4)FV(\\,13\ZS=,4_.NCMX,M_KG32;9JM[:AZWSG;P:+[72^F8
MQXVNV>VT=_!DOM<[Z9IGQQW@E=9KG\Q2.G%$__.J.I%R(;M%4L\8:UM=4CE]
MKL&<5,+DV&QU"M*]U*A[?1X_D,(F20&[A3J-@OEUH(7OD19:YME909D=2.$[
M)(5F\\QLM8]WD1;>6@#@_N:^]VFG2;D-A()@59[S82.6]7.O6S)@<-HT&YW.
M<Z39/HBIJKO=,3GU(GIH-LW.R;'9:!\(XD 0(E#2.C6[[6=-V@,]?!?T ++A
MM&UV3D]WD1[VL7_I7*)1$2@H-3)@AZ%+SY' J'$@\4++H(*Q/X)>2F#;LIXV
MBR(3"< 2@:22Q0W6(5FYYA96JC!G2I!M2G!:53TN+.HAM"81 9RE)>G<MJZ0
MA],& 8DYFD+897%C%,B>6!/\E>O>\_B% D[9+L=<Q8+U4EQHUY^'4^LCO&MA
MPT':>XE5^ Y#G8M^'(.:"+6=T;<+2S(%*AG!OF9Q6@DW2ER(:BD01)$Y:QU*
M> Z!$*89/%?AY!8/D#IGJ8@:7E@W_G#C,0*QEJZ[#%(V\>75$6HUH;-G(7+K
M!J-6SH&0%L793#I40Y]%$]=?#'2-^(1P?+8[%$.U)-*;!G&KL.WQ-P)AMXAV
M7;;<7:D0W_?FV;-#\^S.-[&<(PP\RK_><(AR&X72I4)=W:,.EL^$Y8G21@DE
MVXV&210I8!0YV;1"AHT4DI&"3I<R6V(?:0AL&L0K21\0HR#F&6(5P=CQ3^D3
M<5BC'$5Q3_#]B-?!+9CY(1B9KV?>$V=&%],L9G6I4^#<H50S N]-#GK( ]EH
M/U,(O";P_H2X*#,?5F"D3H3^)E2U?R;V@X#,3 %\Z82C*)E,=<SYT0CQA%.S
M(1*8NND$K])-,Q).[.P)6(>.<*2&.\GC)A!>'#L[E*R:'JI^B$ADRY$HZF()
M;(]MH_AG!J"C'U6!$NW/F4]@LPF##\J3ED!\9+.GL$_484F>5"T8U6CX:83@
MG32MI*3%5<Q.YMD"8@:R8DI?W:#\,<U^T%O\<4DXU2 (P^ )5X"63@K;2'Y
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M8V<O)&;$7A"%K")F6UPX959L/:CX'AS9U+-F/P'9D#ENN/9__N"V?_@9+]R
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M_V1!]YG=3-ZVD"\*O5FD@DV^U-RW#UPI9]8EK;&^O-[ )IIWW],4X@LW9NA
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MWT W*%1=EBPY7F&2@O,A+4O&-5!I7\9'"QE\O\YWA;N$!G8+/M]:H8%32 O
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M8OJK!>*-_A%-UD%8.AJUB'(XKL2PGQZ/^WT[B(T4*IV[8_*3);^7[8U2^F@
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MY$N+2("DGQV<7!?.BFJ%6#KX6;J_9:F;UMZA/7[0_X CO6*E!R.K1C@LYH,
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MMWL#2"@W33#AP^I?X8,=*520@@:>JNR@<-G1 +G6C\+%X]\_1DHY,J:%521
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MW?*U12 I[JQ9)^=1%W?R0;V-LN>2Z1^O^CH#;DOR!^VUTIN@_<N!T']SX+5
M_CYG9 !#_HB/5,]1&Z2C&E.DIQI:_::#&,7T'G?9YI(@8%'U\VH\ 1CN 2>9
M\E_ZX/E9_$EU_8\SH!'T3<P\>?K2N;+Q9^HK?M'O.^/27<:^.1<XYB/0;W_
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M@!W<3:<ZV4\H0>LF/Z2)L9//G'A9L=GK<3S4T!KX/@7>F71DK47/CLAL"@T
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MS)81]M?R8+UL2V"HWW#U<+6"\UQ$2[,082'.EC526@0GV+R]Y?_B^;<@R^F
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MZV*IEOK0Q1=7RN9&+5%YK)SK>T"J',*TB&U)WC5CWAXXU;<3^H@)4/0>%9.
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M[@%WN)X_ZIM]M["^8^W'M3Z,UGO?YA)LEW+/9&?2/UN]IN5#EU#-/>6%HFK
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M[,UX@NU$+D/U*[9$%?7FL^;ZC+2S:WG33KQ=-BF<)0B)QJX$_0:J74G-2NY
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M3,0H@RKS,:FDM-0Q&8+\%&R%6L3]NC1BCC4:VQMC),Y1\AXX/8U+H K5=>K
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MZ:MPUM716 @8H:=OB6=];5VN_(W,'*3Q>2-..M-ZX,5A7P$"@(<K.)V08AC
M,0'>#@<1"&B,'YXO/@#I">'%LJ]Y%0 ,JACX+A" ?6U> N@^G(2("IK=5=AM
M&(VK$#MZ)K#])C[#8]=$9@T34E$)6L'V(W)B4+,WY_?6;'ZWT1>G(OUY[:ND
MG/\:C>E]&%#\Q49-\B7KE&78G9V3@]A#F<P':D5W'@WK&&R.^[X,BGM+[%./
M_)3RK)L"$MSQI.3F>'C-/]F#T!KI]KV6.E&X)5^AU2:LO+KQM]T>G!VWA[E"
M(GCQ%P33-"PXOX^\N4Y!T@/PB&O:=H4;G8S^I/2#/8-$HT'GP@4@6\[];_DO
M\.+FY;Y+HIR7748+5P1";5-O62<\ZV%2L25IFQJJRGL1K?KI@ !![LYOH3KX
M17$#+D3KIMRV:86@8B_/U1:?@@F5O%&'@+'9A":Y1U\^:@CPBG:0[;3CKC9,
M.H+F26<%F^=1QT<QDC.=SOK>O)!#2:_N>S[]Q.]T4_4&-+0-3) <1@!TJP^D
M UO?V)(<3=4B'0HP^E=24'!VMR^BGN)1\27VQM?QCN1"[Z-!1BMVUXN+O#TW
ML3PA\CT1W1&&YZII K^O]?_W[W_L"B@>_FT]37M&;(+-5/=CX(9"50[7]N+S
MHVJ\N]U5AFLRVYV'Z)T1G*7W_L/=&?_CG?2Z*>FR9?2YH[_X.@*@V&,D-27L
M65SB:TTPP>*@G8H6(ITGM?\-VK)D&GDN?%'=: H+)Z[$&ZTJZI!/B[C.YOH,
M3*ZYIN;9954C_5A%0U!>SH]]WJ-#[N-4;8M2-(\GO.^XR9L<N"+:HWNV<[;?
M/I?E"7H#^;GK,51A7VCP9"!+CZ^S]$F@9_ D.*.NR>=G.EEUO:'BR"OBV$?(
M1-9'VQ$9VF,MFHG ;1O5N^#G#W#E"_1[O]9!WW7F*"XOT3KY[[U]]X-^=68$
MPS>+XS7E4/MQH.]):98_O3_]L >1S6UBGWE!Y^O'NW75GW&LZKKS!CA*3(&=
M675UV"G8R<)[]6("G%$HO+=+[=':R.?;N;3]ZJN[4'O9Y%>'VJF*9UE#B^<1
M_MQ\I_6!W6&Y&]0O4[H73S3\AS(+-@[L81&8\U:!?A@+Y#\L(UZR\*/98!SK
M3DH$'N$3-EJZ90R^C)#9W6P_UYP5YB'/XY4OPY*8"2N9^^5\TP1,6?WC?_EC
M_3Q!E/_;-]WJ(ET3DK[LH2  \3IM'ZJR"J\+JTT-YYU_NP[)>6[ F1O\O]FW
MC1.?89G]S.'\NT0H1<GHL_7*C2;@1W#LG"J5KAP!]>7R5ILHK.S]I-WY[;P>
M?+"47];M\[&[DME;31?:$^;M8]J&^>\KZECU&Y945/L1!F=5Z#;$=VW&PL>'
MCL7E<@(R$N:Q  X3[ 4<CA(..JYQJS^C-6C=TD+"HR1>WG?VE;H( 'U,R^AH
ME1+T8%[(D:"]W),+29=U$[SA%Y=B6HYA)N70%K!.M\Q3&V2XO$CYC1G.EAR,
M<F1,_4(7[^A5'O(S%X8,LN/;,Z;9QTK(3PVAJ^9HWFAY.Y(V(K%$NU64K92M
MG^7.\?>Z_'?&2\SC87>2,DC3#9W=[1GBB$"SE1C.%Y$$55.77I@\3T:^'D5B
M-JQDY]>N'0U3?/_=7\;1^GW=6^/WB*KPVW0F(_W=;@7# -ZE*4$0_#+/3N;T
MX>S8Q5F+$IS]AO?NPV'@N555[O]NESI24-L3&3*WO6VW[.?;:=<GI9/P??P_
M,&O'C)#>ETEEU.M86G3Q5S/)#7K89^M(-Y3"-Y\[RHBRH8WRF3!5:F_ZS],)
MK \!8QQO^T(9IBLI$  Z@Q,9Z=:\RT@))D@- C#I&XP Q/5X\6:?5S7],/?C
MO[#\;NE2QW3#HOIK7)=E=I60-;9QD+LO!;_&W3'[/&_T1J.??FSBEU5$D.?;
M=YR_6/<OJZ4CS\_@GW[Q<M@O7GXSA+SRAI_[/D;2G>QCG7-K$6B-$A62LE4A
M/2SXJ]_-!.0@'?8VG^C&"@&XX2Y[_SCDZ]FY%'Z39[?\U$4I9VZ[N(S*G[$V
M<GKW"N+ O0>V"$ >AC^QJ>1<]!+3F.ZL9CT",%:V8_.GB\S_CG#):+<92SQ/
MVUGY%L4H-0^RTL5:.U0::3&DG-\(2[ZR 83!20YU9V1NMV*AJB!3/03@.&V[
M.(?P_Y5BK/5DD'>) =3>P6.5AX/%9AVNKQM]#=HSI0Q<G^S:GEASO",ST02W
MR_:#.F'+.P&^60A BU\\1[I2NL:XR5UL9N/OIPKO-K+LZ>V5%,CQ$KQKO4%T
MI'H\*EOC6U-N&J^030SIR?R7A"=D?JT$*H!>7U9D(S/8_N/\WY8E(FW.:MC@
MHS+RDX,R2TQ[OE*D&J:?LXO_;.L3V69CPJCF>"5S[_G4:Q86EI(J=03@0[/6
M* R)L#;; <?&MO&PRB\,%Y430>(,_]!49I5GVM_\5XNLW/^D?!%RU,I3(%AW
M]?9ICL-S_#>>E9CE^L8JYOX$4Z8^PB-22LZR]/4*\HZ"GL+C"XHN"9RO-?_B
MGF:R;:ZUY7O2N>RA,TNV7+N5=@>OJ$APS'284IM>UXG0->00*>8V9!/NIXT4
M^=49?.";;VUTE&PZL.9'4<!)?#^5_4K*MBX'UR!IS?K&;18(0]ND+_I:]2A9
M*<TR37&P\9&:^](#V_D?N35U]?%KL5MFI"M(]!HT5AVT*L']-I&*J@$T<RL#
MW^[)G&WSWIU:P0>G K='3&\WQC#$'VY?FN0A -(N", R>^Q_=(<W;R\R0R2Y
MPVGE09I^W*(E^VO56VA/P1Y.KM694-3FRY-O.L*B0Y9CNG'^6?N.,.\%9 \I
M" #N;51:.8M<B0JWJ:G\:DV:-IN^:$\KQ1/JAZ8UQH&C!:-WUX&0O(-9T[-]
M5P0@P!3&M7S3P[MMZB/)4#H-5[KB?_A[PXK_T9#S]W9$_]\TV_TOS2BF2Q$
MEMM4,CLH$*[DS_%K\Y6ACNE<9?OVQ#8<U@[5J0\U3U[NN7ES-C]*JWRD#Z9
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M[GL:_/CAZYXV'#2)+Z%7.J#U85^Y0L_$?C5YC8F5VFNR9&IIYR+R0;9XPO>
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M9[<I6T"N![4K$WI4-FO23C%NZ^%\VZ(/^:DJG[5G.>(($^<.]<GM?.^E[BY
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MZ?10RMWF<)$PQKCGM=51RSO;68\>USF->)J[_*]BOC(JKJ7M\A"D"1K<)8$
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M-RK5EH]>];U[Q6)8%8QC)RB2^NWP%PM[F/QL+N0(_?537?VJJKU5PFN1B][
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M@2N7-:C]>I,0U,E'?Z^7Y<*=2D+Q>,CC3R9H30K@T^^HIX]Y7+%E6[+!UGA
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MY.86J#P?^P--T2ET7<K]S#"HR+$FJ=(%]1D=?KO4J1L[UM48*)A]*M'-%E0
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MTP]L/@>+[ZRPOC_9\SOH.K(9Y8RR=-]0#+@%>&Q7J4YW^M:\=DRB^2%^8W*
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M_%26I5#G*]^T]%M%$R'XM?)<7F!::;3'87T)*]GKF>*%5AJ(QCV!%VYPS$6
M6(%W7;Z-6V6Z2R[YFI2_:K]H$/ / ;;\[*ONF/W?^GM5Y? .AUI??WH\,V=H
MCEY[2>LA..)3V75DOU7P45]SI?=2+#SQ8URPM2O@*;R5WG?NO2RAU>GU#($,
M>W[CD)LXU2#^SII[*&1:@D!Q(UF:/DS[9LK.2E&N6UX)S4)UE1.D"?+CWEO]
M6IV-T%F@[7L5S&Q!!,E+_]5*T>%]&0A;KFT:VT7.*0>C^Y/> FV+SS!-Y+V
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M--<J#[&QC]6!:CI'C&EU;;#1G&AJUF@FN32ALYD2LYXGLD35TMK5%;\;\66
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M@9$=F&S+DWYCD;&DU7H+M/BL72%"2WNCBW-UY %:@ U]Y-IR%5^V2_1GZ=S
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M;:*G-B($.8(8;)&LR<Z_L[SM.1>=5M<O(A4H-['P/071%6B4JRDG^Z#A;T2
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MX*(RXMS5!-%<9H1D&:ZYNK5D_:&(9R&<<91]8E+Y9DUN59=J>*;+PSBEN;A
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M(U*'%9>!K<B&:.TDZ[<7?+EVD)]$/9^ JP6G4DO]#T8'">&3ZKK?_?TO^=%
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M<@W%_@=];RAR4_GT@^(5IR8J 36(/%*W;UWI10,@+32PW+IHV/S-^-:PAK<
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MK,='1-JE6;.)-OTL'<QE9F(VT7*ECR@3WH*A'_OXS6_Q'6$%F;TFX4<MD\C
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M/:)B5S[$-7(<0L&CYEBB.?KIVB^>_6>.^?V///O=L3_\F@;0X.%@Y,%C <+
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M)U+%>$0I1TQW#&/,2N>'R"1L>P5=,@?_$=R/Y3&Q!4)2TQ<\[T;-LQNHYFO
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M7O**O+R*V=&H%>10OV<<*F2FUEP*N4:.FEQ\'HP3[5VLL7[H%DIF9KCD;8
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M-+$4PZ^?FA.V"+42!W7M[&@9_ T0D'A/#>ATDO1<.CD[D+E@]^#4LI"S<K^
M.MH TL><NRKVA+^ZQ#L1WO''\RD&_YI+AP[29=P(.>06%3$'A'R\Y'-I+%IU
M]U4M4VJV#:I 94RQ%'3VOP% _K<A+26C9!._*'S-U]QJ6'J>((PM7PR28:0Z
MW SDN6TT9&=*P"5^M_5)!ND1X6S&<.80YPXO1Q_EF8W40!ZJWLMQU.#";FGX
MTO:A_<^!K*N$+XLW-4^W>0TNQ01@_;^L!T.!]VQ0X(C#IYEP>>$:]\SN%BX>
M"@070 &W6<'[#ATRL!U\4W:/ ![?M[)J68:M,U'W<T>AP9SC@.GW =[9=(8Q
MPLQ6L2D9^9OCUVFCM;((%RN2T0R*D% 'FBI04$031>>LQ#K 2D6X#)/?Y<O;
MOX^*_^=1P0UN<YCSN\X5D*%M(K,8!ZY2ZNI6(MT?0;"\*-1'TW&M8L1+2T>%
ME=R(C0H G':J$Y3E(RZHR<)J 9R$SORRYNZVMU<"8]64H])C21+(?1-V+R4Y
M.Z# 7T?)^#O@-0VM9!?&W[V-4,-Q9+ER;6C3:,,-G]2-)E[TD)X[T#KJ6"'2
M\?*+6XKGBB,',9[EWVG9L*"WC388VRC9@8-!E@YLCF]_Z.8%&#E%1<2V_+OA
M-/;/+F ZMO1I5BM@\>.(U7NW<2,AJ&Q)IB!PM4/6^574>G^JP:/=(>E(X<8U
MTN[(]4 Q6E.XM*',ENQ9\T$PJMWQ:F._FFZ^PZ2ZP2UE"A,42#/0@ *-A#Z7
M"<)+:$=V=RC7#?= #VPV'Z[C]'9K6%:HF]PJ8"DLFSR]O)5>?FAG)P^Q=++>
M>LNL/8<;F?KLTY-B$ER"SGYVWY#U-PFP634(E2LKOP>Q9H&5>]Z0B>B 1I.U
M'_DUF3_OGC04>&@0ZK.I,=9PB&1P3QL/RTWX/G^D)E7OA)KU6;NO,V(5D#&.
M&R]!UO+\?'<[IG(-9^QM@VDY:[*Y,5JZU$\R5$9([S9Y2,RY7U6-EPU@6Y+/
MS#-#8O5E8T7OOM.QEC9V4UO"46)]R5G[2$6-9E95].^44W#7I\$V^@[&XO !
M5>D0H_,59Z@F9]M'I4#B4L?"'_+'+\4(12EEOT6]^KJ8M%&G8)C/%5WM:>79
M5MX/L33/Q>)-MA7XX,Z*QD0KY;I0Y;>Z-XO\5H/F;]Y&_L,*3KD#2J^>--K\
M/.E<=UEQG3G1 Y9OM34(?<^B5</CGE91;UC:K'JM5TTOP!(I^R^)%!8%OV12
M21AWS'_F;B=LJTV+E9-NL#$= @5^)1+R+R*'8):8_\F2:L$"_J@>YG9$W(:_
MM43^([*]--TPM%Q?T,-._+NHSYANJ73L*?85A\VM?VOY?1+ZEXC)QDE;XO3"
M4!A\_M9 ?ACH_I<9Y/S'/DG)[ALEV(F_-_V.R:^3BV3Y1_NU>.,'(0O_:/E-
MZ.J_@@7S_R-C#0$.K/[W)N&_0;=G.,MK.OD?@!H)PECZ_RRFO]V53/WUKJ3L
MWWPLOV5:\GFB>3DB5E]SN [&K:L[Q99:;]=]^A$AM692 UV[>-4S@;ZG^ P*
M](E+!YS:W2PU-(<<>41E,W!OIH><*-C3IX< ?Y2JG9O\]3HY%KGC\:6,$Y,4
M-<8?M/880^&]4CR$\'X*K[$8@FM($<G*$\W-G:SZ1ZSPN0L7?< /<=_YJAJ?
M%2S@;^-K&_B>]<FT*SS?'F^W3'=,JZA.HU@\], 9M:/!09_22\;$B3VNOG6<
M4'LY -YFH"=_H>.ES+YW4VUPJ9_0<8?L(GR+6 X%5EP6SHCF)E;N)?''+<_-
MQU0UNAL.ZS@CKS&V?2Y105"@?1,*!&P5^ RZJ< $I&-PSRTYRN!F$'F%/)[[
MO_S^+=C[A9G(F=[^_!&('DTH\&T_&Z:BBH9;V\A+?>T_.V$P=593U'$;<-;M
M_?5,H4>RQX#!I_EX7'B3/Q>6>IF*H !QQCU^7#$4$)U3@ )P-CZ7<^3_NL9_
MY_,-^W8>P]K?@''V:3[]2P>YUP&V.T=0@/+.*M7,6T'\;?%_9=9?NKA/TZF^
M]>DTT,J>2E49V?FW0V2=H?SD0NQZ3*CW.G$M]]\;E;&-^R\G5&%.1,;%KQ7%
M-BQY@,A/27_^(@'>!!0('_JGF3GJ^PWDQ_@3S_Y;C&#N.,,&28V+$.[\3T;)
MOQ&"N%Q"@4_U50JE0KE7%E>@-;N_\N;\#Y)^N\;;$8:QFOC;G]\&'_F_Q;BA
M=.</XQ(8_NT0OV+\\GH.AG'&6M9_8%7VORX1_45=<KC'D%L6)N-[_^K4^P?3
ML)16+?PW+$;N!\!S[X17R75@O*O>ELVR7(#6(O\775?]SQ2<?9?\BQZ%(#!"
M\M+KU?Y!]"V+W)\=,_@M1/Y%?&+ _=Y_K?J_>.;]\D^\_R?#"/_3C[]#-=:P
MR?M?4YB]EO$?B3[__U!:_UU\OU]9SFITP^SY2VQMKT<>Q6N/"8A^MW3820CF
MCG<0<=.9 >!Y$#9Z3CE2'I1H_-)!*:R#Y!EQP[L2GZM+GYLUG^:0]?,G##.-
M"^DA#$F[*/3I[W\OG; )*ZH>"MS7[D&!4]Y\_;]]0 ;*94G+__N7A4 Y/Y^4
MQ/S3DY(<RI<KV\]N&2\39L3'.(,Y"3EFN*ID'VJO+Z;!=P>Y&,<,+/6I#X-7
M:L9/=Z0EC%*VZ9/,"=7M,3>M>+/B^(-;E6N-1(N;68GC!U=RSK-&]NM;\J86
MK$^$^@2<K/NY;=Y,#BP9:&'8**2.B)7;/=SR.4RU_*']U;96T"='VJ+*6AHU
MC7+1D>]%(P44P/[D[>!ON.1ANU=V(@0V-G;++=PAUO&[R48,R67$*3#\\C@K
M:.#'>J&%$$>BV)':?H&U^G[W^5(A34G4(?>^6?A8<4N:+3&)GZ28XM2EOXSF
MZ=<S/3)0S]U3SI"YC$JL-KX,O#"9&NDKZ8YN"1%@!6Q^,ZI1W5O'+5X[6J[E
M?&A<!G*.EOW*+*U:(75_(P0GX-R($/.>E[,.MB;(Y!8B'TF4KBT?9;;C)%S&
MMQH@RI1&X?<(6<29.6&E=MY*Z!QQV6)R29RYN7'PQLLB&=)OJ^EA*\AVPC5,
M+B!&P\!X2(*E?:[_HG3(\(?_R^%]*EG97%LBV<2"+KX>S,^;,O23KKY^=7PG
MK^ZR[H8DXW/5!YHNB++&,K6Y<BU]<'O7)_O*EQ]W%2<A8WQ[WT2,/N*?9.2[
MQ"-<"CZ3.)*(X^@RXP*[!$M%O(&;*C5;)Z#8A[=E'S!V$+ \]Y9H=H\H\D(O
MBV0H3,LAE(T+CU(%'H37!/<_$AKK)Q4A1Q%+NQ+H<)]XY^JYSBE7"8N)#:&S
MDO-(GT'RYYS4ATGG"LZ<?<H]4A&HD!(MV@6*!-7VNS2<9'^&>(&W+;G9W/[[
M8)L#9I=P^1Y92$DMGHI P;!I-[*R+QQSEKPH:54^7WR(<YWG\L:-DU2U._HJ
M) X*F%9IK@9)0]Z^UI(RI1'M!/Q3M=,*W>/DG.2KR^/Z*"R+ J:O;&*#\>!0
M7L&M+JDZ*O"D>6F _%=UGO0MWH32C6* \[0U=:;T4-GME:65I5'LE+F>/0^0
MXD\D]33G^5'_?S7WUE%M?=V?<) B7[04+5Z"%'<I#L5;W(,6#2%H<8<"+>X4
MBA1W)P270G$I!&N"N[L4*'1X=-[YO<]:[SNSULR:_).[3C[[L_<ZY]YS]M[W
MG!U26">BG8/\2^DW9'&#X ]^WH /E>%Z84^#L?B.LZ9K?PW/^"NX5WV!JB/!
M9BPO[7R?LKR.I1A)-<*Q8589?\5'67KPV]0&$RFYD"F 5\5^!?F<AALJ9Y6F
MP3O06,:$N4*S3KG6&#AW"W<^YUAXZ'@S*,@A5KT)=R8QY$EO=%;>2E6C:T9&
M;NKT!.9D5*FT<SB#5\>0L,OJ9!]HA8GAPMN7/B*.<?SEY<%):)Q>5GFW?TU,
M>?QZ?X]VT6+5^3$ZM[%REL+<#JS^HPTH"BSM5Q2C<C:>FI$P*MCO/_6 DN]:
M-4_;3(<9+X8G"2<^5;5)".UBU188O![G0;K[^']H<33(_7:.W)GSK'%LV!LI
M1R)E3J0V,YC#%SWI/H@,RCZ8S'!,$ IU5&W,ME85Y['DQC<I %S>48<>:0]C
M1E$&JUX,'K@;OUU_-^;.O[N%M#\ZY+XX9GE35 :7I['O">%N4YY@2)+<XX)\
MST5ZBFCVLE07'_:JT([G3_62;#,_=1%!=[T^#\8.=$B'=7Z]P;^# E3R>BN6
M]IJ0_A3\*F1=V30QS-;]*T:D'^ZZ"18#LQ!5_J_FD*_3TWRS&^>>@CH02'9E
MRA?XS4L&EB[\JMM?I55AJ\<DQO::=@?79VIIYPQJM5S</3O,'\L&:44EXM5A
MOO34LJ1&=[0/UPC06S_KCI_VP=^LSDDD.X(^ABH/L7;AMJ9[FB>D\VC=PB,%
M[UN=,@HG;#Y?[%Q2[]^0VUCKRWS_(D'&/*.GYV5'!\-*7!6GCLY@;I_)3W^3
M].T(XM>\GD(D3'E-9H-J4=TT#!7#M!(KA4I8"A57<Z^'&JXFJT6J95MF#3#J
M*E!/=M^ W#@(<0[<")0ES"FN"GE>.:3/XD%<(2\6EX\S?F^PC1?&?I1A O"(
M;@N1EZ=&M?.X\],3+)F8VU_-GO>R.^R84=W@A!BEO;VAHA9."JCUFX'2*R4;
MM3;'47^(HK:GVP)G4#7U%:+WZ));G1,"CL<!0C^,'!)V']"GNW'HMC;SIF:*
M"21P7QRVO,.6T;(R2>!7&?#=?N^'@DK] 1Q2H%\JFR^.6+ENO,4+\E''D;"V
MN)TI8<D@CZHK@ZRV>. 955U\XKQ4\D-![*NM[.0S2!3[*0& >37R#2CE^F/X
MQK&-[)C-J '?QCQ=Z $SR0&UZU4W=5=32-J?-;M C'FHVY'M4 @$GXAYK.+F
M>NJ4(4J,R4I,CXJ;6?PS6OQL2=);^E[C)X/P^CN)<P=R@Z>@S@*RA;B$-G'
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M0U65#4V6,0Q='B-!=N.YNIL*,'E(JE%+!B^)4);A[CEI?:W-N\I7Q"X*S*0
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MO8YNLR34()W(M?ZQZNV\Q&!I 9/HA&!(2A(&NI*#!1=I>&K@.=IET>!V3@I
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M6(B-C1=F.D5(4.,A]$6;'K7,V;;2IA758H+,QK;H>N09,IZKW[5?D9!(:]?
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MM3=X."8QN !,_Y%I.R:)]:B\3?C<'L1>1>&X9.]-P7O^J*"T:1^H:0Z2Q:2
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M%^_(FRXG8*<K[NN!FCOWJY5)I=SFIKDAA>189P\1;[CQF3L*B.5[B0+,^5#
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M.('O2(0R27M/LHR.KCH?QIJZ-W8M0RY%5X?CXG/_B5+*P",/<-IUP.;S@8>
M!>U8N6?LY4XB82TZ9HK@9=$WO-!KHU]Q3*AC QA*,R9LUN9V2[_[O+8Q^!&L
MC#4:_7QEOBU441YK)X]]4X]^9P;:@TDSIUM'M2%NL?70A=7BH60E]MWP3_"8
M#^4.R:]V] K*,+"2:FPI!V&WL<)072_-EAO7N^LY'<Z*'XX<L^<'<8Z-NFN*
MLZ8:IH)RYCS*7S[VSX+ZT'Z_%>:B08EZU7=CQ4L@7SMBUUMDBHM"^3?K=U<:
M-F/<^EW6Q_*E50@28B7SK+(?/)XHB(W2DBN1[>DJPP$5L+Q%2)"(7&DM(4K-
MAUYN5Q43<(DBS/38+V'99=NZ^CUZP%&=NMAV]E/J5U&+B!\T\#%Q/;>?&:5S
M%TFA)@J1I9,TY7%5<CX NTM9%'1IY+-Z'HY?B8"+_OE1=8&[V-G9T:GA_Z\)
MY=J4"0HIO)*,7_,8^\=R_[\ B+J_G3Z'W#M>YOZ!/4D/"RAB*%N"Q9X0>!O/
M5\EPF6W="[R*@J-%M8Q;C\UU"17OJ<0_(81$NF&$G\Q8:E6#0H6S$^%D8O.I
M;KF]<V3>8*#R+$W3]R9$<X%DW!ZR4O0-):@HLYU]('ZG -JMYH[G?]E.6:<S
M DLF&3(T)]KE@Z.X+MVCL;"W>\*L^K+!:"6*P"*VU&R;W25#S5P[24;/7(6)
M"?V>?,7JYA33 ]Z2XVV@DC\B:GI $.QD5AIE.(V7O<4+/O/)L8J2NJO2:U@W
ML:8RL7/)/9OQZ/?5OZ!SI.]B2YZ5#TS<ZL^#=MJR0!B\8<Y?42.#;=#<,)GU
M4[9,J4Y31 ^)@Q#.W>&45#[V-_A^,'3Y&T^8RQ]&$+^P< MCX!FC:$LFW3FK
MJW,.FB_Z5%80YYR2JI68^:*H-R,GA5PT*X)RRK3-]_<@:CI@)0X^FH,^+DO2
M6S2EA+)Z;X$3 (Q^DVMN%.>M3(' O(E# #)K9& H9"QXP8PYQ#]""CDB_^+/
MM  ( 83TW'9&SPA5!;)<]/=Q2W:820>WB6OD:S_=.S9U.OYA@UJ"P2& %&B$
MK?LZ.1D(I0IP9Z<@'("WH27L"MAG+O&>]1L#/A='7A^MJ"KP]"& "@^'$2L\
MK=#1L<V6/Z&=E!(DR:1%X8?)]MO$LLGM0IM?R])+$Q:"59^^?]VD=3]^G6K[
MS=Z: 2310CWR.)+-W8TLK?E.HK0K42TG+^2Z!JE*B&[W/J.[HN9EXCM#LJ&<
MO/\Z5;9RUZ*O+I2Z#.%ER;YM"@!Q(2\O CZCB#R[!W*]6Z?^JD.H/=T]]>$2
MR\+5"_SE?6:*MG+;F I10HW3C0"$IT4?O:=GX"WS0Y;EDVVE6S72MLDC&LFY
M5!+]P-AY#WY]5OO<X"7>SX> 5!TI1-4<.7= 77E7W9*/TCJP-@T*>5^XV5"\
M;87XLA<=.DE9+W\KI#S2$P\T\>';GW-J.03P,\H'T2)%*:U^S."G!D:A-P?
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M"G0A\2M(X/HAOP/\+OBH[$WXM5+A"$+C@J'O_ 1A[@8^+&_T0P)2[B@D$.B
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M9!@$7Z\O]&:7HSRQ&>3666GUZ2ES(3[HF+H9"90Y@7?/LM3I47US%[<N$4C
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M6T'?\)Y[@T"B5K,[UZ4S^M?9'0--1;>;IG3*+ +GF>_:*.A>G=&%/9LU])2
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M5**BZ/$;A4[0;*)-J.1:X<J)>'PZI5-2DZ^6'SI B_X#E6:>%TMB BP_:$(
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M_O0^ E!+ 0(4 Q0    ( "V"KUAP&OY#6 X  $^)   0              "
M 0    !C=FTM,C R-# S,S$N>'-D4$L! A0#%     @ +8*O6*^SB\G?#
MGX\  !0              ( !A@X  &-V;2TR,#(T,#,S,5]C86PN>&UL4$L!
M A0#%     @ +8*O6*):W-F]$P  ^A@! !0              ( !EQL  &-V
M;2TR,#(T,#,S,5]D968N>&UL4$L! A0#%     @ +8*O6!F-4H=Z0   :48#
M !0              ( !AB\  &-V;2TR,#(T,#,S,5]L86(N>&UL4$L! A0#
M%     @ +8*O6++RR[B(,   WXD" !0              ( !,G   &-V;2TR
M,#(T,#,S,5]P<F4N>&UL4$L! A0#%     @ +8*O6%,'#V0KOP  @@@*  L
M             ( ![*   &-V;5\Q,'$N:'1M4$L! A0#%     @ +8*O6,#@
M^"!X:   V7P  !               ( !0& ! &-V;5\Q,'%I;6<Q,"YJ<&=0
M2P$"% ,4    "  M@J]8%;,W((%"  !_30  $               @ 'FR $
M8W9M7S$P<6EM9S$Q+FIP9U!+ 0(4 Q0    ( "V"KU@XX12.BVD  .UV   0
M              "  94+ @!C=FU?,3!Q:6UG,3(N:G!G4$L! A0#%     @
M+8*O6,UGV7B,6   ]&0  !               ( !3G4" &-V;5\Q,'%I;6<Q
M,RYJ<&=02P$"% ,4    "  M@J]8)%-V58E^  !'C@  $
M@ $(S@( 8W9M7S$P<6EM9S$T+FIP9U!+ 0(4 Q0    ( "V"KUC!S1(O[TL
M 'I6   /              "  ;], P!C=FU?,3!Q:6UG."YJ<&=02P$"% ,4
M    "  M@J]8?B;:<J=.   V5@  #P              @ ';F , 8W9M7S$P
M<6EM9SDN:G!G4$L! A0#%     @ +8*O6,U5(XKT!P  ^%@   P
M     ( !K^<# &-V;5]E>#,Q+FAT;5!+ 0(4 Q0    ( "V"KU@GAW6HK ,
M %H2   ,              "  <WO P!C=FU?97@S,BYH=&U02P4&      \
,#P"C P  H_,#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>cvm_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cvm="http://cvm.com/20240331"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cvm-20240331.xsd" xlink:type="simple"/>
    <context id="From2023-10-01to2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-08_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-08</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-03-31_cvm_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-03-31_cvm_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-03-31_cvm_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-03-31_cvm_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-01to2023-01-11_cvm_LandlordMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-11</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-03-31_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-03-31_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-10-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-28</endDate>
        </period>
    </context>
    <context id="From2023-01-01to2023-03-31_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-02-01to2024-02-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="From2023-11-01to2023-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-01to2023-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-03-31_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-03-31_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2022-10-28_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-28</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-03-31_cvm_SeriesSSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesSSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MinimumMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_ConsultantsOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-10-01to2024-03-31_srt_MaximumMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-03-31_srt_MinimumMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-03-31_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-03-31_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-03-31_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-03-31_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-03-31_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-03-31_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-03-31_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-01to2023-03-31_cvm_NonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_cvm_NonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-03-31_cvm_NonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-03-31_cvm_NonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-03-31_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-03-31_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-01to2023-03-31_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_cvm_IncentiveStockBonusPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:IncentiveStockBonusPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_cvm_StockBonusPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-01to2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-10-01to2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-01to2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-05-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-10-01to2024-03-31" id="ixv-7010">0000725363</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-10-01to2024-03-31" id="ixv-7011">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-10-01to2024-03-31" id="ixv-7012">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-10-01to2024-03-31" id="ixv-7013">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2023-10-01to2024-03-31" id="ixv-7014">2024</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="ixv-7015"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="ixv-7016"
      unitRef="Shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-7017"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="ixv-7018"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-7019"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="ixv-7020"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-7021"
      unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="ixv-7022"
      unitRef="Shares">54083718</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-7023"
      unitRef="Shares">47422304</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="ixv-7024"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="ixv-7025"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="ixv-7026"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="ixv-7027"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <cvm:NetOfDiscount
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="ixv-7028"
      unitRef="USD">11900000.0</cvm:NetOfDiscount>
    <cvm:NetOfDiscount
      contextRef="From2022-10-01to2023-03-31_cvm_ErgomedMember"
      decimals="0"
      id="ixv-7029"
      unitRef="USD">11900000.0</cvm:NetOfDiscount>
    <cvm:OperatingLeaseWeightedAverageRemainingLeaseTermOne contextRef="From2024-01-01to2024-03-31" id="ixv-7030">P4Y7M2D</cvm:OperatingLeaseWeightedAverageRemainingLeaseTermOne>
    <cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="ixv-7031"
      unitRef="Shares">45581381</cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted>
    <dei:DocumentType contextRef="From2023-10-01to2024-03-31" id="ixv-7767">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2023-10-01to2024-03-31" id="ixv-7768">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-10-01to2024-03-31" id="ixv-7769">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2023-10-01to2024-03-31" id="ixv-7770">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-10-01to2024-03-31" id="ixv-7771">001-11889</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-10-01to2024-03-31" id="ixv-7772">CEL-SCI CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-10-01to2024-03-31" id="ixv-7773">CO</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-10-01to2024-03-31" id="ixv-7774">84-0916344</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-10-01to2024-03-31" id="ixv-7775">8229 Boone Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-10-01to2024-03-31" id="ixv-7776">Suite 802</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-10-01to2024-03-31" id="ixv-7777">Vienna</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-10-01to2024-03-31" id="ixv-7778">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-10-01to2024-03-31" id="ixv-7779">22182</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-10-01to2024-03-31" id="ixv-7780">703</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-10-01to2024-03-31" id="ixv-7781">506-9460</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-10-01to2024-03-31" id="ixv-7782">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-10-01to2024-03-31" id="ixv-7783">CVM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-10-01to2024-03-31" id="ixv-7784">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2023-10-01to2024-03-31" id="ixv-7785">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-10-01to2024-03-31" id="ixv-7786">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-10-01to2024-03-31" id="ixv-7787">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-10-01to2024-03-31" id="ixv-7788">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-10-01to2024-03-31" id="ixv-7789">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2023-10-01to2024-03-31" id="ixv-7790">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-05-09"
      decimals="INF"
      id="ixv-7791"
      unitRef="Shares">54159937</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_1"
      unitRef="USD">5309321</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2"
      unitRef="USD">4145735</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_3"
      unitRef="USD">696648</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_4"
      unitRef="USD">520368</us-gaap:PrepaidExpenseCurrent>
    <cvm:SuppliesUsedForRDAndManufacturingCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_5"
      unitRef="USD">2489284</cvm:SuppliesUsedForRDAndManufacturingCurrent>
    <cvm:SuppliesUsedForRDAndManufacturingCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_6"
      unitRef="USD">2248072</cvm:SuppliesUsedForRDAndManufacturingCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_7"
      unitRef="USD">16129</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_8"
      unitRef="USD">4245</us-gaap:DepositsAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_9"
      unitRef="USD">8511382</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_10"
      unitRef="USD">6918420</us-gaap:AssetsCurrent>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_11"
      unitRef="USD">8251453</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_12"
      unitRef="USD">9131987</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_13"
      unitRef="USD">1598879</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_14"
      unitRef="USD">1698243</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_15"
      unitRef="USD">9113284</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_16"
      unitRef="USD">10188126</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_17"
      unitRef="USD">180482</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_18"
      unitRef="USD">197704</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DepositsAssets
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_159"
      unitRef="USD">2319101</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_158"
      unitRef="USD">2319101</us-gaap:DepositsAssets>
    <cvm:SuppliesUsedForRDAndManufacturingNonCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_160"
      unitRef="USD">73524</cvm:SuppliesUsedForRDAndManufacturingNonCurrent>
    <cvm:SuppliesUsedForRDAndManufacturingNonCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_161"
      unitRef="USD">74669</cvm:SuppliesUsedForRDAndManufacturingNonCurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_23"
      unitRef="USD">30048105</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_24"
      unitRef="USD">30528250</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_27"
      unitRef="USD">1015969</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_28"
      unitRef="USD">2009786</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_29"
      unitRef="USD">1219399</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_30"
      unitRef="USD">1049581</us-gaap:AccruedLiabilitiesCurrent>
    <cvm:DueToEmployeeCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_31"
      unitRef="USD">751607</cvm:DueToEmployeeCurrent>
    <cvm:DueToEmployeeCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_32"
      unitRef="USD">557244</cvm:DueToEmployeeCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_33"
      unitRef="USD">1888767</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_34"
      unitRef="USD">1771804</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_35"
      unitRef="USD">211275</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_36"
      unitRef="USD">197431</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_37"
      unitRef="USD">5087017</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_38"
      unitRef="USD">5585846</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_39"
      unitRef="USD">8987319</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_40"
      unitRef="USD">9949565</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_41"
      unitRef="USD">1544126</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_42"
      unitRef="USD">1652949</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_43"
      unitRef="USD">125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_44"
      unitRef="USD">125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_45"
      unitRef="USD">15743462</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_46"
      unitRef="USD">17313360</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="fid_141"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_143"
      unitRef="Shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_146"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_48"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_49"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="fid_149"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_152"
      unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_153"
      unitRef="Shares">54083718</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_154"
      unitRef="Shares">47422304</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_50"
      unitRef="USD">540837</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_51"
      unitRef="USD">474223</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_52"
      unitRef="USD">514809617</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_53"
      unitRef="USD">499832063</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_54"
      unitRef="USD">-501045811</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_55"
      unitRef="USD">-487091396</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_56"
      unitRef="USD">14304643</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_57"
      unitRef="USD">13214890</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_58"
      unitRef="USD">30048105</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_59"
      unitRef="USD">30528250</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_61"
      unitRef="USD">8981044</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_62"
      unitRef="USD">11476034</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_63"
      unitRef="USD">4580791</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_64"
      unitRef="USD">4350761</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_65"
      unitRef="USD">13561835</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_66"
      unitRef="USD">15826795</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_67"
      unitRef="USD">-13561835</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_68"
      unitRef="USD">-15826795</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_69"
      unitRef="USD">380397</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_70"
      unitRef="USD">311852</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_71"
      unitRef="USD">12183</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_72"
      unitRef="USD">57671</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_73"
      unitRef="USD">-13954415</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_74"
      unitRef="USD">-16196318</us-gaap:NetIncomeLoss>
    <cvm:ModificationOfWarrants
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_75"
      unitRef="USD">0</cvm:ModificationOfWarrants>
    <cvm:ModificationOfWarrants
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_76"
      unitRef="USD">-171552</cvm:ModificationOfWarrants>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_77"
      unitRef="USD">-13954415</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_78"
      unitRef="USD">-16367870</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <cvm:EarningPerShareBasicAndDiluted
      contextRef="From2023-10-01to2024-03-31"
      decimals="INF"
      id="fid_79"
      unitRef="USDPShares">-0.28</cvm:EarningPerShareBasicAndDiluted>
    <cvm:EarningPerShareBasicAndDiluted
      contextRef="From2022-10-01to2023-03-31"
      decimals="INF"
      id="fid_80"
      unitRef="USDPShares">-0.38</cvm:EarningPerShareBasicAndDiluted>
    <cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_81"
      unitRef="Shares">50228860</cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted>
    <cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_82"
      unitRef="Shares">43513571</cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_121"
      unitRef="USD">4628535</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_122"
      unitRef="USD">6083488</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_123"
      unitRef="USD">2447413</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_124"
      unitRef="USD">2092758</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_125"
      unitRef="USD">7075948</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_126"
      unitRef="USD">8176246</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_127"
      unitRef="USD">-7075948</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_128"
      unitRef="USD">-8176246</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_129"
      unitRef="USD">182701</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_130"
      unitRef="USD">159063</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_131"
      unitRef="USD">13758</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_132"
      unitRef="USD">7500</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_133"
      unitRef="USD">-7244891</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_134"
      unitRef="USD">-8342809</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_135"
      unitRef="USD">-7244891</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_136"
      unitRef="USD">-8342809</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <cvm:EarningPerShareBasicAndDiluted
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="fid_137"
      unitRef="USDPShares">-0.14</cvm:EarningPerShareBasicAndDiluted>
    <cvm:EarningPerShareBasicAndDiluted
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      id="fid_138"
      unitRef="USDPShares">-0.19</cvm:EarningPerShareBasicAndDiluted>
    <cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_139"
      unitRef="Shares">52006442</cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted>
    <cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_140"
      unitRef="Shares">43588381</cvm:WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_508"
      unitRef="Shares">47422304</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_509"
      unitRef="USD">474223</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_510"
      unitRef="USD">499832063</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_511"
      unitRef="USD">-487091396</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_512"
      unitRef="USD">13214890</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_513"
      unitRef="Shares">17724</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_514"
      unitRef="USD">177</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_515"
      unitRef="USD">48730</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_516"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_517"
      unitRef="USD">48907</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_518"
      unitRef="Shares">88573</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_519"
      unitRef="USD">886</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_520"
      unitRef="USD">201421</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_521"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_522"
      unitRef="USD">202307</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_523"
      unitRef="Shares">2490000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_524"
      unitRef="USD">24900</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_525"
      unitRef="USD">4955100</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_526"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_527"
      unitRef="USD">4980000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_528"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_529"
      unitRef="USD">1383909</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_530"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_531"
      unitRef="USD">1383909</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cvm:ShareIssuanceCosts
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_532"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_533"
      unitRef="USD">-470229</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_534"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_535"
      unitRef="USD">-470229</cvm:ShareIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_536"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_537"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_538"
      unitRef="USD">-6709524</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2023-12-31"
      decimals="0"
      id="fid_539"
      unitRef="USD">-6709524</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_540"
      unitRef="Shares">50018601</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_541"
      unitRef="USD">500186</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_542"
      unitRef="USD">505950994</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_543"
      unitRef="USD">-493800920</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_544"
      unitRef="USD">12650260</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_545"
      unitRef="Shares">27373</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_546"
      unitRef="USD">274</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_547"
      unitRef="USD">53211</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_548"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_549"
      unitRef="USD">53485</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_550"
      unitRef="Shares">162744</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_551"
      unitRef="USD">1627</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_552"
      unitRef="USD">379243</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_553"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_554"
      unitRef="USD">380870</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_555"
      unitRef="Shares">3875000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_556"
      unitRef="USD">38750</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_557"
      unitRef="USD">7711250</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_558"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_559"
      unitRef="USD">7750000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_560"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_561"
      unitRef="USD">1432540</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_562"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_563"
      unitRef="USD">1432540</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cvm:ShareIssuanceCosts
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_564"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_565"
      unitRef="USD">-717621</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_566"
      unitRef="USD">0</cvm:ShareIssuanceCosts>
    <cvm:ShareIssuanceCosts
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_567"
      unitRef="USD">-717621</cvm:ShareIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_568"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_569"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_570"
      unitRef="USD">-7244891</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_571"
      unitRef="USD">-7244891</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_572"
      unitRef="Shares">54083718</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_573"
      unitRef="USD">540837</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_574"
      unitRef="USD">514809617</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_575"
      unitRef="USD">-501045811</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_576"
      unitRef="USD">14304643</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_577"
      unitRef="Shares">43448317</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_578"
      unitRef="USD">434484</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_579"
      unitRef="USD">486625816</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_580"
      unitRef="USD">-454897093</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_581"
      unitRef="USD">32163207</us-gaap:StockholdersEquity>
    <cvm:WarrantExercisesShares
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_582"
      unitRef="Shares">217752</cvm:WarrantExercisesShares>
    <cvm:WarrantExercisesAmount
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_583"
      unitRef="USD">2177</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_584"
      unitRef="USD">445114</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_585"
      unitRef="USD">0</cvm:WarrantExercisesAmount>
    <cvm:WarrantExercisesAmount
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_586"
      unitRef="USD">447291</cvm:WarrantExercisesAmount>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_587"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_588"
      unitRef="USD">1703931</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_589"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_590"
      unitRef="USD">1703931</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_591"
      unitRef="Shares">21331</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_592"
      unitRef="USD">213</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_593"
      unitRef="USD">49965</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_594"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_595"
      unitRef="USD">50178</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_596"
      unitRef="Shares">40236</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_597"
      unitRef="USD">402</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_598"
      unitRef="USD">91221</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_599"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_600"
      unitRef="USD">91623</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <cvm:IncentiveStockForfeitedShares
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_601"
      unitRef="Shares">-2000</cvm:IncentiveStockForfeitedShares>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_602"
      unitRef="USD">-20</cvm:IncentiveStockForfeitedAmount>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_603"
      unitRef="USD">-11080</cvm:IncentiveStockForfeitedAmount>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_604"
      unitRef="USD">0</cvm:IncentiveStockForfeitedAmount>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_605"
      unitRef="USD">-11100</cvm:IncentiveStockForfeitedAmount>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_606"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_607"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_608"
      unitRef="USD">-7853509</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2022-12-31"
      decimals="0"
      id="fid_609"
      unitRef="USD">-7853509</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_610"
      unitRef="Shares">43725636</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_611"
      unitRef="USD">437256</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_612"
      unitRef="USD">488904967</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_613"
      unitRef="USD">-462750602</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="fid_614"
      unitRef="USD">26591621</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_615"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_616"
      unitRef="USD">1743288</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_617"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_618"
      unitRef="USD">1743288</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_619"
      unitRef="Shares">23627</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_620"
      unitRef="USD">236</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_621"
      unitRef="USD">54629</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_622"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_623"
      unitRef="USD">54865</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_624"
      unitRef="Shares">38562</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_625"
      unitRef="USD">386</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_626"
      unitRef="USD">100249</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_627"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_628"
      unitRef="USD">100635</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_629"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_630"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_631"
      unitRef="USD">-8342809</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_632"
      unitRef="USD">-8342809</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_633"
      unitRef="Shares">43787825</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_634"
      unitRef="USD">437878</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_635"
      unitRef="USD">490803133</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_636"
      unitRef="USD">-471093411</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="fid_637"
      unitRef="USD">20147600</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_162"
      unitRef="USD">-13954415</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_163"
      unitRef="USD">-16196318</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_165"
      unitRef="USD">1993395</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_166"
      unitRef="USD">1973982</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherNoncashExpense
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_167"
      unitRef="USD">4383</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_168"
      unitRef="USD">9545</us-gaap:OtherNoncashExpense>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_169"
      unitRef="USD">547893</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_170"
      unitRef="USD">285722</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_171"
      unitRef="USD">2816449</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_172"
      unitRef="USD">3436119</us-gaap:ShareBasedCompensation>
    <cvm:CommonStockContributedToEmployeeBenefitPlan
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_173"
      unitRef="USD">102392</cvm:CommonStockContributedToEmployeeBenefitPlan>
    <cvm:CommonStockContributedToEmployeeBenefitPlan
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_174"
      unitRef="USD">105043</cvm:CommonStockContributedToEmployeeBenefitPlan>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_176"
      unitRef="USD">-30996</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_177"
      unitRef="USD">180222</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_178"
      unitRef="USD">240067</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_179"
      unitRef="USD">170434</us-gaap:IncreaseDecreaseInInventories>
    <cvm:IncreaseDecreaseInDepositAssets
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_180"
      unitRef="USD">-11884</cvm:IncreaseDecreaseInDepositAssets>
    <cvm:IncreaseDecreaseInDepositAssets
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_181"
      unitRef="USD">-2354723</cvm:IncreaseDecreaseInDepositAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_183"
      unitRef="USD">-896939</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_184"
      unitRef="USD">102841</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_185"
      unitRef="USD">59818</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_186"
      unitRef="USD">111515</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_187"
      unitRef="USD">194363</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_188"
      unitRef="USD">37798</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_189"
      unitRef="USD">-9415608</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_190"
      unitRef="USD">-12137820</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_192"
      unitRef="USD">51650</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_193"
      unitRef="USD">165032</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_194"
      unitRef="USD">13211</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_195"
      unitRef="USD">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_196"
      unitRef="USD">-64861</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_197"
      unitRef="USD">-165032</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_199"
      unitRef="USD">12730000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_200"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_201"
      unitRef="USD">1218937</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_202"
      unitRef="USD">9010</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_203"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_204"
      unitRef="USD">447291</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_205"
      unitRef="USD">867008</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_206"
      unitRef="USD">761223</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_207"
      unitRef="USD">10644055</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_208"
      unitRef="USD">-322942</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_209"
      unitRef="USD">1163586</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_210"
      unitRef="USD">-12625794</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_211"
      unitRef="USD">4145735</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_212"
      unitRef="USD">22672138</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_213"
      unitRef="USD">5309321</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-03-31"
      decimals="0"
      id="fid_214"
      unitRef="USD">10046344</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_230"
      unitRef="USD">0</cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities>
    <cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_231"
      unitRef="USD">176743</cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities>
    <cvm:AssetsPurchasedUnderFinanceLeases
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_232"
      unitRef="USD">20797</cvm:AssetsPurchasedUnderFinanceLeases>
    <cvm:AssetsPurchasedUnderFinanceLeases
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_233"
      unitRef="USD">0</cvm:AssetsPurchasedUnderFinanceLeases>
    <cvm:FinanceLeaseObligationIncludedInAccountsPayable
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_234"
      unitRef="USD">522</cvm:FinanceLeaseObligationIncludedInAccountsPayable>
    <cvm:FinanceLeaseObligationIncludedInAccountsPayable
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_235"
      unitRef="USD">1402</cvm:FinanceLeaseObligationIncludedInAccountsPayable>
    <cvm:ConsultingServicesPaidWithIssuanceOfCommonStock
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_236"
      unitRef="USD">583177</cvm:ConsultingServicesPaidWithIssuanceOfCommonStock>
    <cvm:ConsultingServicesPaidWithIssuanceOfCommonStock
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_237"
      unitRef="USD">192258</cvm:ConsultingServicesPaidWithIssuanceOfCommonStock>
    <cvm:AccruedConsultingServicesToBePaidWithCommonStock
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_238"
      unitRef="USD">165000</cvm:AccruedConsultingServicesToBePaidWithCommonStock>
    <cvm:AccruedConsultingServicesToBePaidWithCommonStock
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_239"
      unitRef="USD">165000</cvm:AccruedConsultingServicesToBePaidWithCommonStock>
    <cvm:FinancingCostsIncludedInCurrentLiabilities
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_240"
      unitRef="USD">46616</cvm:FinancingCostsIncludedInCurrentLiabilities>
    <cvm:FinancingCostsIncludedInCurrentLiabilities
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_241"
      unitRef="USD">0</cvm:FinancingCostsIncludedInCurrentLiabilities>
    <us-gaap:InterestPaidNet
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_242"
      unitRef="USD">480044</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_243"
      unitRef="USD">547765</us-gaap:InterestPaidNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_251">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;A. &lt;span style="text-decoration:underline"&gt;BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The accompanying condensed financial statements of CEL-SCI Corporation (the &#x201c;Company&#x201d;) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#x2019;s annual report on Form 10-K for the year ended September 30, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments (all of which are of a normal recurring nature) and disclosures necessary for a fair presentation of the Company&#x2019;s financial position as of March 31, 2024 and the results of its operations for the six months then ended. The condensed balance sheet as of September 30, 2023 is derived from the September 30, 2023 audited financial statements.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Summary of Significant Accounting Policies:&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Cash and Cash Equivalents &lt;/em&gt;&#x2013; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Supplies used for R&amp;amp;D and manufacturing &#x2013;&lt;/em&gt; Supplies are consumable items kept on hand to support the Company&#x2019;s R&amp;amp;D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Patents&lt;/em&gt; &#x2013; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Leases &#x2013; &lt;/em&gt;The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Share-Based Compensation&lt;/em&gt; &#x2013; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &lt;em&gt;Compensation &#x2013; Stock Compensation&lt;/em&gt; (&#x201c;ASC 718&#x201d;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#x201c;Plans&#x201d;. All Plans have been approved by the Company&#x2019;s stockholders.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company&#x2019;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#x2019;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; &#x2013; Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#x201c;CRO&#x201d;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Net Loss Per Common Share&lt;/em&gt; &#x2013; The Company calculates net loss per common share in accordance with ASC 260, &lt;em&gt;Earnings Per Share&lt;/em&gt;. Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company accounts for income taxes in accordance with the provisions of ASC 740, &lt;em&gt;Income Taxes&lt;/em&gt;, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of March 31, 2024 and September 30, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Impairment of long-lived assets&lt;/em&gt; &#x2013; CEL-SCI&#x2019;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#x2019;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Recently Adopted Accounting Standards&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update No. 2016-13,&lt;em&gt; Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;). &lt;/em&gt;ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no impact on the Company&#x2019;s financial position, results of operations, or cash flows.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;New Accounting Pronouncements&lt;/em&gt; &#x2013; The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_252">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Cash and Cash Equivalents &lt;/em&gt;&#x2013; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_253">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_254">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Supplies used for R&amp;amp;D and manufacturing &#x2013;&lt;/em&gt; Supplies are consumable items kept on hand to support the Company&#x2019;s R&amp;amp;D and manufacturing operations. Supplies are recorded at cost and are charged to expense as they are used in operations.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2023-10-01to2024-03-31" id="fid_255">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Patents&lt;/em&gt; &#x2013; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <cvm:LeasesPolicyTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_256">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Leases &#x2013; &lt;/em&gt;The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material.&lt;/p&gt;</cvm:LeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-10-01to2024-03-31" id="fid_257">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Share-Based Compensation&lt;/em&gt; &#x2013; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, &lt;em&gt;Compensation &#x2013; Stock Compensation&lt;/em&gt; (&#x201c;ASC 718&#x201d;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#x201c;Plans&#x201d;. All Plans have been approved by the Company&#x2019;s stockholders.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company&#x2019;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#x2019;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-10-01to2024-03-31" id="fid_258">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; &#x2013; Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (&#x201c;CRO&#x201d;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_259">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Net Loss Per Common Share&lt;/em&gt; &#x2013; The Company calculates net loss per common share in accordance with ASC 260, &lt;em&gt;Earnings Per Share&lt;/em&gt;. Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_260">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company accounts for income taxes in accordance with the provisions of ASC 740, &lt;em&gt;Income Taxes&lt;/em&gt;, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of March 31, 2024 and September 30, 2023.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <cvm:ImpairmentOfLongLivedAssetsPolicyTextblock contextRef="From2023-10-01to2024-03-31" id="fid_261">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Impairment of long-lived assets&lt;/em&gt; &#x2013; CEL-SCI&#x2019;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#x2019;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.&lt;/p&gt;</cvm:ImpairmentOfLongLivedAssetsPolicyTextblock>
    <us-gaap:UseOfEstimates contextRef="From2023-10-01to2024-03-31" id="fid_262">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <cvm:NewAccountingPronouncementEarlyAdoptionPolicyTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_263">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Recently Adopted Accounting Standards&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update No. 2016-13,&lt;em&gt; Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;). &lt;/em&gt;ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no impact on the Company&#x2019;s financial position, results of operations, or cash flows.&lt;/p&gt;</cvm:NewAccountingPronouncementEarlyAdoptionPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_264">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;New Accounting Pronouncements&lt;/em&gt; &#x2013; The Company has considered all recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <cvm:LiquidityDisclosureTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_244">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;B. &lt;span style="text-decoration:underline"&gt;LIQUIDITY&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company&#x2019;s lead investigational therapy, to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase 3 study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Due to the Company&#x2019;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;</cvm:LiquidityDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_245">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;C. &lt;span style="text-decoration:underline"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Proceeds from the Sale of Common Stock&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In February 2024, the Company sold 3,875,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $7.0 million, net of issuance costs of approximately $0.7 million.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In November 2023, the Company sold 2,490,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $4.5 million, net of issuance costs of approximately $0.5 million.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Equity Compensation&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Underlying share information for equity compensation plans as of March 31, 2024 is as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Name of Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Total Shares Reserved&lt;/strong&gt; &lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Under Plans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;138,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-Qualified Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,787,200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Bonus Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,283,760&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Compensation Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;634,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Bonus Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;640,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Stock option activity&lt;/span&gt;:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"&gt;&lt;strong&gt;Six Months Ended March 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"&gt;&lt;strong&gt;&#160;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;53,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;122,332&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;27,035&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;45,404&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"&gt;&lt;strong&gt;Three Months Ended March 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"&gt;&lt;strong&gt;&#160;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;42,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;27,035&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On March 1, 2024, the Company accelerated the vesting of 234,332 stock options issued to directors to vest on April 19, 2024. The Company concluded that the change in vesting of the options should be treated as a modification in accordance with ASC 718. As such, the Company revalued the options as of March 1, 2024 (the modification date) and subtracted any compensation cost already recognized prior to the modification date. This resulted in remaining compensation cost of approximately $260,000 that will be amortized on a straight-line basis over the remaining service period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Share-Based Compensation Expense&lt;/span&gt;:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"&gt;&lt;strong&gt;Six Months Ended March 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 15pt; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 27.05pt; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,816,449&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,436,119&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;370,163&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;285,722&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"&gt;&lt;strong&gt;Three Months Ended March 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 15pt; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 27.05pt; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,432,540&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,743,288&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;151,777&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;136,864&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Employee compensation expense includes the expense related to options and restricted stock that is expensed over the vesting periods. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of the related service contracts.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Warrants and Non-Employee Options&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The following chart represents the warrants and non-employee options outstanding at March 31, 2024:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;Warrant/&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;Shares Issuable upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;of Warrants/ Options&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2024&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/30/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/13/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/15/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;200,087&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;234,009&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultant Options&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;7/28/2017 &#x2013; 9/2/2023 &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;110,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;$&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;1.39 - $2.18&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;7/27/2027 -&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;9/1/2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;1. &lt;span style="text-decoration:underline"&gt;Equity Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Changes in Equity Warrants&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;No warrants recorded as equity were exercised during the six months ended March 31, 2024. The following warrants recorded as equity were exercised during the six months ended March 31, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,752&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,291&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;418,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;217,752&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;447,291&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;No warrants recorded as equity expired during the six and three months ended March 31 ,2024. On February 5, 2023, 600 Series TT warrants, with an exercise price of $2.24, expired.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;No warrants recorded as equity were extended during the six and three months ended March 31, 2024. On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024. The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend in the financial statements for the three months ended December 31, 2022. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company&#x2019;s CEO, Geert Kersten, is a beneficiary.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;2. &lt;span style="text-decoration:underline"&gt;Options and Shares Issued to Consultants&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the six months ended March 31, 2024 and 2023, the Company issued 251,317 and 78,798 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $1.99 and $2.47 during the six months ended March 31, 2024 and 2023, respectively. During the three months ended March 31, 2024 and 2023, the Company issued 162,744 and 38,562 shares, respectively, of restricted common stock to consultants for services. The weighted average grant date fair value of the shares issued to consultants was $2.22 and $2.42 during the three months ended March 31, 2024 and 2023, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;No options were issued to a consultant during the six months ended March 31, 2024. During the six months ended March 31, 2023, 5,000 options with an exercise price of $11.61 issued to a consultant expired.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the six months ended March 31, 2024 and 2023, the Company recorded total expense of approximately $370,000 and $285,000, respectively, relating to the share-based compensation under various consulting agreements. During the three months ended March 31, 2024 and 2023, the Company recorded total expense of approximately $152,000 and $136,000, respectively, relating to the share-based compensation under these consulting agreements. On March 31, 2024 and September 30, 2023, consulting fees of approximately $351,000 and $205,000, respectively, are included in current assets as prepaid expenses and will be amortized over the remaining service periods. &lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-02-29"
      decimals="0"
      id="fid_374"
      unitRef="Shares">3875000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-02-29"
      decimals="INF"
      id="fid_375"
      unitRef="USDPShares">2</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-02-01to2024-02-29"
      decimals="-6"
      id="fid_377"
      unitRef="USD">7000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:NetofissuanceCosts
      contextRef="From2024-02-01to2024-02-29"
      decimals="-5"
      id="fid_378"
      unitRef="USD">700000</cvm:NetofissuanceCosts>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-11-30"
      decimals="0"
      id="fid_358"
      unitRef="Shares">2490000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-11-30"
      decimals="INF"
      id="fid_359"
      unitRef="USDPShares">2</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-11-01to2023-11-30"
      decimals="-5"
      id="fid_370"
      unitRef="USD">4500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:NetofissuanceCosts
      contextRef="From2023-11-01to2023-11-30"
      decimals="-5"
      id="fid_372"
      unitRef="USD">500000</cvm:NetofissuanceCosts>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_265">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Name of Plan&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;strong&gt;Total Shares Reserved&lt;/strong&gt; &lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Under Plans&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;138,400&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-Qualified Stock Option Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,787,200&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Bonus Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,283,760&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock Compensation Plans&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;634,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Incentive Stock Bonus Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;640,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_274"
      unitRef="Shares">138400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-03-31_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_275"
      unitRef="Shares">15787200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-03-31_cvm_StockBonusPlansMember"
      decimals="0"
      id="fid_276"
      unitRef="Shares">1283760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-03-31_us-gaap_StockCompensationPlanMember"
      decimals="0"
      id="fid_277"
      unitRef="Shares">634000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-03-31_cvm_IncentiveStockBonusPlansMember"
      decimals="0"
      id="fid_278"
      unitRef="Shares">640000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <cvm:ScheduleOfStockOptionActivityTableTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_266">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"&gt;&lt;strong&gt;Six Months Ended March 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"&gt;&lt;strong&gt;&#160;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;53,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;122,332&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;27,035&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;45,404&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 6.5pt; text-align:center;"&gt;&lt;strong&gt;Three Months Ended March 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.05pt; text-align:center;"&gt;&lt;strong&gt;&#160;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;42,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;27,035&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfStockOptionActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_287"
      unitRef="Shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_283"
      unitRef="Shares">4500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_280"
      unitRef="Shares">53000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_289"
      unitRef="Shares">122332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_288"
      unitRef="Shares">27035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_290"
      unitRef="Shares">45404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_284"
      unitRef="Shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_279"
      unitRef="Shares">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_285"
      unitRef="Shares">42000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_281"
      unitRef="Shares">25500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_286"
      unitRef="Shares">27035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-01-01to2023-03-31"
      decimals="-3"
      id="fid_282"
      unitRef="Shares">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_638"
      unitRef="USD">234332</us-gaap:StockOptionPlanExpense>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_488"
      unitRef="USD">260000</us-gaap:AmortizationOfFinancingCosts>
    <cvm:ScheduleOfCompensatingBalancesTableTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_267">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"&gt;&lt;strong&gt;Six Months Ended March 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 15pt; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 27.05pt; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,816,449&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,436,119&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;370,163&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;285,722&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; text-align:center;"&gt;&lt;strong&gt;Three Months Ended March 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 15pt; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.25in; TEXT-INDENT: 27.05pt; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,432,540&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,743,288&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;151,777&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;136,864&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfCompensatingBalancesTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2023-10-01to2024-03-31_us-gaap_EmployeeStockMember"
      decimals="0"
      id="fid_295"
      unitRef="USD">2816449</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2022-10-01to2023-03-31_us-gaap_EmployeeStockMember"
      decimals="0"
      id="fid_334"
      unitRef="USD">3436119</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2023-10-01to2024-03-31_cvm_NonEmployeesMember"
      decimals="0"
      id="fid_297"
      unitRef="USD">370163</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2022-10-01to2023-03-31_cvm_NonEmployeesMember"
      decimals="0"
      id="fid_337"
      unitRef="USD">285722</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2024-01-01to2024-03-31_us-gaap_EmployeeStockMember"
      decimals="0"
      id="fid_336"
      unitRef="USD">1432540</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2023-01-01to2023-03-31_us-gaap_EmployeeStockMember"
      decimals="0"
      id="fid_335"
      unitRef="USD">1743288</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2024-01-01to2024-03-31_cvm_NonEmployeesMember"
      decimals="0"
      id="fid_338"
      unitRef="USD">151777</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2023-01-01to2023-03-31_cvm_NonEmployeesMember"
      decimals="0"
      id="fid_339"
      unitRef="USD">136864</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_268">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;Warrant/&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;Shares Issuable upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 4.1pt; text-align:center;"&gt;of Warrants/ Options&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 3.95pt; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2024&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/30/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/13/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/15/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;200,087&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;234,009&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultant Options&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 13.35pt; text-align:right;"&gt;7/28/2017 &#x2013; 9/2/2023 &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;110,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;$&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;1.39 - $2.18&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;7/27/2027 -&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 9pt; text-align:right;"&gt;9/1/2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfWarrantsAndNonEmployeeOptionsOutstandingTableTextBlock>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesNMember"
      id="fid_299">8/18/2008</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2023-12-31_cvm_SeriesNMember"
      decimals="0"
      id="fid_308"
      unitRef="Shares">85339</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2023-12-31_cvm_SeriesNMember"
      decimals="INF"
      id="fid_316"
      unitRef="USDPShares">3.00</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesNMember"
      id="fid_325">8/18/2024</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesUUMember"
      id="fid_300">6/11/2018</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2023-12-31_cvm_SeriesUUMember"
      decimals="0"
      id="fid_309"
      unitRef="Shares">93603</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2023-12-31_cvm_SeriesUUMember"
      decimals="INF"
      id="fid_317"
      unitRef="USDPShares">2.80</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesUUMember"
      id="fid_326">6/30/2024</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesXMember"
      id="fid_301">1/13/2016</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2023-12-31_cvm_SeriesXMember"
      decimals="0"
      id="fid_310"
      unitRef="Shares">120000</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2023-12-31_cvm_SeriesXMember"
      decimals="INF"
      id="fid_318"
      unitRef="USDPShares">9.25</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesXMember"
      id="fid_327">7/13/2024</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesYMember"
      id="fid_302">2/15/2016</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2023-12-31_cvm_SeriesYMember"
      decimals="0"
      id="fid_311"
      unitRef="Shares">26000</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2023-12-31_cvm_SeriesYMember"
      decimals="INF"
      id="fid_319"
      unitRef="USDPShares">12.00</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesYMember"
      id="fid_328">8/15/2024</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesMMMember"
      id="fid_303">6/22/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2023-12-31_cvm_SeriesMMMember"
      decimals="0"
      id="fid_312"
      unitRef="Shares">333432</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2023-12-31_cvm_SeriesMMMember"
      decimals="INF"
      id="fid_320"
      unitRef="USDPShares">1.86</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesMMMember"
      id="fid_329">6/22/2024</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesNNMember"
      id="fid_304">7/24/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2023-12-31_cvm_SeriesNNMember"
      decimals="0"
      id="fid_313"
      unitRef="Shares">200087</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2023-12-31_cvm_SeriesNNMember"
      decimals="INF"
      id="fid_321"
      unitRef="USDPShares">2.52</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesNNMember"
      id="fid_330">7/24/2024</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesRRMember"
      id="fid_305">10/30/2017</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2023-12-31_cvm_SeriesRRMember"
      decimals="0"
      id="fid_314"
      unitRef="Shares">234009</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2023-12-31_cvm_SeriesRRMember"
      decimals="INF"
      id="fid_322"
      unitRef="USDPShares">1.65</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesRRMember"
      id="fid_331">10/30/2024</cvm:ExpirationDate>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2024-03-31_srt_MinimumMember_cvm_ConsultantsMember"
      id="fid_306">7/28/2017</cvm:IssueDate1>
    <cvm:IssueDate1
      contextRef="From2023-10-01to2024-03-31_srt_MaximumMember_cvm_ConsultantsMember"
      id="fid_307">9/2/2023</cvm:IssueDate1>
    <cvm:SharesIssuableUponExerciseOfWarrantOptions
      contextRef="AsOf2023-12-31_cvm_ConsultantsOptionMember"
      decimals="0"
      id="fid_315"
      unitRef="Shares">110000</cvm:SharesIssuableUponExerciseOfWarrantOptions>
    <cvm:ExercisePrice
      contextRef="AsOf2023-12-31_srt_MinimumMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_323"
      unitRef="USDPShares">1.39</cvm:ExercisePrice>
    <cvm:ExercisePrice
      contextRef="AsOf2023-12-31_cvm_ConsultantsOptionMember"
      decimals="INF"
      id="fid_324"
      unitRef="USDPShares">2.18</cvm:ExercisePrice>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2024-03-31_srt_MinimumMember_cvm_ConsultantsMember"
      id="fid_332">7/27/2027</cvm:ExpirationDate>
    <cvm:ExpirationDate
      contextRef="From2023-10-01to2024-03-31_srt_MaximumMember_cvm_ConsultantsMember"
      id="fid_333">9/1/2028</cvm:ExpirationDate>
    <cvm:ScheduleOfDerivativeLiabilitiesTableTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_269">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,752&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,291&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;418,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;217,752&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;447,291&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfDerivativeLiabilitiesTableTextBlock>
    <cvm:EquityWarrantsExercised
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesRRMember"
      decimals="0"
      id="fid_340"
      unitRef="Shares">17752</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesRRMember"
      decimals="INF"
      id="fid_343"
      unitRef="USDPShares">1.65</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesRRMember"
      decimals="0"
      id="fid_345"
      unitRef="USD">29291</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesSSMember"
      decimals="0"
      id="fid_341"
      unitRef="Shares">200000</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesSSMember"
      decimals="INF"
      id="fid_344"
      unitRef="USDPShares">2.09</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2023-10-01to2024-03-31_cvm_SeriesSSMember"
      decimals="0"
      id="fid_346"
      unitRef="USD">418000</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_347"
      unitRef="Shares">217752</cvm:EquityWarrantsExercised>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_348"
      unitRef="USD">447291</cvm:ProceedsFromEquityWarrantsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-10-01to2024-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_350"
      unitRef="USDPShares">2.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <cvm:IncrementalCostDeemedDividend
      contextRef="From2022-10-01to2022-10-28_cvm_SeriesRRMember"
      decimals="0"
      id="fid_349"
      unitRef="USD">172000</cvm:IncrementalCostDeemedDividend>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-10-01to2024-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="0"
      id="fid_354"
      unitRef="Shares">251317</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-10-01to2023-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="0"
      id="fid_490"
      unitRef="Shares">78798</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-10-01to2024-03-31_cvm_ConsultingAgreementsMember"
      decimals="INF"
      id="fid_492"
      unitRef="USDPShares">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-10-01to2023-03-31_cvm_ConsultingAgreementsMember"
      decimals="INF"
      id="fid_494"
      unitRef="USDPShares">2.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-01-01to2024-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="0"
      id="fid_498"
      unitRef="Shares">162744</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-01to2023-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="0"
      id="fid_499"
      unitRef="Shares">38562</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-01to2024-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_500"
      unitRef="USDPShares">2.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-01to2023-03-31_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_501"
      unitRef="USDPShares">2.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1
      contextRef="From2023-10-01to2024-03-31_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_507"
      unitRef="Shares">5000</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationOptionsIssued1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-10-01to2024-03-31_cvm_ConsultingAgreementsMember"
      decimals="INF"
      id="fid_506"
      unitRef="USDPShares">11.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-10-01to2024-03-31_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_365"
      unitRef="USD">370000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-10-01to2023-03-31_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_502"
      unitRef="USD">285000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-01to2024-03-31_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_503"
      unitRef="USD">152000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-01to2023-03-31_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_504"
      unitRef="USD">136000</us-gaap:AllocatedShareBasedCompensationExpense>
    <cvm:ConsultingFeesIncluedPrepaidExpenses
      contextRef="AsOf2024-03-31_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_367"
      unitRef="USD">351000</cvm:ConsultingFeesIncluedPrepaidExpenses>
    <cvm:ConsultingFeesIncluedPrepaidExpenses
      contextRef="AsOf2023-09-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_353"
      unitRef="USD">205000</cvm:ConsultingFeesIncluedPrepaidExpenses>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_246">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;D. &lt;span style="text-decoration:underline"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the six and three months ended March 31, 2024, no restricted shares of the Company&#x2019;s common stock were purchased by related parties.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024 (Note C). The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend. The Series RR warrants are held by Geert Kersten, Patricia Prichep (current officers of the Company) and the de Clara Trust, of which the Company&#x2019;s CEO, Geert Kersten, is a beneficiary.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <cvm:IncrementalCostDeemedDividend
      contextRef="From2023-10-01to2023-10-28"
      decimals="0"
      id="fid_379"
      unitRef="USD">172000</cvm:IncrementalCostDeemedDividend>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_247">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;E. &lt;span style="text-decoration:underline"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Clinical Research Agreement&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:right;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $12 million towards the Company&#x2019;s Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808, &lt;em&gt;Collaborative Arrangements&lt;/em&gt;. The Company determined the payments to Ergomed are within the scope of ASC 730, &lt;em&gt;Research and Development&lt;/em&gt;. Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its statements of operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $35.8 million for Ergomed&#x2019;s services. This amount is net of Ergomed&#x2019;s discount of approximately $11.9 million. During the six months ended March 31, 2024 and 2023, the Company recorded, net of Ergomed&#x2019;s discount, approximately $0.1 million for each quarter as research and development expense related to Ergomed&#x2019;s services. During the three months ended March 31, 2024 and 2023, the Company recorded, net of Ergomed&#x2019;s discount, less than $0.1 million for each quarter as research and development expense related to Ergomed&#x2019;s services.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Lease Agreements&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#x2019;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#x2019;s Phase 3 clinical trial and sales of the drug if approved by any regulatory agency. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. The renewal options are not included in the calculation of the right of use asset and lease liability because exercise of those options is not reasonably certain.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The San Tomas lease is classified as a finance lease on the Company&#x2019;s balance sheet, as well as several other smaller finance leases for office equipment. The finance right of use assets are being depreciated using the straight-line method over the underlying lease terms. Total cash paid related to finance leases during the six months ended March 31, 2024 and 2023 was approximately $1.3 million for both periods, of which approximately $0.5 and $0.6 million was for interest, respectively, in each six-month period. As of March 31, 2024, the weighted average discount rate of the Company&#x2019;s finance leases is 8.46% and the weighted average time to maturity is 4.59 years.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On January 11, 2023, the Company was required to deposit approximately $2.3 million to its landlord, equivalent to one year&#x2019;s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Approximate future minimum lease payments under finance leases as of March 31, 2024 are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Six months ending September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,333,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,747,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,838,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,929,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,021,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;255,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,123,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,247,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of financing lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,876,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less net present value of financing lease obligations &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,889,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of financing lease obligations - non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;8,987,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company leases two facilities under operating leases. The lease for the Company&#x2019;s office headquarters will expire on November 30, 2025.&#160; The lease for its research and development laboratory was renewed in September 2021 for an additional ten years and will expire on February 29, 2032. The renewal was considered a modification for accounting purposes and the right of use asset and liability were remeasured as of the date of the renewal. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. The Company incurred lease expense for operating leases of approximately $0.2 million for both the six months ended March 31, 2024 and 2023. Total cash paid related to operating leases during the six months ended March 31, 2024 and 2023 was approximately $0.2 million for each period. The weighted average discount rate of the Company&#x2019;s operating leases is 9.03% and the weighted average time to maturity is 7.35 years. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;As of March 31, 2024, approximate future minimum lease payments under operating leases are as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Six months ending September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;180,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;366,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;287,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;277,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;285,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;294,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;746,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,435,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(680,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,755,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less net present value of operating lease obligations - current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(211,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations - non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,544,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <cvm:ClinicalServiceTrial
      contextRef="From2023-10-01to2024-03-31_cvm_ErgomedMember"
      decimals="-6"
      id="fid_472"
      unitRef="USD">12000000</cvm:ClinicalServiceTrial>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2023-10-01to2024-03-31"
      decimals="-4"
      id="fid_469"
      unitRef="USD">3580000</us-gaap:OtherResearchAndDevelopmentExpense>
    <cvm:NetOfDiscount
      contextRef="From2023-10-01to2024-03-31"
      decimals="-4"
      id="fid_456"
      unitRef="USD">1190000</cvm:NetOfDiscount>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-03-31_cvm_ErgomedMember"
      decimals="-5"
      id="fid_479"
      unitRef="USD">100000</us-gaap:OtherResearchAndDevelopmentExpense>
    <cvm:NetOfDiscount
      contextRef="From2024-01-01to2024-03-31_cvm_ErgomedMember"
      decimals="-5"
      id="fid_480"
      unitRef="USD">100000</cvm:NetOfDiscount>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="fid_466"
      unitRef="Pure">0.03</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2023-10-01to2024-03-31"
      decimals="-5"
      id="fid_458"
      unitRef="USD">1300000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:InterestPaid
      contextRef="From2023-10-01to2024-03-31"
      decimals="-5"
      id="fid_459"
      unitRef="USD">500000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="From2022-10-01to2023-03-31"
      decimals="-5"
      id="fid_486"
      unitRef="USD">600000</us-gaap:InterestPaid>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="fid_484"
      unitRef="Pure">0.0846</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <cvm:FinanceLeaseWeightedAverageRemainingLeaseTermOne contextRef="From2023-10-01to2024-03-31" id="fid_461">P4Y7M2D</cvm:FinanceLeaseWeightedAverageRemainingLeaseTermOne>
    <cvm:FinancingArrangementDepositBaseRentAmount
      contextRef="From2023-01-01to2023-01-11_cvm_LandlordMember"
      decimals="-5"
      id="fid_473"
      unitRef="USD">2300000</cvm:FinancingArrangementDepositBaseRentAmount>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_270">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Six months ending September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,333,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,747,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,838,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,929,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,021,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;255,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,123,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,247,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of financing lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;10,876,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less net present value of financing lease obligations &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,889,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of financing lease obligations - non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;8,987,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Six months ending September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;180,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;366,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;287,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;277,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;285,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;294,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;746,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,435,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(680,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,755,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less net present value of operating lease obligations - current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(211,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations - non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,544,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_432"
      unitRef="USD">1333000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_433"
      unitRef="USD">2747000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_434"
      unitRef="USD">2838000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_435"
      unitRef="USD">2929000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_436"
      unitRef="USD">3021000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_437"
      unitRef="USD">255000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_439"
      unitRef="USD">13123000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_440"
      unitRef="USD">2247000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_441"
      unitRef="USD">10876000</us-gaap:FinanceLeaseLiability>
    <cvm:FinanceLeaseLiabilityCurrentPortion
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_442"
      unitRef="USD">1889000</cvm:FinanceLeaseLiabilityCurrentPortion>
    <cvm:FinanceLeaseLiabilityNoncurrentPortion
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_443"
      unitRef="USD">8987000</cvm:FinanceLeaseLiabilityNoncurrentPortion>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-10-01to2024-03-31"
      decimals="-5"
      id="fid_463"
      unitRef="USD">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="From2023-10-01to2024-03-31"
      decimals="-5"
      id="fid_465"
      unitRef="USD">200000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="fid_505"
      unitRef="Pure">0.0903</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <cvm:OperatingLeaseWeightedAverageRemainingLeaseTermOne contextRef="From2023-10-01to2024-03-31" id="fid_467">P7Y4M6D</cvm:OperatingLeaseWeightedAverageRemainingLeaseTermOne>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_444"
      unitRef="USD">180000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_445"
      unitRef="USD">366000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_446"
      unitRef="USD">287000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_447"
      unitRef="USD">277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_448"
      unitRef="USD">285000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_449"
      unitRef="USD">294000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_450"
      unitRef="USD">746000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_451"
      unitRef="USD">2435000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_452"
      unitRef="USD">680000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_453"
      unitRef="USD">1755000</us-gaap:OperatingLeaseLiability>
    <cvm:OperatingLeaseLiabilityCurrentPortion
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_454"
      unitRef="USD">211000</cvm:OperatingLeaseLiabilityCurrentPortion>
    <cvm:OperatingLeaseLiabilityNoncurrentPortion
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_455"
      unitRef="USD">1544000</cvm:OperatingLeaseLiabilityNoncurrentPortion>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_248">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;G. &lt;span style="text-decoration:underline"&gt;PATENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the six and three months ended March 31, 2024 and 2023, there was no impairment of patent costs. The weighted average amortization period for patents&#160;is approximately&#160;8&#160;years. For the six months ended March 31, 2024 and 2023, amortization of patent costs totaled approximately $17,000 and $20,000, respectively. For the three months ended March 31, 2024 and 2023, amortization of patent costs totaled approximately $8,000&#160;and $10,000, respectively. The total estimated future amortization is as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Six months ending September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;54,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;180,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <cvm:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod contextRef="From2023-10-01to2024-03-31" id="fid_424">P8Y</cvm:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_422"
      unitRef="USD">17000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_426"
      unitRef="USD">20000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_430"
      unitRef="USD">8000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_431"
      unitRef="USD">10000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_271">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Six months ending September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;54,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;180,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_412"
      unitRef="USD">15000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_413"
      unitRef="USD">29000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_414"
      unitRef="USD">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_415"
      unitRef="USD">22000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_416"
      unitRef="USD">19000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_417"
      unitRef="USD">16000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_418"
      unitRef="USD">54000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <us-gaap:OtherIndefiniteLivedIntangibleAssets
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_419"
      unitRef="USD">180000</us-gaap:OtherIndefiniteLivedIntangibleAssets>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_249">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;H. &lt;span style="text-decoration:underline"&gt;LOSS PER COMMON SHARE&lt;/span&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, common stock warrants and unvested restricted stock are not included in the computation of diluted net loss per share if their effect would be anti-dilutive.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following table provides a reconciliation of the numerators and denominators of the basic and diluted loss per-share computations:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Six Months&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Ended&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Ended&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Loss per share &#x2013; basic and diluted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Net loss available to common &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(13,954,415&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(16,367,870&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(7,244,891&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(8,342,809&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Weighted average shares outstanding &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;50,228,860&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;43,513,571&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;52,006,442&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;43,588,381&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.28&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.38&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.14&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.19&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;In accordance with the contingently issuable shares guidance of ASC 260, &lt;em&gt;Earnings Per Share&lt;/em&gt;, the calculation of diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive as of March 31:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options and Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,772,993&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,893,248&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested Restricted Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;149,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;15,920,243&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;14,042,498&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_272">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Six Months&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Three Months&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Ended&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Ended&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Loss per share &#x2013; basic and diluted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Net loss available to common &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(13,954,415&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(16,367,870&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(7,244,891&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(8,342,809&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Weighted average shares outstanding &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;50,228,860&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;43,513,571&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;52,006,442&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;43,588,381&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.28&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.38&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.14&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.19&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfReconciliationOfTheNumeratorsAndDenominatorsOfTheBasicAndDilutedPerShareComputationsTableTextBlock>
    <cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_390"
      unitRef="USD">-13954415</cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
    <cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_403"
      unitRef="USD">-16367870</cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
    <cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_406"
      unitRef="USD">-7244891</cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
    <cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
      contextRef="From2023-01-01to2023-03-31"
      decimals="0"
      id="fid_407"
      unitRef="USD">-8342809</cvm:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
    <cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_392"
      unitRef="Shares">50228860</cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted>
    <cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_404"
      unitRef="Shares">43513571</cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted>
    <cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_408"
      unitRef="Shares">52006442</cvm:WeightedAverageNumberOfShareOutstandingBasicsAndDiluted>
    <cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares
      contextRef="From2023-10-01to2024-03-31"
      decimals="INF"
      id="fid_394"
      unitRef="USDPShares">-0.28</cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares>
    <cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares
      contextRef="From2022-10-01to2023-03-31"
      decimals="INF"
      id="fid_405"
      unitRef="USDPShares">-0.38</cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares>
    <cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="fid_409"
      unitRef="USDPShares">-0.14</cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares>
    <cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares
      contextRef="From2023-01-01to2023-03-31"
      decimals="INF"
      id="fid_411"
      unitRef="USDPShares">-0.19</cvm:IncomeLossFromContinuingOperationsPerBasicAndDilutedShares>
    <cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_273">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options and Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,772,993&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13,893,248&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested Restricted Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;149,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;15,920,243&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;14,042,498&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfAntiDilutiveSecuritiesTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2024-03-31_cvm_OptionsMember"
      decimals="0"
      id="fid_396"
      unitRef="Shares">15772993</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-01to2023-03-31_cvm_OptionsMember"
      decimals="0"
      id="fid_397"
      unitRef="Shares">13893248</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2024-03-31_cvm_UnvestedRestrictedStockMember"
      decimals="0"
      id="fid_398"
      unitRef="Shares">147250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-01to2023-03-31_cvm_UnvestedRestrictedStockMember"
      decimals="0"
      id="fid_399"
      unitRef="Shares">149250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2024-03-31"
      decimals="0"
      id="fid_401"
      unitRef="Shares">15920243</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-01to2023-03-31"
      decimals="0"
      id="fid_402"
      unitRef="Shares">14042498</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-10-01to2024-03-31" id="fid_250">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;J. &lt;span style="text-decoration:underline"&gt;SUBSEQUENT EVENTS&lt;/span&gt; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On May 4, 2024, the Company extended for two years the expiration date of 1,092,470 outstanding warrants.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On May 8, 2024, officers and directors purchased 58,000 shares of restricted common stock from the Company at an aggregate fair market value of $80,620.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="AsOf2024-05-08_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_639"
      unitRef="Shares">1092470</us-gaap:ClassOfWarrantOrRightUnissued>
    <cvm:RestrictedCommonStock
      contextRef="AsOf2024-05-08_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_387"
      unitRef="Shares">58000</cvm:RestrictedCommonStock>
    <us-gaap:SecurityOwnedNotReadilyMarketableFairValue
      contextRef="AsOf2024-05-08_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_385"
      unitRef="USD">80620</us-gaap:SecurityOwnedNotReadilyMarketableFairValue>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
